{"5fcb93b865d4cd7475c07683c14f5920bf6fb0f7": [["INTRODUCTIONMycobacterium tuberculosis (Mtb) is a well-known intracellular pathogen which causes almost nine million cases of tuberculosis every year and latently infects up to a third of the world population (World Health Organization [WHO] , 2019).", [["intracellular", "ANATOMY", 61, 74], ["INTRODUCTIONMycobacterium tuberculosis", "DISEASE", 0, 38], ["tuberculosis", "DISEASE", 126, 138], ["INTRODUCTIONMycobacterium tuberculosis", "ORGANISM", 0, 38], ["Mtb", "GENE_OR_GENE_PRODUCT", 40, 43], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 61, 74], ["INTRODUCTIONMycobacterium tuberculosis", "SPECIES", 0, 38], ["INTRODUCTIONMycobacterium tuberculosis (Mtb", "PROBLEM", 0, 43], ["intracellular pathogen", "PROBLEM", 61, 83], ["tuberculosis", "PROBLEM", 126, 138], ["tuberculosis", "OBSERVATION", 26, 38], ["pathogen", "OBSERVATION", 75, 83], ["tuberculosis", "OBSERVATION", 126, 138]]], ["Mtb is able to persist in the host for decades without causing clinical symptoms, and has evolved adaptation mechanisms to survive in the harsh environment of the host, such as hypoxia, nutrient deprivation or low pH (Betts et al., 2002; Fisher et al., 2002; Schnappinger et al., 2003) .", [["hypoxia", "DISEASE", 177, 184], ["Mtb", "GENE_OR_GENE_PRODUCT", 0, 3], ["Mtb", "PROBLEM", 0, 3], ["clinical symptoms", "PROBLEM", 63, 80], ["hypoxia", "PROBLEM", 177, 184], ["nutrient deprivation", "PROBLEM", 186, 206], ["low pH", "PROBLEM", 210, 216]]], ["This adaptation is possible by regulation of gene expression, which in turn can be controlled by DNA methylation (Shell et al., 2013) .INTRODUCTIONDNA methylation has been known since the 1950s (Luria and Human, 1952) .", [["DNA", "CELLULAR_COMPONENT", 97, 100], ["Human", "SPECIES", 205, 210], ["gene expression", "PROBLEM", 45, 60], ["gene expression", "OBSERVATION", 45, 60]]], ["In prokaryotes, it represents a primitive defense mechanism against phages and viruses, known as the Restriction-Modification (RM) system.", [["viruses", "PROBLEM", 79, 86], ["Modification (RM) system", "TREATMENT", 113, 137], ["primitive defense", "OBSERVATION", 32, 49]]], ["Although adenine is the most important methylation target, e.g., N 6methyl-adenosine (m6A), there are other two types of methylation.", [["adenine", "CHEMICAL", 9, 16], ["N 6methyl-adenosine", "CHEMICAL", 65, 84], ["adenine", "CHEMICAL", 9, 16], ["N 6methyl-adenosine", "CHEMICAL", 65, 84], ["adenine", "SIMPLE_CHEMICAL", 9, 16], ["N 6methyl-adenosine (m6A", "GENE_OR_GENE_PRODUCT", 65, 89], ["N 6methyl-adenosine", "TREATMENT", 65, 84], ["methylation", "TREATMENT", 121, 132]]], ["These are found in cytosine and depend on the modification site: m4C (N 4 -methyl-cytosine) and m5C (C 5 -methyl-cytosine) (Murphy et al., 2013) .", [["cytosine", "CHEMICAL", 19, 27], ["N 4 -methyl-cytosine", "CHEMICAL", 70, 90], ["C 5 -methyl-cytosine", "CHEMICAL", 101, 121], ["cytosine", "CHEMICAL", 19, 27], ["m4C (N 4 -methyl-cytosine)", "CHEMICAL", 65, 91], ["m5C (C 5 -methyl-cytosine", "CHEMICAL", 96, 121], ["cytosine", "SIMPLE_CHEMICAL", 19, 27], ["m4C (N 4 -methyl-cytosine", "SIMPLE_CHEMICAL", 65, 90], ["m5C (C 5 -methyl-cytosine", "SIMPLE_CHEMICAL", 96, 121], ["cytosine", "TREATMENT", 19, 27], ["m4C", "TEST", 65, 68], ["methyl-cytosine)", "TREATMENT", 75, 91], ["m5C (C 5 -methyl-cytosine)", "TREATMENT", 96, 122]]], ["In general, m6A has been used as the main signal for epigenetic regulation in bacteria, m5C has been mainly described in mammals and plant studies (Kim et al., 2009) , whereas m4C is mainly present in bacteria (Kumar et al., 2018) .INTRODUCTIONDNA methylation plays an important role in the epigenetic regulation of eukaryotes via gene expression modulation (Moore et al., 2013) .", [["m6A", "CHEMICAL", 12, 15], ["m6A", "GENE_OR_GENE_PRODUCT", 12, 15], ["m5C", "GENE_OR_GENE_PRODUCT", 88, 91], ["m4C", "GENE_OR_GENE_PRODUCT", 176, 179], ["m6A", "PROTEIN", 12, 15], ["m5C", "DNA", 88, 91], ["m4C", "PROTEIN", 176, 179], ["epigenetic regulation in bacteria", "PROBLEM", 53, 86], ["plant studies", "TEST", 133, 146], ["bacteria", "OBSERVATION", 78, 86]]], ["Indeed, methylation of promoter and gene body can either silence or promote expression, respectively (Yang et al., 2014) .", [["body", "ANATOMY", 41, 45], ["promoter", "DNA", 23, 31], ["methylation of promoter and gene body", "TREATMENT", 8, 45]]], ["In bacteria, DNA methylation may also play regulatory roles in the control of DNA replication or transcription (Reisenauer et al., 1999) , and this may contribute to environmental adaptation and metabolic activity (Blow et al., 2016) .INTRODUCTIONSingle-molecule real-time (SMRT) sequencing (Pacific Biosciences) is a recently developed DNA sequencing method where kinetic data can also be used to distinguish base modifications, e.g., methylation, at the single nucleotide level (Flusberg et al., 2010) .", [["nucleotide", "CHEMICAL", 463, 473], ["DNA", "CELLULAR_COMPONENT", 13, 16], ["DNA", "CELLULAR_COMPONENT", 78, 81], ["DNA", "CELLULAR_COMPONENT", 337, 340], ["SMRT", "PROTEIN", 274, 278], ["bacteria", "PROBLEM", 3, 11], ["DNA methylation", "TREATMENT", 13, 28], ["DNA replication", "TREATMENT", 78, 93], ["bacteria", "OBSERVATION", 3, 11]]], ["Several bacterial methylomes have been determined using SMRT sequencing technology (Fang et al., 2012; Krebes et al., 2014; Zhu et al., 2016) .", [["SMRT", "PROTEIN", 56, 60], ["Several bacterial methylomes", "PROBLEM", 0, 28], ["bacterial methylomes", "OBSERVATION", 8, 28]]], ["Specifically, a methylome analysis of M. tuberculosis complex (MTBC) was reported by Zhu et al. (2016) .INTRODUCTIONVitamins are organic compounds that cannot be produced by the host organism.", [["M. tuberculosis complex", "GENE_OR_GENE_PRODUCT", 38, 61], ["M. tuberculosis", "SPECIES", 38, 53], ["M. tuberculosis", "SPECIES", 38, 53], ["a methylome analysis", "TEST", 14, 34], ["M. tuberculosis complex", "PROBLEM", 38, 61], ["organic compounds", "TREATMENT", 129, 146]]], ["Even when they are produced, concentrations are low and external supplementation from the diet or from commensal bacteria is required.", [["external supplementation", "TREATMENT", 56, 80], ["commensal bacteria", "PROBLEM", 103, 121]]], ["Vitamins have been found to regulate immunity, and a number of studies have reported the effect of vitamins as adjunct to treat tuberculosis (Parida et al., 2015; He et al., 2018) .", [["Vitamins", "CHEMICAL", 0, 8], ["vitamins", "CHEMICAL", 99, 107], ["tuberculosis", "DISEASE", 128, 140], ["Vitamins", "CHEMICAL", 0, 8], ["vitamins", "CHEMICAL", 99, 107], ["Vitamins", "SIMPLE_CHEMICAL", 0, 8], ["vitamins", "SIMPLE_CHEMICAL", 99, 107], ["Vitamins", "TREATMENT", 0, 8], ["vitamins", "TREATMENT", 99, 107], ["tuberculosis", "PROBLEM", 128, 140], ["tuberculosis", "OBSERVATION", 128, 140]]], ["For example, vitamins A, C and D have been used as adjunct to complement anti-tuberculosis drugs (Dini and Bianchi, 2012; Vilcheze et al., 2013; Syal et al., 2015) .", [["vitamins A, C and D", "CHEMICAL", 13, 32], ["vitamins A, C and D", "CHEMICAL", 13, 32], ["vitamins A", "SIMPLE_CHEMICAL", 13, 23], ["C", "SIMPLE_CHEMICAL", 25, 26], ["D", "SIMPLE_CHEMICAL", 31, 32], ["vitamins A, C and D", "TREATMENT", 13, 32], ["complement anti-tuberculosis drugs", "TREATMENT", 62, 96]]], ["The active form of thiamin (Vitamin B1, V B1 ), thiamin diphosphate (ThDP) (Begley et al., 1999; Settembre et al., 2003; Pohl et al., 2004) , is an essential cofactor in all organisms, taking an important role in energy metabolism and degradation of sugars.", [["thiamin", "CHEMICAL", 19, 26], ["Vitamin B1", "CHEMICAL", 28, 38], ["thiamin diphosphate", "CHEMICAL", 48, 67], ["ThDP", "CHEMICAL", 69, 73], ["thiamin", "CHEMICAL", 19, 26], ["Vitamin B1, V B1", "CHEMICAL", 28, 44], ["thiamin diphosphate", "CHEMICAL", 48, 67], ["ThDP", "CHEMICAL", 69, 73], ["sugars", "CHEMICAL", 250, 256], ["thiamin", "SIMPLE_CHEMICAL", 19, 26], ["Vitamin B1", "SIMPLE_CHEMICAL", 28, 38], ["V B1", "SIMPLE_CHEMICAL", 40, 44], ["thiamin diphosphate", "SIMPLE_CHEMICAL", 48, 67], ["ThDP", "SIMPLE_CHEMICAL", 69, 73], ["sugars", "SIMPLE_CHEMICAL", 250, 256], ["thiamin (Vitamin B1, V B1 )", "TEST", 19, 46], ["thiamin diphosphate (ThDP)", "TEST", 48, 74], ["an essential cofactor in all organisms", "PROBLEM", 145, 183], ["sugars", "TEST", 250, 256], ["essential", "OBSERVATION_MODIFIER", 148, 157], ["cofactor", "OBSERVATION", 158, 166]]], ["In addition, V B1 plays an important role in the activation of the immune system, nerve tissue repair, neuronal communication and cell-membrane dynamics (Gibson and Blass, 2007; Manzetti et al., 2014) .", [["immune system", "ANATOMY", 67, 80], ["nerve tissue", "ANATOMY", 82, 94], ["neuronal", "ANATOMY", 103, 111], ["cell", "ANATOMY", 130, 134], ["membrane", "ANATOMY", 135, 143], ["V B1", "GENE_OR_GENE_PRODUCT", 13, 17], ["nerve tissue", "TISSUE", 82, 94], ["neuronal", "CELL", 103, 111], ["cell", "CELL", 130, 134], ["membrane", "CELLULAR_COMPONENT", 135, 143], ["V B1", "PROTEIN", 13, 17], ["the immune system", "TREATMENT", 63, 80], ["nerve tissue repair", "TREATMENT", 82, 101], ["nerve tissue", "ANATOMY", 82, 94]]], ["Recent studies have shown the effects of V B1 both in vitro and in vivo; V B1 inhibits in vitro growth of BCG with an MIC of 8 mM, whereas it limits Mtb in vivo growth by regulating innate immunity in a peroxisome proliferatoractivated receptor \u03b3-dependent manner Song et al., 2019) .", [["V B1", "GENE_OR_GENE_PRODUCT", 41, 45], ["V B1", "GENE_OR_GENE_PRODUCT", 73, 77], ["peroxisome proliferatoractivated receptor", "GENE_OR_GENE_PRODUCT", 203, 244], ["V B1", "PROTEIN", 41, 45], ["peroxisome proliferatoractivated receptor", "PROTEIN", 203, 244], ["Recent studies", "TEST", 0, 14], ["V B1", "TREATMENT", 41, 45], ["BCG", "TEST", 106, 109], ["an MIC", "TEST", 115, 121]]], ["V C also can hamper the growth of Mtb by a mechanism that involves the reduction of ferric to ferrous ion and subsequent production of reactive oxygen species (i.e., hydrogen peroxide, superoxide and hydroxyl radicals) through Harber-Weiss cycle and Fenton reactions (Vilcheze et al., 2013) .", [["ferric", "CHEMICAL", 84, 90], ["ferrous", "CHEMICAL", 94, 101], ["oxygen", "CHEMICAL", 144, 150], ["hydrogen peroxide", "CHEMICAL", 166, 183], ["superoxide", "CHEMICAL", 185, 195], ["hydroxyl", "CHEMICAL", 200, 208], ["Fenton", "CHEMICAL", 250, 256], ["ferric", "CHEMICAL", 84, 90], ["ferrous", "CHEMICAL", 94, 101], ["oxygen", "CHEMICAL", 144, 150], ["hydrogen peroxide", "CHEMICAL", 166, 183], ["superoxide", "CHEMICAL", 185, 195], ["hydroxyl", "CHEMICAL", 200, 208], ["C", "SIMPLE_CHEMICAL", 2, 3], ["Mtb", "GENE_OR_GENE_PRODUCT", 34, 37], ["ferric", "SIMPLE_CHEMICAL", 84, 90], ["ferrous ion", "SIMPLE_CHEMICAL", 94, 105], ["reactive oxygen species", "SIMPLE_CHEMICAL", 135, 158], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 166, 183], ["superoxide", "SIMPLE_CHEMICAL", 185, 195], ["hydroxyl radicals", "SIMPLE_CHEMICAL", 200, 217], ["Harber", "SIMPLE_CHEMICAL", 227, 233], ["Fenton", "SIMPLE_CHEMICAL", 250, 256], ["Mtb", "PROBLEM", 34, 37], ["the reduction of ferric to ferrous ion", "TREATMENT", 67, 105], ["reactive oxygen species", "TREATMENT", 135, 158], ["hydrogen peroxide", "TREATMENT", 166, 183], ["superoxide and hydroxyl radicals", "TREATMENT", 185, 217], ["Fenton reactions", "TREATMENT", 250, 266], ["growth", "OBSERVATION_MODIFIER", 24, 30], ["Mtb", "OBSERVATION", 34, 37], ["reactive oxygen species", "OBSERVATION", 135, 158]]], ["BCG is also sensitive to Vc, with an MIC is 0.8 mM (Pei et al., 2019) .INTRODUCTIONMicrobial metabolomics constitutes an integrated component of systems biology.", [["BCG", "TEST", 0, 3], ["Vc", "TEST", 25, 27], [".INTRODUCTIONMicrobial metabolomics", "TEST", 70, 105]]], ["By studying the complete set of metabolites within a microorganism and monitoring the global outcome of interactions between its development processes and the environment, metabolomics can potentially provide a more accurate snap shot of the actual physiological state of the cell.", [["cell", "ANATOMY", 276, 280], ["cell", "CELL", 276, 280], ["a microorganism", "PROBLEM", 51, 66]]], ["Furthermore, when these data are interpreted in combination with genomics, proteomics and transcriptomics data and so on, using what is termed a systems biology approach, a more holistic understanding of these systems can be achieved.", [["these data", "TEST", 18, 28], ["proteomics", "TEST", 75, 85], ["transcriptomics data", "TEST", 90, 110]]], ["Up to now, the metabolomics has contributed to characterize Mtb in terms of metabolism, growth and replication, pathogenicity, and drug resistance, from the perspective of systems biology (Swanepoel and Loots, 2014) .", [["Mtb", "GENE_OR_GENE_PRODUCT", 60, 63], ["the metabolomics", "TEST", 11, 27], ["Mtb", "PROBLEM", 60, 63], ["pathogenicity", "PROBLEM", 112, 125], ["drug resistance", "PROBLEM", 131, 146], ["Mtb", "OBSERVATION", 60, 63], ["drug resistance", "OBSERVATION", 131, 146]]], ["For example, Meissner-Roloff compared the metabolomes of a hypo-and hyper-virulent Beijing Mtb strain and subsequently identified a reduction in various metabolite markers in the relatively hyper-virulent strain (Meissner-Roloff et al., 2012) .", [["a hypo-and hyper-virulent Beijing Mtb strain", "PROBLEM", 57, 101], ["a reduction in various metabolite markers", "PROBLEM", 130, 171], ["Mtb strain", "OBSERVATION", 91, 101], ["reduction", "OBSERVATION_MODIFIER", 132, 141], ["various", "OBSERVATION_MODIFIER", 145, 152], ["metabolite markers", "OBSERVATION", 153, 171], ["relatively", "OBSERVATION_MODIFIER", 179, 189], ["hyper-virulent strain", "OBSERVATION", 190, 211]]], ["Loots used metabolomics approach to identify potentially new metabolic pathways and metabolite markers to explain many of the phenotypical characteristics associated with a katG mutation and the resulting isoniazid-resistance in Mtb (Loots du, 2014).", [["isoniazid", "CHEMICAL", 205, 214], ["isoniazid", "CHEMICAL", 205, 214], ["katG", "GENE_OR_GENE_PRODUCT", 173, 177], ["isoniazid", "SIMPLE_CHEMICAL", 205, 214], ["metabolomics approach", "TEST", 11, 32], ["new metabolic pathways", "PROBLEM", 57, 79], ["metabolite markers", "TEST", 84, 102], ["a katG mutation", "PROBLEM", 171, 186]]], ["Additionally, metabolomics was to identify individual metabolites or metabolite profiles that could be used as biomarkers of early MAP (Mycobacterium avium subsp.", [["MAP", "GENE_OR_GENE_PRODUCT", 131, 134], ["Mycobacterium avium subsp", "GENE_OR_GENE_PRODUCT", 136, 161], ["Mycobacterium avium", "SPECIES", 136, 155], ["subsp", "SPECIES", 156, 161], ["Mycobacterium avium subsp", "SPECIES", 136, 161], ["metabolite profiles", "TEST", 69, 88], ["early MAP (Mycobacterium avium subsp", "PROBLEM", 125, 161]]], ["Paratuberculosis) infection in ruminants (De Buck et al., 2014) .INTRODUCTIONHowever, despite transcriptomics and proteomics efforts have been studied (Shiloh et al., 2008; Mishra and Sarkar, 2015; Batra et al., 2017; Martini et al., 2019) , the effect of vitamin treatment on Mtb metabolomics and gene methylation remains poorly understood.", [["Paratuberculosis) infection", "DISEASE", 0, 27], ["vitamin", "CHEMICAL", 256, 263], ["vitamin", "CHEMICAL", 256, 263], ["Paratuberculosis", "ORGANISM", 0, 16], ["vitamin", "SIMPLE_CHEMICAL", 256, 263], ["Mtb", "GENE_OR_GENE_PRODUCT", 277, 280], ["Paratuberculosis) infection", "PROBLEM", 0, 27], ["vitamin treatment", "TREATMENT", 256, 273], ["Mtb metabolomics", "TREATMENT", 277, 293], ["infection", "OBSERVATION", 18, 27]]], ["DNA methylation and transcriptional regulation are tightly related and play an important role in the epigenetics of living organisms, whereas vitamins have an anti-tuberculosis effect.", [["vitamins", "CHEMICAL", 142, 150], ["vitamins", "CHEMICAL", 142, 150], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["vitamins", "SIMPLE_CHEMICAL", 142, 150], ["DNA methylation", "PROBLEM", 0, 15], ["transcriptional regulation", "TREATMENT", 20, 46], ["living organisms", "PROBLEM", 116, 132], ["vitamins", "TREATMENT", 142, 150], ["an anti-tuberculosis effect", "TREATMENT", 156, 183], ["anti-tuberculosis", "OBSERVATION", 159, 176]]], ["These prompted us to study the methylome, transcriptome and changes in metabolism of Mycobacterium bovis BCG after V B1 and V C stimulation.Bacterial Strains and Culture ConditionsMycobacterium bovis BCG str.", [["Mycobacterium bovis", "ORGANISM", 85, 104], ["BCG", "ORGANISM", 105, 108], ["V B1", "GENE_OR_GENE_PRODUCT", 115, 119], ["V C", "GENE_OR_GENE_PRODUCT", 124, 127], ["Mycobacterium bovis", "ORGANISM", 180, 199], ["Mycobacterium bovis", "SPECIES", 85, 104], ["Mycobacterium bovis", "SPECIES", 180, 199], ["BCG", "SPECIES", 200, 203], ["Mycobacterium bovis", "SPECIES", 85, 104], ["Mycobacterium bovis BCG str", "SPECIES", 180, 207], ["Mycobacterium bovis BCG", "TREATMENT", 85, 108], ["V C stimulation", "TREATMENT", 124, 139], ["Bacterial Strains", "PROBLEM", 140, 157], ["Culture Conditions", "TEST", 162, 180], ["Mycobacterium bovis BCG str", "PROBLEM", 180, 207], ["Mycobacterium bovis", "OBSERVATION", 85, 104], ["Strains", "OBSERVATION", 150, 157]]], ["Tokyo 172 strain was grown in Middlebrook 7H9 medium Becton Dickinson, supplemented with 0.05% Tween-80 (v/v), 10% ADC (Albumin-Dextrose-Catalase, BD) and 0.2% (v/v) glycerol.", [["glycerol", "CHEMICAL", 166, 174], ["Tween-80", "CHEMICAL", 95, 103], ["glycerol", "CHEMICAL", 166, 174], ["ADC", "SIMPLE_CHEMICAL", 115, 118], ["Albumin-Dextrose-Catalase", "SIMPLE_CHEMICAL", 120, 145], ["BD", "SIMPLE_CHEMICAL", 147, 149], ["v/v) glycerol", "SIMPLE_CHEMICAL", 161, 174], ["Catalase", "PROTEIN", 137, 145], ["Albumin", "TEST", 120, 127], ["Dextrose-Catalase, BD)", "TREATMENT", 128, 150], ["glycerol", "TREATMENT", 166, 174]]], ["When OD 600 nm reached 0.3, V B1 and V C were added with final concentrations of 8 and 5 mM, respectively.", [["V C", "GENE_OR_GENE_PRODUCT", 37, 40], ["V C", "PROTEIN", 37, 40], ["V B1 and V C", "TEST", 28, 40]]], ["Different concentrations (0, 1, 2, and 4 mM) of cysteine were used to test the effect for BCG growth.Genomic DNA Extraction and SMRT SequencingBCG pellets were collected by centrifugation and suspended with lysis buffer (20 mM Tris\u00b7Cl, pH 8.0; 2 mM sodium EDTA; 1.2% Triton R X-100, 20 mg/mL lysozyme).", [["cysteine", "CHEMICAL", 48, 56], ["sodium EDTA", "CHEMICAL", 249, 260], ["Triton R X-100", "CHEMICAL", 267, 281], ["cysteine", "CHEMICAL", 48, 56], ["Tris\u00b7Cl", "CHEMICAL", 227, 234], ["sodium EDTA", "CHEMICAL", 249, 260], ["cysteine", "AMINO_ACID", 48, 56], ["DNA", "CELLULAR_COMPONENT", 109, 112], ["Tris\u00b7Cl", "SIMPLE_CHEMICAL", 227, 234], ["sodium EDTA", "SIMPLE_CHEMICAL", 249, 260], ["Triton R X-100", "SIMPLE_CHEMICAL", 267, 281], ["SMRT", "PROTEIN", 128, 132], ["cysteine", "TREATMENT", 48, 56], ["BCG growth", "PROBLEM", 90, 100], ["Genomic DNA Extraction", "TREATMENT", 101, 123], ["SMRT SequencingBCG pellets", "TREATMENT", 128, 154], ["lysis buffer", "TREATMENT", 207, 219], ["Tris\u00b7Cl", "TEST", 227, 234], ["pH", "TEST", 236, 238], ["2 mM sodium EDTA", "TREATMENT", 244, 260], ["concentrations", "OBSERVATION_MODIFIER", 10, 24]]], ["These samples were then sonicated for 5 min and incubated at 37 \u2022 C for 1 h.", [["samples", "ANATOMY", 6, 13]]], ["RNase was added to the sonicated samples and incubated for 5 min at room temperature, followed by protease K addition, according to manufacturer instructions (TIANamp Bacteria DNA Kit protocol, Tiangen Biotech, Beijing, China).", [["samples", "ANATOMY", 33, 40], ["K", "CHEMICAL", 107, 108], ["RNase", "GENE_OR_GENE_PRODUCT", 0, 5], ["RNase", "PROTEIN", 0, 5], ["RNase", "TREATMENT", 0, 5]]], ["The concentration of DNA samples was determined using a NanoDrop ND-2000 spectrophotometer.", [["samples", "ANATOMY", 25, 32], ["DNA", "CELLULAR_COMPONENT", 21, 24], ["DNA samples", "TEST", 21, 32], ["a NanoDrop ND-2000 spectrophotometer", "TREATMENT", 54, 90]]], ["The extracted genomic DNA from BCG was sequenced using the Pacific Biosciences RSII DNA sequencing system (Pacific Biosciences, Menlo Park, CA, United States).", [["DNA", "CELLULAR_COMPONENT", 22, 25], ["genomic DNA", "DNA", 14, 25], ["The extracted genomic DNA", "PROBLEM", 0, 25], ["BCG", "PROBLEM", 31, 34], ["genomic DNA", "OBSERVATION", 14, 25]]], ["A 10-kb SMRTbell library was prepared from sheared genomic DNA (>5 g) using a 10-kb template library preparation workflow, according to the manufacturer.", [["DNA", "CELLULAR_COMPONENT", 59, 62], ["10-kb SMRTbell library", "DNA", 2, 24], ["sheared genomic DNA", "DNA", 43, 62], ["A 10-kb SMRTbell library", "TREATMENT", 0, 24], ["a 10-kb template library preparation workflow", "TREATMENT", 76, 121]]], ["One SMRT cell was used for each sequencing.Bioinformatic Analyses of SMRT Sequencing DataDe novo assembly of the insert reads was performed with the Hierarchical Genome Assembly Process (HGAP.3) algorithm in the SMRT Portal (version 2.2.0).", [["SMRT cell", "ANATOMY", 4, 13], ["SMRT cell", "CELL", 4, 13], ["SMRT", "GENE_OR_GENE_PRODUCT", 69, 73], ["SMRT cell", "CELL_LINE", 4, 13], ["SMRT", "PROTEIN", 69, 73], ["HGAP", "DNA", 187, 191], ["SMRT", "PROTEIN", 212, 216], ["One SMRT cell", "PROBLEM", 0, 13], ["Bioinformatic Analyses", "TEST", 43, 65], ["the insert reads", "TEST", 109, 125], ["algorithm", "TEST", 195, 204], ["SMRT cell", "OBSERVATION", 4, 13], ["Portal", "ANATOMY", 217, 223]]], ["Circularization was achieved by manual comparison and removal of an overlap region.", [["Circularization", "TREATMENT", 0, 15], ["removal", "TREATMENT", 54, 61], ["an overlap region", "TREATMENT", 65, 82], ["overlap", "OBSERVATION", 68, 75]]], ["The final genome was confirmed by remapping of sequence data.", [["sequence data", "TEST", 47, 60]]], ["Promoter regions were analyzed using the Neural Network Promoter Prediction tool 1 and PePPER 2 .Bioinformatic Analyses of SMRT Sequencing DataGenome-wide detection of base modification and sequence motifs was performed using the standard settings (QV of modified motifs are more than 30) in the protocol 'RS Modification and Motif Analysis.1' included in the SMRT Portal version 2.2.0.", [["SMRT", "GENE_OR_GENE_PRODUCT", 123, 127], ["Promoter regions", "DNA", 0, 16], ["PePPER 2", "DNA", 87, 95], ["SMRT", "PROTEIN", 123, 127], ["SMRT", "PROTEIN", 360, 364], ["Bioinformatic Analyses", "TEST", 97, 119], ["SMRT Sequencing", "TEST", 123, 138], ["DataGenome", "TEST", 139, 149], ["base modification", "TREATMENT", 168, 185], ["sequence motifs", "TEST", 190, 205], ["QV of modified motifs", "TREATMENT", 249, 270], ["Motif Analysis", "TEST", 326, 340], ["Portal", "ANATOMY", 365, 371]]], ["'Motif score' = (number of detections matching motif)/(number of genome sites matching motif) \u00d7 (sum of log-p value of detections matching motif) = (fraction methylated) \u00d7 (sum of log-p values of matches).", [["genome sites", "DNA", 65, 77]]], ["The SMRT Portal searches (close to maximize) through of all possible motifs, progressively testing longer motifs using a branch-and-bound search.", [["SMRT", "GENE_OR_GENE_PRODUCT", 4, 8], ["SMRT", "PROTEIN", 4, 8], ["The SMRT Portal searches", "TEST", 0, 24], ["Portal", "ANATOMY", 9, 15], ["branch", "OBSERVATION_MODIFIER", 121, 127]]], ["The minimal term 'motif score' and 'fraction methylated' parameters were 40 and less than 1, respectively.LC-MS Based Metabolomic AnalysisThe BCG strains cultured with 7H9 medium in the absence and/or presence of V B1 and V C were collected after 48 h incubation at 37 \u2022 C. The 60 mg pellets were collected by centrifugation and the supernatant were removed, the metabolites are measured by LC-MS as described (Song et al., 2019) .", [["supernatant", "ANATOMY", 333, 344], ["V B1", "GENE_OR_GENE_PRODUCT", 213, 217], ["V C", "GENE_OR_GENE_PRODUCT", 222, 225], ["V B1", "PROTEIN", 213, 217], ["V C", "PROTEIN", 222, 225], ["'fraction methylated' parameters", "TEST", 35, 67], ["LC", "TEST", 106, 108], ["Metabolomic Analysis", "TEST", 118, 138], ["The BCG strains", "TEST", 138, 153], ["V B1 and V C", "PROBLEM", 213, 225], ["minimal", "OBSERVATION_MODIFIER", 4, 11]]], ["Collected bacteria were ground and dissolved in an aqueous methanol solution (water:methanol, 1:1, v/v) at 4 \u2022 C. After membrane filtration (0.22 \u00b5m), samples were used for LC-MS detection.", [["membrane", "ANATOMY", 120, 128], ["samples", "ANATOMY", 151, 158], ["methanol", "CHEMICAL", 59, 67], ["methanol", "CHEMICAL", 84, 92], ["water", "SIMPLE_CHEMICAL", 78, 83], ["methanol", "SIMPLE_CHEMICAL", 84, 92], ["Collected bacteria", "PROBLEM", 0, 18], ["an aqueous methanol solution", "TREATMENT", 48, 76], ["methanol", "TREATMENT", 84, 92], ["v/v)", "TREATMENT", 99, 103], ["membrane filtration", "TREATMENT", 120, 139], ["LC", "TEST", 173, 175]]], ["Separation was achieved in a Shimadzu LC-30A system equipped with an ACQUITY UPLC HSS T3 (150 \u00d7 2.1 mm, 1.8 \u00b5m, Waters) column maintained at 40 \u2022 C. The temperature of the autosampler was 4 \u2022 C. Gradient elution of analytes was carried out with 0.1% formic acid in water (solvent A) and acetonitrile (solvent B) at a flow rate of 0.3 mL/min.", [["formic acid", "CHEMICAL", 250, 261], ["acetonitrile", "CHEMICAL", 287, 299], ["solvent B", "CHEMICAL", 301, 310], ["formic acid", "CHEMICAL", 250, 261], ["acetonitrile", "CHEMICAL", 287, 299], ["formic acid", "SIMPLE_CHEMICAL", 250, 261], ["water", "SIMPLE_CHEMICAL", 265, 270], ["acetonitrile", "SIMPLE_CHEMICAL", 287, 299], ["a Shimadzu LC", "TEST", 27, 40], ["an ACQUITY UPLC HSS T3", "TEST", 66, 88], ["mm", "TEST", 100, 102], ["Waters) column", "TEST", 112, 126], ["The temperature", "TEST", 149, 164], ["the autosampler", "TEST", 168, 183], ["Gradient elution of analytes", "TREATMENT", 195, 223], ["0.1% formic acid in water (solvent A", "TREATMENT", 245, 281], ["acetonitrile (solvent B", "TREATMENT", 287, 310], ["a flow rate", "TREATMENT", 315, 326]]], ["After equilibration, 5 \u00b5L of each sample were injected.", [["sample", "ANATOMY", 34, 40], ["5 \u00b5L of each sample", "TREATMENT", 21, 40]]], ["Solvent B was increased linearly as follows: 2% (0-0.5 min), from 2 to 50% (0.5-9 min), from 50 to 98% (9-12 min), 98% (12-13 min), from 98 to 2% (13-14 min), and 2% (14-15 min).LC-MS Based Metabolomic AnalysisThe ESI-MS experiments were executed on the AB 5600+ mass spectrometer with the spray voltage of 5.50 kV and \u22124.50 kV in positive and negative modes, respectively.", [["Solvent B", "CHEMICAL", 0, 9], ["Solvent B", "SIMPLE_CHEMICAL", 0, 9], ["LC", "TEST", 178, 180], ["Metabolomic Analysis", "TEST", 190, 210], ["The ESI", "TEST", 210, 217], ["the AB", "TEST", 250, 256], ["the spray voltage", "TEST", 286, 303], ["kV", "TEST", 312, 314], ["kV", "TEST", 325, 327], ["increased", "OBSERVATION_MODIFIER", 14, 23], ["linearly", "OBSERVATION_MODIFIER", 24, 32], ["negative modes", "OBSERVATION_MODIFIER", 344, 358]]], ["Gas1 and gas2 were both set at 50 psi and curtain gas was 35 psi.", [["Gas1", "GENE_OR_GENE_PRODUCT", 0, 4], ["gas2", "GENE_OR_GENE_PRODUCT", 9, 13], ["Gas1", "PROTEIN", 0, 4], ["gas2", "PROTEIN", 9, 13], ["Gas1", "TEST", 0, 4], ["gas2", "TEST", 9, 13], ["curtain gas", "TEST", 42, 53]]], ["The source temperature was 500 \u2022 C. The mass analyzer scanned over a m/z range of 100-1,500 for a full scan at a collision energy of 45 eV with dynamic exclusion.Determination of Amino AcidsThe amino acids of samples treated with V B1 and V C were detected by HR-UPLC-MS (high resolution ultra-performance liquid chromatography-mass spectrometry) as described (Song et al., 2019) .", [["samples", "ANATOMY", 209, 216], ["Amino Acids", "CHEMICAL", 179, 190], ["amino acids", "CHEMICAL", 194, 205], ["Amino Acids", "CHEMICAL", 179, 190], ["amino acids", "CHEMICAL", 194, 205], ["Amino Acids", "SIMPLE_CHEMICAL", 179, 190], ["amino acids", "AMINO_ACID", 194, 205], ["V B1", "GENE_OR_GENE_PRODUCT", 230, 234], ["V C", "GENE_OR_GENE_PRODUCT", 239, 242], ["V B1", "PROTEIN", 230, 234], ["V C", "PROTEIN", 239, 242], ["The source temperature", "TEST", 0, 22], ["The mass analyzer", "TEST", 36, 53], ["a m/z range", "TEST", 67, 78], ["a full scan", "TEST", 96, 107], ["dynamic exclusion", "TEST", 144, 161], ["Amino Acids", "TREATMENT", 179, 190], ["The amino acids", "TEST", 190, 205], ["V B1 and V C", "TREATMENT", 230, 242], ["HR", "TEST", 260, 262], ["UPLC", "TEST", 263, 267], ["MS", "TEST", 268, 270], ["high resolution ultra-performance liquid chromatography", "TREATMENT", 272, 327], ["mass spectrometry", "PROBLEM", 328, 345], ["mass", "OBSERVATION", 40, 44], ["Amino Acids", "OBSERVATION", 179, 190]]], ["Briefly, an equimolar standard mixture of 20 amino acids (i.e., glycine, L-sarcosine, L-alanine, L-valine, L-proline, Lthreonine, L-isoleucine, L-leucine, L-ornithine, L-methionine, Lhistidine, L-phenylalanine, L-arginine, L-tyrosine, L-aspartic acid, L-tryptophan, 4-aminobutyric acid, L-serine, L-lysine, L-glutamic acid) was prepared with concentrations 0.2, 0.5, 1, 2, 5, 10, 20, and 50 \u00b5g/mL.Determination of Amino AcidsPellets of bacteria (100 mg) were ground in liquid nitrogen, and amino acids were extracted with 1 mL HCl overnight.", [["amino acids", "CHEMICAL", 45, 56], ["glycine", "CHEMICAL", 64, 71], ["L-sarcosine", "CHEMICAL", 73, 84], ["L-alanine", "CHEMICAL", 86, 95], ["L-valine", "CHEMICAL", 97, 105], ["L-proline", "CHEMICAL", 107, 116], ["Lthreonine", "CHEMICAL", 118, 128], ["L-isoleucine", "CHEMICAL", 130, 142], ["L-leucine", "CHEMICAL", 144, 153], ["L-ornithine", "CHEMICAL", 155, 166], ["L-methionine", "CHEMICAL", 168, 180], ["Lhistidine", "CHEMICAL", 182, 192], ["L-phenylalanine", "CHEMICAL", 194, 209], ["L-arginine", "CHEMICAL", 211, 221], ["L-tyrosine", "CHEMICAL", 223, 233], ["L-aspartic acid, L-tryptophan, 4-aminobutyric acid", "CHEMICAL", 235, 285], ["L-serine", "CHEMICAL", 287, 295], ["L-lysine", "CHEMICAL", 297, 305], ["L-glutamic acid", "CHEMICAL", 307, 322], ["amino acids", "CHEMICAL", 490, 501], ["HCl", "CHEMICAL", 527, 530], ["amino acids", "CHEMICAL", 45, 56], ["glycine", "CHEMICAL", 64, 71], ["L-sarcosine", "CHEMICAL", 73, 84], ["L-alanine", "CHEMICAL", 86, 95], ["L-valine", "CHEMICAL", 97, 105], ["L-proline", "CHEMICAL", 107, 116], ["Lthreonine", "CHEMICAL", 118, 128], ["L-isoleucine", "CHEMICAL", 130, 142], ["L-leucine", "CHEMICAL", 144, 153], ["L-ornithine", "CHEMICAL", 155, 166], ["L-methionine", "CHEMICAL", 168, 180], ["Lhistidine", "CHEMICAL", 182, 192], ["L-phenylalanine", "CHEMICAL", 194, 209], ["L-arginine", "CHEMICAL", 211, 221], ["L-tyrosine", "CHEMICAL", 223, 233], ["L-aspartic acid", "CHEMICAL", 235, 250], ["L-tryptophan", "CHEMICAL", 252, 264], ["4-aminobutyric acid", "CHEMICAL", 266, 285], ["L-serine", "CHEMICAL", 287, 295], ["L-lysine", "CHEMICAL", 297, 305], ["L-glutamic acid", "CHEMICAL", 307, 322], ["nitrogen", "CHEMICAL", 476, 484], ["amino acids", "CHEMICAL", 490, 501], ["HCl", "CHEMICAL", 527, 530], ["amino acids", "AMINO_ACID", 45, 56], ["glycine", "SIMPLE_CHEMICAL", 64, 71], ["L-sarcosine", "SIMPLE_CHEMICAL", 73, 84], ["L-alanine", "SIMPLE_CHEMICAL", 86, 95], ["L-valine", "SIMPLE_CHEMICAL", 97, 105], ["L-proline", "SIMPLE_CHEMICAL", 107, 116], ["Lthreonine", "SIMPLE_CHEMICAL", 118, 128], ["L-isoleucine", "SIMPLE_CHEMICAL", 130, 142], ["L-leucine", "SIMPLE_CHEMICAL", 144, 153], ["L-ornithine", "SIMPLE_CHEMICAL", 155, 166], ["L-methionine", "SIMPLE_CHEMICAL", 168, 180], ["Lhistidine", "SIMPLE_CHEMICAL", 182, 192], ["L-phenylalanine", "SIMPLE_CHEMICAL", 194, 209], ["L-arginine", "SIMPLE_CHEMICAL", 211, 221], ["L-tyrosine", "SIMPLE_CHEMICAL", 223, 233], ["L-aspartic acid", "SIMPLE_CHEMICAL", 235, 250], ["L-tryptophan", "SIMPLE_CHEMICAL", 252, 264], ["4-aminobutyric acid", "SIMPLE_CHEMICAL", 266, 285], ["L-serine", "SIMPLE_CHEMICAL", 287, 295], ["L-lysine", "SIMPLE_CHEMICAL", 297, 305], ["L-glutamic acid", "SIMPLE_CHEMICAL", 307, 322], ["Amino AcidsPellets", "SIMPLE_CHEMICAL", 414, 432], ["amino acids", "AMINO_ACID", 490, 501], ["20 amino acids", "TREATMENT", 42, 56], ["glycine", "TREATMENT", 64, 71], ["sarcosine", "TREATMENT", 75, 84], ["L-alanine", "TREATMENT", 86, 95], ["L-valine", "TREATMENT", 97, 105], ["L-proline", "TREATMENT", 107, 116], ["Lthreonine", "TREATMENT", 118, 128], ["L-isoleucine", "TREATMENT", 130, 142], ["L-leucine", "TREATMENT", 144, 153], ["L-ornithine", "TREATMENT", 155, 166], ["L-methionine", "TREATMENT", 168, 180], ["Lhistidine", "TREATMENT", 182, 192], ["L-phenylalanine", "TREATMENT", 194, 209], ["L-arginine", "TREATMENT", 211, 221], ["L-tyrosine", "TREATMENT", 223, 233], ["L-aspartic acid", "TREATMENT", 235, 250], ["L-tryptophan", "TREATMENT", 252, 264], ["aminobutyric acid", "TREATMENT", 268, 285], ["L-serine, L-lysine, L-glutamic acid", "TREATMENT", 287, 322], ["Amino AcidsPellets of bacteria", "TREATMENT", 414, 444], ["liquid nitrogen", "TREATMENT", 469, 484], ["amino acids", "TREATMENT", 490, 501]]], ["The supernatant was collected by centrifugation at 12,000 rpm for 5 min.", [["supernatant", "ANATOMY", 4, 15], ["The supernatant", "TREATMENT", 0, 15]]], ["After addition of 100 \u00b5L of an internal standard, isotope-labeled amino acid (Alanine \u2212d4), the sample was dried under a moderate nitrogen gas stream.", [["sample", "ANATOMY", 96, 102], ["amino acid", "CHEMICAL", 66, 76], ["Alanine \u2212d4", "CHEMICAL", 78, 89], ["amino acid", "CHEMICAL", 66, 76], ["Alanine", "CHEMICAL", 78, 85], ["nitrogen", "CHEMICAL", 130, 138], ["amino acid", "SIMPLE_CHEMICAL", 66, 76], ["Alanine \u2212d4", "SIMPLE_CHEMICAL", 78, 89], ["isotope-labeled amino acid (Alanine \u2212d4", "TREATMENT", 50, 89], ["a moderate nitrogen gas stream", "PROBLEM", 119, 149], ["moderate", "OBSERVATION_MODIFIER", 121, 129], ["nitrogen gas", "OBSERVATION", 130, 142]]], ["A volume of 60 \u00b5L of derivatization reagent [hydrochloric acid/n-butyl alcohol (1:3, v/v)] was added into the mixture and incubated for 15 min at 65 \u2022 C, and the sample was analyzed by UPLC-MS.Determination of Amino AcidsChromatographic separation was achieved with an ACQUITY UPLC system equipped with a 1.7 \u00b5m C18 column (ACQUITY UPLC BEH, 2.1 \u00d7 100 mm, Waters) at 40 \u2022 C. Gradient elution of the analytes was implemented with solvent A (0.1% formic acid and 0.1% heptafluorobutyric acid in acetonitrile) and solvent B (0.1% formic acid in water), at a flow rate of 0.25 mL/min.", [["sample", "ANATOMY", 162, 168], ["hydrochloric acid/n-butyl alcohol", "CHEMICAL", 45, 78], ["solvent A", "CHEMICAL", 429, 438], ["formic acid", "CHEMICAL", 445, 456], ["heptafluorobutyric acid", "CHEMICAL", 466, 489], ["acetonitrile", "CHEMICAL", 493, 505], ["solvent B", "CHEMICAL", 511, 520], ["formic acid", "CHEMICAL", 527, 538], ["hydrochloric acid", "CHEMICAL", 45, 62], ["n-butyl alcohol", "CHEMICAL", 63, 78], ["formic acid", "CHEMICAL", 445, 456], ["heptafluorobutyric acid", "CHEMICAL", 466, 489], ["acetonitrile", "CHEMICAL", 493, 505], ["formic acid", "CHEMICAL", 527, 538], ["hydrochloric acid", "SIMPLE_CHEMICAL", 45, 62], ["n-butyl alcohol", "SIMPLE_CHEMICAL", 63, 78], ["v/v)", "SIMPLE_CHEMICAL", 85, 89], ["formic acid", "SIMPLE_CHEMICAL", 445, 456], ["heptafluorobutyric acid", "SIMPLE_CHEMICAL", 466, 489], ["acetonitrile", "SIMPLE_CHEMICAL", 493, 505], ["solvent B", "SIMPLE_CHEMICAL", 511, 520], ["formic acid", "SIMPLE_CHEMICAL", 527, 538], ["A volume", "TEST", 0, 8], ["derivatization reagent", "TREATMENT", 21, 43], ["hydrochloric acid", "TREATMENT", 45, 62], ["n-butyl alcohol", "TREATMENT", 63, 78], ["v/v)", "TREATMENT", 85, 89], ["Amino AcidsChromatographic separation", "TREATMENT", 210, 247], ["a 1.7 \u00b5m C18 column", "TREATMENT", 303, 322], ["BEH", "TEST", 337, 340], ["the analytes", "TREATMENT", 395, 407], ["solvent A", "TREATMENT", 429, 438], ["formic acid", "TREATMENT", 445, 456], ["heptafluorobutyric acid in acetonitrile", "TREATMENT", 466, 505], ["solvent B", "TREATMENT", 511, 520], ["formic acid in water", "TREATMENT", 527, 547], ["a flow rate", "TREATMENT", 553, 564]]], ["Five \u00b5L of sample were injected following equilibration.", [["sample", "ANATOMY", 11, 17]]], ["An increasing linear gradient of solvent A (v/v) was used as follows: 5% A (0-1.5 min); 5 to 20% A (1.5-2 min); 20 to 30% A (2-7 min); 30 to 98% A (7-8.5 min); 98% A (8.5-10.5 min); 98 to 5% A (10.5-11 min) and 5% A (11-12.5 min).Determination of Amino AcidsThe ESI source was applied in positive mode by multiple reaction monitoring (MRM).", [["Amino Acids", "CHEMICAL", 247, 258], ["Amino Acids", "CHEMICAL", 247, 258], ["Amino Acids", "SIMPLE_CHEMICAL", 247, 258], ["An increasing linear gradient", "PROBLEM", 0, 29], ["A", "TEST", 164, 165], ["Amino Acids", "TREATMENT", 247, 258], ["multiple reaction monitoring", "TEST", 305, 333], ["MRM", "TEST", 335, 338], ["increasing", "OBSERVATION_MODIFIER", 3, 13], ["linear", "OBSERVATION_MODIFIER", 14, 20], ["gradient", "OBSERVATION_MODIFIER", 21, 29], ["solvent", "OBSERVATION_MODIFIER", 33, 40]]], ["The ion source capillary voltage and cone voltage were set as 3,200 and 20 V, respectively, and the desolvation temperature was set at 380 \u2022 C.RNA Extraction and Library ConstructionSince methylation and transcriptomics are both ways of studying epigenetics and they have the close relationship, to further investigate how V B1 and V C treatment affect BCG growth, RNA-seq was used to compare the transcriptome of the three replicates of each BCG sample (V B1 -treated, V C -treated and control).", [["capillary", "ANATOMY", 15, 24], ["sample", "ANATOMY", 447, 453], ["capillary", "TISSUE", 15, 24], ["V B1", "GENE_OR_GENE_PRODUCT", 323, 327], ["V C", "GENE_OR_GENE_PRODUCT", 332, 335], ["V C", "SIMPLE_CHEMICAL", 470, 473], ["V B1", "PROTEIN", 323, 327], ["V C", "PROTEIN", 332, 335], ["The ion source capillary voltage", "TEST", 0, 32], ["cone voltage", "TEST", 37, 49], ["the desolvation temperature", "TEST", 96, 123], ["Extraction", "TREATMENT", 147, 157], ["methylation and transcriptomics", "TREATMENT", 188, 219], ["V C treatment", "TREATMENT", 332, 345], ["BCG growth", "TEST", 353, 363], ["RNA", "TEST", 365, 368], ["each BCG sample", "TEST", 438, 453], ["B1", "TEST", 457, 459], ["V C", "TREATMENT", 470, 473], ["capillary voltage", "OBSERVATION", 15, 32]]], ["RNA-seq was performed as described (Song et al., 2019) on three replicates of bacteria treated with V B1 and V C .", [["V C", "GENE_OR_GENE_PRODUCT", 109, 112], ["RNA-seq", "TEST", 0, 7], ["bacteria", "PROBLEM", 78, 86], ["V B1 and V C", "TREATMENT", 100, 112], ["bacteria", "OBSERVATION", 78, 86]]], ["Cell pellets were lysed and homogenized by high-speed agitation in a bead mill in presence of glass beads and lysis buffer.", [["Cell", "ANATOMY", 0, 4], ["agitation", "DISEASE", 54, 63], ["Cell", "CELL", 0, 4], ["Cell pellets", "TEST", 0, 12], ["high-speed agitation", "PROBLEM", 43, 63], ["glass beads", "TREATMENT", 94, 105], ["lysis buffer", "TREATMENT", 110, 122], ["glass beads", "OBSERVATION", 94, 105]]], ["Total RNA was extracted using RNeasy Mini Kit (Qiagen) according to the instructions with one on-column DNase I treatment (Qiagen) at 37 \u2022 C for 30 min, in order to remove any contaminating genomic DNA.", [["DNA", "CELLULAR_COMPONENT", 198, 201], ["DNase I", "PROTEIN", 104, 111], ["genomic DNA", "DNA", 190, 201], ["Total RNA", "TREATMENT", 0, 9], ["RNeasy Mini Kit (Qiagen)", "TREATMENT", 30, 54], ["one on-column DNase I treatment (Qiagen)", "TREATMENT", 90, 130], ["any contaminating genomic DNA", "PROBLEM", 172, 201]]], ["DNase I was removed with RNeasy mini kit, according to the clean-up procedure (Song et al., 2019) .", [["DNase I", "GENE_OR_GENE_PRODUCT", 0, 7], ["DNase I", "PROTEIN", 0, 7], ["the clean-up procedure", "TREATMENT", 55, 77]]], ["The RNA integrity number (RIN) was used to inspect RNA integrity by an Agilent Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA, United States).", [["RNA integrity", "OBSERVATION_MODIFIER", 4, 17]]], ["The concentration of RNA samples was determined with a NanoDrop ND-2000 spectrophotometer.", [["samples", "ANATOMY", 25, 32], ["RNA samples", "TEST", 21, 32], ["a NanoDrop ND", "TREATMENT", 53, 66]]], ["The strand-specific library was constructed using TruSeq R Stranded Total RNA Sample Preparation kit (Illumina, United States).", [["TruSeq R Stranded Total RNA Sample Preparation", "TREATMENT", 50, 96]]], ["The ribosomal RNA was removed and the RNA fragments were cleaved, whereas the first and second strand cDNA were synthesized.", [["ribosomal", "ANATOMY", 4, 13], ["ribosomal", "CELLULAR_COMPONENT", 4, 13], ["ribosomal RNA", "RNA", 4, 17], ["RNA fragments", "DNA", 38, 51], ["first and second strand cDNA", "DNA", 78, 106], ["The ribosomal RNA", "TREATMENT", 0, 17], ["the RNA fragments", "PROBLEM", 34, 51], ["second strand cDNA", "TREATMENT", 88, 106], ["ribosomal RNA", "OBSERVATION", 4, 17], ["RNA fragments", "OBSERVATION", 38, 51]]], ["A single ' A' nucleotide was added to the 3 ends of the blunt DNA fragments with repaired ends, and subsequently connected with adapters.", [["fragments", "ANATOMY", 66, 75], ["nucleotide", "CHEMICAL", 14, 24], ["nucleotide", "CHEMICAL", 14, 24], ["DNA", "CELLULAR_COMPONENT", 62, 65], ["blunt DNA fragments", "DNA", 56, 75], ["A' nucleotide", "TREATMENT", 11, 24], ["the blunt DNA fragments", "PROBLEM", 52, 75], ["repaired ends", "TREATMENT", 81, 94], ["blunt", "OBSERVATION_MODIFIER", 56, 61], ["DNA fragments", "OBSERVATION", 62, 75], ["repaired", "OBSERVATION", 81, 89], ["ends", "OBSERVATION_MODIFIER", 90, 94]]], ["The purified libraries were quantified using Qubit R 2.0 Fluorometer (Life Technologies, United States) and validated by Agilent 2100 bioanalyzer (Agilent Technologies, United States), in order to measure concentration and confirm insert size.", [["The purified libraries", "TREATMENT", 0, 22], ["Qubit R 2.0 Fluorometer (Life Technologies", "TREATMENT", 45, 87], ["size", "OBSERVATION_MODIFIER", 238, 242]]], ["The cluster was generated by cBot, and RNA sequencing was performed using a 150 bp pair-end strategy with the Illumina Hiseq X10 platform (Illumina, United States) to generate three billion bases per sample.", [["cBot", "DNA", 29, 33], ["Illumina Hiseq X10 platform", "DNA", 110, 137], ["RNA sequencing", "TEST", 39, 53], ["a 150 bp pair-end strategy", "TREATMENT", 74, 100], ["the Illumina Hiseq", "TREATMENT", 106, 124]]], ["Thereafter, raw data was acquired, followed by pretreatment using Septk1.", [["Septk1", "GENE_OR_GENE_PRODUCT", 66, 72], ["Septk1", "PROTEIN", 66, 72], ["Septk1", "TREATMENT", 66, 72]]], ["The read length was > 90 nt.", [["The read length", "TEST", 0, 15]]], ["The clean reads were mapped to the Mycobacterium bovis BCG str.", [["Mycobacterium bovis", "ORGANISM", 35, 54], ["Mycobacterium bovis BCG str", "PROTEIN", 35, 62], ["Mycobacterium bovis BCG", "SPECIES", 35, 58], ["Mycobacterium bovis BCG str", "SPECIES", 35, 62], ["the Mycobacterium bovis BCG str", "TREATMENT", 31, 62], ["clean", "OBSERVATION", 4, 9]]], ["Tokyo 172 genome using Bowtie2 (Langmead and Salzberg, 2012) .", [["Tokyo 172 genome", "DNA", 0, 16]]], ["Differential expression analysis was performed using edgeR package (Robinson et al., 2010) .", [["Differential expression analysis", "TEST", 0, 32]]], ["Differentially expressed genes were defined as experiencing more than a 2-fold change and a FDR (false discovery rate) of less than 0.05.RNA Extraction and Library ConstructionEnrichment of KEGG pathways for a given gene list was calculated using a classical hypergeometric distribution statistical comparison of a query gene list against a reference gene list.", [["reference gene list", "DNA", 341, 360], ["a 2-fold change", "PROBLEM", 70, 85], ["a FDR", "TEST", 90, 95], ["false discovery rate", "TEST", 97, 117], ["RNA Extraction", "TREATMENT", 137, 151]]], ["The calculated p-value was FDR-corrected, and the corrected p-value < 0.05 was used as a threshold.", [["The calculated p-value", "TEST", 0, 22], ["FDR", "TEST", 27, 30], ["the corrected p-value", "TEST", 46, 67]]], ["KEGG pathways fulfilling this condition were defined as significantly enriched in regulated genes.RNA Extraction and Library ConstructionThe raw data was deposited in the GEO repository, under accession numbers GSE114949 (V B1 -treated) and GSE141513 (V C -treated).Statistical AnalysisThe experiments were performed at least in biological triplicate and the results are presented as the mean \u00b1 standard deviation (SD).", [["GSE114949", "CHEMICAL", 211, 220], ["GSE141513", "CHEMICAL", 241, 250], ["GSE141513", "SIMPLE_CHEMICAL", 241, 250], ["regulated genes", "DNA", 82, 97], ["KEGG pathways", "TEST", 0, 13], ["RNA Extraction", "TREATMENT", 98, 112], ["GSE", "TEST", 211, 214], ["B1", "TEST", 224, 226], ["GSE", "TEST", 241, 244], ["V C", "TEST", 252, 255], ["Statistical Analysis", "TEST", 266, 286], ["regulated genes", "OBSERVATION", 82, 97]]], ["Values were considered to be statistically significant when P-value was <0.05 and the statistical significance of the observed differences was assessed with one way analysis of variance (oneway ANOVA).DNA Methylome AnalysisSince the CFU counting of BCG is similar after V B1 (8 mM) and V C (5 mM) treatment for 48 h and the differentiation continues comparing with the control group (Figure 1) , all the omics studies were performed with final concentration of 8 mM for V B1 and 5 mM for Vc.", [["DNA", "CELLULAR_COMPONENT", 201, 204], ["V C", "SIMPLE_CHEMICAL", 286, 289], ["P-value", "TEST", 60, 67], ["the CFU counting", "TEST", 229, 245], ["BCG", "TEST", 249, 252], ["V C (5 mM) treatment", "TREATMENT", 286, 306], ["all the omics studies", "TEST", 396, 417]]], ["SMRT sequencing was used to determine the genome-wide distribution of methylated bases in V C -treated, V B1 -treated and control BCG.", [["SMRT", "GENE_OR_GENE_PRODUCT", 0, 4], ["V C", "SIMPLE_CHEMICAL", 90, 93], ["V B1", "SIMPLE_CHEMICAL", 104, 108], ["SMRT", "PROTEIN", 0, 4], ["SMRT sequencing", "TEST", 0, 15], ["methylated bases in V C", "PROBLEM", 70, 93], ["V B1", "TREATMENT", 104, 108], ["methylated bases", "OBSERVATION", 70, 86]]], ["The average sequencing coverage was 363-531X (Supplementary Table 1) .", [["The average sequencing coverage", "TREATMENT", 0, 31]]], ["Analysis of the SMRT-sequenced data detected N 6 -methyladenine (m6A) in the three samples, whereas m4C sites, 5,317, were only detected in the Vc-treated BCG sample (Supplementary Table 2 ).Distribution of m6A LociIn total, 5,191 m6A sites were detected in the three BCG samples and 4,641 of them (89.4%) were common to all three, with 19, 20, and 11 unique sites in V B1 -treated, V C -treated and control BCG samples, respectively (Supplementary Figure 1) .", [["samples", "ANATOMY", 83, 90], ["samples", "ANATOMY", 272, 279], ["samples", "ANATOMY", 412, 419], ["N 6 -methyladenine", "CHEMICAL", 45, 63], ["N 6 -methyladenine", "CHEMICAL", 45, 63], ["SMRT", "GENE_OR_GENE_PRODUCT", 16, 20], ["N 6 -methyladenine", "SIMPLE_CHEMICAL", 45, 63], ["m6A", "GENE_OR_GENE_PRODUCT", 65, 68], ["m4C", "GENE_OR_GENE_PRODUCT", 100, 103], ["m6A", "GENE_OR_GENE_PRODUCT", 207, 210], ["m6A", "GENE_OR_GENE_PRODUCT", 231, 234], ["V C", "SIMPLE_CHEMICAL", 383, 386], ["SMRT", "PROTEIN", 16, 20], ["m4C sites", "DNA", 100, 109], ["5,191 m6A sites", "DNA", 225, 240], ["the SMRT", "TEST", 12, 20], ["sequenced data", "TEST", 21, 35], ["m6A sites", "TREATMENT", 231, 240], ["V C", "TREATMENT", 383, 386], ["BCG samples", "TEST", 408, 419], ["m6A LociIn", "OBSERVATION", 207, 217]]], ["Five m6A sequence motifs were detected (Supplementary Table 3) .", [["m6A sequence motifs", "DNA", 5, 24], ["Five m6A sequence motifs", "TEST", 0, 24]]], ["The CTCCAG/CTGGAG motif represented in approximately 74% of them (1,931) and was distributed randomly across the genome.", [["CTCCAG", "GENE_OR_GENE_PRODUCT", 4, 10], ["CTCCAG/CTGGAG motif", "DNA", 4, 23], ["The CTCCAG/CTGGAG motif", "TEST", 0, 23]]], ["A total of 3,756 adenines in this motif (97.3%) were methylated in the three BCG samples, suggesting that this motif has a protective role.", [["samples", "ANATOMY", 81, 88], ["adenines", "CHEMICAL", 17, 25], ["adenines", "CHEMICAL", 17, 25], ["A total of 3,756 adenines", "TREATMENT", 0, 25], ["this motif", "TEST", 29, 39]]], ["A total of 1,784 protein coding sequences (CDS) were affected by m6A, accounting for 42.6% of BCG genes.", [["m6A", "GENE_OR_GENE_PRODUCT", 65, 68], ["1,784 protein coding sequences", "DNA", 11, 41], ["CDS", "DNA", 43, 46], ["m6A", "DNA", 65, 68], ["BCG genes", "DNA", 94, 103]]], ["Enrichment analysis revealed that important pathways involved in metabolism, cellular processes and environmental information processing were significantly affected by m6A (FDR < 0.05, Supplementary Table 4) .", [["cellular", "ANATOMY", 77, 85], ["cellular", "CELL", 77, 85], ["Enrichment analysis", "TEST", 0, 19], ["FDR", "TEST", 173, 176]]], ["COG class enrichment analysis also revealed that m6A was present in genes participating in cell envelope biogenesis and outer membrane, also suggesting that the m6A modification has a protective role.", [["cell", "ANATOMY", 91, 95], ["outer membrane", "ANATOMY", 120, 134], ["m6A", "GENE_OR_GENE_PRODUCT", 49, 52], ["cell envelope", "CELLULAR_COMPONENT", 91, 104], ["outer membrane", "CELLULAR_COMPONENT", 120, 134], ["m6A", "GENE_OR_GENE_PRODUCT", 161, 164], ["m6A", "DNA", 49, 52], ["m6A", "PROTEIN", 161, 164], ["COG class enrichment analysis", "TEST", 0, 29], ["cell", "OBSERVATION", 91, 95], ["envelope biogenesis", "OBSERVATION", 96, 115], ["outer membrane", "OBSERVATION_MODIFIER", 120, 134]]], ["In contrast, un-methylated genes (i.e., those that did not have m6A or m4C modifications) were enriched in pathways Ribosome and Translation, Membrane transport, and Metabolism of cofactors and vitamins (Supplementary Table 5 ).", [["vitamins", "CHEMICAL", 194, 202], ["m6A", "GENE_OR_GENE_PRODUCT", 64, 67], ["m4C", "GENE_OR_GENE_PRODUCT", 71, 74], ["Membrane", "CELLULAR_COMPONENT", 142, 150], ["vitamins", "SIMPLE_CHEMICAL", 194, 202], ["un-methylated genes", "DNA", 13, 32], ["m6A", "DNA", 64, 67], ["m4C", "DNA", 71, 74], ["m4C modifications", "TREATMENT", 71, 88], ["Membrane transport", "TREATMENT", 142, 160], ["cofactors and vitamins (Supplementary Table", "TREATMENT", 180, 223]]], ["COG class enrichment analysis also revealed abundant unmethylated genes with unknown biological function.Distribution of m4C LociSurprisingly, m4C was observed only in samples treated with V C , with 5,317 m4C sites in three motifs (Supplementary Table 3) .", [["samples", "ANATOMY", 168, 175], ["m4C", "GENE_OR_GENE_PRODUCT", 121, 124], ["m4C", "GENE_OR_GENE_PRODUCT", 143, 146], ["V C", "GENE_OR_GENE_PRODUCT", 189, 192], ["unmethylated genes", "DNA", 53, 71], ["m4C", "DNA", 121, 124], ["m4C", "DNA", 143, 146], ["5,317 m4C sites", "DNA", 200, 215], ["COG class enrichment analysis", "TEST", 0, 29], ["abundant unmethylated genes", "PROBLEM", 44, 71], ["V C", "TREATMENT", 189, 192], ["abundant", "OBSERVATION_MODIFIER", 44, 52], ["unmethylated genes", "OBSERVATION", 53, 71], ["biological function", "OBSERVATION", 85, 104]]], ["2,374 CDSs were affected by m4C, accounting for 56.7% of BCG genes.", [["BCG genes", "DNA", 57, 66], ["CDSs", "TEST", 6, 10]]], ["Among these, 1,221 CDSs were also methylated at adenine sites (i.e., 69.1% of the 1,767 m6A modified genes).", [["adenine", "CHEMICAL", 48, 55], ["adenine", "CHEMICAL", 48, 55], ["adenine", "SIMPLE_CHEMICAL", 48, 55], ["1,221 CDSs", "DNA", 13, 23], ["adenine sites", "DNA", 48, 61], ["1,767 m6A modified genes", "DNA", 82, 106]]], ["Enrichment analysis revealed that m4C modification mainly affected genes involved in amino acid metabolism, cell envelope biogenesis and outer membrane (FDR < 0.05, Supplementary Table 6 ).", [["cell", "ANATOMY", 108, 112], ["outer membrane", "ANATOMY", 137, 151], ["amino acid", "CHEMICAL", 85, 95], ["amino acid", "CHEMICAL", 85, 95], ["m4C", "GENE_OR_GENE_PRODUCT", 34, 37], ["amino acid", "AMINO_ACID", 85, 95], ["cell envelope", "CELLULAR_COMPONENT", 108, 121], ["outer membrane", "CELLULAR_COMPONENT", 137, 151], ["m4C", "DNA", 34, 37], ["Enrichment analysis", "TEST", 0, 19], ["m4C modification", "PROBLEM", 34, 50], ["amino acid metabolism", "TEST", 85, 106], ["cell envelope biogenesis", "TEST", 108, 132], ["outer membrane (FDR", "TEST", 137, 156], ["outer", "ANATOMY_MODIFIER", 137, 142], ["membrane", "ANATOMY_MODIFIER", 143, 151]]], ["This suggests that, since V C treatment hampers BCG growth, genes involved in cell envelope biogenesis become more protected.Presence of m6A and m4C in Intergenic Regions (IGRs)In eukaryotes, promoter methylation has been suggested to inhibit gene expression.", [["cell", "ANATOMY", 78, 82], ["V C", "GENE_OR_GENE_PRODUCT", 26, 29], ["cell", "CELL", 78, 82], ["m6A", "GENE_OR_GENE_PRODUCT", 137, 140], ["m4C", "GENE_OR_GENE_PRODUCT", 145, 148], ["m6A", "DNA", 137, 140], ["m4C", "DNA", 145, 148], ["Intergenic Regions", "DNA", 152, 170], ["IGRs", "DNA", 172, 176], ["V C treatment", "TREATMENT", 26, 39], ["BCG growth", "PROBLEM", 48, 58], ["m6A and m4C in Intergenic Regions", "PROBLEM", 137, 170], ["promoter methylation", "TREATMENT", 192, 212], ["m6A", "OBSERVATION", 137, 140], ["Intergenic", "OBSERVATION_MODIFIER", 152, 162]]], ["Our analysis discovered 4,781 m6A sites located in CDSs, and 410 (7.9%) in IGRs.", [["m6A sites", "ANATOMY", 30, 39], ["IGRs", "PATHOLOGICAL_FORMATION", 75, 79], ["m6A sites", "DNA", 30, 39], ["CDSs", "DNA", 51, 55], ["Our analysis", "TEST", 0, 12], ["CDSs", "TEST", 51, 55]]], ["Since the promoter regions in bacteria are usually located within 100 bp upstream of the start codon (Heyden et al., 1975; Chen et al., 2010) , we calculated the distance between the methylation sites and the downstream start codon.", [["promoter regions", "DNA", 10, 26], ["100 bp upstream", "DNA", 66, 81], ["start codon", "DNA", 89, 100], ["methylation sites", "DNA", 183, 200], ["downstream start codon", "DNA", 209, 231], ["bacteria", "PROBLEM", 30, 38], ["the methylation sites", "TREATMENT", 179, 200], ["bacteria", "OBSERVATION_MODIFIER", 30, 38]]], ["Only m6A modifications located within 200 bp upstream of the start codon were assumed to affect genes.", [["m6A", "GENE_OR_GENE_PRODUCT", 5, 8], ["m6A modifications", "DNA", 5, 22], ["200 bp upstream", "DNA", 38, 53], ["start codon", "DNA", 61, 72], ["m6A modifications", "TREATMENT", 5, 22]]], ["In this way, only 143 out of the 410 m6A sites in IGRs probably affected the promoters of 138 genes (Supplementary Table 12) .", [["m6A", "GENE_OR_GENE_PRODUCT", 37, 40], ["IGRs", "PATHOLOGICAL_FORMATION", 50, 54], ["410 m6A sites", "DNA", 33, 46], ["IGRs", "DNA", 50, 54], ["promoters", "DNA", 77, 86], ["138 genes", "DNA", 90, 99]]], ["In BCG treated with V C , 423 m4C were located in IGRs, where 142 affected promoters of 140 genes (Supplementary Table 12) .", [["V C", "GENE_OR_GENE_PRODUCT", 20, 23], ["m4C", "GENE_OR_GENE_PRODUCT", 30, 33], ["IGRs", "PATHOLOGICAL_FORMATION", 50, 54], ["IGRs", "DNA", 50, 54], ["promoters", "DNA", 75, 84], ["140 genes", "DNA", 88, 97], ["V C", "TREATMENT", 20, 23]]], ["Further analysis revealed a relative enrichment of m6A at positions in the range \u2212180 to \u2212200 bp (Figure 2A ) that was less evident for the m4C sites ( Figure 2B ).The Transcriptome of BCGTo investigate how V B1 and V C treatment affects BCG growth, RNA-seq was used to compare the transcriptome of the three replicates of each BCG sample (V B1 -treated, V C -treated and control).", [["m4C sites", "ANATOMY", 140, 149], ["sample", "ANATOMY", 332, 338], ["m6A", "GENE_OR_GENE_PRODUCT", 51, 54], ["V B1", "GENE_OR_GENE_PRODUCT", 207, 211], ["V C", "GENE_OR_GENE_PRODUCT", 216, 219], ["V C", "SIMPLE_CHEMICAL", 355, 358], ["m6A", "PROTEIN", 51, 54], ["m4C sites", "DNA", 140, 149], ["V B1", "PROTEIN", 207, 211], ["V C", "PROTEIN", 216, 219], ["Further analysis", "TEST", 0, 16], ["bp", "TEST", 94, 96], ["V C treatment", "TREATMENT", 216, 229], ["BCG growth", "TEST", 238, 248], ["RNA", "TEST", 250, 253], ["each BCG sample", "TEST", 323, 338], ["B1", "TEST", 342, 344], ["V C", "TREATMENT", 355, 358], ["relative", "OBSERVATION_MODIFIER", 28, 36], ["enrichment", "OBSERVATION", 37, 47]]], ["The mean FPKM (Fragments Per Kilo bases per Million reads) was 274.4 for V B1 -treated BCG (282.5 for control) and 289.4 for Vc-treated BCG (281.9 for control).", [["V B1", "PROTEIN", 73, 77], ["V B1", "TEST", 73, 77], ["BCG", "TEST", 87, 90], ["Vc", "TEST", 125, 127], ["BCG", "TEST", 136, 139]]], ["A total of 260 genes were regulated in V B1 -treated BCG, and 278 in Vc-treated BCG (Figure 3) .", [["V B1", "GENE_OR_GENE_PRODUCT", 39, 43], ["V B1", "PROTEIN", 39, 43], ["Vc", "TEST", 69, 71]]], ["Of these, more down-regulated genes were found for V B1 -treated BCG, which were enriched in pathways like Nitrogen metabolism and Two-component system (Supplementary Table 7 ).", [["Nitrogen", "CHEMICAL", 107, 115], ["Nitrogen", "CHEMICAL", 107, 115], ["V B1", "GENE_OR_GENE_PRODUCT", 51, 55], ["Nitrogen", "SIMPLE_CHEMICAL", 107, 115], ["V B1", "PROTEIN", 51, 55], ["V B1 -treated BCG", "PROBLEM", 51, 68], ["Nitrogen metabolism", "TEST", 107, 126], ["Nitrogen metabolism", "OBSERVATION", 107, 126]]], ["In contrast, V C -treated BCG showed more up-regulated genes involved in replication and repair.", [["V C", "SIMPLE_CHEMICAL", 13, 16], ["V C", "PROTEIN", 13, 16], ["V C", "TEST", 13, 16], ["BCG", "TEST", 26, 29], ["repair", "TREATMENT", 89, 95], ["repair", "OBSERVATION", 89, 95]]], ["In the Vc-treated BCG samples, lower expression was found in genes involved in energy metabolism.", [["samples", "ANATOMY", 22, 29], ["Vc", "SIMPLE_CHEMICAL", 7, 9], ["BCG samples", "TEST", 18, 29], ["lower expression", "PROBLEM", 31, 47], ["energy metabolism", "OBSERVATION", 79, 96]]], ["In addition, we note that expression of genes involved in biosynthesis of siderophore group non-ribosomal peptides was inhibited by V B1 , but stimulated by V C (Supplementary Table 7) .", [["V B1", "GENE_OR_GENE_PRODUCT", 132, 136], ["V B1", "PROTEIN", 132, 136], ["biosynthesis of siderophore group non-ribosomal peptides", "TREATMENT", 58, 114]]], ["The same pattern was observed for another six genes, with two of them (mycobactin polyketide synthetase gene MbtB and MbtC) participating in this pathway.DNA Methylation and RNA ExpressionTo investigate the relationship between gene methylation and gene expression, we analyzed the methylation changes in significantly regulated genes.", [["mycobactin polyketide synthetase", "GENE_OR_GENE_PRODUCT", 71, 103], ["MbtB", "GENE_OR_GENE_PRODUCT", 109, 113], ["MbtC", "GENE_OR_GENE_PRODUCT", 118, 122], ["DNA", "CELLULAR_COMPONENT", 154, 157], ["mycobactin polyketide synthetase gene", "DNA", 71, 108], ["MbtB", "DNA", 109, 113], ["MbtC", "PROTEIN", 118, 122], ["regulated genes", "DNA", 319, 334], ["them (mycobactin polyketide synthetase gene MbtB", "TREATMENT", 65, 113], ["DNA Methylation", "TREATMENT", 154, 169], ["gene methylation and gene expression", "TREATMENT", 228, 264], ["the methylation changes", "PROBLEM", 278, 301]]], ["There were 19 unique m6A sites in V B1 -treated BCG, but only one of them was located within the coding region of significantly down-regulated genes, away from the promoter region.", [["m6A", "GENE_OR_GENE_PRODUCT", 21, 24], ["V B1", "GENE_OR_GENE_PRODUCT", 34, 38], ["m6A sites", "DNA", 21, 30], ["V B1", "DNA", 34, 38], ["coding region", "DNA", 97, 110], ["down-regulated genes", "DNA", 128, 148], ["promoter region", "DNA", 164, 179], ["19 unique", "OBSERVATION_MODIFIER", 11, 20], ["m6A sites", "OBSERVATION", 21, 30], ["V B1", "OBSERVATION_MODIFIER", 34, 38], ["significantly", "OBSERVATION_MODIFIER", 114, 127], ["regulated genes", "OBSERVATION", 133, 148]]], ["For the 20 unique m6A sites in V C -treated BCG, two were located in the promoter region of significantly up-regulated genes (Supplementary Table 11) .", [["V C", "GENE_OR_GENE_PRODUCT", 31, 34], ["m6A sites", "DNA", 18, 27], ["V C", "DNA", 31, 34], ["promoter region", "DNA", 73, 88], ["up-regulated genes", "DNA", 106, 124], ["V C -treated BCG", "TREATMENT", 31, 47]]], ["In that sample, m4C was found in the coding region of 31 down-regulated genes (47.7%) and 138 up-regulated genes (64.8%) (Supplementary Table 11) , but it was observed in the promoter region only in 11 up-regulated genes (Supplementary Table 12 ).", [["m4C", "GENE_OR_GENE_PRODUCT", 16, 19], ["m4C", "DNA", 16, 19], ["31 down-regulated genes", "DNA", 54, 77], ["138 up-regulated genes", "DNA", 90, 112], ["promoter region", "DNA", 175, 190], ["up-regulated genes", "DNA", 202, 220], ["m4C", "TEST", 16, 19]]], ["These results suggest that gene expression is not affected when methylation is in the coding region, but when m4C is located in the promoter region it contributes to upregulate BCG gene expression.", [["m4C", "GENE_OR_GENE_PRODUCT", 110, 113], ["BCG", "GENE_OR_GENE_PRODUCT", 177, 180], ["m4C", "DNA", 110, 113], ["promoter region", "DNA", 132, 147], ["BCG gene", "DNA", 177, 185], ["gene expression", "PROBLEM", 27, 42]]], ["To validate this hypothesis, we compared the gene expression levels of methylated and non-methylated genes, based on their FPKM.", [["methylated and non-methylated genes", "DNA", 71, 106], ["FPKM", "DNA", 123, 127], ["this hypothesis", "PROBLEM", 12, 27], ["methylated and non-methylated genes", "TREATMENT", 71, 106]]], ["Although no significant changes were observed for m6A-modified genes (Supplementary Figure 2) , the expression levels of 65 genes harboring m4C sites in the promoter region was significantly higher than in the control that had no m4C sites (mean FPKM = 272.3 and 222.9, respectively and p < 0.05) (see Supplementary Figure 3 ).Metabolite AnalysisLiquid chromatography-mass spectrometry (LC-MS) was used to analyze six bacterial sediments of each of the three BCG samples (V B1 -treated, V C -treated and control).", [["samples", "ANATOMY", 463, 470], ["m4C", "GENE_OR_GENE_PRODUCT", 140, 143], ["V C", "SIMPLE_CHEMICAL", 487, 490], ["m6A", "PROTEIN", 50, 53], ["modified genes", "DNA", 54, 68], ["65 genes", "DNA", 121, 129], ["m4C sites", "DNA", 140, 149], ["promoter region", "DNA", 157, 172], ["m4C sites", "DNA", 230, 239], ["significant changes", "PROBLEM", 12, 31], ["the expression levels", "TEST", 96, 117], ["m4C sites", "PROBLEM", 230, 239], ["mean FPKM", "TEST", 241, 250], ["Metabolite AnalysisLiquid chromatography", "TEST", 327, 367], ["mass spectrometry", "PROBLEM", 368, 385], ["LC", "TEST", 387, 389], ["six bacterial sediments", "PROBLEM", 414, 437], ["B1", "TEST", 474, 476], ["V C", "TREATMENT", 487, 490], ["no", "UNCERTAINTY", 9, 11], ["significant", "OBSERVATION_MODIFIER", 12, 23], ["changes", "OBSERVATION", 24, 31], ["significantly", "OBSERVATION_MODIFIER", 177, 190], ["higher", "OBSERVATION_MODIFIER", 191, 197]]], ["After V B1 or V C treatment, the number of differential metabolites was 428 and 3,208, respectively (Figure 4) .Metabolite AnalysisWe identified 41 metabolites with significant variation, 10 in V B1 -treated BCG and 21 in Vc-treated BCG ( Figure 5) .", [["V B1", "GENE_OR_GENE_PRODUCT", 6, 10], ["V C", "SIMPLE_CHEMICAL", 14, 17], ["Vc", "SIMPLE_CHEMICAL", 222, 224], ["V B1", "PROTEIN", 194, 198], ["V C treatment", "TREATMENT", 14, 27], ["differential metabolites", "TEST", 43, 67], ["Metabolite AnalysisWe", "TEST", 112, 133], ["significant variation", "PROBLEM", 165, 186], ["V B1", "TEST", 194, 198], ["BCG", "TEST", 208, 211], ["Vc", "TEST", 222, 224], ["significant", "OBSERVATION_MODIFIER", 165, 176], ["variation", "OBSERVATION_MODIFIER", 177, 186]]], ["In V B1 treated BCG samples, the concentration of LysoPE[0:0/18:2(9Z,12Z)], PE[18:1(9Z)/0:0], 5-S-methyl-5-thioadenosine and S-adenosylhomocysteine increased, FIGURE 4 | The diagram for differential metabolites found in the three BCG samples examined.", [["samples", "ANATOMY", 20, 27], ["samples", "ANATOMY", 234, 241], ["LysoPE", "CHEMICAL", 50, 56], ["PE", "CHEMICAL", 76, 78], ["5-S-methyl-5-thioadenosine", "CHEMICAL", 94, 120], ["S-adenosylhomocysteine", "CHEMICAL", 125, 147], ["LysoPE[0:0/18:2(9Z,12Z)], PE[18:1(9Z)/0:0]", "CHEMICAL", 50, 92], ["5-S-methyl-5-thioadenosine", "CHEMICAL", 94, 120], ["S-adenosylhomocysteine", "CHEMICAL", 125, 147], ["V B1", "GENE_OR_GENE_PRODUCT", 3, 7], ["LysoPE", "SIMPLE_CHEMICAL", 50, 56], [":2(9Z,12Z)", "SIMPLE_CHEMICAL", 63, 73], ["PE[18:1(9Z)/0:0]", "SIMPLE_CHEMICAL", 76, 92], ["5-S-methyl-5-thioadenosine", "SIMPLE_CHEMICAL", 94, 120], ["S-adenosylhomocysteine", "SIMPLE_CHEMICAL", 125, 147], ["V B1", "PROTEIN", 3, 7], ["BCG samples", "TEST", 16, 27], ["LysoPE", "TEST", 50, 56], ["PE", "TEST", 76, 78], ["methyl", "TEST", 98, 104], ["thioadenosine", "TREATMENT", 107, 120], ["S-adenosylhomocysteine increased", "PROBLEM", 125, 157], ["The diagram", "TEST", 170, 181], ["differential metabolites", "TEST", 186, 210], ["the three BCG samples", "TEST", 220, 241], ["PE", "OBSERVATION", 76, 78]]], ["Partial omics data of V B1 can be found in this published paper (Song et al., 2019) . but the concentration of Adenosine 5-phosphate disodium, L-Tryptophan, 4-nonylphenol, inosine, Geranylgeranyl PP and ADP decreased.", [["Adenosine 5-phosphate disodium", "CHEMICAL", 111, 141], ["L-Tryptophan", "CHEMICAL", 143, 155], ["4-nonylphenol", "CHEMICAL", 157, 170], ["inosine", "CHEMICAL", 172, 179], ["Geranylgeranyl PP", "CHEMICAL", 181, 198], ["ADP", "CHEMICAL", 203, 206], ["Adenosine 5-phosphate disodium", "CHEMICAL", 111, 141], ["L-Tryptophan", "CHEMICAL", 143, 155], ["4-nonylphenol", "CHEMICAL", 157, 170], ["inosine", "CHEMICAL", 172, 179], ["Geranylgeranyl PP", "CHEMICAL", 181, 198], ["ADP", "CHEMICAL", 203, 206], ["V B1", "GENE_OR_GENE_PRODUCT", 22, 26], ["Adenosine 5-phosphate disodium", "SIMPLE_CHEMICAL", 111, 141], ["L-Tryptophan", "SIMPLE_CHEMICAL", 143, 155], ["4-nonylphenol", "SIMPLE_CHEMICAL", 157, 170], ["inosine", "SIMPLE_CHEMICAL", 172, 179], ["Geranylgeranyl PP", "SIMPLE_CHEMICAL", 181, 198], ["ADP", "SIMPLE_CHEMICAL", 203, 206], ["V B1", "PROTEIN", 22, 26], ["Adenosine", "TREATMENT", 111, 120], ["phosphate disodium", "TREATMENT", 123, 141], ["L-Tryptophan", "TREATMENT", 143, 155], ["nonylphenol", "TREATMENT", 159, 170], ["inosine", "TREATMENT", 172, 179], ["Geranylgeranyl PP", "TREATMENT", 181, 198], ["ADP", "TEST", 203, 206], ["decreased", "OBSERVATION_MODIFIER", 207, 216]]], ["In Vc treated BCG samples, the concentration of Nylidrin, 2-Phenylbutyrolactone, Oleamide, S-adenosylhomocysteine, diphenylamine, 5-S-methyl-5thioadenosine, 4-nitrophenol, adenosine, Nonanedioic acid and sebacic acid increased, in the contrast, the concentration of 12-OAHSA, ADP, L-tyrosine, 4-nonylphenol, L-Tryptophan, inosine, NAD, Adenosine 5-phosphate disodium, (+)-trans-C75, dodecanedioic acid and 9(S)-HPODE decreased (Figure 5) .", [["samples", "ANATOMY", 18, 25], ["Nylidrin", "CHEMICAL", 48, 56], ["2-Phenylbutyrolactone", "CHEMICAL", 58, 79], ["Oleamide", "CHEMICAL", 81, 89], ["S-adenosylhomocysteine", "CHEMICAL", 91, 113], ["diphenylamine", "CHEMICAL", 115, 128], ["5-S-methyl-5thioadenosine", "CHEMICAL", 130, 155], ["4-nitrophenol", "CHEMICAL", 157, 170], ["adenosine", "CHEMICAL", 172, 181], ["Nonanedioic acid", "CHEMICAL", 183, 199], ["sebacic acid", "CHEMICAL", 204, 216], ["12-OAHSA", "CHEMICAL", 266, 274], ["ADP", "CHEMICAL", 276, 279], ["L-tyrosine", "CHEMICAL", 281, 291], ["4-nonylphenol", "CHEMICAL", 293, 306], ["L-Tryptophan", "CHEMICAL", 308, 320], ["inosine", "CHEMICAL", 322, 329], ["NAD", "CHEMICAL", 331, 334], ["Adenosine 5-phosphate disodium", "CHEMICAL", 336, 366], ["dodecanedioic acid", "CHEMICAL", 383, 401], ["9(S)-HPODE", "CHEMICAL", 406, 416], ["Nylidrin", "CHEMICAL", 48, 56], ["2-Phenylbutyrolactone", "CHEMICAL", 58, 79], ["Oleamide", "CHEMICAL", 81, 89], ["S-adenosylhomocysteine", "CHEMICAL", 91, 113], ["diphenylamine", "CHEMICAL", 115, 128], ["5-S-methyl-5thioadenosine", "CHEMICAL", 130, 155], ["4-nitrophenol", "CHEMICAL", 157, 170], ["adenosine", "CHEMICAL", 172, 181], ["Nonanedioic acid", "CHEMICAL", 183, 199], ["sebacic acid", "CHEMICAL", 204, 216], ["12-OAHSA", "CHEMICAL", 266, 274], ["ADP", "CHEMICAL", 276, 279], ["L-tyrosine", "CHEMICAL", 281, 291], ["4-nonylphenol", "CHEMICAL", 293, 306], ["L-Tryptophan", "CHEMICAL", 308, 320], ["inosine", "CHEMICAL", 322, 329], ["NAD", "CHEMICAL", 331, 334], ["Adenosine 5-phosphate disodium", "CHEMICAL", 336, 366], ["(+)-trans-C75, dodecanedioic acid", "CHEMICAL", 368, 401], ["9(S)-HPODE", "CHEMICAL", 406, 416], ["Nylidrin", "SIMPLE_CHEMICAL", 48, 56], ["2-Phenylbutyrolactone", "SIMPLE_CHEMICAL", 58, 79], ["Oleamide", "SIMPLE_CHEMICAL", 81, 89], ["S-adenosylhomocysteine", "SIMPLE_CHEMICAL", 91, 113], ["diphenylamine", "SIMPLE_CHEMICAL", 115, 128], ["5-S-methyl-5thioadenosine", "SIMPLE_CHEMICAL", 130, 155], ["4-nitrophenol", "SIMPLE_CHEMICAL", 157, 170], ["adenosine", "SIMPLE_CHEMICAL", 172, 181], ["Nonanedioic acid", "SIMPLE_CHEMICAL", 183, 199], ["sebacic acid", "SIMPLE_CHEMICAL", 204, 216], ["12-OAHSA", "SIMPLE_CHEMICAL", 266, 274], ["ADP", "SIMPLE_CHEMICAL", 276, 279], ["L-tyrosine", "SIMPLE_CHEMICAL", 281, 291], ["4-nonylphenol", "SIMPLE_CHEMICAL", 293, 306], ["L-Tryptophan", "SIMPLE_CHEMICAL", 308, 320], ["inosine", "SIMPLE_CHEMICAL", 322, 329], ["NAD", "SIMPLE_CHEMICAL", 331, 334], ["Adenosine 5-phosphate disodium", "SIMPLE_CHEMICAL", 336, 366], ["(+)-trans-C75", "SIMPLE_CHEMICAL", 368, 381], ["dodecanedioic acid", "SIMPLE_CHEMICAL", 383, 401], ["9(S)-HPODE", "SIMPLE_CHEMICAL", 406, 416], ["Nylidrin", "TREATMENT", 48, 56], ["Phenylbutyrolactone", "TREATMENT", 60, 79], ["Oleamide", "TREATMENT", 81, 89], ["S-adenosylhomocysteine", "TREATMENT", 91, 113], ["diphenylamine", "TREATMENT", 115, 128], ["methyl", "TREATMENT", 134, 140], ["5thioadenosine", "TREATMENT", 141, 155], ["nitrophenol", "TREATMENT", 159, 170], ["adenosine", "TREATMENT", 172, 181], ["Nonanedioic acid", "TREATMENT", 183, 199], ["sebacic acid", "TREATMENT", 204, 216], ["the concentration", "TEST", 245, 262], ["ADP", "TEST", 276, 279], ["L-tyrosine", "TREATMENT", 281, 291], ["nonylphenol", "TREATMENT", 295, 306], ["L-Tryptophan", "TREATMENT", 308, 320], ["inosine", "TREATMENT", 322, 329], ["NAD", "PROBLEM", 331, 334], ["Adenosine", "TREATMENT", 336, 345], ["phosphate disodium", "TEST", 348, 366], ["dodecanedioic acid", "TREATMENT", 383, 401]]], ["Enrichment analysis revealed that variant metabolites were mainly clustered in amino acid metabolism pathways (Supplementary Table 8) .", [["amino acid", "CHEMICAL", 79, 89], ["amino acid", "CHEMICAL", 79, 89], ["amino acid", "AMINO_ACID", 79, 89], ["Enrichment analysis", "TEST", 0, 19], ["variant metabolites", "PROBLEM", 34, 53], ["amino acid metabolism pathways", "TREATMENT", 79, 109]]], ["After V B1 treatment, variant metabolites were significantly enriched in cysteine and methionine metabolism (Supplementary Table 7) .Metabolism of Amino AcidsSince exposure to vitamins led to variant metabolites enrichment in amino acid metabolism pathways, we performed additional amino acids content analysis using six bacterial sediments of each of the three BCG samples (V B1 -treated, V C -treated and control).", [["samples", "ANATOMY", 366, 373], ["V B1", "CHEMICAL", 6, 10], ["cysteine", "CHEMICAL", 73, 81], ["methionine", "CHEMICAL", 86, 96], ["Amino Acids", "CHEMICAL", 147, 158], ["vitamins", "CHEMICAL", 176, 184], ["amino acid", "CHEMICAL", 226, 236], ["amino acids", "CHEMICAL", 282, 293], ["cysteine", "CHEMICAL", 73, 81], ["methionine", "CHEMICAL", 86, 96], ["Amino Acids", "CHEMICAL", 147, 158], ["vitamins", "CHEMICAL", 176, 184], ["amino acid", "CHEMICAL", 226, 236], ["amino acids", "CHEMICAL", 282, 293], ["V B1", "GENE_OR_GENE_PRODUCT", 6, 10], ["cysteine", "AMINO_ACID", 73, 81], ["methionine", "SIMPLE_CHEMICAL", 86, 96], ["Amino Acids", "SIMPLE_CHEMICAL", 147, 158], ["vitamins", "SIMPLE_CHEMICAL", 176, 184], ["amino acid", "AMINO_ACID", 226, 236], ["amino acids", "AMINO_ACID", 282, 293], ["V C", "SIMPLE_CHEMICAL", 390, 393], ["V B1", "PROTEIN", 6, 10], ["V B1 treatment", "TREATMENT", 6, 20], ["variant metabolites", "PROBLEM", 22, 41], ["methionine metabolism", "TREATMENT", 86, 107], ["Amino Acids", "TREATMENT", 147, 158], ["vitamins", "TREATMENT", 176, 184], ["variant metabolites enrichment in amino acid metabolism pathways", "PROBLEM", 192, 256], ["additional amino acids content analysis", "TREATMENT", 271, 310], ["six bacterial sediments", "TREATMENT", 317, 340], ["V C", "TREATMENT", 390, 393], ["Amino Acids", "OBSERVATION", 147, 158]]], ["Exposure to vitamins significantly reduced (V B1 ) or increased (V C ) amino acid content (Supplementary Table 9 ).", [["vitamins", "CHEMICAL", 12, 20], ["amino acid", "CHEMICAL", 71, 81], ["vitamins", "CHEMICAL", 12, 20], ["amino acid", "CHEMICAL", 71, 81], ["vitamins", "SIMPLE_CHEMICAL", 12, 20], ["amino acid", "AMINO_ACID", 71, 81], ["vitamins", "TREATMENT", 12, 20], ["increased (V C ) amino acid content", "PROBLEM", 54, 89]]], ["The expression changes associated with amino acid metabolism were also analyzed, as described below.V B1 AdditionAfter V B1 addition to BCG, a key enzyme involved in thiamine (V B1 ) metabolism (hydroxymethylpyrimidine/ phosphomethylpyrimidine kinase [2.7.4.7]) was significantly down-regulated (Supplementary Figure 4) , suggesting that V B1 addition reduced the requirement for de novo synthesis of thiamine.", [["amino acid", "CHEMICAL", 39, 49], ["thiamine", "CHEMICAL", 166, 174], ["hydroxymethylpyrimidine", "CHEMICAL", 195, 218], ["phosphomethylpyrimidine", "CHEMICAL", 220, 243], ["thiamine", "CHEMICAL", 401, 409], ["amino acid", "CHEMICAL", 39, 49], ["thiamine (V B1", "CHEMICAL", 166, 180], ["hydroxymethylpyrimidine", "CHEMICAL", 195, 218], ["phosphomethylpyrimidine", "CHEMICAL", 220, 243], ["thiamine", "CHEMICAL", 401, 409], ["amino acid", "AMINO_ACID", 39, 49], ["V B1", "GENE_OR_GENE_PRODUCT", 100, 104], ["V B1", "GENE_OR_GENE_PRODUCT", 119, 123], ["thiamine", "SIMPLE_CHEMICAL", 166, 174], ["V B1", "SIMPLE_CHEMICAL", 176, 180], ["hydroxymethylpyrimidine", "SIMPLE_CHEMICAL", 195, 218], ["phosphomethylpyrimidine kinase", "GENE_OR_GENE_PRODUCT", 220, 250], ["V B1", "GENE_OR_GENE_PRODUCT", 338, 342], ["thiamine", "SIMPLE_CHEMICAL", 401, 409], ["V B1", "PROTEIN", 100, 104], ["V B1", "PROTEIN", 119, 123], ["phosphomethylpyrimidine kinase", "PROTEIN", 220, 250], ["V B1", "PROTEIN", 338, 342], ["The expression changes", "PROBLEM", 0, 22], ["amino acid metabolism", "PROBLEM", 39, 60], ["BCG", "TEST", 136, 139], ["a key enzyme", "TEST", 141, 153], ["thiamine", "TEST", 166, 174], ["metabolism (hydroxymethylpyrimidine/ phosphomethylpyrimidine kinase", "TREATMENT", 183, 250], ["de novo synthesis of thiamine", "TREATMENT", 380, 409]]], ["Another significantly down-regulated gene was chorismate mutase [5.4.99.5] (Supplementary Figure 5 and Supplementary Table 10), which catalyzes the transformation from chorismate to prephenate, the precursor of phenylalanine and tyrosine.", [["prephenate", "CHEMICAL", 182, 192], ["phenylalanine", "CHEMICAL", 211, 224], ["tyrosine", "CHEMICAL", 229, 237], ["chorismate", "CHEMICAL", 46, 56], ["chorismate", "CHEMICAL", 168, 178], ["prephenate", "CHEMICAL", 182, 192], ["phenylalanine", "CHEMICAL", 211, 224], ["tyrosine", "CHEMICAL", 229, 237], ["chorismate mutase", "GENE_OR_GENE_PRODUCT", 46, 63], ["chorismate", "SIMPLE_CHEMICAL", 168, 178], ["prephenate", "SIMPLE_CHEMICAL", 182, 192], ["phenylalanine", "AMINO_ACID", 211, 224], ["tyrosine", "AMINO_ACID", 229, 237], ["down-regulated gene", "DNA", 22, 41], ["chorismate mutase", "PROTEIN", 46, 63], ["chorismate mutase", "TEST", 46, 63], ["phenylalanine", "TREATMENT", 211, 224], ["tyrosine", "TREATMENT", 229, 237]]], ["This is consistent with the observed 80% reduction in Phe and Tyr after V B1 addition.", [["Phe", "CHEMICAL", 54, 57], ["Phe", "CHEMICAL", 54, 57], ["Tyr", "CHEMICAL", 62, 65], ["Phe", "AMINO_ACID", 54, 57], ["Tyr", "AMINO_ACID", 62, 65], ["V B1", "GENE_OR_GENE_PRODUCT", 72, 76], ["Phe", "TEST", 54, 57], ["consistent with", "UNCERTAINTY", 8, 23], ["reduction", "OBSERVATION_MODIFIER", 41, 50]]], ["This treatment also caused almost 50% reduction in alanine, although the gene expression of alanine dehydrogenase [1.4.1.1] showed no significant down-regulation.", [["alanine", "CHEMICAL", 51, 58], ["alanine", "CHEMICAL", 92, 99], ["alanine", "CHEMICAL", 51, 58], ["alanine", "CHEMICAL", 92, 99], ["alanine", "AMINO_ACID", 51, 58], ["alanine dehydrogenase", "GENE_OR_GENE_PRODUCT", 92, 113], ["alanine dehydrogenase", "PROTEIN", 92, 113], ["This treatment", "TREATMENT", 0, 14], ["alanine", "TREATMENT", 51, 58], ["alanine dehydrogenase", "TEST", 92, 113], ["significant down-regulation", "PROBLEM", 134, 161], ["no", "UNCERTAINTY", 131, 133], ["significant", "OBSERVATION_MODIFIER", 134, 145]]], ["Instead, the gene expression of the two alanine dehydrogenase genes (JTY_RS14370 and JTY_RS14375) increased slightly, which suggests that alanine reduction was caused by lower availability of pyruvate.V B1 AdditionWe then examined the pyruvate metabolism and glycolysis pathways.", [["alanine", "CHEMICAL", 40, 47], ["alanine", "CHEMICAL", 138, 145], ["pyruvate", "CHEMICAL", 192, 200], ["pyruvate", "CHEMICAL", 235, 243], ["alanine", "CHEMICAL", 40, 47], ["alanine", "CHEMICAL", 138, 145], ["pyruvate", "CHEMICAL", 192, 200], ["pyruvate", "CHEMICAL", 235, 243], ["alanine dehydrogenase", "GENE_OR_GENE_PRODUCT", 40, 61], ["JTY_RS14370", "GENE_OR_GENE_PRODUCT", 69, 80], ["JTY_RS14375", "GENE_OR_GENE_PRODUCT", 85, 96], ["alanine", "AMINO_ACID", 138, 145], ["pyruvate", "SIMPLE_CHEMICAL", 192, 200], ["pyruvate", "SIMPLE_CHEMICAL", 235, 243], ["alanine dehydrogenase genes", "DNA", 40, 67], ["JTY_RS14370", "DNA", 69, 80], ["JTY_RS14375", "DNA", 85, 96], ["V B1", "PROTEIN", 201, 205], ["the two alanine dehydrogenase genes", "PROBLEM", 32, 67], ["alanine reduction", "TREATMENT", 138, 155], ["the pyruvate metabolism", "TEST", 231, 254], ["glycolysis pathways", "TEST", 259, 278]]], ["In the pyruvate metabolism pathway, no significant up-regulation was observed, indicating that the conversion of pyruvate to other metabolites did not increase.", [["pyruvate", "CHEMICAL", 7, 15], ["pyruvate", "CHEMICAL", 113, 121], ["pyruvate", "CHEMICAL", 7, 15], ["pyruvate", "CHEMICAL", 113, 121], ["pyruvate", "SIMPLE_CHEMICAL", 7, 15], ["pyruvate", "SIMPLE_CHEMICAL", 113, 121], ["pyruvate", "TREATMENT", 113, 121], ["no", "UNCERTAINTY", 36, 38], ["significant", "OBSERVATION_MODIFIER", 39, 50]]], ["However, in the glycolysis pathway, a 51-fold reduced expression was observed for 6-phosphofructokinase 2 [2.7.1.11], an enzyme that converts fructose-6P into fructose-1,6P2, which may explain the 50% reduction in alanine after V B1 addition (Supplementary Figure 5) .", [["fructose-6P", "CHEMICAL", 142, 153], ["fructose-1,6P2", "CHEMICAL", 159, 173], ["alanine", "CHEMICAL", 214, 221], ["fructose", "CHEMICAL", 142, 150], ["fructose", "CHEMICAL", 159, 167], ["alanine", "CHEMICAL", 214, 221], ["6-phosphofructokinase 2", "GENE_OR_GENE_PRODUCT", 82, 105], ["2.7.1.11", "GENE_OR_GENE_PRODUCT", 107, 115], ["fructose-6P", "SIMPLE_CHEMICAL", 142, 153], ["fructose-1,6P2", "SIMPLE_CHEMICAL", 159, 173], ["alanine", "AMINO_ACID", 214, 221], ["a 51-fold reduced expression", "PROBLEM", 36, 64], ["an enzyme", "TEST", 118, 127], ["fructose", "TEST", 142, 150], ["fructose", "TEST", 159, 167], ["alanine after V B1 addition (Supplementary Figure", "TREATMENT", 214, 263]]], ["For histidine synthesis, although no significant gene expression change was observed, genes involved in five out of nine steps were down-regulated.", [["histidine", "CHEMICAL", 4, 13], ["histidine", "CHEMICAL", 4, 13], ["histidine", "AMINO_ACID", 4, 13], ["histidine synthesis", "PROBLEM", 4, 23], ["significant gene expression change", "PROBLEM", 37, 71], ["no", "UNCERTAINTY", 34, 36], ["significant", "OBSERVATION_MODIFIER", 37, 48], ["expression", "OBSERVATION", 54, 64]]], ["Genes involved in the synthesis of other amino acids also showed the same pattern, where at FIGURE 5 | Correlation of significantly variant metabolites of BCG treated with V B1 (A) and BCG treated with Vc (B) relative to control.", [["amino acids", "CHEMICAL", 41, 52], ["amino acids", "CHEMICAL", 41, 52], ["amino acids", "AMINO_ACID", 41, 52], ["V B1", "PROTEIN", 172, 176], ["other amino acids", "TEST", 35, 52], ["BCG", "PROBLEM", 155, 158], ["V B1", "TREATMENT", 172, 176], ["BCG", "TREATMENT", 185, 188], ["Vc (B)", "TREATMENT", 202, 208]]], ["Partial omics data of V B1 can be found in this published paper (Song et al., 2019). least one gene encoding a key enzyme was down-regulated (Supplementary Table 10 ).V C AdditionV C addition caused ornithine to increase 1.6-fold (Supplementary Table 9 ), consistent with a significant upregulation of genes involved in three out of five steps required to transform glutamate to ornithine (Supplementary Figure 6) .", [["ornithine", "CHEMICAL", 199, 208], ["glutamate", "CHEMICAL", 366, 375], ["ornithine", "CHEMICAL", 379, 388], ["ornithine", "CHEMICAL", 199, 208], ["glutamate", "CHEMICAL", 366, 375], ["ornithine", "CHEMICAL", 379, 388], ["V B1", "GENE_OR_GENE_PRODUCT", 22, 26], ["V C AdditionV C", "GENE_OR_GENE_PRODUCT", 167, 182], ["ornithine", "SIMPLE_CHEMICAL", 199, 208], ["glutamate", "SIMPLE_CHEMICAL", 366, 375], ["ornithine", "SIMPLE_CHEMICAL", 379, 388], ["V B1", "PROTEIN", 22, 26], ["a key enzyme", "TEST", 109, 121], ["ornithine", "PROBLEM", 199, 208], ["significant", "OBSERVATION_MODIFIER", 274, 285], ["upregulation", "OBSERVATION", 286, 298]]], ["Also, three out of four genes encoding enzymes that convert ornithine to arginine doubled their expression levels.", [["ornithine", "CHEMICAL", 60, 69], ["arginine", "CHEMICAL", 73, 81], ["ornithine", "CHEMICAL", 60, 69], ["arginine", "CHEMICAL", 73, 81], ["ornithine", "SIMPLE_CHEMICAL", 60, 69], ["arginine", "AMINO_ACID", 73, 81], ["enzymes", "PROTEIN", 39, 46], ["encoding enzymes", "TEST", 30, 46]]], ["V C addition also increased the content of aspartate 2.7-fold.", [["aspartate", "CHEMICAL", 43, 52], ["V C", "CHEMICAL", 0, 3], ["aspartate", "CHEMICAL", 43, 52], ["V C", "GENE_OR_GENE_PRODUCT", 0, 3], ["aspartate", "SIMPLE_CHEMICAL", 43, 52], ["aspartate", "TEST", 43, 52], ["increased", "OBSERVATION_MODIFIER", 18, 27]]], ["L-asparaginase [3.5.1.1], which converts Asn to Asp, increased 2-fold after V C addition (Supplementary Table 10) .", [["L-asparaginase", "CHEMICAL", 0, 14], ["Asn", "CHEMICAL", 41, 44], ["Asp", "CHEMICAL", 48, 51], ["Asn", "CHEMICAL", 41, 44], ["Asp", "CHEMICAL", 48, 51], ["L-asparaginase", "SIMPLE_CHEMICAL", 0, 14], ["Asn", "AMINO_ACID", 41, 44], ["Asp", "AMINO_ACID", 48, 51], ["V C", "SIMPLE_CHEMICAL", 76, 79], ["Asp", "TEST", 48, 51], ["V C addition (Supplementary Table", "TREATMENT", 76, 109], ["increased", "OBSERVATION_MODIFIER", 53, 62]]], ["Thus, the observed increase of Thr might be due to an increase in Asp content (Supplementary Figure 6) and to a down-regulation of genes degrading Thr (Supplementary Table 10) .", [["Thr", "CHEMICAL", 31, 34], ["Asp", "CHEMICAL", 66, 69], ["Thr", "CHEMICAL", 31, 34], ["Asp", "CHEMICAL", 66, 69], ["Thr", "CHEMICAL", 147, 150], ["Thr", "GENE_OR_GENE_PRODUCT", 31, 34], ["Asp", "AMINO_ACID", 66, 69], ["Thr", "PROTEIN", 147, 150], ["Thr", "TREATMENT", 31, 34], ["an increase in Asp content", "PROBLEM", 51, 77], ["increase", "OBSERVATION_MODIFIER", 19, 27], ["increase", "OBSERVATION_MODIFIER", 54, 62], ["Asp content", "OBSERVATION", 66, 77]]], ["The tryptophan synthase [4.2.1.20] gene was also significantly down-regulated (Supplementary Figure 6) , consistent with the reduction of Trp in these conditions.", [["tryptophan", "CHEMICAL", 4, 14], ["Trp", "CHEMICAL", 138, 141], ["tryptophan", "CHEMICAL", 4, 14], ["Trp", "CHEMICAL", 138, 141], ["tryptophan synthase", "GENE_OR_GENE_PRODUCT", 4, 23], ["Trp", "AMINO_ACID", 138, 141], ["tryptophan synthase [4.2.1.20] gene", "DNA", 4, 39], ["The tryptophan synthase", "TEST", 0, 23], ["consistent with", "UNCERTAINTY", 105, 120]]], ["Strikingly, the cysteine synthase A [2.5.1.47] gene was significantly up-regulated in BCG treated with either V B1 or Vc (Supplementary Figures 5, 6) .", [["cysteine", "CHEMICAL", 16, 24], ["cysteine", "CHEMICAL", 16, 24], ["cysteine synthase A [2.5.1.47", "GENE_OR_GENE_PRODUCT", 16, 45], ["cysteine synthase A [2.5.1.47] gene", "DNA", 16, 51], ["V B1", "PROTEIN", 110, 114], ["the cysteine synthase A", "TEST", 12, 35]]], ["Finally, we found no direct association between base modification in coding or promoter regions and expression of genes involved in amino acid metabolism (Supplementary Table 10) .", [["amino acid", "CHEMICAL", 132, 142], ["amino acid", "CHEMICAL", 132, 142], ["amino acid", "AMINO_ACID", 132, 142], ["promoter regions", "DNA", 79, 95], ["direct association between base modification", "PROBLEM", 21, 65], ["amino acid metabolism", "TREATMENT", 132, 153]]], ["Taken together, we found significant regulation of several genes directly involved in amino acid biosynthesis and metabolism, consistent with amino acid content changes.", [["amino acid", "CHEMICAL", 86, 96], ["amino acid", "CHEMICAL", 142, 152], ["amino acid", "CHEMICAL", 86, 96], ["amino acid", "CHEMICAL", 142, 152], ["amino acid", "AMINO_ACID", 86, 96], ["amino acid", "AMINO_ACID", 142, 152], ["amino acid biosynthesis", "TREATMENT", 86, 109], ["amino acid content changes", "PROBLEM", 142, 168], ["significant", "OBSERVATION_MODIFIER", 25, 36], ["consistent with", "UNCERTAINTY", 126, 141], ["amino acid content", "OBSERVATION", 142, 160]]], ["We speculate that treatment with V B1 and V C changes amino acid levels by altering precursor concentrations.Cysteine Inhibits BCG GrowthFollowing the observation that vitamins treatment increase the transcription levels of cysteine synthase A, we determined the effect of cysteine on BCG replication.", [["amino acid", "CHEMICAL", 54, 64], ["Cysteine", "CHEMICAL", 109, 117], ["vitamins", "CHEMICAL", 168, 176], ["cysteine", "CHEMICAL", 273, 281], ["V B1 and V C", "CHEMICAL", 33, 45], ["amino acid", "CHEMICAL", 54, 64], ["Cysteine", "CHEMICAL", 109, 117], ["vitamins", "CHEMICAL", 168, 176], ["cysteine", "CHEMICAL", 224, 232], ["cysteine", "CHEMICAL", 273, 281], ["V B1", "GENE_OR_GENE_PRODUCT", 33, 37], ["V C", "SIMPLE_CHEMICAL", 42, 45], ["amino acid", "AMINO_ACID", 54, 64], ["Cysteine", "AMINO_ACID", 109, 117], ["vitamins", "SIMPLE_CHEMICAL", 168, 176], ["cysteine synthase A", "GENE_OR_GENE_PRODUCT", 224, 243], ["cysteine", "SIMPLE_CHEMICAL", 273, 281], ["V B1", "PROTEIN", 33, 37], ["V C", "PROTEIN", 42, 45], ["cysteine synthase A", "PROTEIN", 224, 243], ["V B1", "TREATMENT", 33, 37], ["V C changes amino acid levels", "TREATMENT", 42, 71], ["altering precursor concentrations", "PROBLEM", 75, 108], ["Cysteine", "TREATMENT", 109, 117], ["BCG", "PROBLEM", 127, 130], ["vitamins treatment", "TREATMENT", 168, 186], ["cysteine synthase", "TREATMENT", 224, 241], ["cysteine", "TREATMENT", 273, 281], ["BCG replication", "TREATMENT", 285, 300], ["BCG", "OBSERVATION", 127, 130]]], ["Different concentrations of cysteine (0, 1, 2, and 4 mM) were used for CFU calculation and the results are summarized in Figure 6 .", [["cysteine", "CHEMICAL", 28, 36], ["cysteine", "CHEMICAL", 28, 36], ["cysteine", "SIMPLE_CHEMICAL", 28, 36], ["cysteine", "TEST", 28, 36], ["CFU calculation", "TEST", 71, 86], ["concentrations", "OBSERVATION_MODIFIER", 10, 24]]], ["The growth curve demonstrates that cysteine inhibits BCG growth in a concentration-dependent manner.DISCUSSIONVitamins such as biotin and thiamine are essential for M. tuberculosis growth and infection , and Mtb scavenges these vitamins from the host.", [["cysteine", "CHEMICAL", 35, 43], ["biotin", "CHEMICAL", 127, 133], ["thiamine", "CHEMICAL", 138, 146], ["tuberculosis", "DISEASE", 168, 180], ["infection", "DISEASE", 192, 201], ["cysteine", "CHEMICAL", 35, 43], ["biotin", "CHEMICAL", 127, 133], ["thiamine", "CHEMICAL", 138, 146], ["cysteine", "SIMPLE_CHEMICAL", 35, 43], ["BCG", "SIMPLE_CHEMICAL", 53, 56], ["biotin", "SIMPLE_CHEMICAL", 127, 133], ["thiamine", "SIMPLE_CHEMICAL", 138, 146], ["M. tuberculosis", "ORGANISM", 165, 180], ["vitamins", "SIMPLE_CHEMICAL", 228, 236], ["M. tuberculosis", "SPECIES", 165, 180], ["M. tuberculosis", "SPECIES", 165, 180], ["The growth curve", "TEST", 0, 16], ["cysteine inhibits BCG growth", "PROBLEM", 35, 63], ["DISCUSSIONVitamins", "TREATMENT", 100, 118], ["biotin", "TREATMENT", 127, 133], ["thiamine", "TREATMENT", 138, 146], ["M. tuberculosis growth", "PROBLEM", 165, 187], ["infection", "PROBLEM", 192, 201], ["Mtb scavenges these vitamins", "TREATMENT", 208, 236], ["tuberculosis", "OBSERVATION", 168, 180], ["infection", "OBSERVATION", 192, 201]]], ["At the same time, supplementation of some vitamins together with anti-TB drugs has been shown to improve chemotherapy outcomes (Vilcheze et al., 2018) .", [["vitamins", "SIMPLE_CHEMICAL", 42, 50], ["some vitamins", "TREATMENT", 37, 50], ["anti-TB drugs", "TREATMENT", 65, 78], ["chemotherapy outcomes", "TREATMENT", 105, 126]]], ["Clinical trials have shown that Vc supplementation improves the healing process in tuberculosis patients (Tjandrawinata et al., 2018) , although no clinical improvement (sputum conversion) of patients was observed when using vitamin D (V D ).", [["sputum", "ANATOMY", 170, 176], ["tuberculosis", "DISEASE", 83, 95], ["vitamin D", "CHEMICAL", 225, 234], ["vitamin D (V D", "CHEMICAL", 225, 239], ["Vc", "SIMPLE_CHEMICAL", 32, 34], ["patients", "ORGANISM", 96, 104], ["patients", "ORGANISM", 192, 200], ["vitamin D", "SIMPLE_CHEMICAL", 225, 234], ["V D", "SIMPLE_CHEMICAL", 236, 239], ["patients", "SPECIES", 96, 104], ["patients", "SPECIES", 192, 200], ["Clinical trials", "TEST", 0, 15], ["Vc supplementation", "TREATMENT", 32, 50], ["the healing process", "PROBLEM", 60, 79], ["sputum conversion", "TEST", 170, 187], ["vitamin D (V D )", "TREATMENT", 225, 241], ["healing", "OBSERVATION_MODIFIER", 64, 71], ["tuberculosis", "OBSERVATION", 83, 95], ["no", "UNCERTAINTY", 145, 147]]], ["Therefore, the mechanism by which some vitamins can ammeliorate TB requires further investigation.DISCUSSIONMtb growth is inhibited by vitamins A (V A ) and V D (Greenstein et al., 2012 (Greenstein et al., , 2014 , and recent studies have shown that V B1 and Vc also significantly inhibit BCG growth (Pei et al., 2019; Song et al., 2019) .", [["vitamins", "CHEMICAL", 39, 47], ["TB", "DISEASE", 64, 66], ["vitamins A", "CHEMICAL", 135, 145], ["vitamins A (V A ) and V D", "CHEMICAL", 135, 160], ["vitamins", "SIMPLE_CHEMICAL", 39, 47], ["vitamins A", "SIMPLE_CHEMICAL", 135, 145], ["V A", "SIMPLE_CHEMICAL", 147, 150], ["V D", "SIMPLE_CHEMICAL", 157, 160], ["V B1", "GENE_OR_GENE_PRODUCT", 250, 254], ["V B1", "PROTEIN", 250, 254], ["some vitamins", "TREATMENT", 34, 47], ["TB", "PROBLEM", 64, 66], ["further investigation", "TEST", 76, 97], ["recent studies", "TEST", 219, 233], ["V B1", "TEST", 250, 254], ["BCG growth", "PROBLEM", 289, 299]]], ["Thus, due to the potential supplementary role of certain vitamins in TB treatment, analysis of the BCG methylome can help elucidate the relationship between base methylation, gene expression and metabolic products.DISCUSSIONMany DNA methylation enzymes are part of RM systems, and are involved in the defense against phages and viruses.", [["TB", "DISEASE", 69, 71], ["vitamins", "SIMPLE_CHEMICAL", 57, 65], ["DNA", "CELLULAR_COMPONENT", 229, 232], ["DNA methylation enzymes", "PROTEIN", 229, 252], ["certain vitamins", "TREATMENT", 49, 65], ["TB treatment", "TREATMENT", 69, 81], ["the BCG methylome", "TREATMENT", 95, 112], ["base methylation", "TREATMENT", 157, 173], ["gene expression", "TREATMENT", 175, 190], ["metabolic products", "TREATMENT", 195, 213], ["DNA methylation enzymes", "TEST", 229, 252], ["viruses", "PROBLEM", 328, 335], ["metabolic products", "OBSERVATION", 195, 213]]], ["We found 42.6% of BCG genes were m6A methylated, and these were enriched in key metabolism and cellular processes, hinting that essential genes in BCG are always protected by methylation.DISCUSSIONRegulation of gene expression by DNA methylation occurs via more than one mechanism.", [["cellular", "ANATOMY", 95, 103], ["m6A", "GENE_OR_GENE_PRODUCT", 33, 36], ["cellular", "CELL", 95, 103], ["DNA", "CELLULAR_COMPONENT", 230, 233], ["BCG genes", "DNA", 18, 27], ["m6A", "DNA", 33, 36], ["essential genes", "DNA", 128, 143], ["BCG genes", "PROBLEM", 18, 27], ["essential genes in BCG", "PROBLEM", 128, 150], ["gene expression", "PROBLEM", 211, 226], ["cellular processes", "OBSERVATION", 95, 113], ["essential", "OBSERVATION_MODIFIER", 128, 137], ["genes", "OBSERVATION_MODIFIER", 138, 143]]], ["DNA methylation hinders the interaction between DNA and regulatory proteins by direct atomic steric effects (Sanchez-Romero et al., 2015) , or indirectly by altering DNA structure itself; this reduces the thermodynamic stability of the double helix, resulting in alteration of gene expression (Sanchez-Romero et al., 2015) .", [["DNA", "CELLULAR_COMPONENT", 0, 3], ["DNA", "CELLULAR_COMPONENT", 48, 51], ["DNA", "CELLULAR_COMPONENT", 166, 169], ["regulatory proteins", "PROTEIN", 56, 75], ["DNA methylation hinders", "PROBLEM", 0, 23], ["DNA and regulatory proteins", "TREATMENT", 48, 75], ["thermodynamic stability", "OBSERVATION", 205, 228]]], ["Additionally, some DNA-binding proteins inhibit methylation of specific DNA sequences by binding to unmethylated DNA with high affinity.DISCUSSIONIn general, positive or negative transcription regulation depends on differences in the location of methylation sites in the promoter region, modulation of regulatory proteins, or differences in binding between regulatory proteins and unmethylated/methylated DNA target sequences.", [["DNA", "CELLULAR_COMPONENT", 19, 22], ["DNA", "CELLULAR_COMPONENT", 72, 75], ["DNA", "CELLULAR_COMPONENT", 113, 116], ["DNA", "CELLULAR_COMPONENT", 405, 408], ["DNA-binding proteins", "PROTEIN", 19, 39], ["DNA sequences", "DNA", 72, 85], ["unmethylated DNA", "DNA", 100, 116], ["methylation sites", "DNA", 246, 263], ["promoter region", "DNA", 271, 286], ["regulatory proteins", "PROTEIN", 302, 321], ["regulatory proteins", "PROTEIN", 357, 376], ["unmethylated/methylated DNA target sequences", "DNA", 381, 425], ["some DNA-binding proteins", "PROBLEM", 14, 39], ["specific DNA sequences", "PROBLEM", 63, 85], ["unmethylated DNA", "PROBLEM", 100, 116], ["high affinity", "PROBLEM", 122, 135], ["methylation sites", "PROBLEM", 246, 263], ["regulatory proteins", "PROBLEM", 302, 321], ["regulatory proteins", "TEST", 357, 376], ["unmethylated/methylated DNA target sequences", "TEST", 381, 425], ["high affinity", "OBSERVATION_MODIFIER", 122, 135], ["methylation sites", "OBSERVATION", 246, 263], ["regulatory proteins", "OBSERVATION", 302, 321]]], ["In the present study, we found that 138 genes (64.8%) harboring m4C in the coding region, and 11 genes harboring m4C in the promoter region, were up-regulated in Vc-treated BCG.", [["m4C", "GENE_OR_GENE_PRODUCT", 64, 67], ["m4C", "GENE_OR_GENE_PRODUCT", 113, 116], ["Vc", "SIMPLE_CHEMICAL", 162, 164], ["m4C", "DNA", 64, 67], ["coding region", "DNA", 75, 88], ["m4C", "DNA", 113, 116], ["promoter region", "DNA", 124, 139]]], ["Additionally, 65 genes that harbored m4C sites in the promoter region showed expression levels significantly higher than the control (no m4C sites), based on FPKM values.", [["m4C", "GENE_OR_GENE_PRODUCT", 37, 40], ["65 genes", "DNA", 14, 22], ["m4C sites", "DNA", 37, 46], ["promoter region", "DNA", 54, 69], ["m4C sites", "DNA", 137, 146], ["expression levels", "PROBLEM", 77, 94], ["FPKM values", "TEST", 158, 169]]], ["This suggests that m4C can promote gene transcription to some extent, but using mechanisms that are still unknown.", [["m4C", "GENE_OR_GENE_PRODUCT", 19, 22], ["m4C", "DNA", 19, 22]]], ["The m4C modification was observed in type I R-M systems, suggesting that, in addition to m6A modifications, they can also use this modification for host protection (Morgan et al., 2016) .DISCUSSIONRecent studies have shown that N 4 -cytosine DNA methylation can regulate transcription and pathogenesis in Helicobacter pylori (Kumar et al., 2018) .", [["N 4 -cytosine", "CHEMICAL", 228, 241], ["Helicobacter pylori", "DISEASE", 305, 324], ["N 4 -cytosine", "CHEMICAL", 228, 241], ["m4C", "GENE_OR_GENE_PRODUCT", 4, 7], ["type I R-M", "GENE_OR_GENE_PRODUCT", 37, 47], ["m6A", "GENE_OR_GENE_PRODUCT", 89, 92], ["DNA", "CELLULAR_COMPONENT", 242, 245], ["Helicobacter pylori", "ORGANISM", 305, 324], ["m4C", "DNA", 4, 7], ["m6A", "PROTEIN", 89, 92], ["Helicobacter pylori", "SPECIES", 305, 324], ["Helicobacter pylori", "SPECIES", 305, 324], ["The m4C modification", "TREATMENT", 0, 20], ["this modification", "TREATMENT", 126, 143], ["DISCUSSIONRecent studies", "TEST", 187, 211], ["N 4 -cytosine DNA methylation", "TREATMENT", 228, 257], ["Helicobacter pylori", "PROBLEM", 305, 324], ["Helicobacter pylori", "ANATOMY", 305, 324]]], ["Indeed, in human gastric adenocarcinoma cells, H. pylori mutant with increasing m4C methylation increased adhesion, while the bacteria without m4C methyltransferase halved the adhesion rate and significantly reduced H. pylori-induced apoptosis.", [["gastric adenocarcinoma cells", "ANATOMY", 17, 45], ["gastric adenocarcinoma", "DISEASE", 17, 39], ["m4C", "CHEMICAL", 80, 83], ["human", "ORGANISM", 11, 16], ["gastric adenocarcinoma cells", "CELL", 17, 45], ["H. pylori mutant", "ORGANISM", 47, 63], ["m4C", "GENE_OR_GENE_PRODUCT", 80, 83], ["m4C methyltransferase", "GENE_OR_GENE_PRODUCT", 143, 164], ["human gastric adenocarcinoma cells", "CELL_TYPE", 11, 45], ["m4C", "PROTEIN", 80, 83], ["m4C methyltransferase", "PROTEIN", 143, 164], ["human", "SPECIES", 11, 16], ["H. pylori", "SPECIES", 47, 56], ["human", "SPECIES", 11, 16], ["H. pylori", "SPECIES", 47, 56], ["human gastric adenocarcinoma cells", "PROBLEM", 11, 45], ["H. pylori mutant", "PROBLEM", 47, 63], ["increasing m4C methylation increased adhesion", "PROBLEM", 69, 114], ["the bacteria", "PROBLEM", 122, 134], ["m4C methyltransferase", "TREATMENT", 143, 164], ["the adhesion rate", "TEST", 172, 189], ["significantly reduced H. pylori-induced apoptosis", "PROBLEM", 194, 243], ["gastric", "ANATOMY", 17, 24], ["adenocarcinoma cells", "OBSERVATION", 25, 45], ["increasing", "OBSERVATION_MODIFIER", 69, 79], ["increased", "OBSERVATION_MODIFIER", 96, 105], ["adhesion", "OBSERVATION_MODIFIER", 106, 114], ["pylori-induced apoptosis", "OBSERVATION", 219, 243]]], ["Additionally, in Cyanobacterium Synechocystis sp.", [["Cyanobacterium Synechocystis sp", "ORGANISM", 17, 48], ["Cyanobacterium Synechocystis", "SPECIES", 17, 45], ["Cyanobacterium", "OBSERVATION", 17, 31], ["Synechocystis sp", "OBSERVATION", 32, 48]]], ["PCC 6803m4C, methylation is involved in the regulation of gene expression, fine-tuning of DNA replication and DNA repair mechanisms (Gartner et al., 2019) .", [["PCC 6803m4C", "CHEMICAL", 0, 11], ["DNA", "CELLULAR_COMPONENT", 90, 93], ["DNA", "CELLULAR_COMPONENT", 110, 113], ["PCC 6803m4C", "DNA", 0, 11], ["DNA replication", "TREATMENT", 90, 105], ["DNA repair mechanisms", "TREATMENT", 110, 131]]], ["Until now, however, the role of m4c modification in Mtb has been uncertain.DISCUSSIONIn our study, we found 11 up-regulated genes harboring an m4c modification in the promoter region (Supplementary Table 12 ) of BCG genome are homologous with these genes which had been studied to show important roles in Mtb.", [["m4c", "GENE_OR_GENE_PRODUCT", 32, 35], ["Mtb", "GENE_OR_GENE_PRODUCT", 52, 55], ["m4c", "GENE_OR_GENE_PRODUCT", 143, 146], ["Mtb", "GENE_OR_GENE_PRODUCT", 305, 308], ["m4c", "PROTEIN", 32, 35], ["up-regulated genes", "DNA", 111, 129], ["m4c", "DNA", 143, 146], ["promoter region", "DNA", 167, 182], ["Supplementary Table 12", "DNA", 184, 206], ["BCG genome", "DNA", 212, 222], ["m4c modification", "TREATMENT", 32, 48], ["our study", "TEST", 88, 97], ["an m4c modification", "TREATMENT", 140, 159], ["BCG genome", "TREATMENT", 212, 222]]], ["For example, Rv2416c (JTY_RS12525) is a secretory protein that enhances survival inside macrophages (Ganaie et al., 2011) .", [["macrophages", "ANATOMY", 88, 99], ["Rv2416c", "CHEMICAL", 13, 20], ["Rv2416c", "GENE_OR_GENE_PRODUCT", 13, 20], ["JTY_RS12525", "GENE_OR_GENE_PRODUCT", 22, 33], ["macrophages", "CELL", 88, 99], ["secretory protein", "PROTEIN", 40, 57], ["macrophages", "CELL_TYPE", 88, 99], ["Rv", "TEST", 13, 15], ["a secretory protein", "PROBLEM", 38, 57], ["Rv", "ANATOMY", 13, 15]]], ["Rv3130c (JTY_RS16210) encodes a triacylglycerol synthase that synthesizes triacylglycerol.", [["triacylglycerol", "CHEMICAL", 32, 47], ["triacylglycerol", "CHEMICAL", 74, 89], ["triacylglycerol", "CHEMICAL", 32, 47], ["triacylglycerol", "CHEMICAL", 74, 89], ["Rv3130c", "GENE_OR_GENE_PRODUCT", 0, 7], ["JTY_RS16210", "GENE_OR_GENE_PRODUCT", 9, 20], ["triacylglycerol synthase", "GENE_OR_GENE_PRODUCT", 32, 56], ["triacylglycerol", "SIMPLE_CHEMICAL", 74, 89], ["Rv3130c", "PROTEIN", 0, 7], ["triacylglycerol synthase", "PROTEIN", 32, 56], ["a triacylglycerol synthase", "TREATMENT", 30, 56], ["synthesizes triacylglycerol", "TREATMENT", 62, 89]]], ["This is proposed as an energy source during dormancy, and its disruption prevents triacylglycerol accumulation under inducing conditions (Sirakova et al., 2006) .", [["triacylglycerol", "CHEMICAL", 82, 97], ["triacylglycerol", "CHEMICAL", 82, 97], ["triacylglycerol", "SIMPLE_CHEMICAL", 82, 97], ["triacylglycerol accumulation", "PROBLEM", 82, 110], ["triacylglycerol accumulation", "OBSERVATION", 82, 110]]], ["Rv2626c (JTY_RS13655) plays a significant role in macrophage pro-inflammatory response and in mycobacterial survival during infection (Sun et al., 2017) .", [["macrophage", "ANATOMY", 50, 60], ["mycobacterial", "ANATOMY", 94, 107], ["infection", "DISEASE", 124, 133], ["Rv2626c", "GENE_OR_GENE_PRODUCT", 0, 7], ["JTY_RS13655", "GENE_OR_GENE_PRODUCT", 9, 20], ["macrophage", "CELL", 50, 60], ["Rv2626c", "PROTEIN", 0, 7], ["macrophage pro-inflammatory response", "TREATMENT", 50, 86], ["mycobacterial survival during infection", "PROBLEM", 94, 133], ["macrophage pro-inflammatory", "OBSERVATION", 50, 77], ["mycobacterial survival", "OBSERVATION", 94, 116]]], ["Rv0256c (JTY_RS01360), which can be used as a potential marker for the serodiagnosis of tuberculosis patients, may inhibit nitric oxide (NO) production in activated macrophages (Bhat et al., 2013; Abraham et al., 2014) .", [["macrophages", "ANATOMY", 165, 176], ["tuberculosis", "DISEASE", 88, 100], ["nitric oxide", "CHEMICAL", 123, 135], ["NO", "CHEMICAL", 137, 139], ["nitric oxide", "CHEMICAL", 123, 135], ["NO", "CHEMICAL", 137, 139], ["Rv0256c", "GENE_OR_GENE_PRODUCT", 0, 7], ["JTY_RS01360", "GENE_OR_GENE_PRODUCT", 9, 20], ["patients", "ORGANISM", 101, 109], ["nitric oxide", "SIMPLE_CHEMICAL", 123, 135], ["NO", "SIMPLE_CHEMICAL", 137, 139], ["macrophages", "CELL", 165, 176], ["Rv0256c", "PROTEIN", 0, 7], ["activated macrophages", "CELL_TYPE", 155, 176], ["patients", "SPECIES", 101, 109], ["tuberculosis", "PROBLEM", 88, 100], ["nitric oxide", "TREATMENT", 123, 135], ["tuberculosis", "OBSERVATION", 88, 100]]], ["Rv1187 (JTY_RS06330), encoding pyrroline-5-carboxylate dehydrogenase, was shown to be involved in the prolineutilization pathway in Mtb, and this pathway could be a valuable therapeutic target against TB (Jena et al., 2015) .", [["pyrroline-5-carboxylate", "CHEMICAL", 31, 54], ["TB", "DISEASE", 201, 203], ["pyrroline-5-carboxylate", "CHEMICAL", 31, 54], ["Rv1187", "GENE_OR_GENE_PRODUCT", 0, 6], ["JTY_RS06330", "GENE_OR_GENE_PRODUCT", 8, 19], ["pyrroline-5-carboxylate dehydrogenase", "GENE_OR_GENE_PRODUCT", 31, 68], ["Mtb", "GENE_OR_GENE_PRODUCT", 132, 135], ["Rv1187", "DNA", 0, 6], ["pyrroline-5-carboxylate dehydrogenase", "PROTEIN", 31, 68], ["JTY", "TEST", 8, 11], ["encoding pyrroline", "TREATMENT", 22, 40], ["carboxylate dehydrogenase", "TREATMENT", 43, 68], ["TB", "PROBLEM", 201, 203]]], ["Additionally, Rv2308 (JTY_RS11970), Rv2100 (JTY_RS10875) and Rv2015c (JTY_RS10425) encoding hypothetical proteins, Rv2618 (JTY_RS13615) encoding transcription regulator, Rv2893 (JTY_RS14970) encoding oxidoreductase, Rv3892c (JTY_RS20265) encoding PPE protein are also methylated at the promoter region.DISCUSSIONIn metabolomics, we found that the concentrations of several metabolites including tryptophan, inosine, NAD and ADP decreased after V B1 and Vc treatment.", [["tryptophan", "CHEMICAL", 395, 405], ["inosine", "CHEMICAL", 407, 414], ["NAD", "CHEMICAL", 416, 419], ["ADP", "CHEMICAL", 424, 427], ["tryptophan", "CHEMICAL", 395, 405], ["inosine", "CHEMICAL", 407, 414], ["NAD", "CHEMICAL", 416, 419], ["ADP", "CHEMICAL", 424, 427], ["JTY_RS11970", "GENE_OR_GENE_PRODUCT", 22, 33], ["JTY_RS10875", "GENE_OR_GENE_PRODUCT", 44, 55], ["JTY_RS10425", "GENE_OR_GENE_PRODUCT", 70, 81], ["Rv2618", "GENE_OR_GENE_PRODUCT", 115, 121], ["JTY_RS13615", "GENE_OR_GENE_PRODUCT", 123, 134], ["Rv2893", "GENE_OR_GENE_PRODUCT", 170, 176], ["JTY_RS14970) encoding oxidoreductase", "GENE_OR_GENE_PRODUCT", 178, 214], ["Rv3892c", "GENE_OR_GENE_PRODUCT", 216, 223], ["JTY_RS20265", "GENE_OR_GENE_PRODUCT", 225, 236], ["PPE", "GENE_OR_GENE_PRODUCT", 247, 250], ["tryptophan", "SIMPLE_CHEMICAL", 395, 405], ["inosine", "SIMPLE_CHEMICAL", 407, 414], ["NAD", "SIMPLE_CHEMICAL", 416, 419], ["ADP", "SIMPLE_CHEMICAL", 424, 427], ["V B1", "GENE_OR_GENE_PRODUCT", 444, 448], ["Vc", "SIMPLE_CHEMICAL", 453, 455], ["Rv2308", "PROTEIN", 14, 20], ["Rv2100", "PROTEIN", 36, 42], ["RS10875", "PROTEIN", 48, 55], ["Rv2015c", "DNA", 61, 68], ["RS10425", "PROTEIN", 74, 81], ["Rv2618", "PROTEIN", 115, 121], ["JTY", "PROTEIN", 123, 126], ["RS13615", "PROTEIN", 127, 134], ["transcription regulator", "PROTEIN", 145, 168], ["Rv2893", "PROTEIN", 170, 176], ["JTY", "PROTEIN", 178, 181], ["RS14970", "PROTEIN", 182, 189], ["oxidoreductase", "PROTEIN", 200, 214], ["Rv3892c", "PROTEIN", 216, 223], ["JTY", "PROTEIN", 225, 228], ["RS20265", "PROTEIN", 229, 236], ["PPE protein", "PROTEIN", 247, 258], ["promoter region", "DNA", 286, 301], ["JTY", "TEST", 22, 25], ["JTY", "TEST", 44, 47], ["encoding PPE protein", "TREATMENT", 238, 258], ["tryptophan", "TREATMENT", 395, 405], ["inosine", "TREATMENT", 407, 414], ["NAD", "PROBLEM", 416, 419], ["ADP", "TEST", 424, 427], ["V B1 and Vc treatment", "TREATMENT", 444, 465]]], ["Tryptophan is classified as an essential amino acid in humans and must be acquired through the diet.", [["Tryptophan", "CHEMICAL", 0, 10], ["amino acid", "CHEMICAL", 41, 51], ["Tryptophan", "CHEMICAL", 0, 10], ["amino acid", "CHEMICAL", 41, 51], ["Tryptophan", "SIMPLE_CHEMICAL", 0, 10], ["amino acid", "AMINO_ACID", 41, 51], ["humans", "ORGANISM", 55, 61], ["humans", "SPECIES", 55, 61], ["humans", "SPECIES", 55, 61], ["Tryptophan", "TREATMENT", 0, 10], ["an essential amino acid in humans", "TREATMENT", 28, 61], ["amino acid", "OBSERVATION", 41, 51]]], ["This requirement alleviates the concern of common targets within humans.", [["humans", "ORGANISM", 65, 71], ["humans", "SPECIES", 65, 71], ["humans", "SPECIES", 65, 71], ["common", "OBSERVATION_MODIFIER", 43, 49], ["targets", "OBSERVATION", 50, 57]]], ["Recent studies found that tryptophan synthase which catalyzes the final step in tryptophan biosynthesis is one potentially novel anti-tubercular drug target (Abrahams et al., 2017) .", [["anti-tubercular", "ANATOMY", 129, 144], ["tryptophan", "CHEMICAL", 26, 36], ["tryptophan", "CHEMICAL", 80, 90], ["tryptophan", "CHEMICAL", 26, 36], ["tryptophan", "CHEMICAL", 80, 90], ["tryptophan synthase", "GENE_OR_GENE_PRODUCT", 26, 45], ["tryptophan", "SIMPLE_CHEMICAL", 80, 90], ["tryptophan synthase", "PROTEIN", 26, 45], ["Recent studies", "TEST", 0, 14], ["tryptophan synthase", "TREATMENT", 26, 45]]], ["In addition, treatment with 6-FABA 2-amino-6-fluoro-benzoic acid (6-FABA) chemically induces Mtb tryptophan auxotrophy.", [["6-FABA 2-amino-6-fluoro-benzoic acid", "CHEMICAL", 28, 64], ["6-FABA", "CHEMICAL", 66, 72], ["tryptophan", "CHEMICAL", 97, 107], ["6-FABA 2-amino-6-fluoro-benzoic acid", "CHEMICAL", 28, 64], ["6-FABA", "CHEMICAL", 66, 72], ["tryptophan", "CHEMICAL", 97, 107], ["6-FABA 2-amino-6-fluoro-benzoic acid", "SIMPLE_CHEMICAL", 28, 64], ["6-FABA", "SIMPLE_CHEMICAL", 66, 72], ["Mtb", "SIMPLE_CHEMICAL", 93, 96], ["tryptophan", "AMINO_ACID", 97, 107], ["treatment", "TREATMENT", 13, 22], ["amino-6-fluoro-benzoic acid", "TREATMENT", 37, 64], ["Mtb tryptophan auxotrophy", "PROBLEM", 93, 118], ["Mtb", "OBSERVATION", 93, 96], ["tryptophan auxotrophy", "OBSERVATION", 97, 118]]], ["Together with immune-mediated trypothan starvation, this results in mycobacterial death.", [["mycobacterial death", "DISEASE", 68, 87], ["trypothan", "SIMPLE_CHEMICAL", 30, 39], ["immune-mediated trypothan starvation", "TREATMENT", 14, 50], ["mycobacterial death", "PROBLEM", 68, 87], ["mycobacterial death", "OBSERVATION", 68, 87]]], ["The results provide genetic and chemical validation of the tryptophan biosynthesis pathway as a target for highly active antibiotics (Zhang et al., 2013) .DISCUSSIONInosine is made up of deaminizing adenosine and can be released extracellularly under inflammatory conditions (Jabs et al., 1995; Schmidt et al., 1995) .", [["tryptophan", "CHEMICAL", 59, 69], ["adenosine", "CHEMICAL", 199, 208], ["tryptophan", "CHEMICAL", 59, 69], ["adenosine", "CHEMICAL", 199, 208], ["tryptophan", "SIMPLE_CHEMICAL", 59, 69], ["adenosine", "SIMPLE_CHEMICAL", 199, 208], ["the tryptophan biosynthesis pathway", "TREATMENT", 55, 90], ["highly active antibiotics", "TREATMENT", 107, 132], ["deaminizing adenosine", "TREATMENT", 187, 208], ["inflammatory", "OBSERVATION", 251, 263]]], ["Inosine has been reported to exert nutritional and neuroprotective functions in nerve cells, and stimulates mast cell degranulation by activating adenosine A3 receptor (Jin et al., 1997) .", [["nerve cells", "ANATOMY", 80, 91], ["mast cell", "ANATOMY", 108, 117], ["Inosine", "CHEMICAL", 0, 7], ["adenosine", "CHEMICAL", 146, 155], ["Inosine", "CHEMICAL", 0, 7], ["adenosine", "CHEMICAL", 146, 155], ["Inosine", "GENE_OR_GENE_PRODUCT", 0, 7], ["nerve cells", "CELL", 80, 91], ["mast cell", "CELL", 108, 117], ["adenosine A3 receptor", "GENE_OR_GENE_PRODUCT", 146, 167], ["nerve cells", "CELL_TYPE", 80, 91], ["adenosine A3 receptor", "PROTEIN", 146, 167], ["Inosine", "TREATMENT", 0, 7], ["mast cell degranulation", "PROBLEM", 108, 131], ["nerve cells", "ANATOMY", 80, 91], ["mast cell degranulation", "OBSERVATION", 108, 131]]], ["Moreover, inosine exhibits antiinflammatory activity by inhibiting the release of inflammatory cytokine from activated T cells and promoting the formation of IL-10.", [["T cells", "ANATOMY", 119, 126], ["inosine", "CHEMICAL", 10, 17], ["inosine", "CHEMICAL", 10, 17], ["inosine", "SIMPLE_CHEMICAL", 10, 17], ["T cells", "CELL", 119, 126], ["IL-10", "GENE_OR_GENE_PRODUCT", 158, 163], ["inflammatory cytokine", "PROTEIN", 82, 103], ["activated T cells", "CELL_TYPE", 109, 126], ["IL", "PROTEIN", 158, 160], ["inosine", "TREATMENT", 10, 17], ["antiinflammatory activity", "TREATMENT", 27, 52], ["inflammatory cytokine", "PROBLEM", 82, 103], ["activated T cells", "TREATMENT", 109, 126], ["antiinflammatory activity", "OBSERVATION", 27, 52], ["inflammatory", "OBSERVATION_MODIFIER", 82, 94]]], ["Clinical trials have proposed that the use of inosine to raise serum urate levels may have benefits for at least some multiple sclerosis patients.", [["serum", "ANATOMY", 63, 68], ["inosine", "CHEMICAL", 46, 53], ["urate", "CHEMICAL", 69, 74], ["multiple sclerosis", "DISEASE", 118, 136], ["inosine", "CHEMICAL", 46, 53], ["urate", "CHEMICAL", 69, 74], ["inosine", "SIMPLE_CHEMICAL", 46, 53], ["serum", "ORGANISM_SUBSTANCE", 63, 68], ["urate", "SIMPLE_CHEMICAL", 69, 74], ["patients", "ORGANISM", 137, 145], ["patients", "SPECIES", 137, 145], ["inosine", "TREATMENT", 46, 53], ["serum urate levels", "TEST", 63, 81], ["some multiple sclerosis patients", "PROBLEM", 113, 145], ["multiple", "OBSERVATION_MODIFIER", 118, 126], ["sclerosis", "OBSERVATION", 127, 136]]], ["The effect of this treatment is likely to be a consequence of inactivation of peroxynitrite-dependent free radicals (Markowitz et al., 2009) .", [["peroxynitrite", "CHEMICAL", 78, 91], ["peroxynitrite", "CHEMICAL", 78, 91], ["peroxynitrite", "SIMPLE_CHEMICAL", 78, 91], ["free radicals", "SIMPLE_CHEMICAL", 102, 115], ["this treatment", "TREATMENT", 14, 28], ["peroxynitrite", "TREATMENT", 78, 91], ["likely to be", "UNCERTAINTY", 32, 44]]], ["NAD(P) is an indispensable cofactor for all organisms and its biosynthetic pathways are proposed as promising novel antibiotics targets against pathogens such as Mtb.", [["NAD", "CHEMICAL", 0, 3], ["NAD", "CHEMICAL", 0, 3], ["NAD", "SIMPLE_CHEMICAL", 0, 3], ["Mtb", "GENE_OR_GENE_PRODUCT", 162, 165], ["NAD(P)", "PROTEIN", 0, 6], ["NAD", "PROBLEM", 0, 3], ["an indispensable cofactor", "PROBLEM", 10, 35], ["all organisms", "PROBLEM", 40, 53], ["novel antibiotics", "TREATMENT", 110, 127], ["pathogens", "PROBLEM", 144, 153], ["Mtb", "PROBLEM", 162, 165], ["cofactor", "OBSERVATION", 27, 35]]], ["It is reported that NAD(P) play the import role in immune response, gene silencing, DNA repair, regulation, redox reaction, energy and cellular metabolism which participate in more than 300 biochemical reactions, amounting to 17% of all the classical reaction (You, 1985; Bi et al., 2011) .", [["cellular", "ANATOMY", 135, 143], ["NAD", "CHEMICAL", 20, 23], ["NAD(P)", "CHEMICAL", 20, 26], ["NAD", "SIMPLE_CHEMICAL", 20, 23], ["DNA", "CELLULAR_COMPONENT", 84, 87], ["cellular", "CELL", 135, 143], ["NAD", "PROBLEM", 20, 23], ["gene silencing", "TREATMENT", 68, 82], ["DNA repair", "TREATMENT", 84, 94], ["redox reaction", "PROBLEM", 108, 122], ["cellular metabolism", "PROBLEM", 135, 154], ["300 biochemical reactions", "PROBLEM", 186, 211], ["cellular metabolism", "OBSERVATION", 135, 154]]], ["Nicotinamide adenine dinucleotide (NAD+) is essential for a variety of organisms, and it is both a coenzyme for hydride-transfer enzymes and a substrate for NAD+-consuming enzymes, such as ADPribose transferases, poly(ADP-ribose) polymerases, cADP-ribose synthases, and sirtuins.DISCUSSIONSince the synthesis pathways of these significantly reduced metabolites are mostly drug targets for the treatment of tuberculosis, we hypothesized that the addition of vitamins may directly or indirectly affect the synthesis or metabolic processes of these products.", [["Nicotinamide adenine dinucleotide", "CHEMICAL", 0, 33], ["NAD", "CHEMICAL", 35, 38], ["NAD", "CHEMICAL", 157, 160], ["poly(ADP-ribose", "CHEMICAL", 213, 228], ["cADP-ribose", "CHEMICAL", 243, 254], ["tuberculosis", "DISEASE", 406, 418], ["vitamins", "CHEMICAL", 457, 465], ["Nicotinamide adenine dinucleotide", "CHEMICAL", 0, 33], ["NAD+", "CHEMICAL", 35, 39], ["hydride", "CHEMICAL", 112, 119], ["NAD+", "CHEMICAL", 157, 161], ["ADPribose", "CHEMICAL", 189, 198], ["poly(ADP-ribose)", "CHEMICAL", 213, 229], ["cADP", "CHEMICAL", 243, 247], ["ribose", "CHEMICAL", 248, 254], ["Nicotinamide adenine dinucleotide", "SIMPLE_CHEMICAL", 0, 33], ["NAD+", "SIMPLE_CHEMICAL", 35, 39], ["coenzyme", "SIMPLE_CHEMICAL", 99, 107], ["hydride", "SIMPLE_CHEMICAL", 112, 119], ["NAD+", "SIMPLE_CHEMICAL", 157, 161], ["ADPribose transferases", "GENE_OR_GENE_PRODUCT", 189, 211], ["poly(ADP-ribose) polymerases", "GENE_OR_GENE_PRODUCT", 213, 241], ["cADP-ribose synthases", "GENE_OR_GENE_PRODUCT", 243, 264], ["sirtuins", "GENE_OR_GENE_PRODUCT", 270, 278], ["vitamins", "SIMPLE_CHEMICAL", 457, 465], ["hydride-transfer enzymes", "PROTEIN", 112, 136], ["NAD+-consuming enzymes", "PROTEIN", 157, 179], ["ADPribose transferases", "PROTEIN", 189, 211], ["poly(ADP-ribose) polymerases", "PROTEIN", 213, 241], ["cADP-ribose synthases", "PROTEIN", 243, 264], ["sirtuins", "PROTEIN", 270, 278], ["Nicotinamide adenine dinucleotide (NAD+)", "TREATMENT", 0, 40], ["a variety of organisms", "PROBLEM", 58, 80], ["NAD", "PROBLEM", 157, 160], ["enzymes", "TEST", 172, 179], ["ADPribose transferases", "TEST", 189, 211], ["poly(ADP-ribose) polymerases", "TREATMENT", 213, 241], ["cADP-ribose synthases", "TREATMENT", 243, 264], ["these significantly reduced metabolites", "PROBLEM", 321, 360], ["tuberculosis", "PROBLEM", 406, 418], ["vitamins", "TREATMENT", 457, 465], ["the synthesis", "PROBLEM", 500, 513], ["these products", "TREATMENT", 540, 554], ["ribose synthases", "OBSERVATION", 248, 264], ["tuberculosis", "OBSERVATION", 406, 418]]], ["This could potentially inhibit bacterial growth.DISCUSSIONA striking result in this study is that V B1 treatment of BCG resulted in content reduction of almost all types of amino acids, whereas Vc treatment caused the opposite effect.", [["BCG", "CHEMICAL", 116, 119], ["amino acids", "CHEMICAL", 173, 184], ["amino acids", "CHEMICAL", 173, 184], ["V B1", "GENE_OR_GENE_PRODUCT", 98, 102], ["amino acids", "AMINO_ACID", 173, 184], ["Vc", "MULTI-TISSUE_STRUCTURE", 194, 196], ["bacterial growth", "PROBLEM", 31, 47], ["this study", "TEST", 79, 89], ["V B1 treatment of BCG", "TREATMENT", 98, 119], ["content reduction", "TREATMENT", 132, 149], ["amino acids", "TEST", 173, 184], ["Vc treatment", "TREATMENT", 194, 206], ["bacterial", "OBSERVATION_MODIFIER", 31, 40], ["growth", "OBSERVATION_MODIFIER", 41, 47], ["opposite effect", "OBSERVATION", 218, 233]]], ["Through RNA-seq analysis, we found that the gene encoding cysteine synthase A was significantly up-regulated after vitamin treatment, suggesting that Cys synthesis is promoted.", [["cysteine", "CHEMICAL", 58, 66], ["vitamin", "CHEMICAL", 115, 122], ["Cys", "CHEMICAL", 150, 153], ["cysteine", "CHEMICAL", 58, 66], ["vitamin", "CHEMICAL", 115, 122], ["Cys", "CHEMICAL", 150, 153], ["cysteine synthase A", "GENE_OR_GENE_PRODUCT", 58, 77], ["vitamin", "SIMPLE_CHEMICAL", 115, 122], ["Cys", "SIMPLE_CHEMICAL", 150, 153], ["cysteine synthase A", "PROTEIN", 58, 77], ["RNA-seq analysis", "TEST", 8, 24], ["the gene encoding cysteine synthase A", "PROBLEM", 40, 77], ["vitamin treatment", "TREATMENT", 115, 132], ["Cys synthesis", "PROBLEM", 150, 163]]], ["It has been reported that isoniazid (INH)/Cys combination potentiates the killing of Mtb by stimulating respiration of Mtb from non-respiring dormancy (Vilcheze et al., 2017) .", [["isoniazid", "CHEMICAL", 26, 35], ["INH", "CHEMICAL", 37, 40], ["Cys", "CHEMICAL", 42, 45], ["isoniazid", "CHEMICAL", 26, 35], ["INH", "CHEMICAL", 37, 40], ["Cys", "CHEMICAL", 42, 45], ["isoniazid", "SIMPLE_CHEMICAL", 26, 35], ["INH", "SIMPLE_CHEMICAL", 37, 40], ["Cys", "SIMPLE_CHEMICAL", 42, 45], ["Mtb", "GENE_OR_GENE_PRODUCT", 85, 88], ["isoniazid (INH)", "TREATMENT", 26, 41], ["Cys combination", "TREATMENT", 42, 57], ["Mtb", "PROBLEM", 85, 88], ["isoniazid", "OBSERVATION", 26, 35]]], ["High levels of intracellular cysteine can induce ROS production, causing DNA damage and oxidation of cysteine to cystine in E. coli (Park and Imlay, 2003) .", [["intracellular", "ANATOMY", 15, 28], ["cysteine", "CHEMICAL", 29, 37], ["ROS", "CHEMICAL", 49, 52], ["cysteine", "CHEMICAL", 101, 109], ["cystine", "CHEMICAL", 113, 120], ["cysteine", "CHEMICAL", 29, 37], ["cysteine", "CHEMICAL", 101, 109], ["cystine", "CHEMICAL", 113, 120], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 15, 28], ["cysteine", "AMINO_ACID", 29, 37], ["ROS", "SIMPLE_CHEMICAL", 49, 52], ["DNA", "CELLULAR_COMPONENT", 73, 76], ["cysteine", "AMINO_ACID", 101, 109], ["cystine", "SIMPLE_CHEMICAL", 113, 120], ["E. coli", "ORGANISM", 124, 131], ["E. coli", "SPECIES", 124, 131], ["E. coli", "SPECIES", 124, 131], ["High levels of intracellular cysteine", "PROBLEM", 0, 37], ["ROS production", "PROBLEM", 49, 63], ["DNA damage", "PROBLEM", 73, 83], ["cysteine to cystine in E. coli", "PROBLEM", 101, 131], ["intracellular cysteine", "OBSERVATION", 15, 37], ["ROS production", "OBSERVATION", 49, 63], ["E. coli", "OBSERVATION", 124, 131]]], ["Indeed, transition metals, such as copper or iron, catalyze the oxidation of cysteine into cystine, leading to the production of hydrogen peroxide (H 2 O 2 ), superoxide, and hydroxyl radicals (Kachur et al., 1999) .", [["copper", "CHEMICAL", 35, 41], ["iron", "CHEMICAL", 45, 49], ["cysteine", "CHEMICAL", 77, 85], ["cystine", "CHEMICAL", 91, 98], ["hydrogen peroxide", "CHEMICAL", 129, 146], ["H 2 O 2", "CHEMICAL", 148, 155], ["superoxide", "CHEMICAL", 159, 169], ["hydroxyl", "CHEMICAL", 175, 183], ["copper", "CHEMICAL", 35, 41], ["iron", "CHEMICAL", 45, 49], ["cysteine", "CHEMICAL", 77, 85], ["cystine", "CHEMICAL", 91, 98], ["hydrogen peroxide", "CHEMICAL", 129, 146], ["H 2 O 2", "CHEMICAL", 148, 155], ["superoxide", "CHEMICAL", 159, 169], ["hydroxyl", "CHEMICAL", 175, 183], ["copper", "SIMPLE_CHEMICAL", 35, 41], ["iron", "SIMPLE_CHEMICAL", 45, 49], ["cysteine", "AMINO_ACID", 77, 85], ["cystine", "SIMPLE_CHEMICAL", 91, 98], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 129, 146], ["H 2 O 2", "SIMPLE_CHEMICAL", 148, 155], ["superoxide", "SIMPLE_CHEMICAL", 159, 169], ["hydroxyl radicals", "SIMPLE_CHEMICAL", 175, 192], ["transition metals", "TREATMENT", 8, 25], ["iron", "TREATMENT", 45, 49], ["the oxidation of cysteine into cystine", "TREATMENT", 60, 98], ["hydrogen peroxide", "TREATMENT", 129, 146], ["superoxide", "TREATMENT", 159, 169], ["hydroxyl radicals", "TREATMENT", 175, 192]]], ["This high concentration of cysteine could therefore initiate cationic stress, resulting in the formation of ROS and DNA damage (Imlay et al., 1988; Demple and Harrison, 1994) .DISCUSSIONIn our study, the gene encoding cysteine synthase A was significantly up-regulated after V B1 and Vc treatment and this hinting that the synthesis of cysteine is promoted.", [["cysteine", "CHEMICAL", 27, 35], ["ROS", "CHEMICAL", 108, 111], ["cysteine", "CHEMICAL", 218, 226], ["cysteine", "CHEMICAL", 336, 344], ["cysteine", "CHEMICAL", 27, 35], ["cysteine", "CHEMICAL", 218, 226], ["cysteine", "CHEMICAL", 336, 344], ["cysteine", "AMINO_ACID", 27, 35], ["ROS", "SIMPLE_CHEMICAL", 108, 111], ["DNA", "CELLULAR_COMPONENT", 116, 119], ["cysteine synthase A", "GENE_OR_GENE_PRODUCT", 218, 237], ["V B1", "GENE_OR_GENE_PRODUCT", 275, 279], ["Vc", "SIMPLE_CHEMICAL", 284, 286], ["cysteine", "AMINO_ACID", 336, 344], ["cysteine synthase A", "PROTEIN", 218, 237], ["This high concentration of cysteine", "PROBLEM", 0, 35], ["cationic stress", "PROBLEM", 61, 76], ["ROS", "PROBLEM", 108, 111], ["DNA damage", "PROBLEM", 116, 126], ["our study", "TEST", 189, 198], ["V B1 and Vc treatment", "TREATMENT", 275, 296]]], ["In addition, in vitro growth test show that cysteine inhibit the growth of BCG in a concentration-dependent manner.", [["cysteine", "CHEMICAL", 44, 52], ["cysteine", "CHEMICAL", 44, 52], ["cysteine", "SIMPLE_CHEMICAL", 44, 52], ["vitro growth test", "TEST", 16, 33], ["growth", "OBSERVATION_MODIFIER", 65, 71], ["BCG", "OBSERVATION", 75, 78]]], ["Therefore, we hypothesize that V B1 and Vc inhibit BCG growth by increasing the concentration of cysteine, which can eventually damage DNA via Fenton reaction.", [["cysteine", "CHEMICAL", 97, 105], ["cysteine", "CHEMICAL", 97, 105], ["V B1", "GENE_OR_GENE_PRODUCT", 31, 35], ["Vc", "SIMPLE_CHEMICAL", 40, 42], ["cysteine", "AMINO_ACID", 97, 105], ["DNA", "CELLULAR_COMPONENT", 135, 138], ["Fenton", "SIMPLE_CHEMICAL", 143, 149], ["V B1", "PROTEIN", 31, 35], ["Vc inhibit BCG growth", "PROBLEM", 40, 61], ["increasing the concentration of cysteine", "PROBLEM", 65, 105], ["Fenton reaction", "PROBLEM", 143, 158]]], ["This hypothesis is consistent with the transcriptomics results, where Vc induced the expression of genes related to DNA repair, suggesting that Vc may indirectly affect DNA integrity.DISCUSSIONNotably, the scientists found that Vc sterilized Mtb cultures via Fenton reaction and increased iron concentration, which correlates with the bactericidal activity of V C (Vilcheze et al., 2013) .", [["Fenton", "CHEMICAL", 259, 265], ["iron", "CHEMICAL", 289, 293], ["iron", "CHEMICAL", 289, 293], ["DNA", "CELLULAR_COMPONENT", 116, 119], ["Vc", "GENE_OR_GENE_PRODUCT", 144, 146], ["DNA", "CELLULAR_COMPONENT", 169, 172], ["Fenton", "SIMPLE_CHEMICAL", 259, 265], ["iron", "SIMPLE_CHEMICAL", 289, 293], ["V C", "SIMPLE_CHEMICAL", 360, 363], ["Vc", "PROTEIN", 70, 72], ["Vc", "PROTEIN", 144, 146], ["Mtb cultures", "CELL_LINE", 242, 254], ["DNA repair", "TREATMENT", 116, 126], ["Mtb cultures", "TEST", 242, 254], ["Fenton reaction", "PROBLEM", 259, 274], ["increased iron concentration", "TREATMENT", 279, 307], ["consistent with", "UNCERTAINTY", 19, 34], ["DNA repair", "OBSERVATION", 116, 126], ["iron concentration", "OBSERVATION", 289, 307]]], ["The results shown in the present study suggest that BCG growth inhibition may not be due just to high levels of iron, but also to cysteine.", [["iron", "CHEMICAL", 112, 116], ["cysteine", "CHEMICAL", 130, 138], ["iron", "CHEMICAL", 112, 116], ["cysteine", "CHEMICAL", 130, 138], ["iron", "SIMPLE_CHEMICAL", 112, 116], ["cysteine", "SIMPLE_CHEMICAL", 130, 138], ["the present study", "TEST", 21, 38], ["BCG growth inhibition", "PROBLEM", 52, 73], ["iron", "TREATMENT", 112, 116]]], ["In addition, decreased concentrations of tryptophan, NAD(P) and other metabolites are also potential reasons for vitamin inhibition of BCG FIGURE 7 | Schematic representation of the mechanism of action of vitamins against BCG growth. growth (Figure 7) .", [["tryptophan", "CHEMICAL", 41, 51], ["NAD", "CHEMICAL", 53, 56], ["vitamin", "CHEMICAL", 113, 120], ["vitamins", "CHEMICAL", 205, 213], ["tryptophan", "CHEMICAL", 41, 51], ["NAD(P)", "CHEMICAL", 53, 59], ["vitamin", "CHEMICAL", 113, 120], ["tryptophan", "SIMPLE_CHEMICAL", 41, 51], ["NAD", "SIMPLE_CHEMICAL", 53, 56], ["vitamin", "SIMPLE_CHEMICAL", 113, 120], ["vitamins", "SIMPLE_CHEMICAL", 205, 213], ["BCG", "SIMPLE_CHEMICAL", 222, 225], ["decreased concentrations of tryptophan", "PROBLEM", 13, 51], ["NAD", "PROBLEM", 53, 56], ["vitamin inhibition", "TREATMENT", 113, 131], ["vitamins", "TREATMENT", 205, 213], ["BCG growth", "PROBLEM", 222, 232], ["decreased", "OBSERVATION_MODIFIER", 13, 22], ["concentrations", "OBSERVATION_MODIFIER", 23, 37]]], ["Our study also identifies another possible mechanism by which vitamins inhibit BCG growth.", [["vitamins", "CHEMICAL", 62, 70], ["vitamins", "CHEMICAL", 62, 70], ["vitamins", "SIMPLE_CHEMICAL", 62, 70], ["Our study", "TEST", 0, 9], ["vitamins inhibit BCG growth", "PROBLEM", 62, 89]]], ["Therefore, V B1 and Vc supplementation may enhance the action of antituberculosis drugs.DATA AVAILABILITY STATEMENTThe datasets generated for this study can be found in the Gene Expression Omnibus, accession numbers GSE114949 and GSE141513.AUTHOR CONTRIBUTIONSNS designed this study and wrote the manuscript.", [["GSE114949", "CHEMICAL", 216, 225], ["GSE141513", "CHEMICAL", 230, 239], ["V B1", "GENE_OR_GENE_PRODUCT", 11, 15], ["Vc", "SIMPLE_CHEMICAL", 20, 22], ["V B1 and Vc supplementation", "TREATMENT", 11, 38], ["antituberculosis drugs", "TREATMENT", 65, 87], ["this study", "TEST", 142, 152], ["GSE", "TEST", 230, 233], ["this study", "TEST", 272, 282]]], ["YC, ML, YT, ZC, and GD participated in the data analysis.", [["ZC", "CHEMICAL", 12, 14], ["the data analysis", "TEST", 39, 56]]], ["HZ participated in the data analysis and contributed to the writing.", [["HZ", "DISEASE", 0, 2], ["the data analysis", "TEST", 19, 36]]]], "403ce40b5f0daa6b68c28e6c35634f763796a0cb": [["The same month, NATO secretary general Jens Stoltenberg declared that \"The rise of China is fundamentally shifting the global balance of power, heating up the race for economic and technological supremacy, multiplying the threats to open societies and individual freedoms, and increasing the competition over our values and our way of life\".", [["economic and technological supremacy", "TREATMENT", 168, 204]]]], "PMC3487775": [["IntroductionCholera toxin (CT) produced by Vibrio cholerae, the major factor responsible for the severe watery diarrhea characteristic of the disease cholera, acts by intoxicating the intestinal epithelial cells (1).", [["intestinal epithelial cells", "ANATOMY", 184, 211], ["Cholera toxin", "CHEMICAL", 12, 25], ["watery diarrhea", "DISEASE", 104, 119], ["cholera", "DISEASE", 150, 157], ["Cholera toxin", "SIMPLE_CHEMICAL", 12, 25], ["CT", "SIMPLE_CHEMICAL", 27, 29], ["Vibrio cholerae", "ORGANISM", 43, 58], ["intestinal epithelial cells", "CELL", 184, 211], ["Cholera toxin", "PROTEIN", 12, 25], ["CT", "PROTEIN", 27, 29], ["intestinal epithelial cells", "CELL_TYPE", 184, 211], ["Vibrio cholerae", "SPECIES", 43, 58], ["Vibrio cholerae", "SPECIES", 43, 58], ["IntroductionCholera toxin (CT)", "TEST", 0, 30], ["Vibrio cholerae", "PROBLEM", 43, 58], ["the severe watery diarrhea", "PROBLEM", 93, 119], ["the disease cholera", "PROBLEM", 138, 157], ["severe", "OBSERVATION_MODIFIER", 97, 103], ["watery", "OBSERVATION_MODIFIER", 104, 110], ["diarrhea", "OBSERVATION", 111, 119], ["disease", "OBSERVATION", 142, 149], ["intestinal", "ANATOMY", 184, 194], ["epithelial cells", "OBSERVATION", 195, 211]]], ["CT is an AB5 toxin with a single enzymatic A subunit (CTA) and five identical B polypeptides that form a pentameric B subunit (CTB).", [["AB5", "GENE_OR_GENE_PRODUCT", 9, 12], ["B polypeptides", "GENE_OR_GENE_PRODUCT", 78, 92], ["pentameric B subunit", "GENE_OR_GENE_PRODUCT", 105, 125], ["CTB", "GENE_OR_GENE_PRODUCT", 127, 130], ["CT", "PROTEIN", 0, 2], ["AB5 toxin", "PROTEIN", 9, 18], ["enzymatic A subunit", "PROTEIN", 33, 52], ["CTA", "PROTEIN", 54, 57], ["B polypeptides", "PROTEIN", 78, 92], ["pentameric B subunit", "PROTEIN", 105, 125], ["CTB", "PROTEIN", 127, 130], ["CT", "TEST", 0, 2], ["an AB5 toxin", "TEST", 6, 18], ["identical B polypeptides", "TREATMENT", 68, 92], ["a pentameric B subunit (CTB", "TREATMENT", 103, 130]]], ["The toxin must first bind to host cells to begin a complex process whereby it gains access to its target protein in the cytoplasm.", [["cells", "ANATOMY", 34, 39], ["cytoplasm", "ANATOMY", 120, 129], ["cells", "CELL", 34, 39], ["cytoplasm", "ORGANISM_SUBSTANCE", 120, 129], ["toxin", "PROTEIN", 4, 9], ["host cells", "CELL_TYPE", 29, 39], ["The toxin", "TREATMENT", 0, 9], ["a complex process", "PROBLEM", 49, 66]]], ["The B subunit has five identical sites that can bind to ganglioside GM1 (GM1) receptors in the plasma membrane (PM).", [["plasma membrane", "ANATOMY", 95, 110], ["PM", "ANATOMY", 112, 114], ["ganglioside", "CHEMICAL", 56, 67], ["B subunit", "GENE_OR_GENE_PRODUCT", 4, 13], ["ganglioside GM1 (GM1) receptors", "GENE_OR_GENE_PRODUCT", 56, 87], ["plasma membrane", "CELLULAR_COMPONENT", 95, 110], ["PM", "CELLULAR_COMPONENT", 112, 114], ["B subunit", "PROTEIN", 4, 13], ["ganglioside GM1 (GM1) receptors", "PROTEIN", 56, 87], ["ganglioside GM1", "TEST", 56, 71], ["plasma membrane", "ANATOMY", 95, 110]]], ["The receptor-toxin complex formed at the PM is endocytosed and transported to the endoplasmic reticulum (ER) (2, 3).", [["endoplasmic reticulum", "ANATOMY", 82, 103], ["ER", "ANATOMY", 105, 107], ["PM", "CELLULAR_COMPONENT", 41, 43], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 82, 103], ["ER", "GENE_OR_GENE_PRODUCT", 105, 107], ["receptor-toxin complex", "PROTEIN", 4, 26], ["ER", "PROTEIN", 105, 107], ["endocytosed", "OBSERVATION", 47, 58], ["endoplasmic reticulum", "ANATOMY", 82, 103]]], ["Retrograde transport of CT to the ER is not mediated efficiently by other gangliosides and nonceramide lipids.", [["ER", "ANATOMY", 34, 36], ["ER", "GENE_OR_GENE_PRODUCT", 34, 36], ["gangliosides", "SIMPLE_CHEMICAL", 74, 86], ["nonceramide lipids", "SIMPLE_CHEMICAL", 91, 109], ["CT", "PROTEIN", 24, 26], ["ER", "PROTEIN", 34, 36], ["CT", "TEST", 24, 26], ["nonceramide lipids", "TREATMENT", 91, 109]]], ["The A subunit is not required for this trafficking pathway (4).", [["A subunit", "GENE_OR_GENE_PRODUCT", 4, 13], ["A subunit", "PROTEIN", 4, 13], ["this trafficking pathway", "TEST", 34, 58]]], ["The carboxy-terminal (A2) domain of the A subunit interacts noncovalently with the B pentamer to stabilize the heterohexameric AB5 structure of the holotoxin.", [["carboxy", "CHEMICAL", 4, 11], ["A", "GENE_OR_GENE_PRODUCT", 40, 41], ["B pentamer", "GENE_OR_GENE_PRODUCT", 83, 93], ["holotoxin", "GENE_OR_GENE_PRODUCT", 148, 157], ["carboxy-terminal (A2) domain", "PROTEIN", 4, 32], ["A subunit", "PROTEIN", 40, 49], ["B pentamer", "PROTEIN", 83, 93], ["heterohexameric AB5 structure", "PROTEIN", 111, 140], ["holotoxin", "PROTEIN", 148, 157], ["The carboxy-terminal (A2) domain", "TREATMENT", 0, 32], ["the B pentamer", "TREATMENT", 79, 93], ["the holotoxin", "TREATMENT", 144, 157], ["terminal", "OBSERVATION_MODIFIER", 12, 20]]], ["The A subunit has a disulfide-linked loop between Cys-187 and Cys-199, and the enzymatically active A1 fragment (CT-A1) is generated during synthesis of CT by V. cholerae protease(s) or subsequently in the gut or during interaction with the target cell (by host proteases) by cleavage after Arg-192.", [["gut", "ANATOMY", 206, 209], ["cell", "ANATOMY", 248, 252], ["Cys-187", "CHEMICAL", 50, 57], ["Cys-199", "CHEMICAL", 62, 69], ["Arg-192", "CHEMICAL", 291, 298], ["disulfide", "CHEMICAL", 20, 29], ["Cys", "CHEMICAL", 50, 53], ["Cys", "CHEMICAL", 62, 65], ["Arg-192", "CHEMICAL", 291, 298], ["A subunit", "GENE_OR_GENE_PRODUCT", 4, 13], ["Cys-187", "AMINO_ACID", 50, 57], ["Cys-199", "AMINO_ACID", 62, 69], ["CT-A1", "GENE_OR_GENE_PRODUCT", 113, 118], ["V. cholerae", "ORGANISM", 159, 170], ["gut", "ORGANISM_SUBDIVISION", 206, 209], ["cell", "CELL", 248, 252], ["Arg-192", "SIMPLE_CHEMICAL", 291, 298], ["A subunit", "PROTEIN", 4, 13], ["disulfide-linked loop", "PROTEIN", 20, 41], ["A1 fragment", "PROTEIN", 100, 111], ["CT", "PROTEIN", 113, 115], ["A1", "PROTEIN", 116, 118], ["CT", "PROTEIN", 153, 155], ["V. cholerae protease", "PROTEIN", 159, 179], ["target cell", "CELL_TYPE", 241, 252], ["host proteases", "PROTEIN", 257, 271], ["V. cholerae", "SPECIES", 159, 170], ["V. cholerae", "SPECIES", 159, 170], ["Cys", "TEST", 50, 53], ["Cys", "TEST", 62, 65], ["the enzymatically active A1 fragment", "PROBLEM", 75, 111], ["CT", "TEST", 153, 155], ["Arg", "TEST", 291, 294], ["loop", "OBSERVATION_MODIFIER", 37, 41], ["enzymatically", "OBSERVATION_MODIFIER", 79, 92], ["active", "OBSERVATION_MODIFIER", 93, 99], ["A1 fragment", "OBSERVATION", 100, 111], ["gut", "ANATOMY", 206, 209]]], ["Once CT is in the ER, the disulfide bond in CTA is reduced, and in a PDI-dependent process, CT-A1 dissociates from the rest of the toxin (5, 6).", [["disulfide", "CHEMICAL", 26, 35], ["ER", "GENE_OR_GENE_PRODUCT", 18, 20], ["CTA", "SIMPLE_CHEMICAL", 44, 47], ["PDI", "GENE_OR_GENE_PRODUCT", 69, 72], ["CT-A1", "GENE_OR_GENE_PRODUCT", 92, 97], ["CT", "PROTEIN", 5, 7], ["ER", "PROTEIN", 18, 20], ["CTA", "PROTEIN", 44, 47], ["PDI", "PROTEIN", 69, 72], ["CT", "PROTEIN", 92, 94], ["A1", "PROTEIN", 95, 97], ["CT", "TEST", 5, 7], ["the disulfide bond in CTA", "TEST", 22, 47], ["CT", "TEST", 92, 94], ["reduced", "OBSERVATION_MODIFIER", 51, 58]]], ["CT-A1 then retrotranslocates to the cytoplasm by a process that is dependent on the ER-associated degradation pathway (7\u20139).", [["cytoplasm", "ANATOMY", 36, 45], ["ER", "ANATOMY", 84, 86], ["CT-A1", "GENE_OR_GENE_PRODUCT", 0, 5], ["cytoplasm", "ORGANISM_SUBSTANCE", 36, 45], ["ER", "GENE_OR_GENE_PRODUCT", 84, 86], ["CT", "PROTEIN", 0, 2], ["A1", "PROTEIN", 3, 5], ["ER", "PROTEIN", 84, 86], ["CT", "TEST", 0, 2], ["cytoplasm", "OBSERVATION", 36, 45], ["process", "OBSERVATION", 51, 58], ["dependent", "OBSERVATION_MODIFIER", 67, 76]]], ["CT-A1 may masquerade as a misfolded protein, since it is inherently unstable at physiological temperatures and stabilizing it can prevent it from exiting the ER (10).", [["CT-A1", "GENE_OR_GENE_PRODUCT", 0, 5], ["ER", "GENE_OR_GENE_PRODUCT", 158, 160], ["CT", "PROTEIN", 0, 2], ["A1", "PROTEIN", 3, 5], ["misfolded protein", "PROTEIN", 26, 43], ["ER", "PROTEIN", 158, 160], ["CT", "TEST", 0, 2], ["a misfolded protein", "PROBLEM", 24, 43], ["inherently unstable at physiological temperatures", "PROBLEM", 57, 106], ["unstable", "OBSERVATION_MODIFIER", 68, 76]]], ["In the cytosol, CT-A1 escapes degradation by the proteasome due to the paucity of lysine residues in its structure.", [["cytosol", "ANATOMY", 7, 14], ["lysine", "CHEMICAL", 82, 88], ["lysine", "CHEMICAL", 82, 88], ["cytosol", "CELLULAR_COMPONENT", 7, 14], ["CT-A1", "GENE_OR_GENE_PRODUCT", 16, 21], ["CT", "PROTEIN", 16, 18], ["A1", "PROTEIN", 19, 21], ["proteasome", "PROTEIN", 49, 59], ["CT", "TEST", 16, 18], ["the proteasome", "TREATMENT", 45, 59], ["lysine residues in its structure", "PROBLEM", 82, 114], ["lysine residues", "OBSERVATION", 82, 97]]], ["It then forms an allosterically activated complex by binding to an ADP ribosylation factor (ARF), and it ADP ribosylates the alpha subunit of the stimulatory G protein, leading to constitutive activation of adenylate cyclase.", [["ADP", "CHEMICAL", 67, 70], ["ADP", "CHEMICAL", 105, 108], ["ADP", "CHEMICAL", 67, 70], ["ADP", "CHEMICAL", 105, 108], ["adenylate", "CHEMICAL", 207, 216], ["ADP ribosylation factor", "GENE_OR_GENE_PRODUCT", 67, 90], ["ARF", "GENE_OR_GENE_PRODUCT", 92, 95], ["ADP", "SIMPLE_CHEMICAL", 105, 108], ["G protein", "GENE_OR_GENE_PRODUCT", 158, 167], ["adenylate cyclase", "GENE_OR_GENE_PRODUCT", 207, 224], ["allosterically activated complex", "PROTEIN", 17, 49], ["ADP ribosylation factor", "PROTEIN", 67, 90], ["ARF", "PROTEIN", 92, 95], ["alpha subunit", "PROTEIN", 125, 138], ["stimulatory G protein", "PROTEIN", 146, 167], ["adenylate cyclase", "PROTEIN", 207, 224], ["an allosterically activated complex", "PROBLEM", 14, 49], ["an ADP ribosylation factor", "PROBLEM", 64, 90], ["ARF", "PROBLEM", 92, 95], ["the stimulatory G protein", "TREATMENT", 142, 167], ["adenylate cyclase", "PROBLEM", 207, 224], ["adenylate cyclase", "OBSERVATION", 207, 224]]], ["In the human intestinal cell line T84, an increased concentration of cyclic AMP elicits a Cl\u2013 secretory response which can be measured electrophysiologically in real time as a change in short circuit current, Isc (11).IntroductionA key step in the intoxication process is the transport of the toxin from the cell surface to the ER.", [["intestinal cell line T84", "ANATOMY", 13, 37], ["cell surface", "ANATOMY", 308, 320], ["ER", "ANATOMY", 328, 330], ["AMP", "CHEMICAL", 76, 79], ["cyclic AMP", "CHEMICAL", 69, 79], ["human", "ORGANISM", 7, 12], ["intestinal cell line T84", "CELL", 13, 37], ["AMP", "SIMPLE_CHEMICAL", 76, 79], ["cell surface", "CELLULAR_COMPONENT", 308, 320], ["ER", "GENE_OR_GENE_PRODUCT", 328, 330], ["human intestinal cell line T84", "CELL_LINE", 7, 37], ["toxin", "PROTEIN", 293, 298], ["ER", "PROTEIN", 328, 330], ["human", "SPECIES", 7, 12], ["human", "SPECIES", 7, 12], ["an increased concentration of cyclic AMP elicits", "PROBLEM", 39, 87], ["a change in short circuit", "PROBLEM", 174, 199], ["human intestinal", "ANATOMY", 7, 23], ["cell line", "OBSERVATION", 24, 33], ["T84", "OBSERVATION", 34, 37], ["increased", "OBSERVATION_MODIFIER", 42, 51], ["concentration", "OBSERVATION_MODIFIER", 52, 65]]], ["How GM1 confers the specificity for lipid trafficking has not yet been determined.", [["GM1", "GENE_OR_GENE_PRODUCT", 4, 7], ["lipid", "SIMPLE_CHEMICAL", 36, 41], ["GM1", "PROTEIN", 4, 7], ["lipid trafficking", "PROBLEM", 36, 53]]], ["Pentameric binding of GM1 by the B subunit of CT may itself induce membrane curvature and induce invagination to begin the entry process, as is seen with simian virus 40 (SV40) (12) and Shiga toxin (13\u201315).", [["membrane", "ANATOMY", 67, 75], ["Shiga toxin", "CHEMICAL", 186, 197], ["GM1", "GENE_OR_GENE_PRODUCT", 22, 25], ["B subunit", "GENE_OR_GENE_PRODUCT", 33, 42], ["membrane", "CELLULAR_COMPONENT", 67, 75], ["simian virus 40", "ORGANISM", 154, 169], ["SV40", "ORGANISM", 171, 175], ["Shiga toxin", "GENE_OR_GENE_PRODUCT", 186, 197], ["GM1", "PROTEIN", 22, 25], ["B subunit", "PROTEIN", 33, 42], ["CT", "PROTEIN", 46, 48], ["Shiga toxin", "PROTEIN", 186, 197], ["simian virus", "SPECIES", 154, 166], ["simian virus 40", "SPECIES", 154, 169], ["Pentameric binding of GM1", "PROBLEM", 0, 25], ["CT", "TEST", 46, 48], ["membrane curvature", "PROBLEM", 67, 85], ["induce invagination", "PROBLEM", 90, 109], ["simian virus", "PROBLEM", 154, 166], ["Shiga toxin", "TEST", 186, 197], ["membrane curvature", "OBSERVATION", 67, 85], ["invagination", "OBSERVATION", 97, 109]]], ["Interestingly, invasion by SV40 occurs only with GM1 that has native long-chain acyl groups.", [["acyl", "CHEMICAL", 80, 84], ["SV40", "ORGANISM", 27, 31], ["GM1", "SIMPLE_CHEMICAL", 49, 52], ["GM1", "PROBLEM", 49, 52], ["invasion", "OBSERVATION", 15, 23], ["native", "OBSERVATION_MODIFIER", 62, 68], ["long", "OBSERVATION_MODIFIER", 69, 73], ["chain", "OBSERVATION_MODIFIER", 74, 79], ["acyl groups", "OBSERVATION", 80, 91]]], ["Clustering of GM1 may enable the toxin to associate with lipid rafts that serve as platforms for trafficking of CT through the retrograde pathway or parts of it.", [["lipid rafts", "ANATOMY", 57, 68], ["GM1", "GENE_OR_GENE_PRODUCT", 14, 17], ["lipid rafts", "CELLULAR_COMPONENT", 57, 68], ["GM1", "PROTEIN", 14, 17], ["toxin", "PROTEIN", 33, 38], ["CT", "PROTEIN", 112, 114], ["Clustering of GM1", "PROBLEM", 0, 17], ["the toxin", "PROBLEM", 29, 38], ["lipid rafts", "TREATMENT", 57, 68], ["trafficking of CT", "TEST", 97, 114]]], ["Lipid rafts are viewed as highly dynamic microdomains that may self-assemble in membranes from sphingomyelin, cholesterol, glycolipids, and proteins that favor a lipid-ordered microenvironment (reviewed in references 16 to 18).", [["Lipid rafts", "ANATOMY", 0, 11], ["microdomains", "ANATOMY", 41, 53], ["membranes", "ANATOMY", 80, 89], ["sphingomyelin", "CHEMICAL", 95, 108], ["cholesterol", "CHEMICAL", 110, 121], ["sphingomyelin", "CHEMICAL", 95, 108], ["cholesterol", "CHEMICAL", 110, 121], ["Lipid", "SIMPLE_CHEMICAL", 0, 5], ["microdomains", "CELLULAR_COMPONENT", 41, 53], ["membranes", "CELLULAR_COMPONENT", 80, 89], ["sphingomyelin", "SIMPLE_CHEMICAL", 95, 108], ["cholesterol", "SIMPLE_CHEMICAL", 110, 121], ["glycolipids", "SIMPLE_CHEMICAL", 123, 134], ["Lipid rafts", "TREATMENT", 0, 11], ["sphingomyelin, cholesterol, glycolipids", "TEST", 95, 134]]], ["Some functions attributed to lipid rafts may require interactions with protein components or scaffolds to stabilize them, extend their lifetimes, or facilitate their coalescence into larger physiologically significant structures.", [["lipid rafts", "ANATOMY", 29, 40], ["Some functions", "PROBLEM", 0, 14], ["lipid rafts", "TREATMENT", 29, 40], ["protein components", "TREATMENT", 71, 89], ["scaffolds", "TREATMENT", 93, 102], ["lipid rafts", "OBSERVATION", 29, 40], ["significant", "OBSERVATION_MODIFIER", 206, 217]]], ["By binding to and cross-linking five GM1 molecules, CTB might serve as such a protein scaffold and promote the function of lipid rafts in toxin trafficking.", [["lipid rafts", "ANATOMY", 123, 134], ["GM1", "GENE_OR_GENE_PRODUCT", 37, 40], ["CTB", "SIMPLE_CHEMICAL", 52, 55], ["lipid rafts", "CELLULAR_COMPONENT", 123, 134], ["toxin", "SIMPLE_CHEMICAL", 138, 143], ["GM1 molecules", "PROTEIN", 37, 50], ["CTB", "PROTEIN", 52, 55], ["toxin", "PROTEIN", 138, 143], ["CTB", "TREATMENT", 52, 55], ["a protein scaffold", "TREATMENT", 76, 94], ["lipid rafts", "OBSERVATION", 123, 134]]], ["Conversion of PM sphingomyelin to ceramide or acute depletion of membrane cholesterol both prevent endocytosis of CT (19, 20), consistent with a role for lipid rafts in CT trafficking.", [["membrane", "ANATOMY", 65, 73], ["lipid rafts", "ANATOMY", 154, 165], ["sphingomyelin", "CHEMICAL", 17, 30], ["ceramide", "CHEMICAL", 34, 42], ["cholesterol", "CHEMICAL", 74, 85], ["sphingomyelin", "CHEMICAL", 17, 30], ["ceramide", "CHEMICAL", 34, 42], ["cholesterol", "CHEMICAL", 74, 85], ["PM sphingomyelin", "SIMPLE_CHEMICAL", 14, 30], ["ceramide", "SIMPLE_CHEMICAL", 34, 42], ["membrane", "CELLULAR_COMPONENT", 65, 73], ["cholesterol", "SIMPLE_CHEMICAL", 74, 85], ["PM sphingomyelin to ceramide", "TREATMENT", 14, 42], ["acute depletion of membrane cholesterol", "TREATMENT", 46, 85], ["CT", "TEST", 114, 116], ["lipid rafts", "TREATMENT", 154, 165], ["CT trafficking", "TEST", 169, 183], ["PM sphingomyelin", "OBSERVATION_MODIFIER", 14, 30], ["acute", "OBSERVATION_MODIFIER", 46, 51], ["depletion", "OBSERVATION", 52, 61], ["membrane cholesterol", "OBSERVATION", 65, 85], ["endocytosis", "OBSERVATION_MODIFIER", 99, 110]]], ["A requirement for the lipid raft-associated proteins flotillin 1 and flotillin 2 in a zebra fish model of intoxication by cholera toxin (21) also supports the key role of lipid rafts in trafficking of CT.IntroductionOur previous study (22) showed that a mixture of CT holotoxins produced in vivo and having chimeric B pentamers with from zero to two wild-type (wt) GM1 binding sites (BS) was still capable of intoxicating host cells.", [["lipid raft", "ANATOMY", 22, 32], ["lipid rafts", "ANATOMY", 171, 182], ["cells", "ANATOMY", 427, 432], ["cholera toxin", "CHEMICAL", 122, 135], ["holotoxins", "CHEMICAL", 268, 278], ["lipid raft", "CELLULAR_COMPONENT", 22, 32], ["flotillin 1", "GENE_OR_GENE_PRODUCT", 53, 64], ["flotillin 2", "GENE_OR_GENE_PRODUCT", 69, 80], ["zebra fish", "ORGANISM", 86, 96], ["cholera toxin", "SIMPLE_CHEMICAL", 122, 135], ["lipid rafts", "CELLULAR_COMPONENT", 171, 182], ["CT holotoxins", "SIMPLE_CHEMICAL", 265, 278], ["chimeric B pentamers", "GENE_OR_GENE_PRODUCT", 307, 327], ["GM1", "GENE_OR_GENE_PRODUCT", 365, 368], ["host cells", "CELL", 422, 432], ["lipid raft-associated proteins", "PROTEIN", 22, 52], ["flotillin 1", "PROTEIN", 53, 64], ["flotillin 2", "PROTEIN", 69, 80], ["CT", "PROTEIN", 201, 203], ["chimeric B pentamers", "PROTEIN", 307, 327], ["wild-type (wt) GM1 binding sites", "DNA", 350, 382], ["intoxicating host cells", "CELL_TYPE", 409, 432], ["the lipid raft", "TREATMENT", 18, 32], ["associated proteins flotillin", "TREATMENT", 33, 62], ["flotillin", "TREATMENT", 69, 78], ["lipid rafts", "TREATMENT", 171, 182], ["CT", "TEST", 201, 203], ["IntroductionOur previous study", "TEST", 204, 234], ["CT holotoxins", "TREATMENT", 265, 278], ["chimeric B pentamers", "TREATMENT", 307, 327], ["BS", "TEST", 384, 386], ["intoxicating host cells", "PROBLEM", 409, 432], ["lipid rafts", "OBSERVATION", 171, 182], ["host cells", "OBSERVATION", 422, 432]]], ["Because genetic methods, not chemical modifications, were used to prepare these toxin variants, the structures of their GM1 BS were fully defined and were known to be either the same as wt sites or inactive.", [["GM1", "GENE_OR_GENE_PRODUCT", 120, 123], ["these toxin variants", "PROBLEM", 74, 94], ["their GM1 BS", "TEST", 114, 126], ["inactive", "OBSERVATION", 198, 206]]], ["Thus, having at most 2 wt GM1 BS was sufficient for CT to intoxicate host cells, albeit at reduced efficiency.", [["cells", "ANATOMY", 74, 79], ["GM1", "GENE_OR_GENE_PRODUCT", 26, 29], ["host cells", "CELL", 69, 79], ["intoxicate host cells", "CELL_TYPE", 58, 79], ["GM1 BS", "TEST", 26, 32], ["CT", "TEST", 52, 54], ["reduced efficiency", "PROBLEM", 91, 109], ["reduced efficiency", "OBSERVATION", 91, 109]]], ["Left unanswered, however, was the question of whether a holotoxin with only one binding site for the GM1 receptor can function.", [["GM1 receptor", "GENE_OR_GENE_PRODUCT", 101, 113], ["GM1 receptor", "PROTEIN", 101, 113], ["a holotoxin", "TREATMENT", 54, 65]]], ["A toxin molecule able to bind only a single GM1 molecule would be completely unable to cluster GM1 molecules or scaffold them into microdomains and would therefore be unable to induce membrane curvature (2, 23).", [["microdomains", "ANATOMY", 131, 143], ["membrane", "ANATOMY", 184, 192], ["GM1", "GENE_OR_GENE_PRODUCT", 44, 47], ["GM1 molecules", "GENE_OR_GENE_PRODUCT", 95, 108], ["membrane", "CELLULAR_COMPONENT", 184, 192], ["toxin molecule", "PROTEIN", 2, 16], ["GM1 molecule", "PROTEIN", 44, 56], ["GM1 molecules", "PROTEIN", 95, 108], ["A toxin molecule", "PROBLEM", 0, 16], ["a single GM1 molecule", "TREATMENT", 35, 56], ["curvature", "OBSERVATION_MODIFIER", 193, 202]]], ["We designed the experiments reported here to produce defined holotoxin variants that have from zero to five native GM1 BS in their B pentamers, and we compared their abilities to bind to GM1 and intoxicate T84 cells.", [["T84 cells", "ANATOMY", 206, 215], ["B pentamers", "GENE_OR_GENE_PRODUCT", 131, 142], ["GM1", "GENE_OR_GENE_PRODUCT", 187, 190], ["T84 cells", "CELL", 206, 215], ["GM1 BS", "PROTEIN", 115, 121], ["B pentamers", "PROTEIN", 131, 142], ["GM1", "PROTEIN", 187, 190], ["T84 cells", "CELL_LINE", 206, 215], ["holotoxin variants", "PROBLEM", 61, 79], ["T84 cells", "PROBLEM", 206, 215], ["T84 cells", "OBSERVATION", 206, 215]]], ["We found that holotoxins able to interact with only a single GM1 molecule can nevertheless still complete the intoxication process, demonstrating directly that binding a single GM1 molecule permits the toxin to enter the host cell, complete the trafficking process, and deliver the toxic CT-A1 fragment to the cytoplasm.", [["cell", "ANATOMY", 226, 230], ["cytoplasm", "ANATOMY", 310, 319], ["holotoxins", "SIMPLE_CHEMICAL", 14, 24], ["GM1", "GENE_OR_GENE_PRODUCT", 61, 64], ["GM1", "GENE_OR_GENE_PRODUCT", 177, 180], ["host cell", "CELL", 221, 230], ["cytoplasm", "ORGANISM_SUBSTANCE", 310, 319], ["GM1 molecule", "PROTEIN", 61, 73], ["GM1 molecule", "PROTEIN", 177, 189], ["toxin", "PROTEIN", 202, 207], ["CT", "PROTEIN", 288, 290], ["A1 fragment", "PROTEIN", 291, 302], ["holotoxins", "PROBLEM", 14, 24], ["a single GM1 molecule", "TREATMENT", 52, 73], ["the intoxication process", "PROBLEM", 106, 130], ["a single GM1 molecule", "PROBLEM", 168, 189], ["the toxin", "PROBLEM", 198, 207], ["the toxic CT", "TEST", 278, 290], ["intoxication", "OBSERVATION", 110, 122], ["host cell", "OBSERVATION", 221, 230], ["trafficking process", "OBSERVATION", 245, 264], ["toxic", "OBSERVATION_MODIFIER", 282, 287]]], ["However, we also found that eliminating even a single binding site from wt holotoxin produced a detectable attenuation in toxicity.Production and purification of cholera toxin variants with 0, 1, 2, 3, 4, or 5 native GM1 binding sites. ::: RESULTSTo produce CT holotoxins with defined combinations of wt and mutant CTB subunits, we made three compatible plasmid constructs encoding either tagged wt CTB, CTB-G33D, or wt CTA and expressed them in the same Escherichia coli strain to produce a holotoxin pool with B pentamers consisting of tagged wt CTB and/or CTB-G33D, from which to purify all six possible holotoxin variants.", [["toxicity", "DISEASE", 122, 130], ["holotoxin", "GENE_OR_GENE_PRODUCT", 75, 84], ["cholera toxin", "GENE_OR_GENE_PRODUCT", 162, 175], ["GM1", "GENE_OR_GENE_PRODUCT", 217, 220], ["CTB", "GENE_OR_GENE_PRODUCT", 315, 318], ["CTB", "GENE_OR_GENE_PRODUCT", 399, 402], ["CTB-G33D", "GENE_OR_GENE_PRODUCT", 404, 412], ["Escherichia coli", "ORGANISM", 455, 471], ["CTB", "GENE_OR_GENE_PRODUCT", 548, 551], ["CTB", "GENE_OR_GENE_PRODUCT", 559, 562], ["holotoxin", "GENE_OR_GENE_PRODUCT", 607, 616], ["cholera toxin variants", "PROTEIN", 162, 184], ["mutant CTB subunits", "PROTEIN", 308, 327], ["plasmid constructs", "DNA", 354, 372], ["CTB", "PROTEIN", 399, 402], ["CTB", "PROTEIN", 404, 407], ["G33D", "PROTEIN", 408, 412], ["B pentamers", "PROTEIN", 512, 523], ["CTB", "PROTEIN", 548, 551], ["CTB", "PROTEIN", 559, 562], ["G33D", "PROTEIN", 563, 567], ["holotoxin variants", "PROTEIN", 607, 625], ["Escherichia coli", "SPECIES", 455, 471], ["Escherichia coli", "SPECIES", 455, 471], ["a single binding site", "PROBLEM", 45, 66], ["wt holotoxin", "TREATMENT", 72, 84], ["a detectable attenuation in toxicity", "PROBLEM", 94, 130], ["cholera toxin variants", "PROBLEM", 162, 184], ["CT holotoxins", "TREATMENT", 258, 271], ["wt and mutant CTB subunits", "TREATMENT", 301, 327], ["CTB", "TEST", 404, 407], ["wt CTA", "TEST", 417, 423], ["the same Escherichia coli strain", "PROBLEM", 446, 478], ["a holotoxin pool", "TREATMENT", 490, 506], ["B pentamers", "TREATMENT", 512, 523], ["tagged wt CTB", "TREATMENT", 538, 551], ["CTB", "TEST", 559, 562], ["holotoxin variants", "PROBLEM", 607, 625], ["attenuation", "OBSERVATION_MODIFIER", 107, 118], ["Escherichia coli", "OBSERVATION", 455, 471]]], ["The tag is a 34-amino-acid peptide (denoted GSH6) which is genetically appended after the Met103 codon of native ctxB and encodes glycosylation (bold) and sulfation sites (underlined) (24), SSSGGGGSSHPNNTSNNTSSAEDYEYPS, followed by six His residues.", [["34-amino-acid", "CHEMICAL", 13, 26], ["34-amino-acid", "CHEMICAL", 13, 26], ["His", "CHEMICAL", 236, 239], ["GSH6", "GENE_OR_GENE_PRODUCT", 44, 48], ["ctxB", "GENE_OR_GENE_PRODUCT", 113, 117], ["GSH6", "PROTEIN", 44, 48], ["Met103 codon", "DNA", 90, 102], ["ctxB", "PROTEIN", 113, 117], ["sulfation sites", "PROTEIN", 155, 170], ["The tag", "TEST", 0, 7], ["amino-acid peptide", "TREATMENT", 16, 34], ["the Met103 codon", "TREATMENT", 86, 102], ["native ctxB", "TREATMENT", 106, 117], ["encodes glycosylation", "TREATMENT", 122, 143], ["sulfation sites", "TREATMENT", 155, 170], ["SSSGGGGSSHPNNTSNNTSSAEDYEYPS", "TREATMENT", 190, 218]]], ["Each plasmid has a different replication origin, antibiotic selection, and combination of promoters (Fig. 1A; Table 1).", [["plasmid", "ANATOMY", 5, 12], ["promoters", "DNA", 90, 99], ["Each plasmid", "TREATMENT", 0, 12], ["antibiotic selection", "TREATMENT", 49, 69], ["promoters (Fig", "TREATMENT", 90, 104], ["different", "OBSERVATION_MODIFIER", 19, 28], ["replication", "OBSERVATION_MODIFIER", 29, 40], ["origin", "OBSERVATION_MODIFIER", 41, 47]]], ["The ctxA gene, encoding CTA, is expressed from dual pLac and pBAD promoters.", [["ctxA", "GENE_OR_GENE_PRODUCT", 4, 8], ["CTA", "GENE_OR_GENE_PRODUCT", 24, 27], ["pLac", "GENE_OR_GENE_PRODUCT", 52, 56], ["pBAD", "GENE_OR_GENE_PRODUCT", 61, 65], ["ctxA gene", "DNA", 4, 13], ["CTA", "DNA", 24, 27], ["dual pLac and pBAD promoters", "DNA", 47, 75], ["encoding CTA", "TEST", 15, 27], ["dual pLac and pBAD promoters", "TREATMENT", 47, 75]]], ["Holotoxins and free B pentamers were purified from whole-cell lysates by metal-ion affinity chromatography on Talon resin, and free B pentamers were removed by passing the eluate pool over cation exchange resin, resulting in binding of the free CTB pentamers to the resin and recovery of holotoxin in the flowthrough (Fig. 1B).", [["whole-cell lysates", "ANATOMY", 51, 69], ["Holotoxins", "CHEMICAL", 0, 10], ["Holotoxins", "CHEMICAL", 0, 10], ["Holotoxins", "SIMPLE_CHEMICAL", 0, 10], ["free B pentamers", "GENE_OR_GENE_PRODUCT", 15, 31], ["cell lysates", "ORGANISM_SUBSTANCE", 57, 69], ["Talon resin", "SIMPLE_CHEMICAL", 110, 121], ["free B pentamers", "SIMPLE_CHEMICAL", 127, 143], ["cation", "SIMPLE_CHEMICAL", 189, 195], ["CTB", "SIMPLE_CHEMICAL", 245, 248], ["holotoxin", "GENE_OR_GENE_PRODUCT", 288, 297], ["Holotoxins", "TREATMENT", 0, 10], ["free B pentamers", "TREATMENT", 15, 31], ["whole-cell lysates", "TREATMENT", 51, 69], ["Talon resin", "TREATMENT", 110, 121], ["free B pentamers", "TREATMENT", 127, 143], ["cation exchange resin", "TREATMENT", 189, 210], ["the free CTB pentamers", "TREATMENT", 236, 258], ["the resin", "TREATMENT", 262, 271], ["holotoxin", "TREATMENT", 288, 297]]], ["Holotoxins with different numbers of BS were then separated by anion-exchange chromatography (Fig. 1C).", [["Holotoxins", "CHEMICAL", 0, 10], ["Holotoxins", "SIMPLE_CHEMICAL", 0, 10], ["BS", "SIMPLE_CHEMICAL", 37, 39], ["anion", "SIMPLE_CHEMICAL", 63, 68], ["Holotoxins", "TREATMENT", 0, 10], ["BS", "TEST", 37, 39], ["anion-exchange chromatography", "TREATMENT", 63, 92]]], ["By varying the amount of each inducer, we sought to alter the ratio of wt and mutant B subunits in the holotoxin pool.", [["B subunits", "GENE_OR_GENE_PRODUCT", 85, 95], ["holotoxin", "GENE_OR_GENE_PRODUCT", 103, 112], ["mutant B subunits", "PROTEIN", 78, 95], ["mutant B subunits", "TREATMENT", 78, 95], ["the holotoxin pool", "TREATMENT", 99, 117]]], ["However, for practical purposes, we found that a single condition of relatively low levels of arabinose (0.0005% to express GSH6-tagged wt-CTB) and high levels of isopropyl-\u03b2-d-thiogalactopyranoside (IPTG) (400 \u00b5M to express native-size CTB-G33D) gave acceptable yields of holotoxin with homopentameric and singly or doubly tagged heteropentameric B subunits (with zero, one, and two wt BS, respectively) and detectable but lower yields of the triple, quadruple, and homopentameric tagged B subunits as described in detail in the next paragraph.", [["arabinose", "CHEMICAL", 94, 103], ["isopropyl-\u03b2-d-thiogalactopyranoside", "CHEMICAL", 163, 198], ["IPTG", "CHEMICAL", 200, 204], ["arabinose", "CHEMICAL", 94, 103], ["isopropyl-\u03b2-d-thiogalactopyranoside", "CHEMICAL", 163, 198], ["IPTG", "CHEMICAL", 200, 204], ["arabinose", "SIMPLE_CHEMICAL", 94, 103], ["GSH6", "GENE_OR_GENE_PRODUCT", 124, 128], ["wt-CTB", "GENE_OR_GENE_PRODUCT", 136, 142], ["isopropyl-\u03b2-d-thiogalactopyranoside", "SIMPLE_CHEMICAL", 163, 198], ["IPTG", "SIMPLE_CHEMICAL", 200, 204], ["homopentameric", "SIMPLE_CHEMICAL", 288, 302], ["heteropentameric B subunits", "GENE_OR_GENE_PRODUCT", 331, 358], ["B subunits", "GENE_OR_GENE_PRODUCT", 489, 499], ["GSH6", "PROTEIN", 124, 128], ["CTB", "PROTEIN", 139, 142], ["CTB", "PROTEIN", 237, 240], ["G33D", "PROTEIN", 241, 245], ["heteropentameric B subunits", "PROTEIN", 331, 358], ["triple, quadruple, and homopentameric tagged B subunits", "PROTEIN", 444, 499], ["relatively low levels of arabinose", "PROBLEM", 69, 103], ["GSH6", "TEST", 124, 128], ["isopropyl-\u03b2-d-thiogalactopyranoside (IPTG", "TREATMENT", 163, 204], ["holotoxin", "TREATMENT", 273, 282], ["homopentameric", "TREATMENT", 288, 302], ["doubly tagged heteropentameric B subunits", "TREATMENT", 317, 358], ["two wt BS", "TEST", 380, 389], ["the triple, quadruple", "TREATMENT", 440, 461], ["homopentameric tagged B subunits", "TREATMENT", 467, 499]]], ["This production strain we designated AMBT (for A, mutant CTB, wt CTB-tagged).", [["AMBT", "GENE_OR_GENE_PRODUCT", 37, 41], ["mutant CTB", "ORGANISM", 50, 60], ["CTB", "GENE_OR_GENE_PRODUCT", 65, 68], ["AMBT", "PROTEIN", 37, 41], ["mutant CTB", "PROTEIN", 50, 60], ["CTB", "PROTEIN", 65, 68], ["This production strain", "PROBLEM", 0, 22], ["A, mutant CTB", "TREATMENT", 47, 60], ["wt CTB", "TEST", 62, 68]]], ["Simply by swapping the wt and G33D alleles in the respective CTB-encoding vectors and keeping the same inducer ratios, we were able to express the single or double tagged heteropentameric and homopentameric wt CTB subunits with three, four, and five wt BS, respectively, from the production strain designated ABMT (A, wt CTB, mutant CTB-tagged).", [["G33D", "GENE_OR_GENE_PRODUCT", 30, 34], ["CTB", "GENE_OR_GENE_PRODUCT", 61, 64], ["heteropentameric", "GENE_OR_GENE_PRODUCT", 171, 187], ["CTB", "GENE_OR_GENE_PRODUCT", 210, 213], ["CTB", "GENE_OR_GENE_PRODUCT", 321, 324], ["CTB", "GENE_OR_GENE_PRODUCT", 333, 336], ["wt and G33D alleles", "DNA", 23, 42], ["CTB-encoding vectors", "DNA", 61, 81], ["heteropentameric and homopentameric wt CTB subunits", "PROTEIN", 171, 222], ["CTB", "PROTEIN", 321, 324], ["mutant CTB", "PROTEIN", 326, 336], ["the respective CTB", "TREATMENT", 46, 64], ["encoding vectors", "TREATMENT", 65, 81], ["double tagged heteropentameric", "TREATMENT", 157, 187], ["homopentameric wt CTB subunits", "TREATMENT", 192, 222], ["five wt BS", "TEST", 245, 255]]], ["Using these strategies, from two production strains, we produced all six variant holotoxins, which had from zero to five wt BS and a maximum of two tagged subunits.", [["holotoxins", "GENE_OR_GENE_PRODUCT", 81, 91], ["tagged subunits", "PROTEIN", 148, 163], ["these strategies", "TREATMENT", 6, 22], ["two production strains", "PROBLEM", 29, 51], ["wt BS", "TEST", 121, 126], ["two tagged subunits", "TREATMENT", 144, 163]]], ["A third production strain, designated ABBT (A, wt CTB, wt CTB-tagged), in which both the GSH6-tagged and untagged B polypeptides were wt CTB, was used under the same expression conditions to produce control holotoxins with five native BS and zero, one, or two tagged CTB subunits.Production and purification of cholera toxin variants with 0, 1, 2, 3, 4, or 5 native GM1 binding sites. ::: RESULTSFigure 1 shows the purification process for the AMBT strain (mutant CTB-G33D, wt CTB tagged).", [["holotoxins", "CHEMICAL", 207, 217], ["CTB", "GENE_OR_GENE_PRODUCT", 50, 53], ["CTB", "GENE_OR_GENE_PRODUCT", 58, 61], ["GSH6", "GENE_OR_GENE_PRODUCT", 89, 93], ["untagged B polypeptides", "GENE_OR_GENE_PRODUCT", 105, 128], ["CTB", "GENE_OR_GENE_PRODUCT", 137, 140], ["CTB", "GENE_OR_GENE_PRODUCT", 267, 270], ["cholera toxin", "GENE_OR_GENE_PRODUCT", 311, 324], ["GM1", "GENE_OR_GENE_PRODUCT", 366, 369], ["AMBT", "GENE_OR_GENE_PRODUCT", 444, 448], ["CTB", "GENE_OR_GENE_PRODUCT", 477, 480], ["CTB", "PROTEIN", 58, 61], ["GSH6", "PROTEIN", 89, 93], ["untagged B polypeptides", "PROTEIN", 105, 128], ["CTB subunits", "PROTEIN", 267, 279], ["cholera toxin variants", "PROTEIN", 311, 333], ["mutant CTB", "PROTEIN", 457, 467], ["G33D", "PROTEIN", 468, 472], ["A third production strain", "PROBLEM", 0, 25], ["wt CTB", "TEST", 47, 53], ["wt CTB", "TEST", 55, 61], ["the GSH6", "TEST", 85, 93], ["untagged B polypeptides", "PROBLEM", 105, 128], ["control holotoxins", "TREATMENT", 199, 217], ["two tagged CTB subunits", "TREATMENT", 256, 279], ["cholera toxin variants", "PROBLEM", 311, 333], ["the purification process", "PROBLEM", 411, 435], ["the AMBT strain", "PROBLEM", 440, 455], ["mutant CTB", "TEST", 457, 467]]], ["Since CTB pentamers naturally bind to metal affinity resins (25), cholera toxin variants can be purified to near-homogeneity by a single passage over Talon resin.", [["CTB", "GENE_OR_GENE_PRODUCT", 6, 9], ["cholera toxin", "SIMPLE_CHEMICAL", 66, 79], ["CTB pentamers", "PROTEIN", 6, 19], ["metal affinity resins", "TREATMENT", 38, 59], ["cholera toxin variants", "PROBLEM", 66, 88], ["a single passage over Talon resin", "TREATMENT", 128, 161]]], ["The imidazole eluate pool from the Talon resin contained a mixture of holotoxin and some free CTB pentamers.", [["imidazole", "CHEMICAL", 4, 13], ["imidazole", "CHEMICAL", 4, 13], ["imidazole", "SIMPLE_CHEMICAL", 4, 13], ["holotoxin", "GENE_OR_GENE_PRODUCT", 70, 79], ["CTB", "GENE_OR_GENE_PRODUCT", 94, 97], ["The imidazole eluate pool", "TREATMENT", 0, 25], ["the Talon resin", "TREATMENT", 31, 46], ["holotoxin", "TREATMENT", 70, 79], ["some free CTB pentamers", "TREATMENT", 84, 107]]], ["These free pentamers were removed by cation exchange chromatography, where at pH 8.0 in 50 mM Tris buffer, holotoxin passed through the column while free pentamers bound and could be eluted subsequently with a salt gradient (Fig. 1B).", [["Tris", "CHEMICAL", 94, 98], ["cation", "SIMPLE_CHEMICAL", 37, 43], ["cation exchange chromatography", "TEST", 37, 67], ["pH", "TEST", 78, 80], ["50 mM Tris buffer", "TREATMENT", 88, 105], ["holotoxin", "TREATMENT", 107, 116], ["a salt gradient", "TEST", 208, 223], ["column", "ANATOMY", 136, 142]]], ["The heterogenous mixture of holotoxins was further separated into its components by anion-exchange chromatography.", [["anion", "CHEMICAL", 84, 89], ["holotoxins", "CHEMICAL", 28, 38], ["holotoxins", "SIMPLE_CHEMICAL", 28, 38], ["anion", "SIMPLE_CHEMICAL", 84, 89], ["holotoxins", "TREATMENT", 28, 38], ["anion-exchange chromatography", "TEST", 84, 113], ["heterogenous", "OBSERVATION_MODIFIER", 4, 16], ["mixture", "OBSERVATION_MODIFIER", 17, 24]]], ["The GSH6 tag not only changed the size of the B monomer but also changed its predicted pI from 8.24 for native CTB to 6.21 for CTB-GSH6.", [["GSH6", "GENE_OR_GENE_PRODUCT", 4, 8], ["B monomer", "GENE_OR_GENE_PRODUCT", 46, 55], ["CTB-GSH6", "GENE_OR_GENE_PRODUCT", 127, 135], ["GSH6 tag", "DNA", 4, 12], ["B monomer", "PROTEIN", 46, 55], ["CTB", "PROTEIN", 127, 130], ["GSH6", "PROTEIN", 131, 135], ["The GSH6 tag", "TEST", 0, 12], ["native CTB", "TEST", 104, 114], ["CTB", "TEST", 127, 130], ["size", "OBSERVATION_MODIFIER", 34, 38]]], ["The respective predicted pIs for the CTB-G33D variant changed from 7.31 for the native length to 5.91 for the GSH6-tagged variant.", [["pIs", "GENE_OR_GENE_PRODUCT", 25, 28], ["CTB", "GENE_OR_GENE_PRODUCT", 37, 40], ["GSH6", "GENE_OR_GENE_PRODUCT", 110, 114], ["pIs", "DNA", 25, 28], ["CTB-G33D variant", "DNA", 37, 53], ["GSH6", "PROTEIN", 110, 114], ["the CTB", "TEST", 33, 40], ["the GSH6", "TEST", 106, 114], ["tagged variant", "OBSERVATION", 115, 129]]], ["All holotoxins bound to the anion exchange matrix, and at least five peaks could be discerned following elution with a salt gradient (Fig. 1C).", [["holotoxins", "CHEMICAL", 4, 14], ["holotoxins", "SIMPLE_CHEMICAL", 4, 14], ["anion", "SIMPLE_CHEMICAL", 28, 33], ["matrix", "CELLULAR_COMPONENT", 43, 49], ["the anion exchange matrix", "TREATMENT", 24, 49], ["a salt gradient", "TREATMENT", 117, 132], ["salt gradient", "OBSERVATION", 119, 132]]], ["Samples from individual fractions were analyzed by SDS-PAGE either without (Fig. 1D, upper) or after (Fig. 1D, lower) boiling in sample loading buffer.", [["Samples", "ANATOMY", 0, 7], ["fractions", "ANATOMY", 24, 33], ["sample", "ANATOMY", 129, 135], ["Samples from individual fractions", "TEST", 0, 33], ["SDS", "TEST", 51, 54], ["Fig. 1D, lower) boiling in sample loading buffer", "TREATMENT", 102, 150]]], ["The unboiled samples in lanes 4 to 13 showed a single band corresponding to assembled holotoxin (AB5), with a small amount of contaminating protein of slower mobility in lanes 2 and 3.", [["samples", "ANATOMY", 13, 20], ["holotoxin", "GENE_OR_GENE_PRODUCT", 86, 95], ["AB5", "PROTEIN", 97, 100], ["contaminating protein", "PROTEIN", 126, 147], ["The unboiled samples in lanes", "TEST", 0, 29], ["a single band", "PROBLEM", 45, 58], ["small", "OBSERVATION_MODIFIER", 110, 115], ["amount", "OBSERVATION_MODIFIER", 116, 122], ["contaminating protein", "OBSERVATION", 126, 147], ["slower mobility", "OBSERVATION", 151, 166]]], ["The major fractions from each peak are homogenous and are consistent with each peak containing a single species of variant holotoxin, The assembled holotoxins in the unboiled samples bind less SDS than if they were fully denatured and therefore do not migrate in direct proportion to their molecular weights.", [["samples", "ANATOMY", 175, 182], ["SDS", "CHEMICAL", 193, 196], ["holotoxin", "GENE_OR_GENE_PRODUCT", 123, 132], ["holotoxins", "GENE_OR_GENE_PRODUCT", 148, 158], ["variant holotoxin", "TREATMENT", 115, 132], ["The assembled holotoxins", "TREATMENT", 134, 158], ["major", "OBSERVATION_MODIFIER", 4, 9], ["fractions", "OBSERVATION_MODIFIER", 10, 19], ["peak", "OBSERVATION_MODIFIER", 30, 34], ["homogenous", "OBSERVATION_MODIFIER", 39, 49], ["consistent with", "UNCERTAINTY", 58, 73]]], ["The relative molecular weight (Mr) for each holotoxin variant is increased by the presence of one or more tagged CTB subunits.", [["CTB", "GENE_OR_GENE_PRODUCT", 113, 116], ["CTB subunits", "PROTEIN", 113, 125], ["each holotoxin variant", "PROBLEM", 39, 61], ["tagged CTB subunits", "TREATMENT", 106, 125], ["increased", "OBSERVATION_MODIFIER", 65, 74]]], ["Each of these holotoxins completely disassembles into its component polypeptides after boiling (Fig. 1D, lower panel; CTA, 29 kDa; CTB-GSH6-tagged monomer, 14.4 kDa; and native CTB-G33D monomer, 11.5 kDa).", [["holotoxins", "CHEMICAL", 14, 24], ["holotoxins", "SIMPLE_CHEMICAL", 14, 24], ["CTB", "GENE_OR_GENE_PRODUCT", 131, 134], ["CTA", "PROTEIN", 118, 121], ["CTB", "PROTEIN", 131, 134], ["GSH6", "PROTEIN", 135, 139], ["tagged monomer", "PROTEIN", 140, 154], ["14.4 kDa", "PROTEIN", 156, 164], ["CTB", "PROTEIN", 177, 180], ["G33D monomer", "PROTEIN", 181, 193], ["these holotoxins", "TREATMENT", 8, 24], ["lower panel", "TEST", 105, 116], ["CTA", "TEST", 118, 121], ["kDa", "TEST", 126, 129], ["CTB", "TEST", 131, 134], ["GSH6", "TEST", 135, 139], ["kDa", "TEST", 161, 164], ["native CTB", "TEST", 170, 180]]], ["The holotoxin in peak 0 (Fig. 1C) has homopentameric CTB-G33D subunits and no functional GM1 BS, while holotoxins in peaks 1 and 2 have a mixture of wt CTB-GSH6 and CTB-G33D pentamers with 1 and 2 GM1 BS, respectively.", [["CTB", "GENE_OR_GENE_PRODUCT", 53, 56], ["GM1", "GENE_OR_GENE_PRODUCT", 89, 92], ["CTB", "GENE_OR_GENE_PRODUCT", 152, 155], ["GSH6", "GENE_OR_GENE_PRODUCT", 156, 160], ["CTB", "GENE_OR_GENE_PRODUCT", 165, 168], ["homopentameric CTB", "PROTEIN", 38, 56], ["G33D subunits", "PROTEIN", 57, 70], ["GM1 BS", "PROTEIN", 89, 95], ["holotoxins", "PROTEIN", 103, 113], ["CTB", "PROTEIN", 152, 155], ["GSH6", "PROTEIN", 156, 160], ["CTB", "PROTEIN", 165, 168], ["G33D pentamers", "PROTEIN", 169, 183], ["The holotoxin in peak", "TEST", 0, 21], ["homopentameric CTB", "TREATMENT", 38, 56], ["G33D subunits", "TREATMENT", 57, 70], ["functional GM1 BS", "TEST", 78, 95], ["holotoxins", "TEST", 103, 113], ["wt CTB", "TEST", 149, 155], ["GSH6", "TEST", 156, 160], ["CTB", "TEST", 165, 168], ["GM1 BS", "TEST", 197, 203]]], ["The fractions loaded in lanes 2 to 5 contain CTA plus 5 CTB-G33D (peak 0), and those in lanes 6 to 9 contain CTA plus 1 wt CTB-GSH6 and 4 CTB-G33D (peak 1), and those in lanes 10 to 13 contain CTA plus 2 wt CTB-GSH6 and 3 CTB-G33D (peak 2).", [["fractions", "ANATOMY", 4, 13], ["CTB", "GENE_OR_GENE_PRODUCT", 123, 126], ["CTB", "GENE_OR_GENE_PRODUCT", 207, 210], ["CTA", "PROTEIN", 45, 48], ["CTA", "PROTEIN", 109, 112], ["CTB", "PROTEIN", 123, 126], ["GSH6", "PROTEIN", 127, 131], ["CTB", "PROTEIN", 138, 141], ["G33D", "PROTEIN", 142, 146], ["CTA", "PROTEIN", 193, 196], ["CTB", "PROTEIN", 207, 210], ["GSH6", "PROTEIN", 211, 215], ["CTB", "PROTEIN", 222, 225], ["G33D", "PROTEIN", 226, 230], ["CTA", "TEST", 45, 48], ["CTB", "TEST", 56, 59], ["those in lanes", "TEST", 79, 93], ["CTA", "TEST", 109, 112], ["CTB", "TEST", 123, 126], ["GSH6", "TEST", 127, 131], ["CTB", "TEST", 138, 141], ["CTA", "TEST", 193, 196], ["CTB", "TEST", 207, 210], ["GSH6", "TEST", 211, 215], ["CTB", "TEST", 222, 225], ["fractions loaded", "OBSERVATION", 4, 20]]], ["Only these first three peaks were well enough separated to be purified efficiently from the extract of production strain AMBT.", [["extract", "ANATOMY", 92, 99], ["AMBT", "CHEMICAL", 121, 125], ["AMBT", "SIMPLE_CHEMICAL", 121, 125], ["production strain AMBT", "PROBLEM", 103, 125], ["production strain", "OBSERVATION", 103, 120]]], ["The fractions corresponding to each peak were pooled, dialyzed, and rerun over the same anion-exchange column to achieve a very high degree of purity.", [["anion", "SIMPLE_CHEMICAL", 88, 93], ["the same anion-exchange column", "TREATMENT", 79, 109], ["a very high degree of purity", "PROBLEM", 121, 149], ["very", "OBSERVATION_MODIFIER", 123, 127], ["high degree", "OBSERVATION_MODIFIER", 128, 139], ["purity", "OBSERVATION", 143, 149]]], ["To make holotoxins with 3 and 4 native GM1 BS, an expression and purification run was done using strain ABMT, which produced three peaks similar to those shown in Fig. 1C, containing holotoxins with zero, one, or two GSH6-tagged CTB-G33D subunits and five, four, or three native GM1 BS, respectively.", [["holotoxins", "CHEMICAL", 183, 193], ["GM1", "GENE_OR_GENE_PRODUCT", 39, 42], ["holotoxins", "SIMPLE_CHEMICAL", 183, 193], ["GSH6", "GENE_OR_GENE_PRODUCT", 217, 221], ["CTB-G33D subunits", "GENE_OR_GENE_PRODUCT", 229, 246], ["GSH6", "PROTEIN", 217, 221], ["CTB", "PROTEIN", 229, 232], ["G33D subunits", "PROTEIN", 233, 246], ["GM1 BS", "PROTEIN", 279, 285], ["holotoxins", "TREATMENT", 8, 18], ["purification run", "TEST", 65, 81], ["strain ABMT", "TREATMENT", 97, 108]]], ["Finally, as noted above, strain ABBT was used for expression and purification of wt control holotoxins, all with 5 GM1 BS and zero, one, or two GSH6-tagged CTB subunits.Production and purification of cholera toxin variants with 0, 1, 2, 3, 4, or 5 native GM1 binding sites. ::: RESULTSAnalysis of the eight final highly purified holotoxin preparations by SDS-PAGE and Coomassie blue staining is shown in Fig. 2.", [["Coomassie blue", "CHEMICAL", 368, 382], ["holotoxins", "GENE_OR_GENE_PRODUCT", 92, 102], ["GSH6", "GENE_OR_GENE_PRODUCT", 144, 148], ["CTB", "GENE_OR_GENE_PRODUCT", 156, 159], ["cholera toxin", "GENE_OR_GENE_PRODUCT", 200, 213], ["GM1", "GENE_OR_GENE_PRODUCT", 255, 258], ["Coomassie", "SIMPLE_CHEMICAL", 368, 377], ["GSH6", "PROTEIN", 144, 148], ["CTB subunits", "PROTEIN", 156, 168], ["cholera toxin variants", "PROTEIN", 200, 222], ["strain ABBT", "PROBLEM", 25, 36], ["purification of wt control holotoxins", "TREATMENT", 65, 102], ["5 GM1 BS", "TEST", 113, 121], ["tagged CTB subunits", "TREATMENT", 149, 168], ["cholera toxin variants", "PROBLEM", 200, 222], ["purified holotoxin preparations", "TREATMENT", 320, 351], ["Coomassie blue staining", "TEST", 368, 391]]], ["The upper panel shows a gel run with unboiled samples, and the lower panel shows a gel run with samples boiled in sample buffer to dissociate the components.", [["samples", "ANATOMY", 46, 53], ["The upper panel", "TEST", 0, 15], ["the lower panel", "TEST", 59, 74], ["a gel run", "TREATMENT", 81, 90], ["upper", "ANATOMY_MODIFIER", 4, 9], ["components", "OBSERVATION_MODIFIER", 146, 156]]], ["Without boiling, holotoxins with untagged or tagged wt CTB pentamers (Fig. 2, upper panel, lanes 2 to 4) dissociated into free CTA and stable pentameric B subunits that ran near the 45-kDa marker (lane 1).", [["holotoxins", "SIMPLE_CHEMICAL", 17, 27], ["CTB", "GENE_OR_GENE_PRODUCT", 55, 58], ["pentameric B subunits", "GENE_OR_GENE_PRODUCT", 142, 163], ["CTB pentamers", "PROTEIN", 55, 68], ["lanes 2 to 4", "PROTEIN", 91, 103], ["CTA", "PROTEIN", 127, 130], ["pentameric B subunits", "PROTEIN", 142, 163], ["45", "PROTEIN", 182, 184], ["holotoxins", "TREATMENT", 17, 27], ["tagged wt CTB pentamers", "TREATMENT", 45, 68], ["upper panel", "TEST", 78, 89], ["free CTA", "TEST", 122, 130], ["stable pentameric B subunits", "TREATMENT", 135, 163], ["stable", "OBSERVATION_MODIFIER", 135, 141]]], ["Interestingly, the presence of one or more CTB-G33D polypeptides increased stability of the heterohexameric AB5 holotoxins.", [["CTB", "GENE_OR_GENE_PRODUCT", 43, 46], ["AB5", "GENE_OR_GENE_PRODUCT", 108, 111], ["CTB", "PROTEIN", 43, 46], ["G33D polypeptides", "PROTEIN", 47, 64], ["heterohexameric AB5 holotoxins", "PROTEIN", 92, 122], ["G33D polypeptides", "PROBLEM", 47, 64], ["the heterohexameric AB5 holotoxins", "TREATMENT", 88, 122], ["increased", "OBSERVATION_MODIFIER", 65, 74], ["stability", "OBSERVATION_MODIFIER", 75, 84]]], ["Consequently, unboiled holotoxins with three or more CTB-G33D polypeptides (Fig. 2, upper panel, lanes 5 to 7) remained fully associated and ran near the 66-kDa marker (lane 1), whereas unboiled holotoxins with one or two CTB-G33D subunits exhibited partial dissociation into B pentamer and free CTA (Fig. 2, upper panel, lanes 8 and 9).", [["holotoxins", "GENE_OR_GENE_PRODUCT", 23, 33], ["CTB", "GENE_OR_GENE_PRODUCT", 53, 56], ["holotoxins", "GENE_OR_GENE_PRODUCT", 195, 205], ["CTB", "GENE_OR_GENE_PRODUCT", 222, 225], ["B pentamer", "GENE_OR_GENE_PRODUCT", 276, 286], ["CTB", "PROTEIN", 53, 56], ["G33D polypeptides", "PROTEIN", 57, 74], ["CTB", "PROTEIN", 222, 225], ["G33D subunits", "PROTEIN", 226, 239], ["B pentamer", "PROTEIN", 276, 286], ["unboiled holotoxins", "TREATMENT", 14, 33], ["G33D polypeptides", "TREATMENT", 57, 74], ["upper panel, lanes", "TEST", 84, 102], ["partial dissociation", "PROBLEM", 250, 270], ["free CTA", "TEST", 291, 299], ["upper panel, lanes", "TEST", 309, 327], ["partial dissociation", "OBSERVATION", 250, 270], ["upper", "ANATOMY_MODIFIER", 309, 314]]], ["The high stability of the heterohexameric AB5 holotoxins containing five, four, or three CTB-G33D polypeptides is also evident in the upper panel of Fig. 1D.", [["AB5", "GENE_OR_GENE_PRODUCT", 42, 45], ["CTB", "GENE_OR_GENE_PRODUCT", 89, 92], ["heterohexameric AB5 holotoxins", "PROTEIN", 26, 56], ["CTB", "PROTEIN", 89, 92], ["G33D polypeptides", "PROTEIN", 93, 110], ["the heterohexameric AB5 holotoxins containing five, four, or three CTB-G33D polypeptides", "PROBLEM", 22, 110], ["high", "OBSERVATION_MODIFIER", 4, 8], ["stability", "OBSERVATION_MODIFIER", 9, 18], ["upper", "ANATOMY_MODIFIER", 134, 139]]], ["As expected, increasing the number of tagged CTB polypeptides resulted in moderate decreases in observed mobilities of the pentamer bands (Fig. 2, upper panel, compare lanes 2, 3, and 4) and the holotoxin bands (Fig. 2, upper panel, compare lanes 5, 6, and 7), and increasing the number of CTB-G33D polypeptides resulted in slight increases in mobilities of the holotoxin bands (Fig. 2, upper panel, compare lanes 6 to 8 and lanes 7 to 9).", [["CTB", "GENE_OR_GENE_PRODUCT", 45, 48], ["CTB", "GENE_OR_GENE_PRODUCT", 290, 293], ["CTB polypeptides", "PROTEIN", 45, 61], ["pentamer bands", "PROTEIN", 123, 137], ["holotoxin bands", "PROTEIN", 195, 210], ["CTB", "PROTEIN", 290, 293], ["G33D polypeptides", "PROTEIN", 294, 311], ["tagged CTB polypeptides", "PROBLEM", 38, 61], ["moderate decreases", "PROBLEM", 74, 92], ["the pentamer bands", "TEST", 119, 137], ["Fig.", "TEST", 139, 143], ["upper panel", "TEST", 147, 158], ["lanes", "TEST", 168, 173], ["the holotoxin bands (Fig.", "TEST", 191, 216], ["upper panel", "TEST", 220, 231], ["CTB", "TEST", 290, 293], ["G33D polypeptides", "TREATMENT", 294, 311], ["slight increases in mobilities", "PROBLEM", 324, 354], ["the holotoxin bands", "TEST", 358, 377], ["Fig.", "TEST", 379, 383], ["upper panel", "TEST", 387, 398], ["increasing", "OBSERVATION_MODIFIER", 13, 23], ["moderate", "OBSERVATION_MODIFIER", 74, 82], ["decreases", "OBSERVATION_MODIFIER", 83, 92], ["upper", "ANATOMY_MODIFIER", 147, 152], ["slight", "OBSERVATION_MODIFIER", 324, 330], ["increases", "OBSERVATION_MODIFIER", 331, 340], ["upper", "ANATOMY_MODIFIER", 387, 392]]], ["Upon boiling, all holotoxins dissociated and resolved into their individual polypeptide components (Fig. 2, lower panel).", [["all holotoxins", "TREATMENT", 14, 28]]], ["All holotoxins have one CTA subunit.", [["holotoxins", "SIMPLE_CHEMICAL", 4, 14], ["CTA subunit", "PROTEIN", 24, 35]]], ["Holotoxins in lanes 2 and 5 are predicted to have five native CTB monomers; holotoxins in lanes 3, 6, and 8 have are predicted to have one tagged CTB and 4 untagged CTB monomers; and holotoxins in lanes 4, 7, and 9 are predicted to have two tagged and three untagged CTB monomers.Production and purification of cholera toxin variants with 0, 1, 2, 3, 4, or 5 native GM1 binding sites. ::: RESULTSStoichiometry of the individual polypeptides in each purified holotoxin variant was confirmed experimentally by densitometric scanning of the gel in the lower panel of Fig. 2.", [["CTB", "GENE_OR_GENE_PRODUCT", 62, 65], ["holotoxins", "GENE_OR_GENE_PRODUCT", 76, 86], ["CTB", "GENE_OR_GENE_PRODUCT", 146, 149], ["CTB", "GENE_OR_GENE_PRODUCT", 165, 168], ["CTB", "GENE_OR_GENE_PRODUCT", 267, 270], ["cholera toxin", "GENE_OR_GENE_PRODUCT", 311, 324], ["GM1", "GENE_OR_GENE_PRODUCT", 366, 369], ["holotoxin", "GENE_OR_GENE_PRODUCT", 458, 467], ["CTB monomers", "PROTEIN", 62, 74], ["holotoxins", "PROTEIN", 76, 86], ["lanes 3, 6, and 8", "PROTEIN", 90, 107], ["CTB", "PROTEIN", 146, 149], ["CTB monomers", "PROTEIN", 165, 177], ["holotoxins", "PROTEIN", 183, 193], ["lanes 4, 7, and 9", "PROTEIN", 197, 214], ["CTB monomers", "PROTEIN", 267, 279], ["cholera toxin variants", "PROTEIN", 311, 333], ["Holotoxins in lanes", "TREATMENT", 0, 19], ["cholera toxin variants", "PROBLEM", 311, 333], ["the individual polypeptides", "PROBLEM", 413, 440], ["densitometric scanning", "TEST", 508, 530], ["the gel", "TREATMENT", 534, 541], ["lower panel", "ANATOMY", 549, 560]]], ["To adjust for differences in loading of the purified holotoxins (ranging from 0.6 \u00b5g in lane 6 to 2.9 \u00b5g in lane 2), the observed density for each band was expressed as a fraction of the total density for all bands in the same lane.", [["holotoxins", "SIMPLE_CHEMICAL", 53, 63], ["the purified holotoxins", "TREATMENT", 40, 63], ["all bands", "PROBLEM", 205, 214], ["density", "OBSERVATION", 130, 137], ["total", "OBSERVATION_MODIFIER", 187, 192], ["density", "OBSERVATION", 193, 200]]], ["The observed fractional densities were then compared with the expected values based on the predicted molecular mass of each polypeptide (CTA, 27.2 kDa; wt CTB, 11.6 kDa; and tagged CTB, 15.3 kDa) and the assumption that binding of Coomassie blue is proportional to the mass of each peptide.", [["Coomassie blue", "CHEMICAL", 231, 245], ["Coomassie blue", "SIMPLE_CHEMICAL", 231, 245], ["CTB", "PROTEIN", 181, 184], ["The observed fractional densities", "PROBLEM", 0, 33], ["CTA", "TEST", 137, 140], ["kDa", "TEST", 147, 150], ["wt", "TEST", 152, 154], ["CTB", "TEST", 155, 158], ["kDa", "TEST", 165, 168], ["tagged CTB", "TEST", 174, 184], ["Coomassie blue", "PROBLEM", 231, 245], ["fractional", "OBSERVATION_MODIFIER", 13, 23], ["densities", "OBSERVATION", 24, 33], ["mass", "OBSERVATION", 111, 115], ["Coomassie blue", "OBSERVATION", 231, 245], ["mass", "OBSERVATION", 269, 273]]], ["The results (see Table S1 in the supplemental material) were generally within 15% of expected values, but all observed values for tagged B subunits were higher than expected, suggesting that the tagged subunits bound proportionately more Coomassie blue stain than native CTA or CTB.", [["Coomassie blue", "CHEMICAL", 238, 252], ["B subunits", "GENE_OR_GENE_PRODUCT", 137, 147], ["Coomassie", "SIMPLE_CHEMICAL", 238, 247], ["CTB", "SIMPLE_CHEMICAL", 278, 281], ["tagged B subunits", "PROTEIN", 130, 147], ["tagged subunits", "PROTEIN", 195, 210], ["tagged B subunits", "TEST", 130, 147], ["the tagged subunits bound", "PROBLEM", 191, 216], ["Coomassie blue stain", "TEST", 238, 258], ["CTB", "PROBLEM", 278, 281]]], ["Corrected for loading differences, the expected stoichiometric ratios for the tagged B subunit bands in lanes 3 versus 4, 6 versus 7, and 8 versus 9 were 1:2, and the corresponding observed ratios were 1:2.1, 1:1.7, and 1:1.9, respectively.Ganglioside GM1-binding activities of cholera toxin variants. ::: RESULTSRelative binding activity of each holotoxin preparation with from zero to five binding sites (and with zero, one, or two tagged B subunits) to ganglioside GM1 receptor was measured by ELISA with a fixed amount of toxin (5 ng, 60 fmol) added to individual wells coated previously with serial dilutions of GM1, and bound toxin was detected with polyclonal rabbit anti-CTB and horseradish peroxidase (HRP)-conjugated secondary antibody.", [["ganglioside", "CHEMICAL", 456, 467], ["B subunit", "GENE_OR_GENE_PRODUCT", 85, 94], ["Ganglioside GM1", "GENE_OR_GENE_PRODUCT", 240, 255], ["cholera toxin", "SIMPLE_CHEMICAL", 278, 291], ["B subunits", "GENE_OR_GENE_PRODUCT", 441, 451], ["ganglioside GM1 receptor", "GENE_OR_GENE_PRODUCT", 456, 480], ["GM1", "SIMPLE_CHEMICAL", 617, 620], ["rabbit", "ORGANISM", 667, 673], ["anti-CTB", "SIMPLE_CHEMICAL", 674, 682], ["horseradish peroxidase", "SIMPLE_CHEMICAL", 687, 709], ["HRP", "SIMPLE_CHEMICAL", 711, 714], ["tagged B subunit bands", "PROTEIN", 78, 100], ["cholera toxin variants", "PROTEIN", 278, 300], ["tagged B subunits", "PROTEIN", 434, 451], ["ganglioside GM1 receptor", "PROTEIN", 456, 480], ["GM1", "PROTEIN", 617, 620], ["polyclonal rabbit anti-CTB", "PROTEIN", 656, 682], ["horseradish peroxidase (HRP)-conjugated secondary antibody", "PROTEIN", 687, 745], ["rabbit", "SPECIES", 667, 673], ["horseradish", "SPECIES", 687, 698], ["rabbit", "SPECIES", 667, 673], ["loading differences", "PROBLEM", 14, 33], ["the expected stoichiometric ratios", "TEST", 35, 69], ["the tagged B subunit bands", "PROBLEM", 74, 100], ["Ganglioside GM1", "TEST", 240, 255], ["cholera toxin variants", "PROBLEM", 278, 300], ["each holotoxin preparation", "TREATMENT", 342, 368], ["two tagged B subunits", "TREATMENT", 430, 451], ["ganglioside GM1 receptor", "TEST", 456, 480], ["a fixed amount of toxin", "TREATMENT", 508, 531], ["serial dilutions of GM1", "TEST", 597, 620], ["bound toxin", "TEST", 626, 637], ["polyclonal rabbit anti-CTB", "TREATMENT", 656, 682], ["horseradish peroxidase (HRP", "TEST", 687, 714], ["conjugated secondary antibody", "PROBLEM", 716, 745], ["stoichiometric ratios", "OBSERVATION", 48, 69]]], ["Figure 3 shows that at high GM1 density, toxins with more than one native GM1 BS bound almost as well as native cholera toxin.", [["GM1", "GENE_OR_GENE_PRODUCT", 28, 31], ["GM1", "GENE_OR_GENE_PRODUCT", 74, 77], ["cholera toxin", "SIMPLE_CHEMICAL", 112, 125], ["cholera toxin", "PROTEIN", 112, 125], ["high GM1", "OBSERVATION_MODIFIER", 23, 31], ["density", "OBSERVATION", 32, 39]]], ["The single-BS holotoxin showed a lower plateau signal at high GM1 density than holotoxins with more than one BS, which we interpret to be due to a less favorable equilibrium between binding and release for the holotoxin with one BS for GM1.", [["holotoxins", "CHEMICAL", 79, 89], ["GM1", "SIMPLE_CHEMICAL", 62, 65], ["holotoxins", "SIMPLE_CHEMICAL", 79, 89], ["GM1", "SIMPLE_CHEMICAL", 236, 239], ["The single-BS holotoxin", "TEST", 0, 23], ["a lower plateau signal", "PROBLEM", 31, 53], ["a less favorable equilibrium between binding", "PROBLEM", 145, 189], ["the holotoxin", "TREATMENT", 206, 219], ["lower plateau", "ANATOMY", 33, 46], ["high GM1 density", "OBSERVATION_MODIFIER", 57, 73]]], ["With more than one BS, a toxin molecule is expected to exhibit faster initial binding to immobilized GM1, multivalent binding as the density of immobilized GM1 increases, and slower dissociation from GM1, resulting in increased avidity of binding.", [["GM1", "SIMPLE_CHEMICAL", 101, 104], ["GM1", "SIMPLE_CHEMICAL", 156, 159], ["GM1", "SIMPLE_CHEMICAL", 200, 203], ["toxin molecule", "PROTEIN", 25, 39], ["a toxin molecule", "PROBLEM", 23, 39], ["faster initial binding to immobilized GM1", "PROBLEM", 63, 104], ["multivalent binding", "PROBLEM", 106, 125], ["immobilized GM1", "PROBLEM", 144, 159], ["slower dissociation from GM1", "PROBLEM", 175, 203], ["increased avidity of binding", "PROBLEM", 218, 246], ["immobilized GM1", "OBSERVATION", 144, 159], ["slower", "OBSERVATION_MODIFIER", 175, 181], ["dissociation", "OBSERVATION", 182, 194], ["increased", "OBSERVATION_MODIFIER", 218, 227], ["avidity", "OBSERVATION", 228, 235]]], ["In wells coated with 75 nM GM1 (50 \u00b5l, 3.75 pmol), toxins with 2 or more native GM1 BS bound at more than 90% of the wt level, toxin with a single BS bound significantly less at 60% of the wt level, and toxin with no BS gave a minimal signal (4% or less of the wt level).", [["GM1", "SIMPLE_CHEMICAL", 27, 30], ["GM1 BS", "SIMPLE_CHEMICAL", 80, 86], ["toxin", "SIMPLE_CHEMICAL", 203, 208], ["toxins", "TEST", 51, 57], ["the wt level", "TEST", 113, 125], ["toxin", "TEST", 127, 132], ["a single BS bound", "PROBLEM", 138, 155], ["the wt level", "TEST", 185, 197], ["toxin", "TEST", 203, 208], ["BS", "TEST", 217, 219]]], ["At lower GM1 densities, there were significant differences between all variants, and in wells coated with 1.2 nM GM1 (50 \u00b5l, 60 fmol), toxins with four or three BS bound at 54 and 49% of wt levels, respectively, and toxins with 2, 1, or no BS bound at 25, 12, and 1% of wt levels, respectively.", [["GM1", "SIMPLE_CHEMICAL", 9, 12], ["GM1", "SIMPLE_CHEMICAL", 113, 116], ["significant differences between all variants", "PROBLEM", 35, 79], ["nM GM1", "TEST", 110, 116], ["toxins", "TEST", 135, 141], ["three BS bound", "TEST", 155, 169], ["wt levels", "TEST", 187, 196], ["toxins", "TEST", 216, 222], ["BS bound", "PROBLEM", 240, 248], ["lower", "ANATOMY_MODIFIER", 3, 8], ["GM1 densities", "OBSERVATION", 9, 22], ["significant", "OBSERVATION_MODIFIER", 35, 46], ["differences", "OBSERVATION_MODIFIER", 47, 58], ["all variants", "OBSERVATION", 67, 79]]], ["The amount of GM1 required to coat each well and give 50% of the maximal signal was calculated to be 65, 100, 150, 240, and 850 fmol per well for wt holotoxin and for holotoxin variants with 4, 3, 2, or 1 wt BS, respectively.Activities of toxin variants on mouse Y1 cells and real-time electrophysiological measurements of variant toxin activities on polarized human colonic T84 cells. ::: RESULTSBiological activities of the eight holotoxin preparations (the untagged and singly and doubly tagged native holotoxin controls and the variant holotoxins with zero to four wt BS and one or two tags) were initially tested in an overnight assay on mouse Y1 adrenal cell monolayers, on which cholera toxin causes an easily scorable morphological change (rounding of intoxicated cells).", [["Y1 cells", "ANATOMY", 263, 271], ["colonic T84 cells", "ANATOMY", 367, 384], ["adrenal cell monolayers", "ANATOMY", 652, 675], ["cells", "ANATOMY", 772, 777], ["cholera toxin", "CHEMICAL", 686, 699], ["GM1", "GENE_OR_GENE_PRODUCT", 14, 17], ["holotoxin", "GENE_OR_GENE_PRODUCT", 149, 158], ["mouse", "ORGANISM", 257, 262], ["Y1 cells", "CELL", 263, 271], ["human", "ORGANISM", 361, 366], ["colonic T84 cells", "CELL", 367, 384], ["mouse", "ORGANISM", 643, 648], ["Y1 adrenal cell monolayers", "CELL", 649, 675], ["cholera toxin", "SIMPLE_CHEMICAL", 686, 699], ["cells", "CELL", 772, 777], ["GM1", "PROTEIN", 14, 17], ["mouse Y1 cells", "CELL_LINE", 257, 271], ["polarized human colonic T84 cells", "CELL_LINE", 351, 384], ["mouse Y1 adrenal cell monolayers", "CELL_LINE", 643, 675], ["cholera toxin", "PROTEIN", 686, 699], ["intoxicated cells", "CELL_TYPE", 760, 777], ["mouse", "SPECIES", 257, 262], ["human", "SPECIES", 361, 366], ["mouse", "SPECIES", 643, 648], ["mouse", "SPECIES", 257, 262], ["human", "SPECIES", 361, 366], ["mouse", "SPECIES", 643, 648], ["the maximal signal", "TEST", 61, 79], ["wt holotoxin", "TREATMENT", 146, 158], ["holotoxin variants", "TREATMENT", 167, 185], ["toxin variants", "PROBLEM", 239, 253], ["electrophysiological measurements", "TEST", 286, 319], ["variant toxin activities", "PROBLEM", 323, 347], ["the eight holotoxin preparations", "TREATMENT", 422, 454], ["doubly tagged native holotoxin controls", "TREATMENT", 484, 523], ["the variant holotoxins", "TREATMENT", 528, 550], ["wt BS", "TEST", 569, 574], ["an overnight assay", "TEST", 621, 639], ["cholera toxin", "PROBLEM", 686, 699], ["an easily scorable morphological change", "PROBLEM", 707, 746], ["amount", "OBSERVATION_MODIFIER", 4, 10], ["GM1 required to coat", "OBSERVATION_MODIFIER", 14, 34], ["colonic T84", "ANATOMY", 367, 378], ["adrenal cell monolayers", "OBSERVATION", 652, 675]]], ["In this assay, approximately 2 ng of unnicked native cholera toxin caused rounding of 75 to 100% of the cells (48 U/100 ng).", [["cells", "ANATOMY", 104, 109], ["cholera toxin", "CHEMICAL", 53, 66], ["cholera toxin", "SIMPLE_CHEMICAL", 53, 66], ["cells", "CELL", 104, 109], ["cholera toxin", "PROTEIN", 53, 66], ["unnicked native cholera toxin", "PROBLEM", 37, 66]]], ["The G33D holotoxin showed some rounding at only the highest concentration tested (33 ng, extrapolating to less than 1 U/100 ng).", [["G33D holotoxin", "GENE_OR_GENE_PRODUCT", 4, 18], ["The G33D holotoxin", "TEST", 0, 18], ["some rounding", "PROBLEM", 26, 39]]], ["All holotoxin variants with one or more BS showed rounding of Y1 cells at between 24 and 48 U/100 ng, showing that a single GM1 binding site is sufficient to intoxicate mouse Y1 cells at near-wt levels.", [["Y1 cells", "ANATOMY", 62, 70], ["Y1 cells", "ANATOMY", 175, 183], ["Y1 cells", "CELL", 62, 70], ["GM1", "GENE_OR_GENE_PRODUCT", 124, 127], ["mouse", "ORGANISM", 169, 174], ["Y1 cells", "CELL", 175, 183], ["Y1 cells", "CELL_LINE", 62, 70], ["GM1 binding site", "DNA", 124, 140], ["mouse Y1 cells", "CELL_LINE", 169, 183], ["mouse", "SPECIES", 169, 174], ["mouse", "SPECIES", 169, 174], ["All holotoxin variants", "TREATMENT", 0, 22], ["more BS", "TEST", 35, 42], ["a single GM1 binding site", "PROBLEM", 115, 140]]], ["Failure to detect significantly less toxicity after overnight exposure of mouse Y1 adrenal cells to holotoxin variants with from 1 to 4 GM1 binding sites suggests that any differences in delivery of the wt CT-A1 fragment from the cell surface to the cytosol by these holotoxin variants were not rate limiting for development of the morphological manifestations of intoxication.Activities of toxin variants on mouse Y1 cells and real-time electrophysiological measurements of variant toxin activities on polarized human colonic T84 cells. ::: RESULTSTo assess the biological consequences of decreased numbers of BS in a more quantitative manner, we determined the real-time electrophysiological effects of the holotoxin variants on polarized human intestinal cells (T84 cell line) by measuring the short circuit current required to eliminate the potential difference induced by the cAMP-dependent Cl\u2013 secretory response resulting from CT-A1-mediated ADP ribosylation of Gs\u03b1 and constitutive activation of adenylate cyclase.", [["Y1 adrenal cells", "ANATOMY", 80, 96], ["cell surface", "ANATOMY", 230, 242], ["cytosol", "ANATOMY", 250, 257], ["Y1 cells", "ANATOMY", 415, 423], ["colonic T84 cells", "ANATOMY", 519, 536], ["intestinal cells", "ANATOMY", 747, 763], ["T84 cell line", "ANATOMY", 765, 778], ["toxicity", "DISEASE", 37, 45], ["cAMP", "CHEMICAL", 881, 885], ["ADP", "CHEMICAL", 949, 952], ["cAMP", "CHEMICAL", 881, 885], ["ADP", "CHEMICAL", 949, 952], ["adenylate", "CHEMICAL", 1004, 1013], ["mouse", "ORGANISM", 74, 79], ["Y1 adrenal cells", "CELL", 80, 96], ["holotoxin", "GENE_OR_GENE_PRODUCT", 100, 109], ["GM1", "GENE_OR_GENE_PRODUCT", 136, 139], ["CT-A1", "GENE_OR_GENE_PRODUCT", 206, 211], ["cell surface", "CELLULAR_COMPONENT", 230, 242], ["cytosol", "CELLULAR_COMPONENT", 250, 257], ["holotoxin", "GENE_OR_GENE_PRODUCT", 267, 276], ["mouse", "ORGANISM", 409, 414], ["Y1 cells", "CELL", 415, 423], ["human", "ORGANISM", 513, 518], ["colonic T84 cells", "CELL", 519, 536], ["human", "ORGANISM", 741, 746], ["intestinal cells", "CELL", 747, 763], ["T84 cell line", "CELL", 765, 778], ["cAMP", "SIMPLE_CHEMICAL", 881, 885], ["Cl\u2013", "SIMPLE_CHEMICAL", 896, 899], ["CT-A1", "GENE_OR_GENE_PRODUCT", 934, 939], ["ADP", "SIMPLE_CHEMICAL", 949, 952], ["Gs\u03b1", "GENE_OR_GENE_PRODUCT", 969, 972], ["adenylate cyclase", "GENE_OR_GENE_PRODUCT", 1004, 1021], ["mouse Y1 adrenal cells", "CELL_LINE", 74, 96], ["wt CT-A1 fragment", "DNA", 203, 220], ["mouse Y1 cells", "CELL_LINE", 409, 423], ["polarized human colonic T84 cells", "CELL_LINE", 503, 536], ["polarized human intestinal cells", "CELL_LINE", 731, 763], ["T84 cell line", "CELL_LINE", 765, 778], ["A1", "PROTEIN", 937, 939], ["Gs\u03b1", "PROTEIN", 969, 972], ["adenylate cyclase", "PROTEIN", 1004, 1021], ["mouse", "SPECIES", 74, 79], ["mouse", "SPECIES", 409, 414], ["human", "SPECIES", 513, 518], ["human", "SPECIES", 741, 746], ["mouse", "SPECIES", 74, 79], ["mouse", "SPECIES", 409, 414], ["human", "SPECIES", 513, 518], ["human", "SPECIES", 741, 746], ["Failure", "PROBLEM", 0, 7], ["significantly less toxicity", "PROBLEM", 18, 45], ["mouse Y1 adrenal cells", "TREATMENT", 74, 96], ["holotoxin variants", "PROBLEM", 100, 118], ["4 GM1 binding sites", "PROBLEM", 134, 153], ["the wt CT", "TEST", 199, 208], ["A1 fragment", "PROBLEM", 209, 220], ["these holotoxin variants", "TEST", 261, 285], ["intoxication", "PROBLEM", 364, 376], ["toxin variants", "PROBLEM", 391, 405], ["electrophysiological measurements", "TEST", 438, 471], ["variant toxin activities", "PROBLEM", 475, 499], ["decreased numbers of BS", "PROBLEM", 590, 613], ["the holotoxin variants", "TREATMENT", 705, 727], ["polarized human intestinal cells", "TREATMENT", 731, 763], ["T84 cell line", "TREATMENT", 765, 778], ["the short circuit", "TREATMENT", 793, 810], ["the cAMP-dependent Cl\u2013 secretory response", "PROBLEM", 877, 918], ["CT", "TEST", 934, 936], ["ADP ribosylation of Gs\u03b1", "PROBLEM", 949, 972], ["adenylate cyclase", "PROBLEM", 1004, 1021], ["significantly less", "OBSERVATION_MODIFIER", 18, 36], ["colonic T84", "ANATOMY", 519, 530], ["decreased", "OBSERVATION_MODIFIER", 590, 599], ["intestinal cells", "ANATOMY", 747, 763]]], ["Panel A shows that loss of even a single GM1 BS attenuated the activity of cholera toxin to some degree, an effect which increased as the number of native GM1 BS was lost.", [["cholera toxin", "CHEMICAL", 75, 88], ["GM1", "GENE_OR_GENE_PRODUCT", 41, 44], ["cholera toxin", "GENE_OR_GENE_PRODUCT", 75, 88], ["GM1", "GENE_OR_GENE_PRODUCT", 155, 158], ["cholera toxin", "PROTEIN", 75, 88], ["Panel A", "TEST", 0, 7], ["a single GM1 BS", "TEST", 32, 47], ["cholera toxin", "TREATMENT", 75, 88], ["native GM1 BS", "TEST", 148, 161], ["some degree", "OBSERVATION_MODIFIER", 92, 103], ["increased", "OBSERVATION_MODIFIER", 121, 130]]], ["The time of onset of intoxication was also delayed as the number of native GM1 BS decreased.", [["GM1", "GENE_OR_GENE_PRODUCT", 75, 78], ["intoxication", "PROBLEM", 21, 33], ["decreased", "OBSERVATION_MODIFIER", 82, 91]]], ["Nevertheless, toxin with a single native GM1 BS had clearly detectable activity.", [["GM1", "GENE_OR_GENE_PRODUCT", 41, 44], ["toxin", "PROBLEM", 14, 19], ["a single native GM1 BS", "TEST", 25, 47], ["detectable activity", "OBSERVATION", 60, 79]]], ["As expected, the G33D holotoxin with no native GM1 BS had almost no activity over the time frame of the experiment: 1.5% of wt toxin signal over baseline at 90 min and less than 9% of wt signal at 120 min.", [["G33D holotoxin", "GENE_OR_GENE_PRODUCT", 17, 31], ["GM1 BS", "SIMPLE_CHEMICAL", 47, 53], ["toxin", "GENE_OR_GENE_PRODUCT", 127, 132], ["the G33D holotoxin", "TREATMENT", 13, 31], ["native GM1 BS", "PROBLEM", 40, 53], ["wt toxin signal", "TEST", 124, 139]]], ["Since these variants have differing numbers of C-terminal GSH6 tags (zero, one, or two), we also examined the effect that the number of tags had on the activity of wt holotoxin with five BS (Fig. 4B).", [["C-", "CHEMICAL", 47, 49], ["holotoxin", "GENE_OR_GENE_PRODUCT", 167, 176], ["C-terminal GSH6 tags", "DNA", 47, 67], ["C-terminal GSH6 tags", "TEST", 47, 67], ["wt holotoxin", "TREATMENT", 164, 176], ["differing", "OBSERVATION_MODIFIER", 26, 35], ["numbers", "OBSERVATION_MODIFIER", 36, 43]]], ["The presence of the tags modestly affected both the time of onset of intoxication, a measure of toxin-GM1 trafficking from the PM to the ER of host cells, and the rate of increase of Isc.", [["ER", "ANATOMY", 137, 139], ["cells", "ANATOMY", 148, 153], ["toxin-GM1", "GENE_OR_GENE_PRODUCT", 96, 105], ["PM", "CELLULAR_COMPONENT", 127, 129], ["ER", "GENE_OR_GENE_PRODUCT", 137, 139], ["host cells", "CELL", 143, 153], ["toxin", "PROTEIN", 96, 101], ["ER", "PROTEIN", 137, 139], ["host cells", "CELL_TYPE", 143, 153], ["the tags", "PROBLEM", 16, 24], ["intoxication", "PROBLEM", 69, 81], ["toxin", "TEST", 96, 101], ["host cells", "OBSERVATION", 143, 153], ["increase", "OBSERVATION_MODIFIER", 171, 179]]], ["The effect was greater for doubly tagged holotoxin, although it eventually showed a similar maximal Isc.", [["holotoxin", "GENE_OR_GENE_PRODUCT", 41, 50], ["doubly tagged holotoxin", "TREATMENT", 27, 50]]], ["To control for these effects of the B-subunit tags, toxins with different numbers of native GM1 BS but the same number of tags were compared.", [["GM1", "GENE_OR_GENE_PRODUCT", 92, 95], ["B-subunit tags", "PROTEIN", 36, 50], ["the B-subunit tags", "TREATMENT", 32, 50], ["toxins", "PROBLEM", 52, 58], ["native GM1 BS", "PROBLEM", 85, 98], ["GM1 BS", "OBSERVATION", 92, 98]]], ["For these analyses, data were normalized by setting the maximal signal for the five native GM1 BS toxins in each comparison to 1.00 (Fig. 4C to F).", [["these analyses", "TEST", 4, 18], ["the maximal signal", "TEST", 52, 70]]], ["For the toxin variants with one tag on the B subunit, the holotoxin with four native GM1 BS exhibited a slight (25%) attenuation of toxicity relative to holotoxin with five native GM1 BS, seen as a decrease in maximal Isc but with no delay in onset of intoxication (Fig. 4C).", [["toxicity", "DISEASE", 132, 140], ["B subunit", "GENE_OR_GENE_PRODUCT", 43, 52], ["holotoxin", "GENE_OR_GENE_PRODUCT", 58, 67], ["GM1", "SIMPLE_CHEMICAL", 180, 183], ["B subunit", "PROTEIN", 43, 52], ["the toxin variants", "PROBLEM", 4, 22], ["the B subunit", "TREATMENT", 39, 52], ["the holotoxin", "TREATMENT", 54, 67], ["four native GM1 BS", "TEST", 73, 91], ["a slight (25%) attenuation of toxicity", "PROBLEM", 102, 140], ["holotoxin", "TREATMENT", 153, 162], ["a decrease in maximal Isc", "PROBLEM", 196, 221], ["intoxication", "PROBLEM", 252, 264], ["slight", "OBSERVATION_MODIFIER", 104, 110], ["GM1 BS", "OBSERVATION", 180, 186], ["decrease", "OBSERVATION_MODIFIER", 198, 206], ["maximal Isc", "OBSERVATION", 210, 221], ["no", "UNCERTAINTY", 231, 233]]], ["A similar result (30% decrease of maximal Isc) was seen for comparisons of the holotoxin variants with three or five native GM1 BS and two CTB-GSH6-tagged subunits (Fig. 4D).", [["CTB", "GENE_OR_GENE_PRODUCT", 139, 142], ["holotoxin variants", "PROTEIN", 79, 97], ["GM1 BS", "PROTEIN", 124, 130], ["CTB", "PROTEIN", 139, 142], ["GSH6", "PROTEIN", 143, 147], ["tagged subunits", "PROTEIN", 148, 163], ["Fig. 4D", "PROTEIN", 165, 172], ["the holotoxin variants", "TREATMENT", 75, 97], ["two CTB", "TREATMENT", 135, 142]]], ["When the number of native GM1 BS was reduced to two or one in doubly or singly wt B-subunit-tagged holotoxin variants, the peak Isc decreased by more than 50% and also the onset of intoxication was delayed (Fig. 4E and 4F), suggesting defects in entry of CT into the cell or transport to the ER (or both).Activities of toxin variants on mouse Y1 cells and real-time electrophysiological measurements of variant toxin activities on polarized human colonic T84 cells. ::: RESULTSAs an initial step toward investigating whether CT variants with five and one native GM1 BS trafficked from the cell surface to the ER by the same pathway, we examined the effects of brefeldin A (BFA) on their toxicity for T84 cell monolayers.", [["cell", "ANATOMY", 267, 271], ["ER", "ANATOMY", 292, 294], ["Y1 cells", "ANATOMY", 343, 351], ["colonic T84 cells", "ANATOMY", 447, 464], ["cell surface", "ANATOMY", 589, 601], ["ER", "ANATOMY", 609, 611], ["T84 cell monolayers", "ANATOMY", 700, 719], ["brefeldin A", "CHEMICAL", 660, 671], ["BFA", "CHEMICAL", 673, 676], ["toxicity", "DISEASE", 687, 695], ["brefeldin A", "CHEMICAL", 660, 671], ["BFA", "CHEMICAL", 673, 676], ["GM1", "GENE_OR_GENE_PRODUCT", 26, 29], ["B", "GENE_OR_GENE_PRODUCT", 82, 83], ["holotoxin", "GENE_OR_GENE_PRODUCT", 99, 108], ["cell", "CELL", 267, 271], ["ER", "GENE_OR_GENE_PRODUCT", 292, 294], ["mouse", "ORGANISM", 337, 342], ["Y1 cells", "CELL", 343, 351], ["human", "ORGANISM", 441, 446], ["colonic T84 cells", "CELL", 447, 464], ["GM1 BS", "GENE_OR_GENE_PRODUCT", 562, 568], ["cell surface", "CELLULAR_COMPONENT", 589, 601], ["ER", "GENE_OR_GENE_PRODUCT", 609, 611], ["brefeldin A", "SIMPLE_CHEMICAL", 660, 671], ["BFA", "SIMPLE_CHEMICAL", 673, 676], ["T84 cell monolayers", "CELL", 700, 719], ["B", "PROTEIN", 82, 83], ["tagged holotoxin variants", "PROTEIN", 92, 117], ["CT", "PROTEIN", 255, 257], ["ER", "PROTEIN", 292, 294], ["mouse Y1 cells", "CELL_LINE", 337, 351], ["polarized human colonic T84 cells", "CELL_LINE", 431, 464], ["GM1 BS", "PROTEIN", 562, 568], ["ER", "PROTEIN", 609, 611], ["T84 cell monolayers", "CELL_LINE", 700, 719], ["mouse", "SPECIES", 337, 342], ["human", "SPECIES", 441, 446], ["mouse", "SPECIES", 337, 342], ["human", "SPECIES", 441, 446], ["native GM1 BS", "TEST", 19, 32], ["tagged holotoxin variants", "TREATMENT", 92, 117], ["the peak Isc", "TEST", 119, 131], ["intoxication", "PROBLEM", 181, 193], ["defects", "PROBLEM", 235, 242], ["CT", "TEST", 255, 257], ["toxin variants", "PROBLEM", 319, 333], ["electrophysiological measurements", "TEST", 366, 399], ["variant toxin activities", "PROBLEM", 403, 427], ["CT variants", "TEST", 525, 536], ["brefeldin A (BFA", "TREATMENT", 660, 676], ["their toxicity", "PROBLEM", 681, 695], ["T84 cell monolayers", "PROBLEM", 700, 719], ["defects", "OBSERVATION", 235, 242], ["colonic T84", "ANATOMY", 447, 458], ["T84 cell monolayers", "OBSERVATION", 700, 719]]], ["We found that BFA completely inhibited the Isc (Fig. 5) induced by both single and five native GM1 BS toxin variants.", [["BFA", "CHEMICAL", 14, 17], ["BFA", "CHEMICAL", 14, 17], ["BFA", "SIMPLE_CHEMICAL", 14, 17], ["GM1 BS toxin", "GENE_OR_GENE_PRODUCT", 95, 107], ["BFA", "PROBLEM", 14, 17], ["toxin variants", "OBSERVATION", 102, 116]]], ["BFA- treated cells, however, still responded to addition of the cAMP agonist vasoactive intestinal polypeptide (VIP) at 90 min, showing that the toxin-treated cells retained viability and were competent for cAMP-dependent Cl\u2013 secretion (Isc).", [["cells", "ANATOMY", 13, 18], ["cells", "ANATOMY", 159, 164], ["BFA", "CHEMICAL", 0, 3], ["cAMP", "CHEMICAL", 64, 68], ["cAMP", "CHEMICAL", 207, 211], ["BFA", "CHEMICAL", 0, 3], ["cAMP", "CHEMICAL", 64, 68], ["cAMP", "CHEMICAL", 207, 211], ["BFA", "SIMPLE_CHEMICAL", 0, 3], ["cells", "CELL", 13, 18], ["cAMP", "SIMPLE_CHEMICAL", 64, 68], ["vasoactive intestinal polypeptide", "GENE_OR_GENE_PRODUCT", 77, 110], ["VIP", "GENE_OR_GENE_PRODUCT", 112, 115], ["toxin", "SIMPLE_CHEMICAL", 145, 150], ["cells", "CELL", 159, 164], ["cAMP", "SIMPLE_CHEMICAL", 207, 211], ["Cl\u2013", "SIMPLE_CHEMICAL", 222, 225], ["Isc", "SIMPLE_CHEMICAL", 237, 240], ["BFA- treated cells", "CELL_LINE", 0, 18], ["toxin-treated cells", "CELL_LINE", 145, 164], ["the cAMP agonist vasoactive intestinal polypeptide", "TREATMENT", 60, 110], ["the toxin-treated cells", "PROBLEM", 141, 164], ["cAMP-dependent Cl\u2013 secretion", "PROBLEM", 207, 235]]], ["Thus, a toxin variant with a single native GM1 BS, like native CT holotoxin, traffics through a BFA-sensitive pathway to exert its toxic effects.DISCUSSIONPrevious studies have shown that holotoxins with reduced numbers of GM1 BS are still able to intoxicate host cells, albeit with attenuated activity.", [["cells", "ANATOMY", 264, 269], ["BFA", "CHEMICAL", 96, 99], ["BFA", "CHEMICAL", 96, 99], ["holotoxins", "CHEMICAL", 188, 198], ["GM1", "GENE_OR_GENE_PRODUCT", 43, 46], ["BFA", "SIMPLE_CHEMICAL", 96, 99], ["holotoxins", "SIMPLE_CHEMICAL", 188, 198], ["GM1 BS", "GENE_OR_GENE_PRODUCT", 223, 229], ["host cells", "CELL", 259, 269], ["host cells", "CELL_TYPE", 259, 269], ["a toxin variant", "PROBLEM", 6, 21], ["a single native GM1 BS", "TEST", 27, 49], ["native CT holotoxin", "TREATMENT", 56, 75], ["a BFA", "TEST", 94, 99], ["DISCUSSIONPrevious studies", "TEST", 145, 171], ["holotoxins", "TREATMENT", 188, 198], ["reduced numbers of GM1 BS", "PROBLEM", 204, 229]]], ["The initial studies (26, 27) used chemical modification and denaturation-renaturation to generate mixed populations of holotoxins predicted to have one or two (nonnative but active) GM1 BS.", [["holotoxins", "GENE_OR_GENE_PRODUCT", 119, 129], ["The initial studies", "TEST", 0, 19], ["chemical modification", "TREATMENT", 34, 55], ["denaturation-renaturation", "TREATMENT", 60, 85], ["holotoxins", "TREATMENT", 119, 129], ["active", "OBSERVATION_MODIFIER", 174, 180]]], ["In our previous study (22), we used genetic methods to create populations of chimeric holotoxins with only one or two completely native GM1 BS and showed that these chimeras were still capable of intoxicating host cells but with attenuated activity.DISCUSSIONMore recently, we studied how a membrane lipid might specify trafficking of toxin in the retrograde pathway by using fluorophore-labeled GM1 and imaging toxin trafficking in live cells (28).", [["cells", "ANATOMY", 214, 219], ["membrane", "ANATOMY", 291, 299], ["cells", "ANATOMY", 438, 443], ["holotoxins", "GENE_OR_GENE_PRODUCT", 86, 96], ["GM1", "GENE_OR_GENE_PRODUCT", 136, 139], ["host cells", "CELL", 209, 219], ["membrane", "CELLULAR_COMPONENT", 291, 299], ["fluorophore", "SIMPLE_CHEMICAL", 376, 387], ["GM1", "SIMPLE_CHEMICAL", 396, 399], ["cells", "CELL", 438, 443], ["chimeric holotoxins", "PROTEIN", 77, 96], ["GM1 BS", "PROTEIN", 136, 142], ["intoxicating host cells", "CELL_TYPE", 196, 219], ["toxin", "PROTEIN", 335, 340], ["live cells", "CELL_TYPE", 433, 443], ["our previous study", "TEST", 3, 21], ["genetic methods", "TREATMENT", 36, 51], ["chimeric holotoxins", "TREATMENT", 77, 96], ["these chimeras", "PROBLEM", 159, 173], ["intoxicating host cells", "PROBLEM", 196, 219], ["a membrane lipid", "TREATMENT", 289, 305], ["toxin", "PROBLEM", 335, 340], ["fluorophore", "TEST", 376, 387], ["imaging toxin trafficking", "TEST", 404, 429], ["attenuated", "OBSERVATION_MODIFIER", 229, 239], ["activity", "OBSERVATION_MODIFIER", 240, 248]]], ["We found that a subset of GM1 species, those with unsaturated ceramide domains, sorted efficiently from the PM to the trans-Golgi network and the ER.", [["ER", "ANATOMY", 146, 148], ["ceramide", "CHEMICAL", 62, 70], ["GM1", "GENE_OR_GENE_PRODUCT", 26, 29], ["ceramide", "SIMPLE_CHEMICAL", 62, 70], ["PM", "CELLULAR_COMPONENT", 108, 110], ["Golgi network", "CELLULAR_COMPONENT", 124, 137], ["ER", "GENE_OR_GENE_PRODUCT", 146, 148], ["GM1 species", "PROTEIN", 26, 37], ["unsaturated ceramide domains", "PROTEIN", 50, 78], ["trans-Golgi network", "PROTEIN", 118, 137], ["ER", "PROTEIN", 146, 148], ["GM1 species", "PROBLEM", 26, 37], ["unsaturated ceramide domains", "PROBLEM", 50, 78], ["GM1 species", "OBSERVATION", 26, 37]]], ["Cross-linking by toxin binding was dispensable for such GM1 trafficking, but membrane cholesterol and the lipid raft-associated proteins actin and flotillin were required.", [["membrane", "ANATOMY", 77, 85], ["lipid raft", "ANATOMY", 106, 116], ["cholesterol", "CHEMICAL", 86, 97], ["cholesterol", "CHEMICAL", 86, 97], ["toxin", "SIMPLE_CHEMICAL", 17, 22], ["GM1", "GENE_OR_GENE_PRODUCT", 56, 59], ["membrane", "CELLULAR_COMPONENT", 77, 85], ["cholesterol", "SIMPLE_CHEMICAL", 86, 97], ["lipid raft", "CELLULAR_COMPONENT", 106, 116], ["actin", "GENE_OR_GENE_PRODUCT", 137, 142], ["flotillin", "GENE_OR_GENE_PRODUCT", 147, 156], ["lipid raft-associated proteins", "PROTEIN", 106, 136], ["actin", "PROTEIN", 137, 142], ["flotillin", "PROTEIN", 147, 156], ["membrane cholesterol", "TEST", 77, 97], ["the lipid raft", "TEST", 102, 116], ["proteins actin", "TREATMENT", 128, 142], ["flotillin", "TREATMENT", 147, 156], ["proteins actin", "OBSERVATION", 128, 142]]], ["Our results implicated an endogenous protein-dependent mechanism of lipid sorting that is dependent on ceramide structure and could explain how the toxin gains access to the ER of host cells to induce disease (28).DISCUSSIONThis work shows that multivalent binding to GM1 is indeed dispensable for CT toxicity.", [["ER", "ANATOMY", 174, 176], ["cells", "ANATOMY", 185, 190], ["ceramide", "CHEMICAL", 103, 111], ["toxicity", "DISEASE", 301, 309], ["ceramide", "CHEMICAL", 103, 111], ["lipid", "SIMPLE_CHEMICAL", 68, 73], ["ceramide", "SIMPLE_CHEMICAL", 103, 111], ["ER", "GENE_OR_GENE_PRODUCT", 174, 176], ["host cells", "CELL", 180, 190], ["GM1", "GENE_OR_GENE_PRODUCT", 268, 271], ["toxin", "PROTEIN", 148, 153], ["ER", "PROTEIN", 174, 176], ["host cells", "CELL_TYPE", 180, 190], ["an endogenous protein", "PROBLEM", 23, 44], ["lipid sorting", "PROBLEM", 68, 81], ["dependent on ceramide structure", "PROBLEM", 90, 121], ["disease", "PROBLEM", 201, 208], ["multivalent binding", "PROBLEM", 245, 264], ["CT toxicity", "PROBLEM", 298, 309], ["endogenous protein", "OBSERVATION", 26, 44], ["-dependent", "OBSERVATION_MODIFIER", 44, 54], ["lipid sorting", "OBSERVATION", 68, 81]]], ["To do this, we prepared and purified homogenous preparations of holotoxins with defined numbers of GM1 BS.", [["holotoxins", "CHEMICAL", 64, 74], ["holotoxins", "SIMPLE_CHEMICAL", 64, 74], ["holotoxins", "TREATMENT", 64, 74], ["GM1 BS", "TEST", 99, 105], ["GM1 BS", "OBSERVATION", 99, 105]]], ["Monomeric binding of CT to single molecules of GM1 permits the holotoxin to intoxicate the host cell.", [["cell", "ANATOMY", 96, 100], ["GM1", "GENE_OR_GENE_PRODUCT", 47, 50], ["host cell", "CELL", 91, 100], ["CT", "PROTEIN", 21, 23], ["GM1", "PROTEIN", 47, 50], ["host cell", "CELL_TYPE", 91, 100], ["CT", "TEST", 21, 23], ["the holotoxin", "TREATMENT", 59, 72], ["host cell", "OBSERVATION", 91, 100]]], ["Our results confirm and expand our studies on trafficking of the single GM1 lipids.", [["GM1", "GENE_OR_GENE_PRODUCT", 72, 75], ["our studies", "TEST", 31, 42], ["the single GM1 lipids", "TREATMENT", 61, 82]]], ["Conversely, loss of even a single GM1 BS resulted in a measurable diminishment of toxicity in the T84 line of polarized human intestinal cells.", [["T84 line", "ANATOMY", 98, 106], ["intestinal cells", "ANATOMY", 126, 142], ["toxicity", "DISEASE", 82, 90], ["T84 line", "CELL", 98, 106], ["human", "ORGANISM", 120, 125], ["intestinal cells", "CELL", 126, 142], ["T84 line", "CELL_LINE", 98, 106], ["polarized human intestinal cells", "CELL_TYPE", 110, 142], ["human", "SPECIES", 120, 125], ["human", "SPECIES", 120, 125], ["a single GM1 BS", "TEST", 25, 40], ["a measurable diminishment of toxicity", "PROBLEM", 53, 90], ["toxicity", "OBSERVATION", 82, 90], ["T84 line", "OBSERVATION", 98, 106], ["polarized human intestinal cells", "OBSERVATION", 110, 142]]], ["This result is also consistent with findings of our studies of trafficking of the non-cross-linked GM1 molecules, where we found that GM1 cross-linking by toxin binding enhanced entry of CT into the ER.", [["ER", "ANATOMY", 199, 201], ["GM1", "GENE_OR_GENE_PRODUCT", 99, 102], ["GM1", "GENE_OR_GENE_PRODUCT", 134, 137], ["ER", "GENE_OR_GENE_PRODUCT", 199, 201], ["non-cross-linked GM1 molecules", "PROTEIN", 82, 112], ["CT", "PROTEIN", 187, 189], ["ER", "PROTEIN", 199, 201], ["our studies", "TEST", 48, 59], ["CT", "TEST", 187, 189], ["consistent with", "UNCERTAINTY", 20, 35]]], ["Thus, although multivalent binding to GM1 by CT is fundamentally dispensable, it does have a significant effect on retrograde trafficking from the cell surface to the ER and on toxicity.DISCUSSIONOne way that multivalent binding could affect CT function would be by enhancing the binding avidity for cell membranes containing GM1.", [["cell surface", "ANATOMY", 147, 159], ["ER", "ANATOMY", 167, 169], ["cell membranes", "ANATOMY", 300, 314], ["toxicity", "DISEASE", 177, 185], ["GM1", "GENE_OR_GENE_PRODUCT", 38, 41], ["cell surface", "CELLULAR_COMPONENT", 147, 159], ["ER", "GENE_OR_GENE_PRODUCT", 167, 169], ["cell membranes", "CELLULAR_COMPONENT", 300, 314], ["GM1", "SIMPLE_CHEMICAL", 326, 329], ["GM1", "PROTEIN", 38, 41], ["CT", "PROTEIN", 45, 47], ["ER", "PROTEIN", 167, 169], ["CT", "PROTEIN", 242, 244], ["multivalent binding", "PROBLEM", 15, 34], ["CT", "TEST", 45, 47], ["toxicity", "PROBLEM", 177, 185], ["multivalent binding", "PROBLEM", 209, 228], ["CT function", "TEST", 242, 253], ["cell membranes", "PROBLEM", 300, 314], ["significant", "OBSERVATION_MODIFIER", 93, 104], ["effect", "OBSERVATION", 105, 111]]], ["In this and in our previous studies of the CT binding site mutants, we observe a loss of avidity for binding GM1 when the GM1 binding pockets are mutated.", [["GM1", "GENE_OR_GENE_PRODUCT", 109, 112], ["GM1", "GENE_OR_GENE_PRODUCT", 122, 125], ["CT binding site mutants", "DNA", 43, 66], ["GM1 binding pockets", "PROTEIN", 122, 141], ["a loss of avidity", "PROBLEM", 79, 96], ["the GM1 binding pockets", "PROBLEM", 118, 141]]], ["In the current studies, the loss of apparent avidity for the one-binding-site species is 10-fold, but the toxin still binds to GM1 applied to the well at nanomolar concentrations, suggesting this may not fully explain the strong loss of toxin function.DISCUSSIONIt is possible that the attenuated toxicity seen with holotoxins with reduced numbers of native GM1 BS could be enhanced by the presence of one or more CTB-G33D polypeptides that confer increased stability to the holotoxins (and thus might decrease the delivery of the CT-A1 subunit to the cytosol).", [["cytosol", "ANATOMY", 552, 559], ["toxicity", "DISEASE", 297, 305], ["holotoxins", "CHEMICAL", 316, 326], ["holotoxins", "CHEMICAL", 316, 326], ["GM1", "SIMPLE_CHEMICAL", 127, 130], ["toxin", "GENE_OR_GENE_PRODUCT", 237, 242], ["holotoxins", "SIMPLE_CHEMICAL", 316, 326], ["GM1 BS", "GENE_OR_GENE_PRODUCT", 358, 364], ["CTB", "GENE_OR_GENE_PRODUCT", 414, 417], ["holotoxins", "GENE_OR_GENE_PRODUCT", 475, 485], ["CT-A1", "GENE_OR_GENE_PRODUCT", 531, 536], ["cytosol", "CELLULAR_COMPONENT", 552, 559], ["toxin", "PROTEIN", 106, 111], ["toxin", "PROTEIN", 237, 242], ["CTB", "PROTEIN", 414, 417], ["CT", "PROTEIN", 531, 533], ["A1 subunit", "PROTEIN", 534, 544], ["the current studies", "TEST", 3, 22], ["the loss of apparent avidity", "PROBLEM", 24, 52], ["the one-binding-site species", "PROBLEM", 57, 85], ["the toxin", "PROBLEM", 102, 111], ["the strong loss of toxin function", "PROBLEM", 218, 251], ["the attenuated toxicity", "PROBLEM", 282, 305], ["holotoxins", "TREATMENT", 316, 326], ["reduced numbers of native GM1 BS", "PROBLEM", 332, 364], ["G33D polypeptides", "TREATMENT", 418, 435], ["the CT", "TEST", 527, 533], ["avidity", "OBSERVATION", 45, 52], ["10-fold", "OBSERVATION_MODIFIER", 89, 96], ["suggesting this may not fully explain", "UNCERTAINTY", 180, 217], ["strong", "OBSERVATION_MODIFIER", 222, 228], ["loss", "OBSERVATION", 229, 233], ["increased", "OBSERVATION_MODIFIER", 448, 457], ["stability", "OBSERVATION_MODIFIER", 458, 467]]], ["We raise this idea because we observed that insertion of even a single CTB-G33D monomer into the pentameric B subunit rendered the holotoxin partially resistant to dissociation by SDS, and increasing the number of CTB-G33D monomers resulted in holotoxins that were completely resistant to dissociation by SDS.", [["SDS", "CHEMICAL", 180, 183], ["CTB", "GENE_OR_GENE_PRODUCT", 71, 74], ["pentameric B subunit", "GENE_OR_GENE_PRODUCT", 97, 117], ["CTB", "GENE_OR_GENE_PRODUCT", 214, 217], ["holotoxins", "SIMPLE_CHEMICAL", 244, 254], ["CTB", "PROTEIN", 71, 74], ["G33D monomer", "PROTEIN", 75, 87], ["pentameric B subunit", "PROTEIN", 97, 117], ["CTB", "PROTEIN", 214, 217], ["a single CTB-G33D monomer", "TREATMENT", 62, 87], ["the pentameric B subunit", "TREATMENT", 93, 117], ["the holotoxin", "TREATMENT", 127, 140], ["SDS", "PROBLEM", 180, 183], ["CTB-G33D monomers", "TREATMENT", 214, 231], ["holotoxins", "TREATMENT", 244, 254]]], ["Conversely, there is no a priori reason to assume that the presence of one or more CTB-G33D polypeptides would affect chaperone-mediated release of CT-A1 from the nicked and reduced holotoxin in the ER, which appears to facilitate CT-A1 retrotranslocation from the ER to the cytosol (29).", [["ER", "ANATOMY", 199, 201], ["ER", "ANATOMY", 265, 267], ["cytosol", "ANATOMY", 275, 282], ["CTB", "GENE_OR_GENE_PRODUCT", 83, 86], ["CT-A1", "GENE_OR_GENE_PRODUCT", 148, 153], ["holotoxin", "GENE_OR_GENE_PRODUCT", 182, 191], ["ER", "GENE_OR_GENE_PRODUCT", 199, 201], ["CT-A1", "GENE_OR_GENE_PRODUCT", 231, 236], ["ER", "GENE_OR_GENE_PRODUCT", 265, 267], ["cytosol", "CELLULAR_COMPONENT", 275, 282], ["CTB", "PROTEIN", 83, 86], ["CT", "PROTEIN", 148, 150], ["A1", "PROTEIN", 151, 153], ["ER", "PROTEIN", 199, 201], ["CT", "PROTEIN", 231, 233], ["A1", "PROTEIN", 234, 236], ["ER", "PROTEIN", 265, 267], ["CT", "TEST", 148, 150], ["CT", "TEST", 231, 233], ["cytosol", "ANATOMY", 275, 282]]], ["Further experiments will be required to test these possibilities.DISCUSSIONAnother way that multivalent binding to GM1 might affect CT function would be through reorganization of membrane structure and function induced by scaffolding GM1 into ceramide-based nanodomains, as suggested by studies in vitro and in vivo (14, 15, 30\u201333).", [["membrane", "ANATOMY", 179, 187], ["ceramide", "CHEMICAL", 243, 251], ["ceramide", "CHEMICAL", 243, 251], ["GM1", "GENE_OR_GENE_PRODUCT", 115, 118], ["CT", "CANCER", 132, 134], ["membrane", "CELLULAR_COMPONENT", 179, 187], ["GM1", "GENE_OR_GENE_PRODUCT", 234, 237], ["ceramide", "SIMPLE_CHEMICAL", 243, 251], ["GM1", "PROTEIN", 115, 118], ["CT", "PROTEIN", 132, 134], ["multivalent binding", "PROBLEM", 92, 111], ["CT function", "TEST", 132, 143]]], ["Significantly, studies of the closely related AB5 subunit Shiga toxin show that multivalent binding to the glycosphingolipid GB3 spontaneously induces high-curvature membrane tubules by coupling the toxin-lipid complex to membrane shape (31).", [["membrane tubules", "ANATOMY", 166, 182], ["membrane", "ANATOMY", 222, 230], ["GB3", "CHEMICAL", 125, 128], ["AB5", "GENE_OR_GENE_PRODUCT", 46, 49], ["Shiga toxin", "GENE_OR_GENE_PRODUCT", 58, 69], ["membrane tubules", "CELLULAR_COMPONENT", 166, 182], ["membrane", "CELLULAR_COMPONENT", 222, 230], ["AB5 subunit", "PROTEIN", 46, 57], ["Shiga toxin", "PROTEIN", 58, 69], ["glycosphingolipid GB3", "PROTEIN", 107, 128], ["toxin-lipid complex", "PROTEIN", 199, 218], ["AB5 subunit Shiga toxin", "TEST", 46, 69], ["multivalent binding", "PROBLEM", 80, 99], ["the glycosphingolipid GB3", "TEST", 103, 128], ["high-curvature membrane tubules", "PROBLEM", 151, 182], ["the toxin", "TEST", 195, 204], ["glycosphingolipid GB3", "ANATOMY", 107, 128]]], ["Multivalent binding of CT to GM1 in model membranes also induces spontaneous membrane curvature, implying a similar coupling of the toxin-glycosphingolipid complex formation to membrane shape (32, 34, 35).", [["membranes", "ANATOMY", 42, 51], ["membrane", "ANATOMY", 77, 85], ["membrane", "ANATOMY", 177, 185], ["GM1", "GENE_OR_GENE_PRODUCT", 29, 32], ["membranes", "CELLULAR_COMPONENT", 42, 51], ["membrane", "CELLULAR_COMPONENT", 77, 85], ["membrane", "CELLULAR_COMPONENT", 177, 185], ["CT", "PROTEIN", 23, 25], ["GM1", "PROTEIN", 29, 32], ["toxin", "PROTEIN", 132, 137], ["glycosphingolipid complex", "PROTEIN", 138, 163], ["CT to GM1 in model membranes", "TEST", 23, 51], ["spontaneous membrane curvature", "PROBLEM", 65, 95], ["model membranes", "ANATOMY", 36, 51], ["spontaneous", "OBSERVATION_MODIFIER", 65, 76], ["membrane curvature", "OBSERVATION", 77, 95], ["glycosphingolipid complex", "OBSERVATION_MODIFIER", 138, 163], ["membrane shape", "OBSERVATION_MODIFIER", 177, 191]]], ["This could allow partitioning of the CT-GM1 complex into highly curved sorting tubules of the sorting endosome, which is required for retrograde transport, and explain why the toxins with more than 1 GM1 binding site are more potent in intoxication.", [["sorting tubules", "ANATOMY", 71, 86], ["sorting endosome", "ANATOMY", 94, 110], ["GM1", "GENE_OR_GENE_PRODUCT", 40, 43], ["sorting tubules", "CELLULAR_COMPONENT", 71, 86], ["sorting endosome", "CELLULAR_COMPONENT", 94, 110], ["GM1", "GENE_OR_GENE_PRODUCT", 200, 203], ["CT", "PROTEIN", 37, 39], ["GM1 complex", "PROTEIN", 40, 51], ["the CT", "TEST", 33, 39], ["retrograde transport", "TEST", 134, 154], ["the toxins", "PROBLEM", 172, 182], ["1 GM1 binding site", "PROBLEM", 198, 216], ["intoxication", "PROBLEM", 236, 248], ["more potent", "OBSERVATION_MODIFIER", 221, 232]]], ["It is also possible that multivalent binding to GM1 may be needed to activate intracellular signaling pathways that enhance uptake and trafficking, as for Shiga toxin (36).DISCUSSIONEffects either on binding avidity or on membrane structure and trafficking dynamics could underlie how the CTB subunit, and the other AB5 toxins, evolved as pentameric structures.", [["intracellular", "ANATOMY", 78, 91], ["membrane", "ANATOMY", 222, 230], ["Shiga toxin", "CHEMICAL", 155, 166], ["GM1", "GENE_OR_GENE_PRODUCT", 48, 51], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 78, 91], ["Shiga toxin", "GENE_OR_GENE_PRODUCT", 155, 166], ["membrane", "CELLULAR_COMPONENT", 222, 230], ["CTB", "GENE_OR_GENE_PRODUCT", 289, 292], ["AB5", "GENE_OR_GENE_PRODUCT", 316, 319], ["GM1", "PROTEIN", 48, 51], ["Shiga toxin", "PROTEIN", 155, 166], ["CTB subunit", "PROTEIN", 289, 300], ["AB5 toxins", "PROTEIN", 316, 326], ["multivalent binding to GM1", "PROBLEM", 25, 51], ["intracellular signaling pathways", "PROBLEM", 78, 110], ["Shiga toxin", "TEST", 155, 166], ["binding avidity", "PROBLEM", 200, 215], ["the CTB subunit", "TEST", 285, 300], ["the other AB5 toxins", "TEST", 306, 326], ["also possible", "UNCERTAINTY", 6, 19]]], ["This and our other recent studies, however, show that the most fundamental function exploited by CT is to coopt an endogenous glycosphingolipid sorting pathway from the PM to the ER that is essential for toxin entry into the cytosol and the induction of disease.Bacterial strains and construction of expression clones. ::: MATERIALS AND METHODSAll chimeric toxins in this study were produced by expression from recombinant plasmids in Escherichia coli BW27784 (araFGH pCP18-araE [37]).", [["ER", "ANATOMY", 179, 181], ["cytosol", "ANATOMY", 225, 232], ["plasmids", "ANATOMY", 423, 431], ["PM", "CELLULAR_COMPONENT", 169, 171], ["ER", "GENE_OR_GENE_PRODUCT", 179, 181], ["toxin", "SIMPLE_CHEMICAL", 204, 209], ["cytosol", "CELLULAR_COMPONENT", 225, 232], ["Escherichia coli", "ORGANISM", 435, 451], ["BW27784", "ORGANISM", 452, 459], ["araFGH pCP18-araE [37]", "GENE_OR_GENE_PRODUCT", 461, 483], ["CT", "PROTEIN", 97, 99], ["ER", "PROTEIN", 179, 181], ["toxin", "PROTEIN", 204, 209], ["recombinant plasmids", "DNA", 411, 431], ["Escherichia coli", "SPECIES", 435, 451], ["Escherichia coli", "SPECIES", 435, 451], ["our other recent studies", "TEST", 9, 33], ["CT", "TEST", 97, 99], ["disease", "PROBLEM", 254, 261], ["Bacterial strains", "PROBLEM", 262, 279], ["expression clones", "PROBLEM", 300, 317], ["METHODSAll chimeric toxins", "PROBLEM", 337, 363], ["this study", "TEST", 367, 377], ["recombinant plasmids", "TREATMENT", 411, 431], ["Escherichia coli", "TEST", 435, 451], ["disease", "OBSERVATION", 254, 261], ["strains", "OBSERVATION", 272, 279], ["expression clones", "OBSERVATION", 300, 317], ["Escherichia coli", "OBSERVATION", 435, 451]]], ["This strain does not metabolize arabinose and constitutively expresses the arabinose transporter, and therefore a uniform degree of induction occurs in all cells of a culture at any arabinose concentration.", [["cells", "ANATOMY", 156, 161], ["arabinose", "CHEMICAL", 32, 41], ["arabinose", "CHEMICAL", 75, 84], ["arabinose", "CHEMICAL", 182, 191], ["arabinose", "CHEMICAL", 32, 41], ["arabinose", "CHEMICAL", 75, 84], ["arabinose", "CHEMICAL", 182, 191], ["arabinose", "SIMPLE_CHEMICAL", 32, 41], ["arabinose", "SIMPLE_CHEMICAL", 75, 84], ["cells", "CELL", 156, 161], ["arabinose", "SIMPLE_CHEMICAL", 182, 191], ["arabinose transporter", "PROTEIN", 75, 96], ["the arabinose transporter", "PROBLEM", 71, 96], ["a culture", "TEST", 165, 174]]], ["To produce the expression strains, genes encoding native-length CTB or carboxy-terminally extended CTB tagged with a glycosylation-sulfation signal (24) followed by a hexahistidine peptide were cloned on compatible plasmids with different selectable markers and inducible promoters.", [["plasmids", "ANATOMY", 215, 223], ["carboxy", "CHEMICAL", 71, 78], ["CTB", "GENE_OR_GENE_PRODUCT", 64, 67], ["CTB", "GENE_OR_GENE_PRODUCT", 99, 102], ["native-length CTB", "PROTEIN", 50, 67], ["carboxy-terminally extended CTB", "PROTEIN", 71, 102], ["inducible promoters", "DNA", 262, 281], ["the expression strains", "PROBLEM", 11, 33], ["a hexahistidine peptide", "TREATMENT", 165, 188], ["compatible plasmids", "TREATMENT", 204, 223], ["different selectable markers", "TREATMENT", 229, 257], ["inducible promoters", "TREATMENT", 262, 281]]], ["These encoded resistance to ampicillin (Ap) with the IPTG-inducible lacUV5 promoter or resistance to chloramphenicol (Cm) and the arabinose-inducible araBAD promoter, along with the regulator araC.", [["ampicillin", "CHEMICAL", 28, 38], ["Ap", "CHEMICAL", 40, 42], ["IPTG", "CHEMICAL", 53, 57], ["chloramphenicol", "CHEMICAL", 101, 116], ["Cm", "CHEMICAL", 118, 120], ["arabinose", "CHEMICAL", 130, 139], ["araC", "CHEMICAL", 192, 196], ["ampicillin", "CHEMICAL", 28, 38], ["Ap", "CHEMICAL", 40, 42], ["IPTG", "CHEMICAL", 53, 57], ["chloramphenicol", "CHEMICAL", 101, 116], ["Cm", "CHEMICAL", 118, 120], ["arabinose", "CHEMICAL", 130, 139], ["ampicillin", "SIMPLE_CHEMICAL", 28, 38], ["Ap", "SIMPLE_CHEMICAL", 40, 42], ["IPTG", "SIMPLE_CHEMICAL", 53, 57], ["lacUV5", "GENE_OR_GENE_PRODUCT", 68, 74], ["chloramphenicol", "SIMPLE_CHEMICAL", 101, 116], ["Cm", "SIMPLE_CHEMICAL", 118, 120], ["arabinose", "SIMPLE_CHEMICAL", 130, 139], ["araBAD", "GENE_OR_GENE_PRODUCT", 150, 156], ["araC", "SIMPLE_CHEMICAL", 192, 196], ["lacUV5 promoter", "DNA", 68, 83], ["araBAD promoter", "DNA", 150, 165], ["regulator araC", "DNA", 182, 196], ["ampicillin (Ap)", "TREATMENT", 28, 43], ["the IPTG", "TREATMENT", 49, 57], ["inducible lacUV5 promoter", "TREATMENT", 58, 83], ["chloramphenicol", "TREATMENT", 101, 116], ["the arabinose-inducible araBAD promoter", "TREATMENT", 126, 165], ["the regulator araC", "TREATMENT", 178, 196], ["resistance", "OBSERVATION_MODIFIER", 14, 24], ["araC", "ANATOMY", 192, 196]]], ["Variants of these CTB clones were also made with G33D substitutions that eliminate GM1 binding.", [["CTB", "GENE_OR_GENE_PRODUCT", 18, 21], ["GM1", "SIMPLE_CHEMICAL", 83, 86], ["CTB clones", "CELL_LINE", 18, 28], ["these CTB clones", "TREATMENT", 12, 28], ["G33D substitutions", "TREATMENT", 49, 67], ["GM1 binding", "PROBLEM", 83, 94]]], ["A separate plasmid (pSlacbadCTA) selectable with spectinomycin (Sp) and compatible (with a pSC101 origin) with both ctxB plasmids was used to independently express the ctxA gene under control of both the lac and araBAD promoters.", [["plasmid", "ANATOMY", 11, 18], ["spectinomycin", "CHEMICAL", 49, 62], ["spectinomycin", "CHEMICAL", 49, 62], ["spectinomycin", "SIMPLE_CHEMICAL", 49, 62], ["ctxB", "GENE_OR_GENE_PRODUCT", 116, 120], ["ctxA", "GENE_OR_GENE_PRODUCT", 168, 172], ["lac", "GENE_OR_GENE_PRODUCT", 204, 207], ["araBAD", "GENE_OR_GENE_PRODUCT", 212, 218], ["plasmid", "DNA", 11, 18], ["pSlacbadCTA", "DNA", 20, 31], ["Sp", "DNA", 64, 66], ["pSC101 origin", "DNA", 91, 104], ["ctxB plasmids", "DNA", 116, 129], ["ctxA gene", "DNA", 168, 177], ["lac and araBAD promoters", "DNA", 204, 228], ["A separate plasmid (pSlacbadCTA)", "TREATMENT", 0, 32], ["spectinomycin", "TREATMENT", 49, 62], ["a pSC101 origin", "TREATMENT", 89, 104], ["both ctxB plasmids", "TREATMENT", 111, 129], ["the lac and araBAD promoters", "TREATMENT", 200, 228], ["plasmid", "OBSERVATION", 11, 18], ["lac", "ANATOMY", 204, 207]]], ["Each expression strain thus contained three plasmids, encoding a native CTB subunit (wt or G33D variant, Ap, and lac promoter), a GSH6-tagged CTB subunit (G33D or wt, Cm, and ara promoter), and the wt CTA subunit (Sp and ara and lac promoters).", [["plasmids", "ANATOMY", 44, 52], ["CTB", "GENE_OR_GENE_PRODUCT", 72, 75], ["G33D", "GENE_OR_GENE_PRODUCT", 91, 95], ["Ap", "GENE_OR_GENE_PRODUCT", 105, 107], ["lac promoter", "GENE_OR_GENE_PRODUCT", 113, 125], ["GSH6", "GENE_OR_GENE_PRODUCT", 130, 134], ["CTB", "GENE_OR_GENE_PRODUCT", 142, 145], ["Cm", "GENE_OR_GENE_PRODUCT", 167, 169], ["ara", "GENE_OR_GENE_PRODUCT", 175, 178], ["CTA subunit", "GENE_OR_GENE_PRODUCT", 201, 212], ["Sp", "GENE_OR_GENE_PRODUCT", 214, 216], ["ara", "GENE_OR_GENE_PRODUCT", 221, 224], ["lac promoters", "GENE_OR_GENE_PRODUCT", 229, 242], ["plasmids", "DNA", 44, 52], ["CTB subunit", "PROTEIN", 72, 83], ["G33D variant", "PROTEIN", 91, 103], ["Ap", "PROTEIN", 105, 107], ["lac promoter", "DNA", 113, 125], ["GSH6", "PROTEIN", 130, 134], ["CTB subunit", "PROTEIN", 142, 153], ["G33D", "PROTEIN", 155, 159], ["Cm", "PROTEIN", 167, 169], ["ara promoter", "DNA", 175, 187], ["CTA subunit", "PROTEIN", 201, 212], ["Sp", "PROTEIN", 214, 216], ["ara", "PROTEIN", 221, 224], ["lac promoters", "DNA", 229, 242], ["Each expression strain", "PROBLEM", 0, 22], ["a native CTB subunit", "TREATMENT", 63, 83], ["Ap, and lac promoter", "TREATMENT", 105, 125], ["the wt CTA subunit", "TREATMENT", 194, 212], ["Sp and ara and lac promoters", "TREATMENT", 214, 242]]], ["Details of construction, including full DNA sequences, are available on request.", [["DNA", "CELLULAR_COMPONENT", 40, 43], ["DNA sequences", "DNA", 40, 53], ["full DNA sequences", "TEST", 35, 53]]], ["Plasmids created or used in this study are listed in Table 1.", [["Plasmids", "TREATMENT", 0, 8], ["this study", "TEST", 28, 38]]], ["Plasmids pAlacCTB and pAlacCTBG33D encode Ap resistance and the wt and G33D native-length variants of CTB, respectively, under control of the lac promoter and have previously been published as pLMP1 and pLMP148, respectively (38).", [["pAlacCTB", "GENE_OR_GENE_PRODUCT", 9, 17], ["pAlacCTBG33D", "GENE_OR_GENE_PRODUCT", 22, 34], ["Ap", "GENE_OR_GENE_PRODUCT", 42, 44], ["CTB", "GENE_OR_GENE_PRODUCT", 102, 105], ["lac", "GENE_OR_GENE_PRODUCT", 142, 145], ["pLMP1", "GENE_OR_GENE_PRODUCT", 193, 198], ["pLMP148", "GENE_OR_GENE_PRODUCT", 203, 210], ["pAlacCTB", "PROTEIN", 9, 17], ["pAlacCTBG33D", "DNA", 22, 34], ["wt and G33D native-length variants", "DNA", 64, 98], ["lac promoter", "DNA", 142, 154], ["pLMP1", "DNA", 193, 198], ["pLMP148", "DNA", 203, 210], ["Plasmids pAlacCTB", "TREATMENT", 0, 17], ["Ap resistance", "TEST", 42, 55], ["the wt", "TEST", 60, 66], ["the lac promoter", "TREATMENT", 138, 154], ["lac", "ANATOMY", 142, 145]]], ["Carboxy-terminally linker-hexahistidine-tagged variants of CTB and CTB-G33D were made in a compatible Cmr arabinose-inducible vector, pAR3 (39), using the hexa-His tag from pT7sh6 (40) and a glycine-rich repeat from the M13 phage PIII protein, encoding XX (EX)4XDPRVPSS (where X is GGGS) inserted between residues 102 and 103 of CTB.", [["arabinose", "CHEMICAL", 106, 115], ["glycine", "CHEMICAL", 191, 198], ["Carboxy", "CHEMICAL", 0, 7], ["arabinose", "CHEMICAL", 106, 115], ["hexa-His", "CHEMICAL", 155, 163], ["glycine", "CHEMICAL", 191, 198], ["CTB", "GENE_OR_GENE_PRODUCT", 59, 62], ["CTB-G33D", "GENE_OR_GENE_PRODUCT", 67, 75], ["Cmr arabinose", "GENE_OR_GENE_PRODUCT", 102, 115], ["pAR3 (39)", "GENE_OR_GENE_PRODUCT", 134, 143], ["PIII", "GENE_OR_GENE_PRODUCT", 230, 234], ["CTB", "GENE_OR_GENE_PRODUCT", 329, 332], ["Carboxy-terminally linker-hexahistidine-tagged variants", "PROTEIN", 0, 55], ["CTB", "PROTEIN", 59, 62], ["CTB", "PROTEIN", 67, 70], ["G33D", "PROTEIN", 71, 75], ["Cmr arabinose-inducible vector", "DNA", 102, 132], ["pAR3 (39)", "DNA", 134, 143], ["hexa-His tag", "DNA", 155, 167], ["glycine-rich repeat", "PROTEIN", 191, 210], ["M13 phage PIII protein", "PROTEIN", 220, 242], ["XX (EX)4XDPRVPSS", "PROTEIN", 253, 269], ["GGGS", "PROTEIN", 282, 286], ["CTB", "PROTEIN", 329, 332], ["Carboxy-terminally linker", "TREATMENT", 0, 25], ["hexahistidine", "TREATMENT", 26, 39], ["pAR3", "TEST", 134, 138], ["the hexa", "TEST", 151, 159], ["His tag", "TEST", 160, 167], ["a glycine", "TEST", 189, 198], ["the M13 phage PIII protein", "TREATMENT", 216, 242], ["encoding XX (EX)4XDPRVPSS", "TREATMENT", 244, 269], ["CTB", "PROBLEM", 329, 332]]], ["Initial experiments to make wt and CTB-G33D mixed pentamers were done using these plasmids, but we saw significant proteolysis of the polyglycine linker-tagged variants, and subsequent experiments were done with variants that had the linker replaced with the GSH6 tag\u2014pCbadCTBGSH6 and pCbadCTBG33DGSH6.Toxin expression and purification. ::: MATERIALS AND METHODSA 400-ml LB culture at 30\u00b0C was inoculated with a 1/8 volume of an overnight culture with appropriate antibiotic selection (Sp and Ap at 100 \u00b5g/ml and Cm at 25 \u00b5g/ml) and grown to an A600 of 1.2, when it was induced with 400 \u00b5M IPTG and 0.0005% l-arabinose with incubation continued overnight.", [["plasmids", "ANATOMY", 82, 90], ["polyglycine", "CHEMICAL", 134, 145], ["IPTG", "CHEMICAL", 590, 594], ["l-arabinose", "CHEMICAL", 607, 618], ["polyglycine", "CHEMICAL", 134, 145], ["IPTG", "CHEMICAL", 590, 594], ["l-arabinose", "CHEMICAL", 607, 618], ["CTB", "GENE_OR_GENE_PRODUCT", 35, 38], ["polyglycine", "SIMPLE_CHEMICAL", 134, 145], ["GSH6", "GENE_OR_GENE_PRODUCT", 259, 263], ["pCbadCTBG33DGSH6", "GENE_OR_GENE_PRODUCT", 285, 301], ["Toxin", "GENE_OR_GENE_PRODUCT", 302, 307], ["IPTG", "SIMPLE_CHEMICAL", 590, 594], ["l-arabinose", "SIMPLE_CHEMICAL", 607, 618], ["CTB", "PROTEIN", 35, 38], ["polyglycine linker", "PROTEIN", 134, 152], ["GSH6 tag\u2014pCbadCTBGSH6", "PROTEIN", 259, 280], ["pCbadCTBG33DGSH6", "PROTEIN", 285, 301], ["wt", "TEST", 28, 30], ["CTB", "TEST", 35, 38], ["G33D mixed pentamers", "TREATMENT", 39, 59], ["these plasmids", "TREATMENT", 76, 90], ["the polyglycine linker", "TREATMENT", 130, 152], ["subsequent experiments", "TEST", 174, 196], ["the linker", "TREATMENT", 230, 240], ["the GSH6 tag\u2014pCbadCTBGSH6", "TREATMENT", 255, 280], ["pCbadCTBG33DGSH6", "TREATMENT", 285, 301], ["Toxin expression", "PROBLEM", 302, 318], ["purification", "TEST", 323, 335], ["METHODSA", "TEST", 355, 363], ["LB culture", "TEST", 371, 381], ["an overnight culture", "TEST", 426, 446], ["appropriate antibiotic selection", "TREATMENT", 452, 484], ["Ap", "TEST", 493, 495], ["400 \u00b5M IPTG", "TREATMENT", 583, 594], ["0.0005% l-arabinose", "TREATMENT", 599, 618], ["incubation", "TREATMENT", 624, 634]]], ["Cells were collected by centrifugation, resuspended in 20 ml phosphate-buffered saline (PBS), and lysed by mixing for 20 min at room temperature with 0.5 mg/ml lysozyme and Elugent detergent (EMD Biosciences, Inc., La Jolla, CA) to 2%.", [["Cells", "ANATOMY", 0, 5], ["phosphate", "CHEMICAL", 61, 70], ["phosphate", "CHEMICAL", 61, 70], ["Cells", "CELL", 0, 5], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 61, 86], ["buffered saline (PBS", "TREATMENT", 71, 91], ["Elugent detergent", "TREATMENT", 173, 190], ["EMD Biosciences", "TEST", 192, 207]]], ["Viscosity was reduced by sonication four times (10 s each) on ice, and the lysate was cleared by centrifugation at 15,000 rpm for 20 min in an SS34 rotor.", [["lysate", "ANATOMY", 75, 81], ["ice", "TREATMENT", 62, 65], ["the lysate", "TREATMENT", 71, 81], ["an SS34 rotor", "TREATMENT", 140, 153], ["reduced", "OBSERVATION_MODIFIER", 14, 21]]], ["Toxin was purified from the supernatants by Talon chromatography as detailed by the manufacturer (Clontech Laboratories, Inc., Mountain View, CA).", [["supernatants", "ANATOMY", 28, 40], ["Toxin", "GENE_OR_GENE_PRODUCT", 0, 5], ["Toxin", "TEST", 0, 5], ["Talon chromatography", "TEST", 44, 64]]], ["Imidazole eluates were dialyzed against 50 mM Tris-HCl (pH 8.0) (buffer A).", [["Imidazole", "CHEMICAL", 0, 9], ["Tris-HCl", "CHEMICAL", 46, 54], ["Imidazole", "CHEMICAL", 0, 9], ["Tris-HCl", "CHEMICAL", 46, 54], ["Imidazole", "SIMPLE_CHEMICAL", 0, 9], ["Tris-HCl", "SIMPLE_CHEMICAL", 46, 54], ["Imidazole eluates", "TREATMENT", 0, 17], ["pH", "TEST", 56, 58]]], ["All chromatographic separations were conducted on an Akta purifier (GE Healthcare Biosciences, Pittsburgh, PA) in 4.6-mm by 100-mm Poros perfusion chromatography columns packed with Poros HS 20 cation exchange medium or Poros HQ 20 anion exchange medium.", [["Poros HQ 20 anion", "CHEMICAL", 220, 237], ["Poros HQ 20", "CHEMICAL", 220, 231], ["Poros", "SIMPLE_CHEMICAL", 131, 136], ["cation", "SIMPLE_CHEMICAL", 194, 200], ["Poros HQ 20 anion", "SIMPLE_CHEMICAL", 220, 237], ["All chromatographic separations", "TREATMENT", 0, 31], ["Poros perfusion chromatography columns", "TREATMENT", 131, 169], ["Poros HS 20 cation exchange medium", "TREATMENT", 182, 216], ["Poros HQ 20 anion exchange medium", "TREATMENT", 220, 253]]], ["For cation exchange, the column was equilibrated with 5 column volumes (CV) buffer A and washed with 5 CV buffer A after sample loading.", [["sample", "ANATOMY", 121, 127], ["cation", "SIMPLE_CHEMICAL", 4, 10], ["cation exchange", "TREATMENT", 4, 19], ["the column", "TREATMENT", 21, 31], ["5 column volumes (CV) buffer A", "TREATMENT", 54, 84], ["5 CV buffer A after sample loading", "TREATMENT", 101, 135]]], ["Bound material was eluted with 10 CV of a linear gradient of 0 to 100% buffer B (50 mM Tris-HCl, pH 8.0, 1M NaCl).", [["Tris-HCl", "CHEMICAL", 87, 95], ["NaCl", "CHEMICAL", 108, 112], ["Tris-HCl", "CHEMICAL", 87, 95], ["NaCl", "CHEMICAL", 108, 112], ["Tris-HCl", "SIMPLE_CHEMICAL", 87, 95], ["a linear gradient", "TEST", 40, 57], ["Tris", "TEST", 87, 91], ["HCl", "TEST", 92, 95], ["pH", "TEST", 97, 99], ["1M NaCl", "TREATMENT", 105, 112]]], ["For anion exchange, the column was equilibrated with 5 CV buffer A, washed with 5 CV of buffer A after sample loading, and was eluted with a 40-CV (initial separation) or 10-CV (second purification) linear gradient of 0 to 100% buffer B. Anion exchange fractions were pooled and concentrated using Microcon Ultracel YM-10 filter devices (EMD Millipore, Billerica, MA).Ganglioside GM1 ELISA. ::: MATERIALS AND METHODSNinety-six-well microtiter plates were coated overnight with 50 \u00b5l of 2-fold serial dilutions of ganglioside GM1 (Supelco, Sigma-Aldrich, St. Louis, MO) in PBS, starting at 150 nM, and then blocked with 10% horse serum in PBS.", [["sample", "ANATOMY", 103, 109], ["serum", "ANATOMY", 629, 634], ["ganglioside GM1", "CHEMICAL", 513, 528], ["ganglioside", "CHEMICAL", 513, 524], ["anion", "SIMPLE_CHEMICAL", 4, 9], ["Anion", "SIMPLE_CHEMICAL", 238, 243], ["Ganglioside GM1", "GENE_OR_GENE_PRODUCT", 368, 383], ["ganglioside GM1", "SIMPLE_CHEMICAL", 513, 528], ["Supelco", "SIMPLE_CHEMICAL", 530, 537], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 539, 552], ["St. Louis", "ORGANISM", 554, 563], ["MO", "ORGANISM", 565, 567], ["horse", "ORGANISM", 623, 628], ["serum", "ORGANISM_SUBSTANCE", 629, 634], ["anion exchange", "TREATMENT", 4, 18], ["5 CV buffer A", "TREATMENT", 53, 66], ["buffer A after sample loading", "TREATMENT", 88, 117], ["a 40-CV (initial separation", "TREATMENT", 139, 166], ["linear gradient", "TEST", 199, 214], ["Anion exchange fractions", "TREATMENT", 238, 262], ["Microcon Ultracel YM-10 filter devices (EMD Millipore", "TREATMENT", 298, 351], ["METHODSNinety-six-well microtiter plates", "TREATMENT", 409, 449], ["ganglioside GM1", "TREATMENT", 513, 528], ["10% horse serum in PBS", "TREATMENT", 619, 641], ["column", "ANATOMY", 24, 30], ["GM1 ELISA", "OBSERVATION", 380, 389]]], ["All steps were performed at 37\u00b0C for 1 h, after which samples were aspirated off and wells were washed three times with PBS plus 0.05% Tween 20.", [["samples", "ANATOMY", 54, 61], ["Tween 20", "CHEMICAL", 135, 143], ["PBS", "TREATMENT", 120, 123]]], ["Each holotoxin was assayed in triplicate by incubating 100 \u00b5l of 50-ng/ml holotoxin per well (approximately 60 fmol), followed by 1/5,000 rabbit anti-cholera toxin B subunit (B10) and then 1/2,000 HRP-conjugated goat anti-rabbit serum (Thermo Fisher Scientific Inc., Rockford, IL), followed by o-phenylenediamine (OPD) substrate (Sigma-Aldrich), and the reaction was stopped with 3 M HCl.", [["serum", "ANATOMY", 229, 234], ["o-phenylenediamine", "CHEMICAL", 294, 312], ["HCl", "CHEMICAL", 384, 387], ["o-phenylenediamine", "CHEMICAL", 294, 312], ["OPD", "CHEMICAL", 314, 317], ["HCl", "CHEMICAL", 384, 387], ["holotoxin", "GENE_OR_GENE_PRODUCT", 5, 14], ["rabbit", "ORGANISM", 138, 144], ["anti-cholera toxin B subunit", "GENE_OR_GENE_PRODUCT", 145, 173], ["HRP", "SIMPLE_CHEMICAL", 197, 200], ["goat", "ORGANISM", 212, 216], ["serum", "ORGANISM_SUBSTANCE", 229, 234], ["o-phenylenediamine", "SIMPLE_CHEMICAL", 294, 312], ["OPD", "SIMPLE_CHEMICAL", 314, 317], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 330, 343], ["anti-cholera toxin B subunit", "PROTEIN", 145, 173], ["B10", "PROTEIN", 175, 178], ["1/2,000 HRP", "PROTEIN", 189, 200], ["rabbit", "SPECIES", 138, 144], ["goat", "SPECIES", 212, 216], ["anti-rabbit", "SPECIES", 217, 228], ["rabbit", "SPECIES", 138, 144], ["goat", "SPECIES", 212, 216], ["anti-rabbit", "SPECIES", 217, 228], ["Each holotoxin", "TREATMENT", 0, 14], ["holotoxin", "TREATMENT", 74, 83], ["rabbit anti-cholera toxin B subunit (B10)", "TREATMENT", 138, 179], ["HRP", "TEST", 197, 200], ["the reaction", "PROBLEM", 350, 362]]], ["Absorbance was read at 450 nm.Y1 assay. ::: MATERIALS AND METHODSMouse Y1 adrenal cells (ATCC CCL-79) were grown at 37\u00b0C in a humidified 5% CO2 atmosphere in RPMI medium with 5% fetal bovine serum with 1\u00d7 penicillin-streptomycin (Life Technologies), and 96-well plates were seeded with 104 cells per well.", [["Y1 adrenal cells", "ANATOMY", 71, 87], ["ATCC CCL-79", "ANATOMY", 89, 100], ["fetal bovine serum", "ANATOMY", 178, 196], ["cells", "ANATOMY", 290, 295], ["CO2", "CHEMICAL", 140, 143], ["penicillin", "CHEMICAL", 205, 215], ["streptomycin", "CHEMICAL", 216, 228], ["CO2", "CHEMICAL", 140, 143], ["penicillin", "CHEMICAL", 205, 215], ["streptomycin", "CHEMICAL", 216, 228], ["Y1 adrenal cells", "CELL", 71, 87], ["ATCC CCL-79", "CELL", 89, 100], ["CO2", "SIMPLE_CHEMICAL", 140, 143], ["bovine", "ORGANISM", 184, 190], ["serum", "ORGANISM_SUBSTANCE", 191, 196], ["penicillin-streptomycin", "SIMPLE_CHEMICAL", 205, 228], ["cells", "CELL", 290, 295], ["Y1 adrenal cells", "CELL_LINE", 71, 87], ["ATCC CCL-79", "CELL_LINE", 89, 100], ["104 cells", "CELL_LINE", 286, 295], ["bovine", "SPECIES", 184, 190], ["ATCC CCL-79", "SPECIES", 89, 100], ["bovine", "SPECIES", 184, 190], ["ATCC CCL", "TEST", 89, 97], ["a humidified 5% CO2 atmosphere", "TREATMENT", 124, 154], ["RPMI medium", "TEST", 158, 169], ["5% fetal bovine serum", "TREATMENT", 175, 196], ["penicillin", "TREATMENT", 205, 215], ["streptomycin", "TREATMENT", 216, 228], ["adrenal cells", "ANATOMY", 74, 87]]], ["One-hundred-microliter volumes of 2-fold serial dilutions of toxins were added to semiconfluent monolayers and incubated overnight, followed by scoring for toxin-induced rounding.", [["monolayers", "ANATOMY", 96, 106], ["monolayers", "CELL", 96, 106], ["toxin", "SIMPLE_CHEMICAL", 156, 161], ["semiconfluent monolayers", "CELL_LINE", 82, 106], ["toxin", "PROTEIN", 156, 161], ["One-hundred-microliter volumes", "TEST", 0, 30], ["toxins", "TREATMENT", 61, 67], ["semiconfluent monolayers", "PROBLEM", 82, 106], ["toxin", "TEST", 156, 161]]], ["One unit of toxin was defined as the amount contained in the last dilution giving 75 to 100% rounding of cells.T84 cells and electrophysiology. ::: MATERIALS AND METHODSMeasurements of short-circuit current (Isc) on monolayers (0.33-cm2 inserts) of the polarized human intestinal cell line T84 were performed as previously described (41).", [["cells", "ANATOMY", 105, 110], ["T84 cells", "ANATOMY", 111, 120], ["monolayers", "ANATOMY", 216, 226], ["intestinal cell line T84", "ANATOMY", 269, 293], ["cells", "CELL", 105, 110], ["T84 cells", "CELL", 111, 120], ["monolayers", "CELL", 216, 226], ["human", "ORGANISM", 263, 268], ["intestinal cell line T84", "CELL", 269, 293], ["T84 cells", "CELL_LINE", 111, 120], ["polarized human intestinal cell line T84", "CELL_LINE", 253, 293], ["human", "SPECIES", 263, 268], ["human", "SPECIES", 263, 268], ["toxin", "TREATMENT", 12, 17], ["electrophysiology", "TEST", 125, 142], ["short-circuit current (Isc) on monolayers", "TREATMENT", 185, 226], ["amount", "OBSERVATION_MODIFIER", 37, 43], ["short", "OBSERVATION_MODIFIER", 185, 190], ["polarized", "ANATOMY_MODIFIER", 253, 262], ["human intestinal", "ANATOMY", 263, 279], ["cell line", "OBSERVATION", 280, 289]]]], "PMC7491593": [], "98c7813a75f2b207b3fc4d530183d9a8c8410257": [["| INTRODUCTIONThe coronavirus disease (COVID- 19) pandemic, which began in China in December 2019 and spread around the world, has given rise to new issues and debates.", [["coronavirus disease", "DISEASE", 18, 37], ["COVID- 19) pandemic", "DISEASE", 39, 58], ["coronavirus disease", "PROBLEM", 18, 37], ["COVID", "TEST", 39, 44], ["pandemic", "PROBLEM", 50, 58], ["coronavirus disease", "OBSERVATION", 18, 37]]], ["1 Social, economic, political, and, of course, spiritual resources, and consequences must be addressed, and it is necessary that we manage the outbreak through basic principles of public health, and operate the country in a manner that respects basic human rights.", [["human", "ORGANISM", 251, 256], ["human", "SPECIES", 251, 256], ["human", "SPECIES", 251, 256]]], ["3 Many countries have implemented various isolation measures to prevent the spread of the outbreak until a vaccine or drug is found.", [["various isolation measures", "TREATMENT", 34, 60], ["a vaccine", "TREATMENT", 105, 114]]], ["These measures include home isolation, social distancing, closing schools/universities and businesses, canceling or postponing events, canceling or postponing congresses and seminars, postponing sports events, and travel restrictions.", [["home isolation", "TREATMENT", 23, 37]]], ["1, 4 After the first COVID-19 patients were reported in Turkey, on March 12, 2020 , one of the most significant measures taken by the Ministry of Education and Higher Education Institutions, was to close school for 3 weeks.", [["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38]]], ["Young people worry about the course of COVID-19, how long the pandemic will last, and when they will be able to return to normal life, while being away from friends and with limited to no social life, which causes them to experience stress and tension.", [["people", "ORGANISM", 6, 12], ["people", "SPECIES", 6, 12], ["stress and tension", "PROBLEM", 233, 251], ["tension", "OBSERVATION", 244, 251]]], ["6 Having limited knowledge with regard to COVID-19 and being overwhelmed by its coverage in the media can cause anxiety and fear in the community.", [["anxiety", "DISEASE", 112, 119], ["COVID", "TEST", 42, 47], ["anxiety", "PROBLEM", 112, 119]]], ["In general, the public may experience distress, frustration, and irritability during the implementation of isolation measures.", [["irritability", "DISEASE", 65, 77], ["distress", "PROBLEM", 38, 46], ["frustration", "PROBLEM", 48, 59], ["irritability", "PROBLEM", 65, 77], ["isolation measures", "TREATMENT", 107, 125]]], ["7, 8 Quarantine can lead to loneliness, physical distancing from loved ones, grief, anxiety, and chronic stress, which can have long-term psychological effects.", [["Quarantine", "CHEMICAL", 5, 15], ["loneliness", "DISEASE", 28, 38], ["grief", "DISEASE", 77, 82], ["anxiety", "DISEASE", 84, 91], ["grief", "PROBLEM", 77, 82], ["anxiety", "PROBLEM", 84, 91], ["chronic stress", "PROBLEM", 97, 111], ["long-term psychological effects", "PROBLEM", 128, 159], ["chronic", "OBSERVATION_MODIFIER", 97, 104], ["stress", "OBSERVATION", 105, 111]]], ["9 It has been demonstrated that the presence of mass traumas and infectious diseases negatively affects the behavior and psychology of society.", [["traumas", "DISEASE", 53, 60], ["infectious diseases", "DISEASE", 65, 84], ["mass traumas", "PROBLEM", 48, 60], ["infectious diseases", "PROBLEM", 65, 84], ["mass", "OBSERVATION", 48, 52], ["infectious", "OBSERVATION_MODIFIER", 65, 75]]], ["10 The level of anxiety increases even more because the outbreak and ending process are unknown.", [["anxiety", "DISEASE", 16, 23], ["anxiety", "PROBLEM", 16, 23]]], ["6 The interruption of education for nursing students has been unexpected from students.", [["nursing students", "TREATMENT", 36, 52]]], ["So, this study aimed to evaluate nursing students' views on the COVID-19 pandemic and their perceived stress levels.| Study designThis was a cross-sectional study, and conducted between April and May 2020.| Study sampleThe research population consisted of nursing students at three universities in eastern Turkey (Inonu, Kilis and Bingol University).", [["this study", "TEST", 4, 14], ["the COVID", "TEST", 60, 69], ["a cross-sectional study", "TEST", 139, 162], ["Study sample", "TEST", 207, 219]]], ["The sample size was determined to be 630 student by conducting power analysis.", [["The sample size", "TEST", 0, 15], ["conducting power analysis", "TEST", 52, 77], ["size", "OBSERVATION_MODIFIER", 11, 15]]], ["The power analysis was based on an alpha of 0.05 error level, power of 0.99, and assumed effect size of 0.5 for the sample size estimation.", [["The power analysis", "TEST", 0, 18], ["an alpha", "TEST", 32, 40], ["the sample size estimation", "TEST", 112, 138], ["size", "OBSERVATION_MODIFIER", 96, 100], ["size", "OBSERVATION_MODIFIER", 123, 127]]], ["A random sampling method was used.| Study sampleTo increase the representation power of the universe, a total of 662 people were surveyed and 662 surveys were included in the analysis.| Inclusion criteriaNursing students over the age of 18 with internet access were included in the study.| Variables of the studyThe dependent variable of the study was the perceived stress.| Variables of the studyThe independent variables of the study were insight, age, sex, class level, and responses to various COVID-19-related questions.| Information formAn information form containing items on students' sociodemographic characteristics, such as age, sex, and year level, and nine items on the COV\u0130D-19 pandemic, was used in this study.", [["people", "ORGANISM", 117, 123], ["people", "SPECIES", 117, 123], ["A random sampling method", "TREATMENT", 0, 24], ["Study sample", "TEST", 36, 48], ["the analysis", "TEST", 171, 183], ["the study", "TEST", 278, 287], ["the study", "TEST", 303, 312], ["the study", "TEST", 338, 347], ["the study", "TEST", 388, 397], ["the study", "TEST", 426, 435], ["this study", "TEST", 714, 724], ["dependent", "OBSERVATION_MODIFIER", 316, 325], ["variable", "OBSERVATION_MODIFIER", 326, 334]]], ["These nine items were created by researchers, considering current issues related to the pandemic process, and reviewing the literature.", [["the pandemic process", "PROBLEM", 84, 104]]], ["2, 11, 12 These items; listen to news, follow the developments in other countries, be worried about getting infected, to recognize someone who has positive coronavirus test results, think of taken enough precautions, taken the precautions, be successful in the fight against the pandemic, evaluate curfew and the feeling felt for staying at home during the pandemic.| Information formContent validity of information form was made to assess whether the questions generated were appropriate for the purpose of measurement and whether they represented the space to be measured.| Information formThe content validity was conducted with expert opinion method.", [["2, 11, 12", "CHEMICAL", 0, 9], ["positive coronavirus test", "PROBLEM", 147, 172], ["the precautions", "TREATMENT", 223, 238], ["The content validity", "TEST", 592, 612]]], ["For this purpose, expert opinions were obtained from six academicians (two from Psychiatric Nursing had conducted research on anxiety and depression in nursing students, two from psychiatric specialist, and two from Fundamentals of Nursing had conducted research on COV\u0130D-19 pandemic).", [["anxiety", "DISEASE", 126, 133], ["depression", "DISEASE", 138, 148], ["psychiatric", "DISEASE", 179, 190], ["anxiety", "PROBLEM", 126, 133], ["depression", "PROBLEM", 138, 148]]], ["The agreement level of the expert opinions was examined using nonparametric test, Kendall's W analysis.", [["nonparametric test", "TEST", 62, 80], ["Kendall's W analysis", "TEST", 82, 102]]], ["The scores given by the experts were not statistically different (Kendall W = 0.355; P > .05), and there was agreement among the experts.| Information formThus, content validity of the items was provided for the students.| Perceived Stress ScaleThe Perceived Stress Scale, developed by Cohen et al 13 was used in this study to assess students' stress levels.", [["Kendall W", "TEST", 66, 75], ["The Perceived Stress Scale", "TEST", 245, 271], ["this study", "TEST", 313, 323], ["stress levels", "TEST", 344, 357]]], ["Total score on the PSS ranges from 0 to 56.", [["Total score", "TEST", 0, 11], ["the PSS", "TEST", 15, 22]]], ["There is no cut-off value on the scale, and a high score indicates an excessive perception of stress.", [["the scale", "TEST", 29, 38], ["a high score", "PROBLEM", 44, 56], ["stress", "PROBLEM", 94, 100], ["no", "UNCERTAINTY", 9, 11], ["cut", "OBSERVATION_MODIFIER", 12, 15], ["off value", "OBSERVATION_MODIFIER", 16, 25], ["excessive", "OBSERVATION_MODIFIER", 70, 79]]], ["The reliability of the scale was evaluated by examining internal consistency (Cronbach's \u03b1 and factor analysis) coefficients.", [["the scale", "TEST", 19, 28], ["Cronbach", "TEST", 78, 86], ["factor analysis", "TEST", 95, 110]]], ["A Cronbach's alpha of the scale was found to be 0.84 in a study of its validity and reliability.", [["Cronbach's alpha", "GENE_OR_GENE_PRODUCT", 2, 18], ["A Cronbach's alpha of the scale", "TEST", 0, 31], ["a study", "TEST", 56, 63]]], ["14 A Cronbach's \u03b1 of 0.82 was found in this study.| Data collectionAn online questionnaire was used to collect data.", [["A Cronbach's \u03b1", "TEST", 3, 17], ["this study", "TEST", 39, 49]]], ["The questionnaire consisted of the information form developed for the study and the PSS.", [["the study", "TEST", 66, 75], ["the PSS", "TEST", 80, 87]]], ["A link to the questionnaire was provided to the students via WhatsApp (WhatsApp Inc., Menlo Park, CA), and any forms that were incomplete or had errors were to be removed from the analysis.| Statistical analysisData were analyzed with Statistical Package for the Social Sciences 23.0 software.", [["Statistical analysisData", "TEST", 191, 215]]], ["Values for the demographic characteristics of the students and their views on the COV\u0130D-19 pandemic were expressed as numbers, percentages, averages, and standard deviations.", [["their views", "TEST", 63, 74], ["the COV\u0130D", "TEST", 78, 87]]], ["Data were analyzed using the independent-samples T, Kruskal-Wallis H, and linear regression tests.| RESULTSThe average age of the students participating in the study was 20.67 \u00b1 1.61 years.", [["linear regression tests", "TEST", 74, 97], ["the study", "TEST", 156, 165]]], ["Of all the students, 51.7% were in the 18 to 20 age range, 71.9% were female, and 44.4% were in their first year of nursing school (Table 1) .| RESULTSResults indicated that 48% of the students frequently consumed news about the COVID-19 pandemic, and 91.5% followed the developments in other countries.", [["the COVID", "TEST", 225, 234]]], ["It was determined that 68.1% of students were worried about being infected, and 78.9% thought that they took adequate measures against infection.", [["infection", "DISEASE", 135, 144], ["infection", "PROBLEM", 135, 144], ["infection", "OBSERVATION", 135, 144]]], ["With regard to the measures taken to prevent infection, 97% washed their hands frequently, 92.9% practiced social distancing, and 91.1% took steps to ensure that their environment was well-ventilated.", [["infection", "DISEASE", 45, 54], ["the measures", "TREATMENT", 15, 27], ["infection", "PROBLEM", 45, 54], ["infection", "OBSERVATION", 45, 54]]], ["In addition, 23.6% of the students knew people who had tested positive for the disease, 77.9% thought that Turkey was successful in fighting the COVID-19 pandemic, and 69.5% considered the curfew to be the right decision.| RESULTSDue to the a curfew for people under the age of 20, the students stayed at their homes during the day.", [["people", "ORGANISM", 40, 46], ["people", "ORGANISM", 254, 260], ["people", "SPECIES", 40, 46], ["people", "SPECIES", 254, 260], ["the disease", "PROBLEM", 75, 86], ["the COVID", "TEST", 141, 150], ["right", "ANATOMY_MODIFIER", 206, 211]]], ["Of the students who stayed at home, the majority (66.2%) reported being bored at home, but 44.9% felt safe ( Table 2 ).| RESULTSThe PSS was used to evaluate the stress level of the students.| RESULTSThis scale is used to assess the stress experienced in the past month.| RESULTSThe average score on the PSS was 31.69 \u00b1 6.91, indicating that the students had a moderate level of stress.", [["RESULTSThe PSS", "TEST", 121, 135], ["RESULTSThis scale", "TEST", 192, 209], ["the stress", "PROBLEM", 228, 238], ["the PSS", "TEST", 299, 306], ["stress", "PROBLEM", 378, 384], ["moderate", "OBSERVATION_MODIFIER", 360, 368]]], ["In the analysis, it was determined that there were significant differences in PSS score in terms of age (P < .001), and those between 18 and 20 years of age had higher stress levels.", [["significant differences in PSS score", "PROBLEM", 51, 87], ["higher stress levels", "PROBLEM", 161, 181], ["significant", "OBSERVATION_MODIFIER", 51, 62]]], ["Significant differences in PSS score in terms of sex were also found (P < .001).", [["Significant differences in PSS score", "PROBLEM", 0, 36]]], ["The stress levels of female students were found to be higher.", [["The stress levels", "TEST", 0, 17], ["higher", "OBSERVATION_MODIFIER", 54, 60]]], ["It was also determined that the stress levels of the students studying in the first and fourth years were higher, but the difference between year level and PSS was not significant (Kruskal-Wallis: 3.655; P > .05) ( Table 3) .", [["the stress levels", "TEST", 28, 45], ["PSS", "TEST", 156, 159], ["Kruskal-Wallis", "TEST", 181, 195], ["P", "TEST", 204, 205]]], ["Table 4 ).| DISCUSSIONThe COVID-19 pandemic revealed the need to treat the psychological aspects of epidemics and pandemics and to treat these events as phenomena that have psychological effects.", [["epidemics", "PROBLEM", 100, 109], ["pandemics", "PROBLEM", 114, 123], ["these events", "PROBLEM", 137, 149], ["phenomena", "PROBLEM", 153, 162], ["psychological effects", "PROBLEM", 173, 194]]], ["15 In this study, nursing students' views on the COVID-19 pandemic and their perceived stress levels were evaluated.", [["this study", "TEST", 6, 16], ["the COVID", "TEST", 45, 54], ["their perceived stress levels", "TEST", 71, 100]]], ["It was determined that the students perceived moderate levels of stress, but they had higher levels of stress than students assessed in previous years.", [["moderate levels of stress", "PROBLEM", 46, 71]]], ["12, 16 In this study, students scored that many factors such as giving care to sick individuals, lack of selfconfidence in practical applications, insufficient support from instructors, and communication problems with other health professionals affect students' stress levels.", [["this study", "TEST", 10, 20], ["stress levels", "TEST", 262, 275]]], ["[17] [18] [19] It is seen that, besides many academic, social, and psychological stress factors that put nursing students in stress, many unusual new developments experienced in the pandemic process may have increased the stress level of the students.", [["psychological stress factors", "PROBLEM", 67, 95], ["new", "OBSERVATION_MODIFIER", 146, 149], ["increased", "OBSERVATION_MODIFIER", 208, 217]]], ["Like nurses, who are at the forefront of combating the virus, reducing the stress levels of nurse candidates is important in terms of protecting both themselves and their families and society.| DISCUSSIONAge was found to have an effect on the level of stress perceived by the students, and there were statistically significant differences in PSS score between age groups (P < .001).", [["PSS", "DISEASE", 342, 345], ["the virus", "PROBLEM", 51, 60], ["statistically significant differences in PSS score", "PROBLEM", 301, 351], ["significant", "OBSERVATION_MODIFIER", 315, 326]]], ["A study with nursing students before the pandemic found that there was no significant difference between age and perceived stress, but the perceived stress level of students under 20, was higher.", [["A study", "TEST", 0, 7], ["perceived stress", "PROBLEM", 113, 129], ["the perceived stress level", "TEST", 135, 161], ["no", "UNCERTAINTY", 71, 73], ["significant", "OBSERVATION_MODIFIER", 74, 85]]], ["12 With the pandemic process, the stress level of students under-20, was significantly increased.", [["the pandemic process", "PROBLEM", 8, 28], ["the stress level", "TEST", 30, 46], ["increased", "OBSERVATION_MODIFIER", 87, 96]]], ["Also, it is thought that the ability to cope with stress of younger students is not fully developed, and inadequate training received in university about infectious diseases may also have increased the level of stress (because under-20 age students are more likely to be in first or second grade).| DISCUSSIONThere were significant differences in PSS score in terms of sex (P < .001).", [["infectious diseases", "DISEASE", 154, 173], ["infectious diseases", "PROBLEM", 154, 173], ["significant differences in PSS score", "PROBLEM", 320, 356], ["significant", "OBSERVATION_MODIFIER", 320, 331]]], ["It was observed that the stress level perceived by female students was higher than that of male students.", [["the stress level", "TEST", 21, 37]]], ["In a study by Turan et al, 12 it was found that the female students' score on the PSS (27.92 \u00b1 6.64) were significantly higher than those of the male students [20] [21] [22] In a community based study conducted by Ekiz and colleagues on the pandemic process, it was found that the health anxiety levels of females were significantly higher than those of males.| DISCUSSION(\u03b2 = \u2212.12; P < .01).", [["PSS", "DISEASE", 82, 85], ["anxiety", "DISEASE", 288, 295], ["a study", "TEST", 3, 10], ["the PSS", "TEST", 78, 85], ["a community based study", "TEST", 177, 200], ["the health anxiety levels of females", "PROBLEM", 277, 313]]], ["6 Females are thought to have increased stress levels due to being more emotional.| DISCUSSIONNo significant difference in PSS score was found between year levels; however, the stress levels of the firstand fourth-year students were higher than those of students at other year levels.", [["increased stress levels", "PROBLEM", 30, 53], ["significant difference in PSS score", "PROBLEM", 97, 132], ["the stress levels", "TEST", 173, 190]]], ["In the studies The COVID-19 pandemic is a trauma that threatens individuals' lives, and emotionally affects us all.", [["trauma", "DISEASE", 42, 48], ["the studies", "TEST", 3, 14]]], ["2 The fear of getting sick, uncertainty, the fear that the disease will affect one's family, lack of safety in one's own community, and similar factors are sources of intense anxiety.", [["anxiety", "DISEASE", 175, 182], ["the disease", "PROBLEM", 55, 66], ["intense anxiety", "PROBLEM", 167, 182], ["disease", "OBSERVATION", 59, 66]]], ["15 In this study, it was determined that the students' concerns regarding the transmission of the virus affected their perceived stress (\u03b2 = \u22122.11; P < .001).", [["this study", "TEST", 6, 16], ["the virus", "PROBLEM", 94, 103]]], ["In addition, it was determined that the percentage of students who knew people who had positive tests results for the coronav\u0131rus was 23.6%, which increased their stress levels.| DISCUSSIONIt was determined that 48% of the students listened to the news frequently, and 91.5% followed the developments in other countries.| IMPLICATIONS FOR NURSING PRACTICEThe COVID-19 pandemic has affected the entire world, and it has also affected nursing students in different ways.", [["coronav\u0131rus", "DISEASE", 118, 129], ["people", "ORGANISM", 72, 78], ["COVID-19", "ORGANISM", 359, 367], ["people", "SPECIES", 72, 78], ["the coronav\u0131rus", "TEST", 114, 129]]], ["Our study found that the stress levels of nursing students have increased during the pandemic.", [["Our study", "TEST", 0, 9], ["the stress levels", "TEST", 21, 38], ["increased", "OBSERVATION_MODIFIER", 64, 73]]], ["Therefore, nursing students should be bring the ability to cope with stress in cases of pandemic.", [["pandemic", "PROBLEM", 88, 96]]], ["Thus, in dealing with stress, nursing students will contribute to helping individuals in society cope with stress.", [["stress", "PROBLEM", 107, 113]]], ["This study may have contributed to nursing practice, considering that nursing students should develop skills to protect themselves, their families and the community during their training on epidemic infections.", [["infections", "DISEASE", 199, 209], ["This study", "TEST", 0, 10], ["epidemic infections", "PROBLEM", 190, 209]]], ["Psychiatric nurses can benefit from the results of this study in clinical practice.", [["this study", "TEST", 51, 61]]], ["The results of the research will enable psychiatric nurses to be aware that nursing students will be affected by Pandemic periods and that their stress levels will increase.| LIMITATIONSThe limitation of the research is that there is only one dependent variable.", [["psychiatric", "DISEASE", 40, 51], ["their stress levels", "TEST", 139, 158], ["one dependent", "OBSERVATION_MODIFIER", 239, 252], ["variable", "OBSERVATION_MODIFIER", 253, 261]]], ["Another limitation of this study is that only age, gender, and class variables are taken in the sample group.| CONCLUSION AND RECOMMENDATIONIt was determined that student nurses perceived a moderate level of stress during the COVID-19 pandemic.", [["this study", "TEST", 22, 32], ["a moderate level of stress", "PROBLEM", 188, 214], ["the COVID", "TEST", 222, 231], ["pandemic", "PROBLEM", 235, 243]]], ["Those between the ages of 18 and 20 years and female students were found to have higher levels of stress.", [["stress", "PROBLEM", 98, 104]]], ["Watching news, worrying about the risk of infection, and the imposed curfew were found to affect stress levels.", [["infection", "DISEASE", 42, 51], ["infection", "PROBLEM", 42, 51], ["stress levels", "PROBLEM", 97, 110], ["infection", "OBSERVATION", 42, 51]]], ["In line with these results, it may be suggested that nursing trainers give training and counseling, especially in the development of stress management skills for students under 20 years old and female students.", [["counseling", "TREATMENT", 88, 98], ["stress management", "TREATMENT", 133, 150]]], ["To help students reduce their stress levels, they should be given up-to-date information about the pandemic.", [["their stress levels", "PROBLEM", 24, 43]]], ["Besides, to reduce the anxiety of infection transmission, it may be recommended to provide students with training on measures to be taken, protective equipment, and hygiene issues via distance education.", [["anxiety", "DISEASE", 23, 30], ["infection", "DISEASE", 34, 43], ["the anxiety of infection transmission", "PROBLEM", 19, 56], ["measures", "TREATMENT", 117, 125], ["protective equipment", "TREATMENT", 139, 159], ["infection", "OBSERVATION", 34, 43]]]], "3b2bdb3169245a06f91b2bcec1cc228eb52ab1dd": [["In December 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 62 2) was reported in Wuhan, China [1] .", [["acute respiratory syndrome coronavirus", "DISEASE", 29, 67], ["SARS-CoV- 62 2", "ORGANISM", 71, 85], ["severe acute respiratory syndrome coronavirus", "SPECIES", 22, 67], ["SARS-CoV- 62", "SPECIES", 71, 83], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 18, 67], ["SARS-CoV", "TEST", 71, 79], ["severe", "OBSERVATION_MODIFIER", 22, 28], ["acute", "OBSERVATION_MODIFIER", 29, 34], ["respiratory syndrome", "OBSERVATION", 35, 55]]], ["The resulting coronavirus disease COVID-19 has 63 become a global pandemic with 16.5 million reported cases as of July 29th, 2020 64 (World Health Organization, 2020).", [["coronavirus disease", "DISEASE", 14, 33], ["coronavirus", "ORGANISM", 14, 25], ["coronavirus", "SPECIES", 14, 25], ["coronavirus disease COVID-19", "SPECIES", 14, 42], ["The resulting coronavirus disease COVID", "PROBLEM", 0, 39], ["coronavirus disease", "OBSERVATION", 14, 33]]], ["When assessing SARS-CoV-2 infection, clinicians 65 initially focused on the most common symptoms at the onset of COVID-19 illness such 66 as fever, cough, and fatigue.", [["SARS-CoV-2 infection", "DISEASE", 15, 35], ["COVID", "DISEASE", 113, 118], ["illness", "DISEASE", 122, 129], ["fever", "DISEASE", 141, 146], ["cough", "DISEASE", 148, 153], ["fatigue", "DISEASE", 159, 166], ["SARS-CoV-2", "ORGANISM", 15, 25], ["SARS-CoV", "SPECIES", 15, 23], ["SARS", "PROBLEM", 15, 19], ["CoV-2 infection", "PROBLEM", 20, 35], ["the most common symptoms", "PROBLEM", 72, 96], ["COVID", "TEST", 113, 118], ["fever", "PROBLEM", 141, 146], ["cough", "PROBLEM", 148, 153], ["fatigue", "PROBLEM", 159, 166]]], ["Other reported signs and symptoms included sputum 67 production, headache, hemoptysis, diarrhea, and dyspnea [2] .", [["headache", "DISEASE", 65, 73], ["hemoptysis", "DISEASE", 75, 85], ["diarrhea", "DISEASE", 87, 95], ["dyspnea", "DISEASE", 101, 108], ["symptoms", "PROBLEM", 25, 33], ["sputum 67 production", "PROBLEM", 43, 63], ["headache", "PROBLEM", 65, 73], ["hemoptysis", "PROBLEM", 75, 85], ["diarrhea", "PROBLEM", 87, 95], ["dyspnea", "PROBLEM", 101, 108], ["hemoptysis", "OBSERVATION", 75, 85], ["diarrhea", "OBSERVATION", 87, 95]]], ["68 Since March 2020, an increasing number of reports regarding taste and smell loss in 69 COVID-19 infections appeared in preprints [3, 4] and in general press, and it is currently 70 well established that taste and smell loss is common in COVID-19 patients [5] [6] [7] [8] .", [["taste and smell loss", "DISEASE", 63, 83], ["infections", "DISEASE", 99, 109], ["smell loss", "DISEASE", 216, 226], ["taste", "ORGANISM_SUBDIVISION", 63, 68], ["smell", "ORGANISM_SUBDIVISION", 73, 78], ["taste", "ORGANISM_SUBDIVISION", 206, 211], ["smell", "ORGANISM_SUBDIVISION", 216, 221], ["patients", "ORGANISM", 249, 257], ["5] [6] [7] [8]", "SIMPLE_CHEMICAL", 259, 273], ["patients", "SPECIES", 249, 257], ["smell loss", "PROBLEM", 73, 83], ["COVID", "TEST", 90, 95], ["infections", "PROBLEM", 99, 109], ["smell loss", "PROBLEM", 216, 226]]], ["71 Earlier studies have already suggested associations between anosmia (loss of smell) 72 and the coronavirus causing Severe Acute Respiratory Syndrome (SARS), SARS-CoV-1.", [["anosmia", "DISEASE", 63, 70], ["loss of smell)", "DISEASE", 72, 86], ["coronavirus", "DISEASE", 98, 109], ["Acute Respiratory Syndrome", "DISEASE", 125, 151], ["SARS", "DISEASE", 153, 157], ["SARS", "DISEASE", 160, 164], ["Severe Acute Respiratory Syndrome (SARS)", "SPECIES", 118, 158], ["SARS-CoV-1", "SPECIES", 160, 170], ["Earlier studies", "TEST", 3, 18], ["anosmia (loss of smell)", "PROBLEM", 63, 86], ["the coronavirus", "PROBLEM", 94, 109], ["Severe Acute Respiratory Syndrome (SARS)", "PROBLEM", 118, 158], ["SARS", "PROBLEM", 160, 164], ["Severe", "OBSERVATION_MODIFIER", 118, 124], ["Acute", "OBSERVATION_MODIFIER", 125, 130], ["Respiratory Syndrome", "OBSERVATION", 131, 151]]], ["73 Olfactory symptoms[9] and taste disorders [10] have also been associated also with 74 viral upper respiratory tract infections caused by other viruses, as well.", [["Olfactory", "ANATOMY", 3, 12], ["taste disorders", "DISEASE", 29, 44], ["respiratory tract infections", "DISEASE", 101, 129], ["tract", "ORGANISM_SUBDIVISION", 113, 118], ["Olfactory symptoms", "PROBLEM", 3, 21], ["taste disorders", "PROBLEM", 29, 44], ["74 viral upper respiratory tract infections", "PROBLEM", 86, 129], ["other viruses", "PROBLEM", 140, 153], ["upper", "ANATOMY_MODIFIER", 95, 100], ["respiratory tract", "ANATOMY", 101, 118], ["infections", "OBSERVATION", 119, 129], ["viruses", "OBSERVATION", 146, 153]]], ["However, the 75 prevalence of olfactory loss in COVID-19 is usually reported as much higher [11] [12] [13] [14] [15] 76 than in other diseases [16] .", [["olfactory", "ANATOMY", 30, 39], ["olfactory loss", "DISEASE", 30, 44], ["COVID-19", "CHEMICAL", 48, 56], ["olfactory", "ORGAN", 30, 39], ["[11] [12] [13] [14] [15] 76", "SIMPLE_CHEMICAL", 92, 119], ["olfactory loss", "PROBLEM", 30, 44], ["COVID", "TEST", 48, 53]]], ["In a recent crowd-sourced study, ~7000 app users reported 77 testing positive for COVID-19, with 65% of those reporting that they lost their sense 78 of smell or taste [14] , a three-fold increase in prevalence compared to COVID-19 79 negatives [17] .", [["smell", "ORGANISM_SUBDIVISION", 153, 158], ["COVID", "TEST", 82, 87], ["COVID", "TEST", 223, 228]]], ["The severity of smell and taste loss in COVID-19 patients is striking: 80 these sensory abilities were reduced by -79.7 \u00b1 28.7, -69.0 \u00b1 32.6 (mean \u00b1 SD), 81 respectively, as reported by about 4000 participants using a 0-100 visual analog scale 82 (VAS) [7] .A follow-up study found that recent smell loss is the best predictor for COVID-", [["taste loss", "DISEASE", 26, 36], ["smell loss", "DISEASE", 294, 304], ["taste", "ORGANISM_SUBDIVISION", 26, 31], ["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57], ["participants", "SPECIES", 197, 209], ["The severity of smell", "PROBLEM", 0, 21], ["taste loss", "PROBLEM", 26, 36], ["COVID", "TEST", 40, 45], ["A follow-up study", "TEST", 258, 275], ["recent smell loss", "PROBLEM", 287, 304], ["smell", "OBSERVATION", 16, 21]]]], "PMC7315029": [["INTRODUCTIONLower respiratory tract infections (LRTI) are clinical conditions that arise throughout the population.", [["respiratory tract", "ANATOMY", 18, 35], ["respiratory tract infections", "DISEASE", 18, 46], ["LRTI", "DISEASE", 48, 52], ["INTRODUCTIONLower respiratory tract infections", "PROBLEM", 0, 46], ["clinical conditions", "PROBLEM", 58, 77], ["respiratory tract", "ANATOMY", 18, 35], ["infections", "OBSERVATION", 36, 46]]], ["Community-acquired pneumonia is estimated to be the most common cause of infectious disease-related mortality in the United States and globally (1, 2) and is a leading cause of hospital and emergency room visits.", [["pneumonia", "DISEASE", 19, 28], ["Community-acquired pneumonia", "PROBLEM", 0, 28], ["infectious disease", "PROBLEM", 73, 91], ["pneumonia", "OBSERVATION", 19, 28], ["most common", "OBSERVATION_MODIFIER", 52, 63], ["infectious", "OBSERVATION", 73, 83]]], ["The highest morbidity and mortality of these illnesses are frequently seen in the elderly, children <5 years of age, and the immunocompromised (3).", [["children", "ORGANISM", 91, 99], ["children", "SPECIES", 91, 99], ["The highest morbidity", "PROBLEM", 0, 21], ["these illnesses", "PROBLEM", 39, 54], ["highest", "OBSERVATION_MODIFIER", 4, 11], ["morbidity", "OBSERVATION", 12, 21], ["illnesses", "OBSERVATION", 45, 54]]], ["Pneumonia-like illness is also a frequent hospital-acquired infection that can result in increased mortality and unnecessary economic burden (4).INTRODUCTIONBacteria and viruses are the most common etiologies of lower respiratory tract infections.", [["lower respiratory tract", "ANATOMY", 212, 235], ["Pneumonia", "DISEASE", 0, 9], ["illness", "DISEASE", 15, 22], ["infection", "DISEASE", 60, 69], ["respiratory tract infections", "DISEASE", 218, 246], ["lower", "ORGANISM", 212, 217], ["respiratory tract", "ORGANISM_SUBDIVISION", 218, 235], ["Pneumonia", "PROBLEM", 0, 9], ["a frequent hospital-acquired infection", "PROBLEM", 31, 69], ["increased mortality", "PROBLEM", 89, 108], ["unnecessary economic burden", "PROBLEM", 113, 140], ["INTRODUCTIONBacteria", "PROBLEM", 145, 165], ["viruses", "PROBLEM", 170, 177], ["lower respiratory tract infections", "PROBLEM", 212, 246], ["illness", "OBSERVATION", 15, 22], ["infection", "OBSERVATION", 60, 69], ["increased", "OBSERVATION_MODIFIER", 89, 98], ["mortality", "OBSERVATION", 99, 108], ["viruses", "OBSERVATION", 170, 177], ["most common", "OBSERVATION_MODIFIER", 186, 197], ["lower", "ANATOMY_MODIFIER", 212, 217], ["respiratory tract", "ANATOMY", 218, 235], ["infections", "OBSERVATION", 236, 246]]], ["Patients with viral pneumonia may be managed differently than those with bacterial infections, but due to similarities in clinical presentation and symptomatology, it is not possible to distinguish viral from bacterial infections without the aid of laboratory diagnostic testing.", [["viral pneumonia", "DISEASE", 14, 29], ["bacterial infections", "DISEASE", 73, 93], ["bacterial infections", "DISEASE", 209, 229], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["viral pneumonia", "PROBLEM", 14, 29], ["bacterial infections", "PROBLEM", 73, 93], ["symptomatology", "PROBLEM", 148, 162], ["viral from bacterial infections", "PROBLEM", 198, 229], ["laboratory diagnostic testing", "TEST", 249, 278], ["viral", "OBSERVATION_MODIFIER", 14, 19], ["pneumonia", "OBSERVATION", 20, 29], ["infections", "OBSERVATION", 83, 93], ["bacterial", "OBSERVATION_MODIFIER", 209, 218], ["infections", "OBSERVATION", 219, 229]]], ["Rapid diagnostics for specific entities (Streptococcus pneumoniae and respiratory syncytial virus [RSV]) and host markers (procalcitonin) exist for the detection of common viral and bacterial illness and/or to aid in distinguishing bacterial from viral infections (5\u20137).", [["Streptococcus pneumoniae", "DISEASE", 41, 65], ["respiratory syncytial virus", "DISEASE", 70, 97], ["viral and bacterial illness", "DISEASE", 172, 199], ["viral infections", "DISEASE", 247, 263], ["Streptococcus pneumoniae", "ORGANISM", 41, 65], ["respiratory syncytial virus", "ORGANISM", 70, 97], ["RSV", "ORGANISM", 99, 102], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 123, 136], ["procalcitonin", "PROTEIN", 123, 136], ["Streptococcus pneumoniae", "SPECIES", 41, 65], ["respiratory syncytial virus", "SPECIES", 70, 97], ["Streptococcus pneumoniae", "SPECIES", 41, 65], ["respiratory syncytial virus", "SPECIES", 70, 97], ["RSV", "SPECIES", 99, 102], ["Rapid diagnostics", "TEST", 0, 17], ["specific entities", "PROBLEM", 22, 39], ["Streptococcus pneumoniae", "PROBLEM", 41, 65], ["respiratory syncytial virus", "PROBLEM", 70, 97], ["host markers (procalcitonin)", "TREATMENT", 109, 137], ["the detection", "TEST", 148, 161], ["common viral and bacterial illness", "PROBLEM", 165, 199], ["bacterial from viral infections", "PROBLEM", 232, 263], ["Streptococcus pneumoniae", "OBSERVATION", 41, 65], ["syncytial virus", "OBSERVATION", 82, 97], ["viral infections", "OBSERVATION", 247, 263]]], ["These methods alone are frequently inadequate as a means to diagnose and treat pneumonia (8, 9).INTRODUCTIONRapid resolution of the etiology of lower respiratory tract infections can aid in the ability to ensure that appropriate antimicrobial therapy is initiated and that patients are put on the appropriate infection control precautions and to prevent unnecessary downstream testing.", [["lower respiratory tract", "ANATOMY", 144, 167], ["pneumonia", "DISEASE", 79, 88], ["respiratory tract infections", "DISEASE", 150, 178], ["infection", "DISEASE", 309, 318], ["lower", "ORGANISM_SUBDIVISION", 144, 149], ["respiratory tract", "ORGANISM_SUBDIVISION", 150, 167], ["patients", "ORGANISM", 273, 281], ["patients", "SPECIES", 273, 281], ["pneumonia", "PROBLEM", 79, 88], ["lower respiratory tract infections", "PROBLEM", 144, 178], ["appropriate antimicrobial therapy", "TREATMENT", 217, 250], ["the appropriate infection control precautions", "TREATMENT", 293, 338], ["unnecessary downstream testing", "TEST", 354, 384], ["pneumonia", "OBSERVATION", 79, 88], ["lower", "ANATOMY_MODIFIER", 144, 149], ["respiratory tract", "ANATOMY", 150, 167], ["infections", "OBSERVATION", 168, 178]]], ["In adult populations, broad-spectrum antibiotics are often initiated before bacterial culture results are available, if there is suspicion of bacterial pneumonia or if the patient requires ICU admission (6).", [["pneumonia", "DISEASE", 152, 161], ["patient", "ORGANISM", 172, 179], ["patient", "SPECIES", 172, 179], ["broad-spectrum antibiotics", "TREATMENT", 22, 48], ["bacterial culture", "TEST", 76, 93], ["bacterial pneumonia", "PROBLEM", 142, 161], ["adult", "OBSERVATION_MODIFIER", 3, 8], ["populations", "OBSERVATION_MODIFIER", 9, 20], ["suspicion of", "UNCERTAINTY", 129, 141], ["bacterial", "OBSERVATION_MODIFIER", 142, 151], ["pneumonia", "OBSERVATION", 152, 161]]], ["In children, viral entities are the most frequent cause of pneumonia, and directed antiviral therapy is recommended for severely ill patients (10).", [["pneumonia", "DISEASE", 59, 68], ["children", "ORGANISM", 3, 11], ["patients", "ORGANISM", 133, 141], ["children", "SPECIES", 3, 11], ["patients", "SPECIES", 133, 141], ["viral entities", "PROBLEM", 13, 27], ["pneumonia", "PROBLEM", 59, 68], ["directed antiviral therapy", "TREATMENT", 74, 100], ["viral entities", "OBSERVATION", 13, 27], ["pneumonia", "OBSERVATION", 59, 68]]], ["Rapid detection of the causative agent of respiratory infection, coupled with detection of prominent markers of antibiotic resistance, can aid in limiting unnecessary broad-spectrum antimicrobial treatment.INTRODUCTIONThe BioFire FilmArray Pneumonia Panel (PN panel) and Pneumonia Plus Panel (PNplus panel) (BioFire Diagnostics, LLC, Salt Lake City, UT) were designed to provide a means of rapidly detecting nucleic acids from common agents of community- and hospital-acquired lower respiratory tract infections (Table 1).", [["respiratory", "ANATOMY", 42, 53], ["lower respiratory tract", "ANATOMY", 477, 500], ["respiratory infection", "DISEASE", 42, 63], ["Pneumonia", "DISEASE", 240, 249], ["Pneumonia", "DISEASE", 271, 280], ["nucleic acids", "CHEMICAL", 408, 421], ["lower respiratory tract infections", "DISEASE", 477, 511], ["lower", "ORGANISM_SUBDIVISION", 477, 482], ["respiratory tract", "ORGANISM_SUBDIVISION", 483, 500], ["respiratory infection", "PROBLEM", 42, 63], ["antibiotic resistance", "TREATMENT", 112, 133], ["unnecessary broad-spectrum antimicrobial treatment", "TREATMENT", 155, 205], ["BioFire FilmArray Pneumonia Panel", "TEST", 222, 255], ["PN panel", "TEST", 257, 265], ["Pneumonia", "PROBLEM", 271, 280], ["Panel (PNplus panel", "TEST", 286, 305], ["Diagnostics", "TEST", 316, 327], ["nucleic acids", "PROBLEM", 408, 421], ["acquired lower respiratory tract infections", "PROBLEM", 468, 511], ["respiratory", "ANATOMY", 42, 53], ["infection", "OBSERVATION", 54, 63], ["prominent", "OBSERVATION_MODIFIER", 91, 100], ["antibiotic resistance", "OBSERVATION", 112, 133], ["antimicrobial treatment", "OBSERVATION", 182, 205], ["Pneumonia", "OBSERVATION", 240, 249], ["Pneumonia", "OBSERVATION", 271, 280], ["LLC", "ANATOMY", 329, 332], ["lower", "ANATOMY_MODIFIER", 477, 482], ["respiratory tract", "ANATOMY", 483, 500]]], ["The panel integrates nucleic acid extraction, reverse transcription, and nested multiplex PCR amplification for 8 (PN panel) or 9 (PNplus panel) viruses, 18 bacteria (including 3 atypical bacteria associated with community-acquired pneumonia), and 7 antimicrobial resistance (AMR) genes.", [["nucleic acid", "CHEMICAL", 21, 33], ["pneumonia", "DISEASE", 232, 241], ["antimicrobial resistance (AMR) genes", "DNA", 250, 286], ["The panel", "TEST", 0, 9], ["nucleic acid extraction", "TREATMENT", 21, 44], ["reverse transcription", "TREATMENT", 46, 67], ["nested multiplex PCR amplification", "TEST", 73, 107], ["PN panel", "TEST", 115, 123], ["PNplus panel", "TEST", 131, 143], ["viruses", "PROBLEM", 145, 152], ["18 bacteria", "PROBLEM", 154, 165], ["3 atypical bacteria", "PROBLEM", 177, 196], ["community-acquired pneumonia", "PROBLEM", 213, 241], ["7 antimicrobial resistance (AMR) genes", "PROBLEM", 248, 286], ["pneumonia", "OBSERVATION", 232, 241], ["antimicrobial resistance", "OBSERVATION", 250, 274]]], ["The PN panel and PNplus panel test reagents are identical, with results for Middle East respiratory syndrome coronavirus (MERS-CoV) masked by the software for the PN panel version; for simplicity, the tests are referred to collectively as the PN panel throughout this paper except where a distinction is required.", [["respiratory syndrome coronavirus", "DISEASE", 88, 120], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 76, 120], ["Middle East respiratory syndrome coronavirus", "SPECIES", 76, 120], ["MERS-CoV", "SPECIES", 122, 130], ["The PN panel", "TEST", 0, 12], ["PNplus panel test reagents", "TEST", 17, 43], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 76, 120], ["the PN panel version", "TREATMENT", 159, 179], ["the tests", "TEST", 197, 206], ["the PN panel", "TEST", 239, 251]]], ["The device is intended for use with sputum-like specimens (expectorated or induced sputum and endotracheal aspirates [ETA]) and bronchoalveolar lavage (BAL) specimens tested directly, without pretreatment.", [["sputum", "ANATOMY", 36, 42], ["specimens", "ANATOMY", 48, 57], ["sputum", "ANATOMY", 83, 89], ["endotracheal aspirates", "ANATOMY", 94, 116], ["bronchoalveolar lavage (BAL) specimens", "ANATOMY", 128, 166], ["endotracheal aspirates", "MULTI-TISSUE_STRUCTURE", 94, 116], ["bronchoalveolar lavage", "CELL", 128, 150], ["The device", "TREATMENT", 0, 10], ["sputum-like specimens", "TEST", 36, 57], ["induced sputum", "PROBLEM", 75, 89], ["endotracheal aspirates", "TEST", 94, 116], ["bronchoalveolar lavage (BAL) specimens", "TEST", 128, 166], ["endotracheal", "ANATOMY", 94, 106], ["bronchoalveolar lavage", "OBSERVATION", 128, 150]]], ["In addition to nucleic acid detection, the panel is able to provide a semiquantitative estimate of abundance for 15 of the bacterial targets (reported in log10 increments from 104 to 107 genomic copies/ml).", [["nucleic acid", "CHEMICAL", 15, 27], ["nucleic acid detection", "TEST", 15, 37], ["the panel", "TEST", 39, 48], ["the bacterial targets", "PROBLEM", 119, 140]]], ["All testing is done in the closed sample-to-answer FilmArray system, which provides automated analysis and results in about 75 min.INTRODUCTIONHere, we report on studies performed to characterize the linearity and accuracy of the semiquantitative results provided for the bacteria detected by the PN panel as well as a multicenter prospective study, where the performance of the panel was evaluated in comparison to several reference methods that included conventional and quantitative culture and molecular detection.Contrived samples for linearity and accuracy validation. ::: MATERIALS AND METHODSDilutions of contrived BAL samples containing cultured bacterial isolates in a matrix of sterile physiological saline and 20 ng/\u03bcl human genomic DNA were tested repeatedly with the PN panel (90 replicates) to assess both the linearity and accuracy of the test\u2019s semiquantitative bin results.", [["samples", "ANATOMY", 528, 535], ["BAL samples", "ANATOMY", 623, 634], ["matrix", "ANATOMY", 679, 685], ["BAL samples", "CANCER", 623, 634], ["saline", "SIMPLE_CHEMICAL", 711, 717], ["human", "ORGANISM", 731, 736], ["DNA", "CELLULAR_COMPONENT", 745, 748], ["human genomic DNA", "DNA", 731, 748], ["human", "SPECIES", 731, 736], ["human", "SPECIES", 731, 736], ["All testing", "TEST", 0, 11], ["automated analysis", "TEST", 84, 102], ["studies", "TEST", 162, 169], ["the bacteria", "PROBLEM", 268, 280], ["the PN panel", "TEST", 293, 305], ["a multicenter prospective study", "TEST", 317, 348], ["the panel", "TEST", 375, 384], ["quantitative culture", "TEST", 473, 493], ["molecular detection", "TEST", 498, 517], ["linearity", "TEST", 540, 549], ["accuracy validation", "TEST", 554, 573], ["contrived BAL samples", "TREATMENT", 613, 634], ["bacterial isolates", "PROBLEM", 655, 673], ["sterile physiological saline", "TREATMENT", 689, 717], ["20 ng/\u03bcl human genomic DNA", "TREATMENT", 722, 748], ["the PN panel", "TEST", 777, 789], ["the test", "TEST", 851, 859]]], ["Each bacterium was tested at six concentrations in 1-log intervals extending above and below the reportable range of the panel (<103.5 through \u2265107 copies/ml).", [["Each bacterium", "PROBLEM", 0, 14], ["the panel", "TEST", 117, 126]]], ["The reference or input concentration of bacterial genomic DNA (copies per milliliter) in each contrived sample was determined by digital PCR (dPCR).", [["sample", "ANATOMY", 104, 110], ["DNA", "CELLULAR_COMPONENT", 58, 61], ["bacterial genomic DNA", "DNA", 40, 61], ["bacterial genomic DNA", "PROBLEM", 40, 61], ["digital PCR", "TEST", 129, 140], ["bacterial genomic DNA", "OBSERVATION", 40, 61]]], ["The nucleic acid quantification method implemented mechanical and chemical lysis of each cultured bacterium (bead-beating on the Disruptor Genie [Scientific Industries] at approximately 3,000 rpm for 3 min and Magna Pure bacterial lysis/binding buffer) followed by total nucleic acid extraction and purification using the Roche Magna Pure LC 2.0 platform (Roche Diagnostics, Indianapolis, IN).", [["nucleic acid", "CHEMICAL", 4, 16], ["nucleic acid", "CHEMICAL", 271, 283], ["The nucleic acid quantification method", "TREATMENT", 0, 38], ["mechanical and chemical lysis", "TREATMENT", 51, 80], ["each cultured bacterium", "PROBLEM", 84, 107], ["Magna Pure bacterial lysis/binding buffer", "TREATMENT", 210, 251], ["total nucleic acid extraction", "TREATMENT", 265, 294], ["purification", "TREATMENT", 299, 311], ["chemical lysis", "OBSERVATION", 66, 80]]], ["Extracts were quantified by dPCR (QuantStudio 3D digital PCR system; Thermo Fisher Scientific, Waltham, MA) using single-copy target assays with sequence-specific fluorescent probes and QuantStudio 3D dPCR Master Mix, according to the QuantStudio user guide.", [["Extracts", "ANATOMY", 0, 8], ["Extracts", "ORGANISM_SUBSTANCE", 0, 8], ["dPCR", "TEST", 28, 32]]], ["The Thermo Fisher QuantStudio 3D Analysis suite was used to calculate the concentration (copies per milliliter) of the DNA in the culture based upon negative well fractions and the partition volume.Contrived polymicrobial clinical specimens. ::: MATERIALS AND METHODSIndividual prescreened and PN panel analyte-negative BAL and sputum specimens were multispiked with Acinetobacter baumannii, Enterobacter cloacae, and Escherichia coli or with Klebsiella oxytoca, Proteus mirabilis, and Serratia marcescens at various concentrations (104 copies/ml, 105.5 copies/ml, or 107 copies/ml) (Table 2).", [["specimens", "ANATOMY", 231, 240], ["BAL", "ANATOMY", 320, 323], ["sputum specimens", "ANATOMY", 328, 344], ["DNA", "CELLULAR_COMPONENT", 119, 122], ["BAL", "CELL", 320, 323], ["sputum specimens", "ORGANISM_SUBSTANCE", 328, 344], ["Acinetobacter baumannii", "ORGANISM", 367, 390], ["Enterobacter cloacae", "ORGANISM", 392, 412], ["Escherichia coli", "ORGANISM", 418, 434], ["Klebsiella oxytoca", "ORGANISM", 443, 461], ["Proteus mirabilis", "ORGANISM", 463, 480], ["Serratia marcescens", "ORGANISM", 486, 505], ["Acinetobacter baumannii", "SPECIES", 367, 390], ["Enterobacter cloacae", "SPECIES", 392, 412], ["Escherichia coli", "SPECIES", 418, 434], ["Klebsiella oxytoca", "SPECIES", 443, 461], ["Proteus mirabilis", "SPECIES", 463, 480], ["Serratia marcescens", "SPECIES", 486, 505], ["Acinetobacter baumannii", "SPECIES", 367, 390], ["Enterobacter cloacae", "SPECIES", 392, 412], ["Escherichia coli", "SPECIES", 418, 434], ["Klebsiella oxytoca", "SPECIES", 443, 461], ["Proteus mirabilis", "SPECIES", 463, 480], ["Serratia marcescens", "SPECIES", 486, 505], ["the DNA", "TEST", 115, 122], ["the culture", "TEST", 126, 137], ["the partition volume", "TEST", 177, 197], ["polymicrobial clinical specimens", "PROBLEM", 208, 240], ["PN panel", "TEST", 294, 302], ["analyte", "TEST", 303, 310], ["BAL", "TEST", 320, 323], ["sputum specimens", "TEST", 328, 344], ["Acinetobacter baumannii", "PROBLEM", 367, 390], ["Enterobacter cloacae", "PROBLEM", 392, 412], ["Escherichia coli", "PROBLEM", 418, 434], ["Klebsiella oxytoca", "PROBLEM", 443, 461], ["Proteus mirabilis", "PROBLEM", 463, 480], ["Serratia marcescens", "PROBLEM", 486, 505], ["polymicrobial", "OBSERVATION_MODIFIER", 208, 221], ["Escherichia coli", "OBSERVATION", 418, 434], ["Klebsiella oxytoca", "OBSERVATION", 443, 461], ["Proteus mirabilis", "OBSERVATION", 463, 480], ["Serratia marcescens", "OBSERVATION", 486, 505]]], ["Six different organism-concentration combinations were prepared in replicates of 10 for both sample types (120 contrived samples in total).Clinical specimens. ::: MATERIALS AND METHODSSputum specimens (including ETA) and BAL specimens (including mini-BAL specimens, which do not require bronchoscopy) were enrolled at eight geographically distinct U.S. sites (Medical College of Wisconsin, Milwaukee, WI; Children\u2019s Hospital of Los Angeles, Los Angeles, CA; The Ohio State University Wexner Medical Center, Columbus, OH; Nationwide Children\u2019s Hospital, Columbus, OH; Loyola University Medical Center, Maywood, IL; Indiana University School of Medicine, Indianapolis, IN; University of Nebraska Medical Center, Omaha, NE; and University of California Los Angeles Health, Los Angeles, CA) from October 2016 until July 2017.", [["sample", "ANATOMY", 93, 99], ["specimens", "ANATOMY", 148, 157], ["METHODSSputum specimens", "ANATOMY", 177, 200], ["BAL specimens", "ANATOMY", 221, 234], ["mini-BAL specimens", "ANATOMY", 246, 264], ["METHODSSputum specimens", "CANCER", 177, 200], ["BAL specimens", "CANCER", 221, 234], ["Children", "SPECIES", 532, 540], ["Six different organism", "PROBLEM", 0, 22], ["concentration combinations", "TREATMENT", 23, 49], ["Clinical specimens", "TEST", 139, 157], ["METHODSSputum specimens", "TEST", 177, 200], ["ETA", "TEST", 212, 215], ["BAL specimens", "TEST", 221, 234], ["mini-BAL specimens", "TEST", 246, 264], ["bronchoscopy", "TEST", 287, 299], ["different", "OBSERVATION_MODIFIER", 4, 13], ["organism", "OBSERVATION", 14, 22]]], ["Residual specimens from subjects of all ages that had been submitted to the laboratory for bacterial culture were enrolled if they met the following criteria: sufficient volume (at least 1.5 ml), no processing or pretreatment (i.e., \u201cnative\u201d specimens), and the ability to be enrolled within 24 h of collection.", [["specimens", "ANATOMY", 9, 18], ["specimens", "ANATOMY", 242, 251], ["specimens", "CANCER", 9, 18], ["Residual specimens", "PROBLEM", 0, 18], ["bacterial culture", "TEST", 91, 108], ["pretreatment", "TEST", 213, 225], ["collection", "PROBLEM", 300, 310]]], ["Sites followed their own procedures and criteria for determining whether specimens were of appropriate quality for culture workup; specimens that were rejected (and thus did not have an associated standard-of-care [SOC] culture result) were not eligible for enrollment in the study.", [["specimens", "ANATOMY", 73, 82], ["specimens", "ANATOMY", 131, 140], ["culture workup", "TEST", 115, 129], ["specimens", "TEST", 131, 140], ["SOC] culture result", "TEST", 215, 234], ["the study", "TEST", 272, 281]]], ["A waiver of the requirement for informed consent was obtained from the institutional review board (IRB) at each study site for the use of residual specimens and in order to collect subject information from the medical records.", [["specimens", "ANATOMY", 147, 156], ["residual specimens", "TEST", 138, 156]]], ["Clinical and demographic data were collected, including hospitalization status at the time of specimen collection, the results of the clinician-ordered SOC culture, subject sex, and subject age category.", [["specimen", "ANATOMY", 94, 102], ["Clinical and demographic data", "TEST", 0, 29], ["specimen collection", "TEST", 94, 113], ["SOC culture", "TEST", 152, 163]]], ["Sites were instructed to enroll specimens in the morning as the first study activity of the day so that all specimen aliquoting, shipping, freezing, and PN panel testing were performed in temporal proximity.", [["specimens", "ANATOMY", 32, 41], ["specimen", "ANATOMY", 108, 116], ["enroll specimens", "TEST", 25, 41], ["all specimen aliquoting", "TEST", 104, 127], ["PN panel testing", "TEST", 153, 169]]], ["Specimens were coded or pseudonymized by the study enroller, thoroughly mixed by vortexing, and then pipetted into various aliquots for testing.", [["Specimens", "ANATOMY", 0, 9], ["Specimens", "TEST", 0, 9], ["testing", "TEST", 136, 143]]], ["One aliquot was used for testing on-site with the PN panel.", [["One aliquot", "TREATMENT", 0, 11], ["testing", "TEST", 25, 32], ["the PN panel", "TEST", 46, 58]]], ["An additional aliquot was shipped overnight at refrigeration temperature to a central reference laboratory (MRIGlobal, Palm Bay, FL) for reference culture, and finally, several aliquots were immediately frozen for molecular comparator testing.PN panel testing. ::: MATERIALS AND METHODSThis study was conducted with an investigational-use-only (IUO) version of the PN panel that is identical to the commercial (i.e., FDA-cleared, CE-marked) in vitro diagnostic (IVD) version.", [["An additional aliquot", "TREATMENT", 0, 21], ["reference culture", "TEST", 137, 154], ["molecular comparator testing", "TEST", 214, 242], ["PN panel testing", "TEST", 243, 259], ["METHODSThis study", "TEST", 279, 296], ["the PN panel", "TEST", 361, 373], ["FDA", "TEST", 417, 420], ["CE", "TEST", 430, 432]]], ["All specimen handling occurred in a biosafety cabinet with operators wearing appropriate personal protective equipment, preparing one specimen at a time, and cleaning between specimens, all according to the manufacturer\u2019s instructions (11).", [["specimen", "ANATOMY", 4, 12], ["specimen", "ANATOMY", 134, 142], ["specimens", "ANATOMY", 175, 184], ["appropriate personal protective equipment", "TREATMENT", 77, 118]]], ["In contrast to other BioFire FilmArray test panels, which use a transfer pipette for specimen loading, specimens are introduced into the PN panel test with a provided flocked swab.", [["specimen", "ANATOMY", 85, 93], ["specimens", "ANATOMY", 103, 112], ["other BioFire FilmArray test panels", "TEST", 15, 50], ["a transfer pipette", "TREATMENT", 62, 80], ["the PN panel test", "TEST", 133, 150]]], ["This facilitates recovery of organisms from viscous lower respiratory tract specimens.", [["lower respiratory tract specimens", "ANATOMY", 52, 85], ["lower respiratory", "ORGANISM_SUBDIVISION", 52, 69], ["tract", "ORGANISM_SUBDIVISION", 70, 75], ["specimens", "ORGANISM_SUBSTANCE", 76, 85], ["organisms", "PROBLEM", 29, 38], ["viscous lower respiratory tract specimens", "PROBLEM", 44, 85], ["respiratory tract", "ANATOMY", 58, 75]]], ["Briefly, the native specimen was collected on the provided sample transfer swab (approximately 200 \u03bcl) and placed in sample buffer within the FilmArray injection vial (FAIV).", [["specimen", "ANATOMY", 20, 28], ["sample", "ANATOMY", 59, 65]]], ["The sample swab was broken off inside the FAIV at a prescored breakpoint.", [["sample swab", "ANATOMY", 4, 15], ["FAIV", "DNA", 42, 46], ["prescored breakpoint", "DNA", 52, 72], ["The sample swab", "TEST", 0, 15]]], ["After the lid was closed, the FAIV was gently inverted three times to facilitate organism release, and then the contents were injected into the PN panel pouch before testing with the FilmArray instrument.", [["FAIV", "DNA", 30, 34], ["the FAIV", "TREATMENT", 26, 34], ["organism release", "TREATMENT", 81, 97], ["the FilmArray instrument", "TEST", 179, 203], ["panel pouch", "OBSERVATION", 147, 158]]], ["The PN panel test consists of automated nucleic acid extraction, reverse transcription, nucleic acid amplification, and automated results analysis in approximately 75 min per run (i.e., per specimen).", [["specimen", "ANATOMY", 190, 198], ["nucleic acid", "CHEMICAL", 40, 52], ["nucleic acid", "CHEMICAL", 88, 100], ["The PN panel test", "TEST", 0, 17], ["automated nucleic acid extraction", "TREATMENT", 30, 63], ["nucleic acid amplification", "TEST", 88, 114]]], ["If either of two internal controls fails, the software automatically provides a result of \u201cinvalid\u201d for all panel analytes.", [["two internal controls fails", "PROBLEM", 13, 40], ["all panel analytes", "TEST", 104, 122]]], ["Viruses and atypical bacteria are reported qualitatively as \u201cdetected\u201d or \u201cnot detected\u201d (an \u201cequivocal\u201d result is also possible for MERS-CoV on the PNplus panel).", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 133, 141], ["MERS-CoV", "SPECIES", 133, 141], ["Viruses", "PROBLEM", 0, 7], ["atypical bacteria", "PROBLEM", 12, 29], ["MERS", "PROBLEM", 133, 137], ["the PNplus panel", "TEST", 145, 161], ["atypical", "OBSERVATION_MODIFIER", 12, 20], ["bacteria", "OBSERVATION", 21, 29]]], ["The AMR genes are also reported qualitatively (\u201cdetected\u201d or \u201cnot detected\u201d), but only if one or more applicable bacteria (i.e., potential carriers of the AMR gene) are also detected in the sample (Table 1, footnotes c and d); if no applicable bacteria are detected, the AMR gene results are reported as \u201cN/A\u201d (not applicable).", [["AMR", "GENE_OR_GENE_PRODUCT", 155, 158], ["AMR genes", "DNA", 4, 13], ["AMR gene", "DNA", 155, 163], ["AMR gene", "DNA", 271, 279], ["more applicable bacteria", "PROBLEM", 97, 121], ["the sample", "TEST", 186, 196], ["footnotes c and d)", "TEST", 207, 225], ["applicable bacteria", "PROBLEM", 233, 252], ["AMR genes", "OBSERVATION", 4, 13], ["bacteria", "OBSERVATION", 113, 121]]], ["For 15 bacterial targets, the BioFire PN panel calculates an approximate quantity of the gene target (i.e., bacterial DNA, in copies per milliliter) based on real-time amplification curves for the bacterial assays relative to a quantified internal reference standard manufactured into each PN panel test cartridge.", [["DNA", "CELLULAR_COMPONENT", 118, 121], ["gene target", "DNA", 89, 100], ["bacterial DNA", "DNA", 108, 121], ["15 bacterial targets", "PROBLEM", 4, 24], ["the BioFire PN panel", "TEST", 26, 46], ["bacterial DNA", "PROBLEM", 108, 121], ["the bacterial assays", "PROBLEM", 193, 213]]], ["The assays are designed to amplify genes that are present in single copies within the chromosome of the target bacterium and thus to estimate a concentration of targeted bacterial genome equivalents in the specimen.", [["chromosome", "ANATOMY", 86, 96], ["specimen", "ANATOMY", 206, 214], ["chromosome", "CELLULAR_COMPONENT", 86, 96], ["The assays", "TEST", 0, 10], ["targeted bacterial genome equivalents", "PROBLEM", 161, 198], ["bacterial genome equivalents", "OBSERVATION", 170, 198]]], ["The calculated value is rounded to the nearest 10n value and reported as a bin result (104, 105, 106, or \u2265107 genomic copies/ml).", [["The calculated value", "TEST", 0, 20], ["rounded", "OBSERVATION_MODIFIER", 24, 31]]], ["Assays with no measurable amplification or a calculated value below 103.5 (3,162) copies/ml are considered negative and reported as \u201cnot detected.\u201dComparator testing. ::: MATERIALS AND METHODS(i) Standard-of-care culture.", [["Assays", "TEST", 0, 6], ["measurable amplification", "PROBLEM", 15, 39], ["a calculated value", "TEST", 43, 61], ["copies/ml", "TEST", 82, 91], ["Comparator testing", "TEST", 147, 165], ["culture", "TEST", 213, 220]]], ["All eight study sites followed their own standard procedures to determine SOC culture results, independent of the study.", [["SOC culture", "TEST", 74, 85], ["the study", "TEST", 110, 119]]], ["While the methods for culture of lower respiratory tract specimens are relatively standardized, each site (and sometimes technicians within a site) had variation with respect to whether and how organisms were reported (12).", [["lower respiratory tract specimens", "ANATOMY", 33, 66], ["the methods", "TEST", 6, 17], ["culture", "TEST", 22, 29], ["lower respiratory tract specimens", "PROBLEM", 33, 66], ["lower", "ANATOMY_MODIFIER", 33, 38], ["respiratory tract", "ANATOMY", 39, 56]]], ["Results were obtained from chart review of subject medical information.Comparator testing. ::: MATERIALS AND METHODS(ii) Quantitative reference culture.", [["Comparator testing", "TEST", 71, 89], ["Quantitative reference culture", "TEST", 121, 151]]], ["A central reference laboratory (MRIGlobal, Palm Bay, FL) was used to perform quantitative reference culture (qRefCx).", [["quantitative reference culture", "TEST", 77, 107], ["central", "ANATOMY_MODIFIER", 2, 9]]], ["This approach was similar to the method that the study sites use for routine standard-of-care (SOC) culture; however, different sites\u2019 SOC protocols varied.", [["culture", "TEST", 100, 107], ["SOC protocols", "TREATMENT", 135, 148]]], ["The reference lab was used in order to standardize the plating protocol and results and, in particular, to ensure that quantitative results were obtained over the reportable range of the PN panel for both specimen types.", [["specimen", "ANATOMY", 205, 213], ["the plating protocol", "TEST", 51, 71], ["the PN panel", "TEST", 183, 195]]], ["Aliquots of enrolled specimens were shipped overnight at refrigeration temperature (on ice) to the central reference laboratory.", [["Aliquots", "ANATOMY", 0, 8], ["specimens", "ANATOMY", 21, 30], ["specimens", "CELL", 21, 30], ["enrolled specimens", "PROBLEM", 12, 30], ["central", "ANATOMY_MODIFIER", 99, 106]]], ["Specimens were excluded if they did not arrive at the reference lab with sufficient time to be processed for culture within one calendar day of enrollment or if they were no longer at refrigeration temperature upon arrival.", [["Specimens", "ANATOMY", 0, 9], ["Specimens", "TEST", 0, 9], ["culture", "TEST", 109, 116]]], ["BAL and sputum specimens were treated the same except that sputum specimens were pretreated with an equal volume of SnotBuster (Copan, Murrieta, CA) mucolytic reagent to reduce viscosity before plating.Comparator testing. ::: MATERIALS AND METHODSSpecimens were streaked onto four different media (blood agar, chocolate agar, MacConkey agar, and Columbia colistin-nalidixic acid [CNA] agar) at four different concentrations: 10 \u03bcl and 1 \u03bcl of both undiluted and 1:100-diluted specimen.", [["BAL", "ANATOMY", 0, 3], ["sputum specimens", "ANATOMY", 8, 24], ["sputum specimens", "ANATOMY", 59, 75], ["blood", "ANATOMY", 298, 303], ["specimen", "ANATOMY", 476, 484], ["colistin-nalidixic acid", "CHEMICAL", 355, 378], ["CNA", "CHEMICAL", 380, 383], ["nalidixic acid", "CHEMICAL", 364, 378], ["BAL", "ORGANISM_SUBSTANCE", 0, 3], ["sputum specimens", "CANCER", 8, 24], ["SnotBuster", "SIMPLE_CHEMICAL", 116, 126], ["blood", "ORGANISM_SUBSTANCE", 298, 303], ["colistin-nalidixic acid", "SIMPLE_CHEMICAL", 355, 378], ["BAL and sputum specimens", "TEST", 0, 24], ["sputum specimens", "TEST", 59, 75], ["SnotBuster (Copan", "TREATMENT", 116, 133], ["Murrieta", "TREATMENT", 135, 143], ["CA) mucolytic reagent", "TREATMENT", 145, 166], ["viscosity before plating", "TREATMENT", 177, 201], ["Comparator testing", "TEST", 202, 220], ["METHODSSpecimens", "TEST", 240, 256], ["Columbia colistin", "TREATMENT", 346, 363], ["nalidixic acid [CNA] agar", "TREATMENT", 364, 389]]], ["Plates were incubated at 35\u00b0C and inspected for growth at 24 and 48 h.", [["C", "GENE_OR_GENE_PRODUCT", 28, 29]]], ["Quantity was determined by counting colonies of each unique morphology on the plate type with the most robust growth of that morphology and at the dilution with 20 to 200 colonies of that morphology.", [["colonies", "ANATOMY", 36, 44], ["counting colonies", "OBSERVATION", 27, 44], ["unique", "OBSERVATION_MODIFIER", 53, 59], ["morphology", "OBSERVATION_MODIFIER", 60, 70], ["plate type", "OBSERVATION_MODIFIER", 78, 88], ["most robust", "OBSERVATION_MODIFIER", 98, 109], ["growth", "OBSERVATION_MODIFIER", 110, 116]]], ["If an organism was observed on multiple plates, the highest quantification value was used.", [["an organism", "PROBLEM", 3, 14], ["multiple plates", "TEST", 31, 46], ["the highest quantification value", "TEST", 48, 80]]], ["Identification was described first by colony morphology and then confirmed by Vitek 2 ID (bioM\u00e9rieux, Durham, NC) following isolation and subculturing.", [["colony", "ANATOMY", 38, 44], ["Vitek", "TEST", 78, 83], ["NC", "TREATMENT", 110, 112], ["isolation", "TREATMENT", 124, 133], ["subculturing", "PROBLEM", 138, 150]]], ["Vitek 2 was also used for phenotypic antimicrobial susceptibility testing (AST).", [["Vitek 2", "GENE_OR_GENE_PRODUCT", 0, 7], ["Vitek", "TEST", 0, 5], ["phenotypic antimicrobial susceptibility testing", "TEST", 26, 73], ["AST", "TEST", 75, 78]]], ["Glycerol stocks of relevant bacterial isolates were prepared for molecular AMR gene testing and discrepancy investigation.Comparator testing. ::: MATERIALS AND METHODS(iii) Real-time PCR and sequencing.", [["Glycerol", "CHEMICAL", 0, 8], ["Glycerol", "CHEMICAL", 0, 8], ["Glycerol", "SIMPLE_CHEMICAL", 0, 8], ["Glycerol stocks", "TREATMENT", 0, 15], ["relevant bacterial isolates", "PROBLEM", 19, 46], ["molecular AMR gene testing", "TEST", 65, 91], ["discrepancy investigation", "TEST", 96, 121], ["Comparator testing", "TEST", 122, 140], ["time PCR", "TEST", 178, 186], ["sequencing", "TEST", 191, 201], ["bacterial isolates", "OBSERVATION", 28, 46]]], ["Total nucleic acids were extracted from clinical specimens using a Magna Pure LC 2.0 instrument.", [["specimens", "ANATOMY", 49, 58], ["nucleic acids", "CHEMICAL", 6, 19], ["Total nucleic acids", "TEST", 0, 19], ["clinical specimens", "TEST", 40, 58], ["a Magna Pure LC", "TREATMENT", 65, 80], ["nucleic acids", "OBSERVATION", 6, 19]]], ["Atypical bacteria and viruses were tested with two well-validated nested PCR assays; AMR genes were tested with a single assay.", [["AMR genes", "DNA", 85, 94], ["Atypical bacteria", "PROBLEM", 0, 17], ["viruses", "PROBLEM", 22, 29], ["nested PCR assays", "TEST", 66, 83], ["a single assay", "TEST", 112, 126], ["bacteria", "OBSERVATION", 9, 17], ["viruses", "OBSERVATION", 22, 29]]], ["Whenever possible, the comparator PCR assays targeted different genes (or different regions of the same gene) than are targeted by the PN panel assays.", [["the comparator PCR assays", "TEST", 19, 44], ["the PN panel assays", "TEST", 131, 150]]], ["Assays were designed to generate amplicons that would provide sufficient sequence information for conclusive analyte identification (between 100 and 200 bp).", [["Assays", "TEST", 0, 6], ["conclusive analyte identification", "TEST", 98, 131]]], ["A sequence-confirmed positive result from either assay was considered positive for a given analyte.", [["A sequence", "TEST", 0, 10], ["assay", "TEST", 49, 54]]], ["Validation testing demonstrated that most assays (at least one or both per analyte in both BAL and sputum sample types) had a limit of detection (LoD) that was within at least 5-fold that of the PN panel, which was considered \u201cequivalent\u201d sensitivity.", [["BAL", "ANATOMY", 91, 94], ["sputum sample", "ANATOMY", 99, 112], ["Validation testing", "TEST", 0, 18], ["most assays", "PROBLEM", 37, 48], ["the PN panel", "TEST", 191, 203]]], ["All specimens were assumed to be negative for MERS-CoV, as it was not circulating in the United States during the time of enrollment for the study; no comparator testing was performed for this analyte.Comparator testing. ::: MATERIALS AND METHODSResults and discrepant analysis.", [["specimens", "ANATOMY", 4, 13], ["specimens", "CANCER", 4, 13], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 46, 54], ["MERS-CoV", "SPECIES", 46, 54], ["All specimens", "TEST", 0, 13], ["MERS", "PROBLEM", 46, 50], ["the study", "TEST", 137, 146], ["comparator testing", "TEST", 151, 169], ["this analyte", "TEST", 188, 200], ["Comparator testing", "TEST", 201, 219], ["METHODSResults", "TEST", 239, 253], ["discrepant analysis", "TEST", 258, 277]]], ["A PN panel result was considered a true positive (TP) or true negative (TN) when it agreed with the result from the comparator method.", [["TP", "GENE_OR_GENE_PRODUCT", 50, 52], ["TN", "PROTEIN", 72, 74], ["A PN panel", "TEST", 0, 10], ["a true positive (TP)", "PROBLEM", 33, 53], ["the comparator method", "TEST", 112, 133]]], ["Discrepant analysis was performed when results were discordant, i.e., false-positive (FP) or false-negative (FN) results.", [["FN", "PROTEIN", 109, 111], ["Discrepant analysis", "TEST", 0, 19], ["false", "TEST", 70, 75], ["FP", "TEST", 86, 88], ["false", "TEST", 93, 98]]], ["When sufficient specimen volume was available, discordant specimens were investigated using a combination of retesting with the PN panel or comparator methods as well as testing with additional, independent molecular assays.", [["specimen", "ANATOMY", 16, 24], ["specimens", "ANATOMY", 58, 67], ["specimen", "TISSUE", 16, 24], ["specimen volume", "TEST", 16, 31], ["discordant specimens", "PROBLEM", 47, 67], ["the PN panel", "TEST", 124, 136], ["comparator methods", "TEST", 140, 158], ["testing", "TEST", 170, 177]]], ["Note that the performance data for positive percent agreement (PPA) and negative percent agreement (NPA) presented in this paper consist of unresolved data as presented in the package insert for the commercial test; discrepancy investigation is provided but was not used to recalculate performance data.Statistical analysis. ::: MATERIALS AND METHODSThe exact binomial two-sided 95% confidence intervals (95% CI) were calculated for performance measures according to the Wilson score method (13).Linearity and accuracy of PN panel semiquantitative bin results for bacteria. ::: RESULTSEach PN panel bacterial assay was designed to be efficient and linear and to provide accurate bin results within \u00b10.5 log10 copies/ml of the input concentration over a reportable range of 104 to >107 copies/ml.", [["the commercial test", "TEST", 195, 214], ["discrepancy investigation", "TEST", 216, 241], ["Statistical analysis", "TEST", 303, 323], ["the Wilson score method", "TEST", 467, 490], ["PN panel", "TEST", 522, 530], ["bacteria", "PROBLEM", 564, 572], ["PN panel bacterial assay", "TEST", 590, 614]]], ["The linearity and accuracy of the assays were validated by testing a 1-log dilution series of contrived samples containing each bacterium detected by the panel.", [["samples", "ANATOMY", 104, 111], ["the assays", "TEST", 30, 40], ["contrived samples", "TREATMENT", 94, 111], ["each bacterium", "PROBLEM", 123, 137], ["the panel", "TEST", 150, 159], ["linearity", "OBSERVATION_MODIFIER", 4, 13]]], ["Results for Staphylococcus aureus and Klebsiella aerogenes are shown in Fig. 1 as representative of Gram-positive and Gram-negative organisms, respectively; additional data for all other bacteria can be found in the product instructions for use (11).", [["Staphylococcus aureus", "DISEASE", 12, 33], ["Staphylococcus aureus", "ORGANISM", 12, 33], ["Klebsiella aerogenes", "ORGANISM", 38, 58], ["Gram-positive", "GENE_OR_GENE_PRODUCT", 100, 113], ["Gram", "GENE_OR_GENE_PRODUCT", 118, 122], ["Staphylococcus aureus", "SPECIES", 12, 33], ["Klebsiella aerogenes", "SPECIES", 38, 58], ["Staphylococcus aureus", "SPECIES", 12, 33], ["Klebsiella aerogenes", "SPECIES", 38, 58], ["Staphylococcus aureus", "PROBLEM", 12, 33], ["Klebsiella aerogenes", "PROBLEM", 38, 58], ["Gram-positive and Gram-negative organisms", "PROBLEM", 100, 141], ["all other bacteria", "PROBLEM", 177, 195], ["Staphylococcus aureus", "OBSERVATION", 12, 33], ["Klebsiella aerogenes", "OBSERVATION", 38, 58], ["negative organisms", "OBSERVATION_MODIFIER", 123, 141]]], ["Each of the samples at six concentrations was tested repeatedly (90 pouches) and the bin results of the test (in copies per milliliter) were compared to the input concentration (also in copies per milliliter) of the sample.Linearity and accuracy of PN panel semiquantitative bin results for bacteria. ::: RESULTSContrived samples containing Staphylococcus aureus at input concentrations of 102, 103, 104, 105, 106, and 107 copies/ml (representing the \u201cmiddle\u201d of the bin) were tested with the PN panel, and S. aureus was detected in 99% (359/360) of all replicates with concentrations within the reportable range of 104 copies/ml and higher (Fig. 1a).", [["samples", "ANATOMY", 12, 19], ["samples", "ANATOMY", 322, 329], ["pouches", "ORGANISM_SUBDIVISION", 68, 75], ["Staphylococcus aureus", "ORGANISM", 341, 362], ["S. aureus", "ORGANISM", 507, 516], ["Staphylococcus aureus", "SPECIES", 341, 362], ["S. aureus", "SPECIES", 507, 516], ["Staphylococcus aureus", "SPECIES", 341, 362], ["S. aureus", "SPECIES", 507, 516], ["the test", "TEST", 100, 108], ["PN panel", "TEST", 249, 257], ["bacteria", "PROBLEM", 291, 299], ["RESULTSContrived samples", "TEST", 305, 329], ["Staphylococcus aureus", "PROBLEM", 341, 362], ["input concentrations", "TEST", 366, 386], ["the PN panel", "TEST", 489, 501], ["S. aureus", "TEST", 507, 516], ["Staphylococcus aureus", "OBSERVATION", 341, 362], ["aureus", "OBSERVATION", 510, 516]]], ["Over the dilution series, the semiquantitative bin result changed linearly, in direct proportion to the change in sample input concentration (e.g., an increase in concentration of 1 log10 copies/ml generated a change in bin result equivalent to 1 log10 copies/ml).", [["sample", "ANATOMY", 114, 120], ["the dilution series", "TEST", 5, 24], ["linearly", "OBSERVATION_MODIFIER", 66, 74], ["change", "OBSERVATION_MODIFIER", 104, 110], ["increase", "OBSERVATION_MODIFIER", 151, 159]]], ["In addition, the semiquantitative bin result reflected the sample input concentration within the stated \u00b10.5-log10-copies/ml accuracy of the panel.", [["the panel", "TEST", 137, 146]]], ["For example, the sample input concentration of 105 copies/ml has an expected accuracy range of 104.5 to 105.5, and an accurate bin result of 105 copies/ml was reported by the PN panel for 100% of the sample replicates tested.Linearity and accuracy of PN panel semiquantitative bin results for bacteria. ::: RESULTSContrived samples containing K. aerogenes were tested at input concentrations of 102.5, 103.5, 104.5, 105.5, 106.5, and 107.5 copies/ml (representing the \u201cedge\u201d of the bin), and K. aerogenes was detected in 87% (392/450) of all replicates at a concentration of 103.5 copies/ml and higher (Fig. 1b).", [["samples", "ANATOMY", 324, 331], ["K. aerogenes", "ORGANISM", 343, 355], ["K. aerogenes", "ORGANISM", 492, 504], ["K. aerogenes", "SPECIES", 343, 355], ["K. aerogenes", "SPECIES", 492, 504], ["K. aerogenes", "SPECIES", 343, 355], ["K. aerogenes", "SPECIES", 492, 504], ["the PN panel", "TEST", 171, 183], ["the sample", "TEST", 196, 206], ["PN panel", "TEST", 251, 259], ["bacteria", "PROBLEM", 293, 301], ["K. aerogenes", "TEST", 343, 355], ["concentrations", "TEST", 377, 391], ["K. aerogenes", "TEST", 492, 504], ["a concentration", "TEST", 556, 571]]], ["The semiquantitative bin result changed linearly, in direct proportion to the change in sample concentration, though at each concentration except the highest two bins, results were reported in variable proportions over the 90 replicates.", [["sample", "ANATOMY", 88, 94], ["changed", "OBSERVATION_MODIFIER", 32, 39], ["linearly", "OBSERVATION_MODIFIER", 40, 48]]], ["For example, the sample input concentration of 105.5 copies/ml has an accuracy range of 105.0 to 106.0 copies/ml (spanning two bins).", [["the sample input concentration", "TEST", 13, 43]]], ["The PN panel provided an accurate bin result of 105 copies/ml in 42.2% of the replicates tested at this concentration with an equally accurate bin result of 106 copies/ml for the remaining 57.8% of the sample replicates tested.Semiquantification in contrived polymicrobial specimens. ::: RESULTSThe organisms are reported at a semiquantitative level, and thus, the accuracy of the expected relative rank order among contrived polymicrobial specimens (low, medium, and high) was tested.", [["specimens", "ANATOMY", 273, 282], ["specimens", "ANATOMY", 440, 449], ["polymicrobial", "DISEASE", 426, 439], ["The PN panel", "TEST", 0, 12], ["the sample", "TEST", 198, 208], ["Semiquantification in contrived polymicrobial specimens", "PROBLEM", 227, 282], ["polymicrobial specimens", "TEST", 426, 449], ["polymicrobial specimens", "OBSERVATION", 259, 282]]], ["In 60 (100%) contrived sputum specimens and in 55 of 60 (91.6%) BAL specimens (Table 2), the correct relative rank was observed.", [["sputum specimens", "ANATOMY", 23, 39], ["BAL specimens", "ANATOMY", 64, 77], ["sputum specimens", "CANCER", 23, 39], ["BAL specimens", "CANCER", 64, 77], ["sputum specimens", "TEST", 23, 39], ["BAL specimens", "TEST", 64, 77]]], ["Four specimens in BAL sample set 1 that were spiked with E. cloacae at a medium level of 105.5 genomic copies/ml were reported by the PN panel as \u201cdetected\u201d at \u2265107 (high) instead of the expected level of 106.", [["specimens", "ANATOMY", 5, 14], ["BAL sample", "ANATOMY", 18, 28], ["E. cloacae", "ORGANISM", 57, 67], ["E. cloacae", "SPECIES", 57, 67], ["E. cloacae", "SPECIES", 57, 67], ["Four specimens in BAL sample set", "TEST", 0, 32], ["E. cloacae", "PROBLEM", 57, 67], ["a medium level", "TEST", 71, 85], ["the PN panel", "TEST", 130, 142], ["BAL", "ANATOMY", 18, 21]]], ["All other organisms in these four samples were reported at the correct level, and this organism was reported at the correct level in all 10 specimens of the corresponding sputum sample set, set 1.", [["samples", "ANATOMY", 34, 41], ["specimens", "ANATOMY", 140, 149], ["sputum sample", "ANATOMY", 171, 184], ["samples", "CANCER", 34, 41], ["All other organisms", "TEST", 0, 19], ["this organism", "PROBLEM", 82, 95], ["the corresponding sputum sample set", "TEST", 153, 188]]], ["One additional specimen in BAL sample set 6 that was spiked with P. mirabilis at 107 genomic copies/ml was unexpectedly negative, but the other two organisms in the specimen were reported correctly.", [["specimen", "ANATOMY", 15, 23], ["BAL sample", "ANATOMY", 27, 37], ["specimen", "ANATOMY", 165, 173], ["BAL", "ORGANISM_SUBSTANCE", 27, 30], ["P. mirabilis", "ORGANISM", 65, 77], ["P. mirabilis", "SPECIES", 65, 77], ["P. mirabilis", "SPECIES", 65, 77], ["One additional specimen in BAL sample set", "TEST", 0, 41], ["P. mirabilis", "PROBLEM", 65, 77], ["genomic copies/ml", "TEST", 85, 102], ["the other two organisms in the specimen", "PROBLEM", 134, 173]]], ["All other results for P. mirabilis in all other samples were reported correctly.Clinical demographics. ::: RESULTSA total of 904 BAL specimens (821 BAL and 83 mini-BAL specimens) and 925 sputum specimens (478 sputum specimens and 447 ETA) were collected for the prospective clinical study from eight U.S. clinical sites.", [["samples", "ANATOMY", 48, 55], ["BAL specimens", "ANATOMY", 129, 142], ["BAL", "ANATOMY", 148, 151], ["mini-BAL specimens", "ANATOMY", 159, 177], ["sputum specimens", "ANATOMY", 187, 203], ["sputum specimens", "ANATOMY", 209, 225], ["P. mirabilis", "ORGANISM", 22, 34], ["samples", "CANCER", 48, 55], ["BAL specimens", "CANCER", 129, 142], ["BAL", "CANCER", 148, 151], ["BAL specimens", "CANCER", 164, 177], ["sputum specimens", "CANCER", 187, 203], ["P. mirabilis", "SPECIES", 22, 34], ["P. mirabilis", "SPECIES", 22, 34], ["P. mirabilis", "PROBLEM", 22, 34], ["all other samples", "TEST", 38, 55], ["BAL specimens", "TEST", 129, 142], ["BAL", "TEST", 148, 151], ["mini-BAL specimens", "TEST", 159, 177], ["sputum specimens", "TEST", 187, 203], ["sputum specimens", "TEST", 209, 225], ["ETA", "TEST", 234, 237], ["the prospective clinical study", "TEST", 258, 288]]], ["Fifty-eight BAL and 89 sputum specimens were excluded after enrollment.", [["BAL", "ANATOMY", 12, 15], ["sputum specimens", "ANATOMY", 23, 39], ["BAL", "CANCER", 12, 15], ["sputum specimens", "CANCER", 23, 39], ["eight BAL", "TEST", 6, 15], ["sputum specimens", "TEST", 23, 39]]], ["The most common reasons for specimen exclusion was that reference culture could not be performed within the required time frame (as described in Materials and Methods).", [["specimen", "ANATOMY", 28, 36], ["specimen exclusion", "TEST", 28, 46], ["reference culture", "TEST", 56, 73]]], ["Sex, age, and patient care setting (hospitalized, outpatient, or emergency department [ED]) were recorded for all subjects from whom specimens were enrolled.", [["specimens", "ANATOMY", 133, 142], ["patient", "ORGANISM", 14, 21], ["patient", "SPECIES", 14, 21]]], ["The clinical demographics associated with the 1,682 valid enrolled specimens are presented in Table 3.", [["specimens", "ANATOMY", 67, 76], ["specimens", "CANCER", 67, 76]]], ["There were slightly more specimens collected from male subjects (480 BAL [57%] and 481 sputum [58%] specimens) than from female subjects (366 BAL [43%] and 355 sputum [42%] specimens).", [["specimens", "ANATOMY", 25, 34], ["sputum", "ANATOMY", 87, 93], ["specimens", "ANATOMY", 100, 109], ["sputum", "ANATOMY", 160, 166], ["specimens", "ANATOMY", 173, 182], ["specimens", "CANCER", 100, 109], ["specimens", "CANCER", 173, 182], ["slightly more specimens", "PROBLEM", 11, 34], ["BAL", "TEST", 69, 72], ["sputum", "TEST", 87, 93], ["specimens", "TEST", 100, 109], ["BAL", "TEST", 142, 145], ["sputum", "TEST", 160, 166], ["specimens", "TEST", 173, 182], ["slightly", "OBSERVATION_MODIFIER", 11, 19]]], ["The age distribution of subjects with enrolled specimens included pediatric patients less than 18 years of age (50 BAL [6%] and 245 sputum [29%] specimens), adults between 18 and 65 years of age (540 BAL [64%] and 370 sputum [44%] specimens), and adults older than 65 years of age (255 BAL [30%] and 221 sputum [26%] specimens).", [["specimens", "ANATOMY", 47, 56], ["BAL", "ANATOMY", 115, 118], ["sputum", "ANATOMY", 132, 138], ["specimens", "ANATOMY", 145, 154], ["BAL", "ANATOMY", 200, 203], ["sputum", "ANATOMY", 218, 224], ["specimens", "ANATOMY", 231, 240], ["BAL", "ANATOMY", 286, 289], ["sputum", "ANATOMY", 304, 310], ["specimens", "ANATOMY", 317, 326], ["patients", "ORGANISM", 76, 84], ["specimens", "CANCER", 145, 154], ["specimens", "CANCER", 231, 240], ["specimens", "CANCER", 317, 326], ["patients", "SPECIES", 76, 84], ["BAL", "TEST", 115, 118], ["sputum", "TEST", 132, 138], ["specimens", "TEST", 145, 154], ["BAL", "TEST", 200, 203], ["sputum", "TEST", 218, 224], ["specimens", "TEST", 231, 240], ["BAL", "TEST", 286, 289], ["sputum", "TEST", 304, 310], ["specimens", "TEST", 317, 326]]], ["The subject\u2019s age could not be determined for one BAL specimen enrolled.", [["BAL specimen", "ANATOMY", 50, 62], ["one BAL specimen", "TEST", 46, 62]]], ["The majority of specimens (80%) were collected from hospitalized subjects (666/846 [79%] BAL and 682/836 [82%] sputum specimens), with outpatient and ED collections accounting for 19% of BAL specimens (159/845 outpatient [19%] and 21/845 ED [2.5%] specimens) and 18% of sputum specimens (73/836 outpatient [8.5%] and 81/836 ED [10%] specimens).Test performance and summary of the PN panel. ::: RESULTSIn the prospective clinical evaluation, a total of 1,796 of 1,798 PN panel test runs (889 BAL and 909 sputum specimens) were completed on the first attempt, for an overall instrument success rate of 99.9%.", [["specimens", "ANATOMY", 16, 25], ["BAL", "ANATOMY", 89, 92], ["sputum specimens", "ANATOMY", 111, 127], ["BAL specimens", "ANATOMY", 187, 200], ["specimens", "ANATOMY", 248, 257], ["sputum specimens", "ANATOMY", 270, 286], ["specimens", "ANATOMY", 333, 342], ["BAL", "ANATOMY", 491, 494], ["sputum specimens", "ANATOMY", 503, 519], ["specimens", "CANCER", 16, 25], ["BAL specimens", "CANCER", 187, 200], ["sputum specimens", "CANCER", 270, 286], ["specimens", "TEST", 16, 25], ["BAL", "TEST", 89, 92], ["sputum specimens", "TEST", 111, 127], ["ED collections", "TEST", 150, 164], ["BAL specimens", "TEST", 187, 200], ["specimens", "TEST", 248, 257], ["sputum specimens", "TEST", 270, 286], ["specimens", "TEST", 333, 342], ["Test performance", "TEST", 344, 360], ["the PN panel", "TEST", 376, 388], ["the prospective clinical evaluation", "TEST", 404, 439], ["PN panel test runs", "TEST", 467, 485], ["BAL", "TEST", 491, 494], ["sputum specimens", "TEST", 503, 519], ["an overall instrument success rate", "TEST", 562, 596]]], ["Of the 1,796 completed runs, 1,764 (98.2%) produced a valid result (i.e., successful pouch controls).", [["pouch", "ANATOMY", 85, 90], ["a valid result", "TEST", 52, 66], ["successful pouch controls", "TREATMENT", 74, 99]]], ["Twenty-eight of the 32 specimens with control failures had sufficient volume for retesting and were able to be retested within study-defined time interval (without specimen dilution or manipulation); 25 produced a valid result on the single retest.", [["specimens", "ANATOMY", 23, 32], ["specimens", "CANCER", 23, 32], ["control failures", "PROBLEM", 38, 54], ["specimen dilution", "TEST", 164, 181]]], ["The pouch controls failed a second time for the remaining three specimens, and there was no further specimen volume for testing.Test performance and summary of the PN panel. ::: RESULTSOf the valid runs, the PN panel detected at least one analyte in 413 of 846 BAL specimens and in 602 of 836 sputum specimens for an overall positivity rate of 48.8 and 72.0%, respectively (Table 4).", [["pouch", "ANATOMY", 4, 9], ["specimens", "ANATOMY", 64, 73], ["specimen", "ANATOMY", 100, 108], ["BAL specimens", "ANATOMY", 261, 274], ["sputum specimens", "ANATOMY", 293, 309], ["BAL specimens", "CANCER", 261, 274], ["the remaining three specimens", "TEST", 44, 73], ["further specimen volume", "TEST", 92, 115], ["testing", "TEST", 120, 127], ["Test performance", "TEST", 128, 144], ["the PN panel", "TEST", 160, 172], ["the PN panel", "TEST", 204, 216], ["BAL specimens", "TEST", 261, 274], ["sputum specimens", "TEST", 293, 309], ["an overall positivity rate", "TEST", 314, 340], ["pouch", "ANATOMY", 4, 9]]], ["Codetections were observed in 37.8% (156/413) of BAL specimens and 56.5% (340/836) of sputum specimens.", [["BAL specimens", "ANATOMY", 49, 62], ["sputum specimens", "ANATOMY", 86, 102], ["BAL specimens", "CANCER", 49, 62], ["sputum specimens", "CANCER", 86, 102], ["Codetections", "TEST", 0, 12], ["BAL specimens", "TEST", 49, 62], ["sputum specimens", "TEST", 86, 102]]], ["The most commonly detected analytes were Staphylococcus aureus, Pseudomonas aeruginosa, Haemophilus influenzae, and human rhinovirus/enterovirus (HRV/EV), which were found in 320 (19%), 234 (13.9%), 189 (11.2%), and 176 (10.5%) specimens, respectively.", [["specimens", "ANATOMY", 228, 237], ["Staphylococcus aureus", "DISEASE", 41, 62], ["Haemophilus influenzae", "DISEASE", 88, 110], ["Staphylococcus aureus", "ORGANISM", 41, 62], ["Pseudomonas aeruginosa", "ORGANISM", 64, 86], ["Haemophilus influenzae", "ORGANISM", 88, 110], ["human", "ORGANISM", 116, 121], ["rhinovirus/enterovirus", "ORGANISM", 122, 144], ["HRV/EV", "ORGANISM", 146, 152], ["Staphylococcus aureus", "SPECIES", 41, 62], ["Pseudomonas aeruginosa", "SPECIES", 64, 86], ["Haemophilus influenzae", "SPECIES", 88, 110], ["human", "SPECIES", 116, 121], ["rhinovirus", "SPECIES", 122, 132], ["Staphylococcus aureus", "SPECIES", 41, 62], ["Pseudomonas aeruginosa", "SPECIES", 64, 86], ["Haemophilus influenzae", "SPECIES", 88, 110], ["human rhinovirus/enterovirus (HRV/EV)", "SPECIES", 116, 153], ["Staphylococcus aureus", "PROBLEM", 41, 62], ["Pseudomonas aeruginosa", "PROBLEM", 64, 86], ["Haemophilus influenzae", "PROBLEM", 88, 110], ["human rhinovirus", "PROBLEM", 116, 132], ["enterovirus", "PROBLEM", 133, 144], ["HRV/EV)", "TEST", 146, 153], ["specimens", "TEST", 228, 237]]], ["All other analytes were detected in fewer than 105 (6.2%) specimens.", [["specimens", "ANATOMY", 58, 67], ["All other analytes", "TEST", 0, 18]]], ["The overall prevalence of each analyte stratified by collection location is shown in Table 5.Qualitative analysis of typical bacteria. ::: RESULTSThe performance characteristics of the PN panel for semiquantifiable bacterial targets compared to the reference method of qRefCx performed at the central lab are presented in Table 6.", [["qRefCx", "DNA", 269, 275], ["Qualitative analysis", "TEST", 93, 113], ["typical bacteria", "PROBLEM", 117, 133], ["the PN panel", "TEST", 181, 193], ["semiquantifiable bacterial targets", "PROBLEM", 198, 232], ["typical", "OBSERVATION_MODIFIER", 117, 124], ["bacteria", "OBSERVATION", 125, 133]]], ["A specimen was considered positive for a particular organism by qRefCx when it was recovered and enumerated at a level greater than 3,162 (103.5) CFU/ml approximated using dilution plating, which is equal to or greater than the PN panel reporting threshold of 103.5 genomic copies/ml.", [["specimen", "ANATOMY", 2, 10], ["specimen", "CANCER", 2, 10], ["qRefCx", "SIMPLE_CHEMICAL", 64, 70], ["A specimen", "TEST", 0, 10], ["a particular organism", "PROBLEM", 39, 60], ["dilution plating", "TREATMENT", 172, 188], ["the PN panel", "TEST", 224, 236]]], ["The overall sensitivity for sputum samples ranged from 75% to 100%, and that for BAL specimens ranged from 85.7% to 100%.", [["sputum samples", "ANATOMY", 28, 42], ["BAL specimens", "ANATOMY", 81, 94], ["The overall sensitivity", "TEST", 0, 23], ["sputum samples", "TEST", 28, 42], ["BAL specimens", "TEST", 81, 94]]], ["Sensitivity for A. calcoaceticus-A. baumannii, Moraxella catarrhalis, and Streptococcus agalactiae could not be calculated for BAL specimens due to limited detections by the qRefCx comparator method.", [["BAL specimens", "ANATOMY", 127, 140], ["A. calcoaceticus-A. baumannii", "ORGANISM", 16, 45], ["Moraxella catarrhalis", "ORGANISM", 47, 68], ["Streptococcus agalactiae", "ORGANISM", 74, 98], ["A. calcoaceticus", "SPECIES", 16, 32], ["A. baumannii", "SPECIES", 33, 45], ["Moraxella catarrhalis", "SPECIES", 47, 68], ["Streptococcus agalactiae", "SPECIES", 74, 98], ["A. calcoaceticus", "SPECIES", 16, 32], ["A. baumannii", "SPECIES", 33, 45], ["Moraxella catarrhalis", "SPECIES", 47, 68], ["Streptococcus agalactiae", "SPECIES", 74, 98], ["Sensitivity", "TEST", 0, 11], ["A. calcoaceticus", "TEST", 16, 32], ["baumannii", "PROBLEM", 36, 45], ["Moraxella catarrhalis", "PROBLEM", 47, 68], ["Streptococcus agalactiae", "PROBLEM", 74, 98], ["BAL specimens", "TEST", 127, 140]]], ["Specificity for all analytes in both specimen types ranged from 88.9% to 99.5%.Qualitative analysis of typical bacteria. ::: RESULTSCompared to a quantitative reference culture, false-negative results were uncommon, with no more than 3 observed for any organism and 16 total among the 1,682 specimens tested.", [["specimen", "ANATOMY", 37, 45], ["specimens", "ANATOMY", 291, 300], ["specimens", "CANCER", 291, 300], ["Specificity", "TEST", 0, 11], ["all analytes", "TEST", 16, 28], ["specimen types", "TEST", 37, 51], ["Qualitative analysis", "TEST", 79, 99], ["typical bacteria", "PROBLEM", 103, 119], ["a quantitative reference culture", "TEST", 144, 176], ["any organism", "PROBLEM", 249, 261], ["typical", "OBSERVATION_MODIFIER", 103, 110], ["bacteria", "OBSERVATION", 111, 119]]], ["Comparatively, false-positive results were relatively common in both specimen types.", [["specimen", "ANATOMY", 69, 77]]], ["The highest rates of false-positive detections were seen for the organisms most frequently detected: 163 total for both S. aureus and H. influenzae, 99 for M. catarrhalis, and 95 for P. aeruginosa.Qualitative analysis of typical bacteria. ::: RESULTSDiscrepancies between positive detection by PN panel and negative qRefCx culture report were evaluated by first determining if the organism was reported as negative because it was enumerated below the threshold of <103.5 (3,162) CFU/ml set for culture.", [["S. aureus", "ORGANISM", 120, 129], ["H. influenzae", "ORGANISM", 134, 147], ["M. catarrhalis", "ORGANISM", 156, 170], ["P. aeruginosa", "ORGANISM", 183, 196], ["S. aureus", "SPECIES", 120, 129], ["H. influenzae", "SPECIES", 134, 147], ["M. catarrhalis", "SPECIES", 156, 170], ["P. aeruginosa", "SPECIES", 183, 196], ["S. aureus", "SPECIES", 120, 129], ["H. influenzae", "SPECIES", 134, 147], ["M. catarrhalis", "SPECIES", 156, 170], ["P. aeruginosa", "SPECIES", 183, 196], ["false-positive detections", "PROBLEM", 21, 46], ["the organisms", "PROBLEM", 61, 74], ["both S. aureus", "PROBLEM", 115, 129], ["H. influenzae", "TEST", 134, 147], ["M. catarrhalis", "PROBLEM", 156, 170], ["P. aeruginosa", "PROBLEM", 183, 196], ["Qualitative analysis", "TEST", 197, 217], ["typical bacteria", "PROBLEM", 221, 237], ["PN panel", "TEST", 294, 302], ["the organism", "TEST", 377, 389], ["CFU/ml", "TEST", 479, 485], ["culture", "TEST", 494, 501], ["aureus", "OBSERVATION", 123, 129], ["typical", "OBSERVATION_MODIFIER", 221, 228], ["bacteria", "OBSERVATION", 229, 237]]], ["If discrepancies remained unresolved, the results of an independent molecular assay were considered.", [["discrepancies", "PROBLEM", 3, 16], ["an independent molecular assay", "TEST", 53, 83]]], ["Finally, if discrepancies remained, the results from SOC testing at the individual sites were considered.", [["discrepancies", "PROBLEM", 12, 25], ["SOC testing", "TEST", 53, 64]]], ["Results of discrepancy analysis are shown in Table 7.", [["discrepancy analysis", "TEST", 11, 31]]], ["A total of 875 discrepant false-positive results were observed between the PN panel and comparator qRefCx.", [["the PN panel", "TEST", 71, 83]]], ["A quarter (25.1%; 220/875) of the discrepancies between the PN panel and qRefCx were resolved as the organism being present but enumerated below the reference culture cutoff of 103.5 CFU/ml.", [["qRefCx", "GENE_OR_GENE_PRODUCT", 73, 79], ["the PN panel", "TEST", 56, 68], ["qRefCx", "TEST", 73, 79], ["the organism", "PROBLEM", 97, 109], ["the reference culture cutoff", "TEST", 145, 173], ["PN panel", "OBSERVATION", 60, 68]]], ["An additional 74.5% (652/875) were resolved using the results of an alternative molecular method or by evaluating the results of SOC culture.", [["SOC culture", "TEST", 129, 140]]], ["Among 16 specimens with false-negative results, evidence of the target organism was found in 10 specimens by molecular testing (9 specimens) or SOC culture (1 specimen); the false-negative results were attributed to low levels of organism in the specimen, i.e., at or below the PN panel reporting cutoff.", [["specimens", "ANATOMY", 9, 18], ["specimens", "ANATOMY", 96, 105], ["specimens", "ANATOMY", 130, 139], ["specimen", "ANATOMY", 159, 167], ["specimen", "ANATOMY", 246, 254], ["specimens", "CANCER", 9, 18], ["the target organism", "PROBLEM", 60, 79], ["molecular testing", "TEST", 109, 126], ["SOC culture", "TEST", 144, 155], ["the false", "TEST", 170, 179], ["low levels of organism in the specimen", "PROBLEM", 216, 254], ["cutoff", "TEST", 297, 303]]], ["Sequencing of bacterial isolates recovered from five remaining false-negative specimens indicated misidentification by the reference lab performing qRefCx (one A. baumannii isolate sequenced as Pseudomonas fluorescens, one H. influenzae isolate sequenced as Haemophilus haemolyticus, one K. aerogenes isolate sequenced as Hafnia paralvei, and two P. aeruginosa isolates sequenced as Pseudomonas denitrificans and Pseudomonas fluorescens).", [["specimens", "ANATOMY", 78, 87], ["Haemophilus haemolyticus", "DISEASE", 258, 282], ["qRefCx", "GENE_OR_GENE_PRODUCT", 148, 154], ["A. baumannii", "ORGANISM", 160, 172], ["Pseudomonas fluorescens", "ORGANISM", 194, 217], ["H. influenzae", "ORGANISM", 223, 236], ["Haemophilus haemolyticus", "ORGANISM", 258, 282], ["K. aerogenes", "ORGANISM", 288, 300], ["Hafnia paralvei", "ORGANISM", 322, 337], ["P. aeruginosa", "ORGANISM", 347, 360], ["Pseudomonas denitrificans", "ORGANISM", 383, 408], ["Pseudomonas fluorescens", "ORGANISM", 413, 436], ["A. baumannii", "SPECIES", 160, 172], ["Pseudomonas fluorescens", "SPECIES", 194, 217], ["H. influenzae", "SPECIES", 223, 236], ["Haemophilus haemolyticus", "SPECIES", 258, 282], ["K. aerogenes", "SPECIES", 288, 300], ["Hafnia paralvei", "SPECIES", 322, 337], ["P. aeruginosa", "SPECIES", 347, 360], ["Pseudomonas denitrificans", "SPECIES", 383, 408], ["Pseudomonas fluorescens", "SPECIES", 413, 436], ["A. baumannii", "SPECIES", 160, 172], ["Pseudomonas fluorescens", "SPECIES", 194, 217], ["H. influenzae", "SPECIES", 223, 236], ["Haemophilus haemolyticus", "SPECIES", 258, 282], ["K. aerogenes", "SPECIES", 288, 300], ["Hafnia paralvei", "SPECIES", 322, 337], ["P. aeruginosa", "SPECIES", 347, 360], ["Pseudomonas denitrificans", "SPECIES", 383, 408], ["Pseudomonas fluorescens", "SPECIES", 413, 436], ["bacterial isolates", "TEST", 14, 32], ["A. baumannii isolate", "TREATMENT", 160, 180], ["Pseudomonas fluorescens", "PROBLEM", 194, 217], ["H. influenzae isolate", "TEST", 223, 244], ["Haemophilus haemolyticus", "PROBLEM", 258, 282], ["aerogenes isolate", "TREATMENT", 291, 308], ["Hafnia paralvei", "PROBLEM", 322, 337], ["two P. aeruginosa isolates", "TREATMENT", 343, 369], ["Pseudomonas denitrificans and Pseudomonas fluorescens", "PROBLEM", 383, 436], ["bacterial isolates", "OBSERVATION", 14, 32]]], ["Investigation of the final false-negative K. pneumoniae result uncovered evidence of a specimen swap or paperwork error.", [["specimen", "ANATOMY", 87, 95], ["K. pneumoniae", "ORGANISM", 42, 55], ["K. pneumoniae", "SPECIES", 42, 55], ["K. pneumoniae", "SPECIES", 42, 55], ["pneumoniae", "PROBLEM", 45, 55], ["a specimen swap", "TEST", 85, 100]]], ["Following discrepancy testing and analysis, only three false positives remained unresolved.", [["discrepancy testing", "TEST", 10, 29], ["analysis", "TEST", 34, 42]]], ["No evidence of nonspecific amplification was observed for the PN panel.Qualitative analysis of typical bacteria. ::: RESULTSAn additional qualitative analysis of the PN panel semiquantitative results for bacteria was performed by comparing them to SOC culture results (Table 6).", [["nonspecific amplification", "PROBLEM", 15, 40], ["the PN panel", "TEST", 58, 70], ["Qualitative analysis", "TEST", 71, 91], ["typical bacteria", "PROBLEM", 95, 111], ["the PN panel", "TEST", 162, 174], ["bacteria", "PROBLEM", 204, 212], ["SOC culture", "TEST", 248, 259], ["evidence of", "UNCERTAINTY", 3, 14], ["nonspecific", "OBSERVATION_MODIFIER", 15, 26], ["amplification", "OBSERVATION", 27, 40], ["typical", "OBSERVATION_MODIFIER", 95, 102], ["bacteria", "OBSERVATION", 103, 111]]], ["In this analysis, an organism was considered positive by SOC if a result for the particular bacterial analyte was entered in the subject\u2019s medical record, regardless of any quantity information that may have been indicated.", [["this analysis", "TEST", 3, 16], ["an organism", "TEST", 18, 29], ["the particular bacterial analyte", "PROBLEM", 77, 109]]], ["While specificity by this method is similar to that of the qRefCx culture method, sensitivity is lower for some analytes.", [["the qRefCx culture method", "TEST", 55, 80], ["sensitivity", "TEST", 82, 93]]], ["This was attributed to the fact that the analysis considered an analyte positive by SOC if it was reported at any level.", [["the analysis", "TEST", 37, 49]]], ["While some organisms were reported in subject medical records with a numerical quantity, most were reported with qualitative descriptions such as \u201cfew,\u201d \u201cmost abundant,\u201d \u201c2+,\u201d etc., and therefore, this information could not uniformly be converted to a numeric value equivalent to the PN panel reporting threshold.", [["the PN panel", "TEST", 280, 292]]], ["An investigation of 59 PN panel false-negative results relative to SOC revealed that the majority (34; 57.6%) had been reported as being present at a low level (i.e., \u201cfew\u201d) and may have been present below the PN panel cutoff.", [["An investigation", "TEST", 0, 16], ["PN panel false", "TEST", 23, 37], ["SOC", "TEST", 67, 70]]], ["Thirteen (22%) were reported at higher levels, and 12 (20.3%) could not be categorized because the reported quantities were described in relative terms (e.g., \u201clisted first\u201d or \u201cleast of three\u201d).Quantitative analysis of typical bacteria. ::: RESULTSPN panel semiquantitative results were compared to qRefCx results (Table 8) using the following analysis. qRefCx results for each organism were stratified into 1-log10 ranges (e.g., 104 to <105, 105 to <106, etc.)", [["qRefCx", "PROTEIN", 355, 361], ["typical bacteria", "PROBLEM", 220, 236], ["RESULTSPN panel semiquantitative", "TEST", 242, 274], ["the following analysis", "TEST", 331, 353], ["each organism", "PROBLEM", 374, 387], ["typical", "OBSERVATION_MODIFIER", 220, 227], ["bacteria", "OBSERVATION", 228, 236]]], ["The PN panel bin result for a particular analyte was considered concordant if the reported bin value was at either end of that range (e.g., a qRefCx value of 35,000 CFU/ml, or 3.5 \u00d7 104, which falls between 104 and 105, was concordant with a PN panel bin result of either 104 or 105).", [["The PN panel", "TEST", 0, 12], ["a particular analyte", "TEST", 28, 48], ["a qRefCx value", "TEST", 140, 154], ["a PN panel", "TEST", 240, 250]]], ["Concordance was low for qRefCx values below 106 CFU/ml, with overall values ranging from 3.1% to 38.9% for both specimen types (Table 8, \u201c=\u201d columns).", [["specimen", "ANATOMY", 112, 120], ["qRefCx", "PROTEIN", 24, 30], ["Concordance", "TEST", 0, 11], ["qRefCx values", "TEST", 24, 37], ["CFU/ml", "TEST", 48, 54], ["overall values", "TEST", 61, 75], ["specimen types", "TEST", 112, 126], ["Table", "TEST", 128, 133]]], ["However, when qRefCx values were above 106, PN panel concordance was 90.9% to 100% for both specimen types.", [["specimen", "ANATOMY", 92, 100], ["qRefCx", "PROTEIN", 14, 20], ["qRefCx values", "TEST", 14, 27], ["PN panel concordance", "TEST", 44, 64]]], ["When discrepant results were examined for a particular concentration range, there were very few instances where the PN panel result was \u201cnot detected\u201d or was a value lower than that from qRefCx (Table 8, \u201cND\u201d and \u201c<\u201d columns).", [["the PN panel", "TEST", 112, 124], ["qRefCx", "TEST", 187, 193], ["Table", "TEST", 195, 200]]], ["However, the PN panel reported organism levels higher than the qRefCx range for 58.9 to 93.8% of specimens with qRefCx values below 106 (Table 8, \u201c>\u201d columns).", [["specimens", "ANATOMY", 97, 106], ["the PN panel", "TEST", 9, 21], ["organism levels", "TEST", 31, 46], ["specimens", "TEST", 97, 106], ["qRefCx values", "TEST", 112, 125], ["Table", "TEST", 137, 142]]], ["Performance was similar for all organisms.S. aureusmecA/mecC and MREJ determinants. ::: RESULTSWhen S. aureus is detected on the PN panel, it is accompanied by a result for the detection of mecA and mecC.", [["aureusmecA", "GENE_OR_GENE_PRODUCT", 45, 55], ["mecC", "GENE_OR_GENE_PRODUCT", 56, 60], ["S. aureus", "ORGANISM", 100, 109], ["mecA", "GENE_OR_GENE_PRODUCT", 190, 194], ["mecC", "GENE_OR_GENE_PRODUCT", 199, 203], ["S. aureusmecA/mecC and MREJ determinants", "PROTEIN", 42, 82], ["mecA", "DNA", 190, 194], ["mecC", "DNA", 199, 203], ["S. aureus", "SPECIES", 100, 109], ["S. aureus", "SPECIES", 100, 109], ["all organisms", "PROBLEM", 28, 41], ["S. aureus", "PROBLEM", 100, 109], ["the PN panel", "TEST", 125, 137], ["mecA and mecC", "TREATMENT", 190, 203], ["mecC", "OBSERVATION", 56, 60], ["aureus", "OBSERVATION", 103, 109]]], ["These genes encode a penicillin-binding protein (PBP2a) that has low affinity for beta-lactams and are carried on a chromosomally integrated mobile genetic element called the staphylococcal cassette chromosome mec (SCCmec), which may be found in many Staphylococcus spp.", [["penicillin", "CHEMICAL", 21, 31], ["Staphylococcus spp", "DISEASE", 251, 269], ["penicillin", "CHEMICAL", 21, 31], ["penicillin-binding protein", "GENE_OR_GENE_PRODUCT", 21, 47], ["PBP2a", "GENE_OR_GENE_PRODUCT", 49, 54], ["beta-lactams", "GENE_OR_GENE_PRODUCT", 82, 94], ["staphylococcal cassette chromosome mec", "GENE_OR_GENE_PRODUCT", 175, 213], ["SCCmec", "GENE_OR_GENE_PRODUCT", 215, 221], ["Staphylococcus spp", "ORGANISM", 251, 269], ["penicillin-binding protein", "PROTEIN", 21, 47], ["PBP2a", "PROTEIN", 49, 54], ["beta-lactams", "PROTEIN", 82, 94], ["mobile genetic element", "DNA", 141, 163], ["staphylococcal cassette chromosome mec", "DNA", 175, 213], ["SCCmec", "DNA", 215, 221], ["Staphylococcus", "SPECIES", 251, 265], ["Staphylococcus spp", "SPECIES", 251, 269], ["a penicillin-binding protein (PBP2a", "TREATMENT", 19, 54], ["low affinity", "PROBLEM", 65, 77], ["beta-lactams", "PROBLEM", 82, 94], ["a chromosomally integrated mobile genetic element", "PROBLEM", 114, 163], ["the staphylococcal cassette chromosome mec", "TREATMENT", 171, 213], ["many Staphylococcus spp", "PROBLEM", 246, 269], ["low affinity", "OBSERVATION_MODIFIER", 65, 77], ["Staphylococcus spp", "OBSERVATION", 251, 269]]], ["To distinguish between methicillin-resistant S. aureus (MRSA) or codetection of methicillin-sensitive S. aureus (MSSA) and another Staphylococcus sp. carrying the SCCmec cassette and mecA/mecC, the PN panel contains an additional assay that amplifies the SCCmec right-extremity junction (MREJ), which links the SCCmec cassette to the S. aureus genome and indicates MRSA.", [["right-extremity junction", "ANATOMY", 262, 286], ["methicillin", "CHEMICAL", 23, 34], ["methicillin", "CHEMICAL", 80, 91], ["methicillin", "CHEMICAL", 23, 34], ["methicillin", "CHEMICAL", 80, 91], ["methicillin-resistant S. aureus", "ORGANISM", 23, 54], ["MRSA", "CANCER", 56, 60], ["methicillin-sensitive S. aureus", "ORGANISM", 80, 111], ["MSSA", "CANCER", 113, 117], ["Staphylococcus sp", "ORGANISM", 131, 148], ["SCCmec", "GENE_OR_GENE_PRODUCT", 163, 169], ["mecA", "GENE_OR_GENE_PRODUCT", 183, 187], ["mecC", "GENE_OR_GENE_PRODUCT", 188, 192], ["S. aureus", "ORGANISM", 334, 343], ["SCCmec cassette", "DNA", 163, 178], ["mecA", "DNA", 183, 187], ["mecC", "DNA", 188, 192], ["SCCmec right-extremity junction", "DNA", 255, 286], ["MREJ", "DNA", 288, 292], ["SCCmec cassette", "DNA", 311, 326], ["S. aureus genome", "DNA", 334, 350], ["S. aureus", "SPECIES", 45, 54], ["MRSA", "SPECIES", 56, 60], ["S. aureus", "SPECIES", 102, 111], ["Staphylococcus", "SPECIES", 131, 145], ["S. aureus", "SPECIES", 334, 343], ["MRSA", "SPECIES", 365, 369], ["S. aureus", "SPECIES", 45, 54], ["MRSA", "SPECIES", 56, 60], ["S. aureus", "SPECIES", 102, 111], ["MSSA", "SPECIES", 113, 117], ["S. aureus", "SPECIES", 334, 343], ["methicillin-resistant S. aureus", "PROBLEM", 23, 54], ["MRSA", "PROBLEM", 56, 60], ["methicillin", "PROBLEM", 80, 91], ["sensitive S. aureus", "PROBLEM", 92, 111], ["MSSA", "PROBLEM", 113, 117], ["another Staphylococcus sp", "PROBLEM", 123, 148], ["mecA/mecC", "TREATMENT", 183, 192], ["the PN panel", "TEST", 194, 206], ["an additional assay", "TEST", 216, 235], ["the S. aureus genome", "PROBLEM", 330, 350], ["MRSA", "PROBLEM", 365, 369], ["aureus", "OBSERVATION", 48, 54], ["aureus", "OBSERVATION", 105, 111], ["MSSA", "OBSERVATION", 113, 117], ["Staphylococcus sp", "OBSERVATION", 131, 148], ["right", "ANATOMY_MODIFIER", 262, 267], ["extremity junction", "ANATOMY", 268, 286], ["aureus genome", "OBSERVATION", 337, 350], ["MRSA", "OBSERVATION", 365, 369]]], ["S. aureus was detected in 116 BAL and 204 sputum samples.", [["BAL", "ANATOMY", 30, 33], ["sputum samples", "ANATOMY", 42, 56], ["S. aureus", "ORGANISM", 0, 9], ["BAL", "CELL", 30, 33], ["sputum samples", "CANCER", 42, 56], ["S. aureus", "SPECIES", 0, 9], ["S. aureus", "SPECIES", 0, 9], ["S. aureus", "PROBLEM", 0, 9], ["116 BAL", "TEST", 26, 33], ["sputum samples", "TEST", 42, 56], ["aureus", "OBSERVATION", 3, 9]]], ["The PN panel mecA/mecC and MREJ \u201cdetected\u201d results for these specimens were compared to results of molecular testing performed directly from the specimen, with PPA and NPA of 88.9% and 91.4% for BAL and 95.9% and 87.5% for sputum, respectively (Table 9).", [["specimens", "ANATOMY", 61, 70], ["specimen", "ANATOMY", 145, 153], ["BAL", "ANATOMY", 195, 198], ["sputum", "ANATOMY", 223, 229], ["mecC", "GENE_OR_GENE_PRODUCT", 18, 22], ["specimens", "CANCER", 61, 70], ["mecA", "DNA", 13, 17], ["mecC", "DNA", 18, 22], ["MREJ", "DNA", 27, 31], ["The PN panel mecA", "TEST", 0, 17], ["MREJ \u201c", "TEST", 27, 33], ["these specimens", "TEST", 55, 70], ["molecular testing", "TEST", 99, 116], ["PPA", "TEST", 160, 163], ["NPA", "TEST", 168, 171], ["BAL", "TEST", 195, 198], ["sputum", "TEST", 223, 229]]], ["Investigation of the 28 false-positive and false-negative specimens using independent molecular methods found evidence of mecA/mecC and MREJ in 27 of them (Table 10; one specimen could not be investigated due to lack of remaining volume).", [["specimens", "ANATOMY", 58, 67], ["specimens", "CANCER", 58, 67], ["mecA", "GENE_OR_GENE_PRODUCT", 122, 126], ["mecC", "GENE_OR_GENE_PRODUCT", 127, 131], ["mecA", "DNA", 122, 126], ["mecC", "DNA", 127, 131], ["MREJ", "DNA", 136, 140], ["mecA/mecC", "TREATMENT", 122, 131], ["MREJ", "TREATMENT", 136, 140]]], ["A review of AST testing performed on S. aureus isolates recovered by SOC and qRefCx methods (data not shown) revealed that many of the specimens with discrepant results were polymicrobial with both MRSA and MSSA.", [["specimens", "ANATOMY", 135, 144], ["polymicrobial", "DISEASE", 174, 187], ["MSSA", "CHEMICAL", 207, 211], ["S. aureus", "ORGANISM", 37, 46], ["specimens", "CANCER", 135, 144], ["AST", "PROTEIN", 12, 15], ["S. aureus", "SPECIES", 37, 46], ["MRSA", "SPECIES", 198, 202], ["S. aureus", "SPECIES", 37, 46], ["MRSA", "SPECIES", 198, 202], ["A review of AST testing", "TEST", 0, 23], ["S. aureus isolates", "PROBLEM", 37, 55], ["qRefCx methods", "TEST", 77, 91], ["the specimens", "TEST", 131, 144], ["polymicrobial", "PROBLEM", 174, 187], ["MRSA", "PROBLEM", 198, 202], ["MSSA", "PROBLEM", 207, 211], ["polymicrobial", "OBSERVATION", 174, 187], ["MRSA", "OBSERVATION", 198, 202], ["MSSA", "OBSERVATION", 207, 211]]], ["Some specimens were polymicrobial with other methicillin-resistant Staphylococcus spp. (i.e., organisms carrying mecA/mecC) and an MSSA isolate which may have carried an empty SCCmec cassette (and thus was positive for MREJ and mecA/mecC but was not MRSA).", [["specimens", "ANATOMY", 5, 14], ["polymicrobial", "DISEASE", 20, 33], ["methicillin", "CHEMICAL", 45, 56], ["Staphylococcus spp.", "CHEMICAL", 67, 86], ["methicillin", "CHEMICAL", 45, 56], ["Staphylococcus spp.", "ORGANISM", 67, 86], ["mecA", "GENE_OR_GENE_PRODUCT", 113, 117], ["mecC", "GENE_OR_GENE_PRODUCT", 118, 122], ["SCCmec", "GENE_OR_GENE_PRODUCT", 176, 182], ["MREJ", "GENE_OR_GENE_PRODUCT", 219, 223], ["mecA", "GENE_OR_GENE_PRODUCT", 228, 232], ["mecA", "DNA", 113, 117], ["mecC", "DNA", 118, 122], ["empty SCCmec cassette", "DNA", 170, 191], ["MREJ", "PROTEIN", 219, 223], ["mecA", "DNA", 228, 232], ["mecC", "DNA", 233, 237], ["Staphylococcus spp.", "SPECIES", 67, 86], ["MRSA", "SPECIES", 250, 254], ["Staphylococcus spp.", "SPECIES", 67, 86], ["Some specimens", "TEST", 0, 14], ["polymicrobial", "PROBLEM", 20, 33], ["other methicillin-resistant Staphylococcus spp.", "PROBLEM", 39, 86], ["mecA/mecC", "TREATMENT", 113, 122], ["an MSSA isolate", "PROBLEM", 128, 143], ["an empty SCCmec cassette", "PROBLEM", 167, 191], ["MREJ", "TEST", 219, 223], ["mecA/mecC", "TREATMENT", 228, 237], ["MRSA", "PROBLEM", 250, 254], ["polymicrobial", "OBSERVATION_MODIFIER", 20, 33], ["Staphylococcus spp.", "OBSERVATION", 67, 86]]], ["When these different organisms are present together at near-LoD levels in polymicrobial specimens, differential detection by the PN panel and reference methods (including phenotypic AST) leads to discordant results (14).", [["specimens", "ANATOMY", 88, 97], ["LoD", "GENE_OR_GENE_PRODUCT", 60, 63], ["LoD", "DNA", 60, 63], ["these different organisms", "PROBLEM", 5, 30], ["polymicrobial specimens", "TEST", 74, 97], ["differential detection", "TEST", 99, 121], ["the PN panel", "TEST", 125, 137], ["reference methods", "TEST", 142, 159], ["phenotypic AST", "TEST", 171, 185], ["polymicrobial specimens", "OBSERVATION", 74, 97]]], ["The MREJ sequence from one false-negative specimen was found to contain a sequence that is nonreactive to the PN panel MREJ primers; this limitation is noted in the product instructions for use (11).Carbapenemase and extended-spectrum beta-lactamase AMR performance. ::: RESULTSThe PN panel includes assays for six AMR genes associated with carbapenem and extended-spectrum beta-lactam resistance that are reported for select Gram-negative bacteria.", [["specimen", "ANATOMY", 42, 50], ["carbapenem", "CHEMICAL", 341, 351], ["beta-lactam", "CHEMICAL", 374, 385], ["carbapenem", "CHEMICAL", 341, 351], ["beta-lactam", "CHEMICAL", 374, 385], ["carbapenem", "SIMPLE_CHEMICAL", 341, 351], ["Gram", "GENE_OR_GENE_PRODUCT", 426, 430], ["MREJ sequence", "DNA", 4, 17], ["PN panel MREJ primers", "DNA", 110, 131], ["AMR genes", "DNA", 315, 324], ["The MREJ sequence", "TEST", 0, 17], ["a sequence", "TEST", 72, 82], ["Carbapenemase", "TREATMENT", 199, 212], ["RESULTSThe PN panel", "TEST", 271, 290], ["assays", "TEST", 300, 306], ["six AMR genes", "PROBLEM", 311, 324], ["carbapenem", "TREATMENT", 341, 351], ["extended-spectrum beta-lactam resistance", "TREATMENT", 356, 396], ["Gram", "TEST", 426, 430], ["nonreactive", "OBSERVATION", 91, 102], ["negative bacteria", "OBSERVATION", 431, 448]]], ["These genes are reported as \u201cN/A\u201d if no applicable host organism is detected in the specimen (Table 1, footnotes b, c, and d).", [["specimen", "ANATOMY", 84, 92], ["applicable host organism", "PROBLEM", 40, 64]]], ["CTX-M and KPC were the most commonly detected AMR targets in both BAL and sputum samples (Table 5).", [["BAL", "ANATOMY", 66, 69], ["sputum samples", "ANATOMY", 74, 88], ["CTX", "CHEMICAL", 0, 3], ["CTX-M", "GENE_OR_GENE_PRODUCT", 0, 5], ["KPC", "GENE_OR_GENE_PRODUCT", 10, 13], ["BAL", "CELL", 66, 69], ["CTX", "TEST", 0, 3], ["KPC", "TREATMENT", 10, 13], ["both BAL", "TEST", 61, 69], ["sputum samples", "TEST", 74, 88], ["BAL", "ANATOMY", 66, 69]]], ["VIM was detected in two sputum samples, NDM was detected in one BAL specimen, and IMP and OXA-48-like genes were not detected.", [["sputum samples", "ANATOMY", 24, 38], ["BAL specimen", "ANATOMY", 64, 76], ["NDM", "DISEASE", 40, 43], ["IMP", "CHEMICAL", 82, 85], ["OXA", "CHEMICAL", 90, 93], ["VIM", "GENE_OR_GENE_PRODUCT", 0, 3], ["BAL specimen", "CANCER", 64, 76], ["IMP", "SIMPLE_CHEMICAL", 82, 85], ["OXA-48", "GENE_OR_GENE_PRODUCT", 90, 96], ["VIM", "PROTEIN", 0, 3], ["IMP and OXA-48-like genes", "DNA", 82, 107], ["two sputum samples", "TEST", 20, 38], ["NDM", "PROBLEM", 40, 43], ["one BAL specimen", "TEST", 60, 76], ["IMP and OXA", "TEST", 82, 93]]], ["The comparator method for AMR gene performance was an independent molecular method performed on the specimen (a comparison of PN panel AMR gene detection to phenotypic AST of recovered isolates may be found in the PN panel instructions for use [11]; however, this method was not used as a primary comparator because the PN panel detected more organisms than were recovered by culture [Table 7] and also because phenotypic antimicrobial susceptibility may be conferred by mechanisms other than the genes reported by the PN panel, thus confounding interpretation of such results).", [["specimen", "ANATOMY", 100, 108], ["AMR gene", "DNA", 26, 34], ["AMR gene performance", "TEST", 26, 46], ["PN panel", "TEST", 126, 134], ["phenotypic AST", "TEST", 157, 171], ["the PN panel", "TEST", 316, 328], ["culture", "TEST", 376, 383], ["phenotypic antimicrobial susceptibility", "PROBLEM", 411, 450], ["the PN panel", "TEST", 515, 527]]], ["KPC detection had a performance of 100% PPA in both sample types, with 100% NPA in sputum and 99.3% NPA in BAL.", [["sample", "ANATOMY", 52, 58], ["sputum", "ANATOMY", 83, 89], ["BAL", "ANATOMY", 107, 110], ["PPA", "CHEMICAL", 40, 43], ["NPA", "CHEMICAL", 76, 79], ["NPA", "CHEMICAL", 100, 103], ["PPA", "CHEMICAL", 40, 43], ["NPA", "CHEMICAL", 76, 79], ["NPA", "CHEMICAL", 100, 103], ["BAL", "ORGANISM_SUBSTANCE", 107, 110], ["KPC detection", "TEST", 0, 13], ["PPA", "TEST", 40, 43], ["sputum", "TEST", 83, 89], ["NPA in BAL", "TEST", 100, 110], ["BAL", "ANATOMY", 107, 110]]], ["CTX-M detection had a PPA of 85.7% in BALs and 80% in sputum samples and NPA of 100% in BALs and 99.6% in sputum samples.", [["BALs", "ANATOMY", 38, 42], ["sputum samples", "ANATOMY", 54, 68], ["BALs", "ANATOMY", 88, 92], ["sputum samples", "ANATOMY", 106, 120], ["CTX", "CHEMICAL", 0, 3], ["CTX", "SIMPLE_CHEMICAL", 0, 3], ["BALs", "CANCER", 38, 42], ["sputum samples", "CANCER", 54, 68], ["BALs", "CANCER", 88, 92], ["sputum samples", "CANCER", 106, 120], ["CTX", "TEST", 0, 3], ["a PPA", "TEST", 20, 25], ["BALs", "TEST", 38, 42], ["sputum samples", "TEST", 54, 68], ["NPA", "TEST", 73, 76], ["BALs", "TEST", 88, 92], ["sputum samples", "TEST", 106, 120]]], ["Of two VIM detections in sputum specimens, one was true positive (100% PPA) and one false positive (resulting in 99.7% NPA).", [["sputum specimens", "ANATOMY", 25, 41], ["VIM", "GENE_OR_GENE_PRODUCT", 7, 10], ["sputum specimens", "CANCER", 25, 41], ["VIM", "PROTEIN", 7, 10], ["two VIM detections in sputum specimens", "TEST", 3, 41], ["true positive", "PROBLEM", 51, 64], ["PPA", "TEST", 71, 74], ["one false positive", "PROBLEM", 80, 98]]], ["There was one NDM detection in BAL, but it was a false positive (99.3% NPA); the comparator method also detected a single NDM, but this was not observed by the PN panel and was considered to be a false negative (0% PPA).", [["BAL", "ANATOMY", 31, 34], ["NDM", "DISEASE", 14, 17], ["NDM", "DISEASE", 122, 125], ["BAL", "ORGANISM_SUBSTANCE", 31, 34], ["BAL", "TEST", 31, 34], ["a false positive", "PROBLEM", 47, 63], ["the comparator method", "TEST", 77, 98], ["a single NDM", "PROBLEM", 113, 125], ["the PN panel", "TEST", 156, 168]]], ["Discrepancy investigation with independent molecular methods found evidence of the AMR gene in several of the discrepant positive and negative results (resolved true positives and confirmed false negatives) (Table 10), suggesting analyte presence near the LoD of both the PN panel and comparator assays.", [["AMR gene", "DNA", 83, 91], ["Discrepancy investigation", "TEST", 0, 25], ["independent molecular methods", "PROBLEM", 31, 60], ["the AMR gene", "PROBLEM", 79, 91], ["the PN panel", "TEST", 268, 280], ["comparator assays", "TEST", 285, 302]]], ["As overall prevalence of these resistance gene markers was low in the study population, contrived specimens were utilized to further demonstrate the positive and negative percent agreement of the resistance targets as described in the product instructions for use (11).Analysis of viruses and atypical bacteria. ::: RESULTSThe overall performance of atypical bacterial and viral targets on the PN panel is summarized in Table 11.", [["specimens", "ANATOMY", 98, 107], ["specimens", "CANCER", 98, 107], ["resistance gene markers", "DNA", 31, 54], ["these resistance gene markers", "PROBLEM", 25, 54], ["the resistance targets", "PROBLEM", 192, 214], ["viruses", "PROBLEM", 281, 288], ["atypical bacteria", "PROBLEM", 293, 310], ["atypical bacterial and viral targets", "PROBLEM", 350, 386], ["the PN panel", "TEST", 390, 402], ["viruses", "OBSERVATION", 281, 288], ["atypical", "OBSERVATION_MODIFIER", 293, 301], ["bacteria", "OBSERVATION", 302, 310], ["atypical", "OBSERVATION_MODIFIER", 350, 358], ["bacterial", "OBSERVATION", 359, 368], ["viral targets", "OBSERVATION", 373, 386]]], ["The PPA, NPA, and 95% CI were calculated compared to comparator methods of PCR and sequencing.", [["PPA", "CHEMICAL", 4, 7], ["NPA", "CHEMICAL", 9, 12], ["The PPA", "TEST", 0, 7], ["NPA", "TEST", 9, 12], ["95% CI", "TEST", 18, 24], ["PCR", "TEST", 75, 78], ["sequencing", "TEST", 83, 93], ["PPA", "OBSERVATION_MODIFIER", 4, 7]]], ["PPA for MERS-CoV could not be calculated, as no detections occurred during the course of this study; NPA was 100%.", [["PPA", "CHEMICAL", 0, 3], ["NPA", "CHEMICAL", 101, 104], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 8, 16], ["MERS-CoV", "SPECIES", 8, 16], ["PPA", "TEST", 0, 3], ["this study", "TEST", 89, 99], ["NPA", "TEST", 101, 104]]], ["The PPA for 2/8 targets was 100% for both BAL and sputum.", [["BAL", "ANATOMY", 42, 45], ["sputum", "ANATOMY", 50, 56], ["PPA", "CHEMICAL", 4, 7], ["BAL", "ORGANISM_SUBSTANCE", 42, 45], ["sputum", "ORGANISM_SUBSTANCE", 50, 56], ["The PPA", "TEST", 0, 7], ["both BAL and sputum", "TEST", 37, 56], ["sputum", "OBSERVATION", 50, 56]]], ["The lowest PPA for sputum was 76.5% for adenovirus, with discordant results observed among all age groups; PPA for adenovirus was 100% in BAL.", [["sputum", "ANATOMY", 19, 25], ["BAL", "ANATOMY", 138, 141], ["PPA", "CHEMICAL", 11, 14], ["adenovirus", "ORGANISM", 40, 50], ["adenovirus", "ORGANISM", 115, 125], ["BAL", "ORGANISM_SUBSTANCE", 138, 141], ["adenovirus", "SPECIES", 40, 50], ["adenovirus", "SPECIES", 115, 125], ["The lowest PPA", "TEST", 0, 14], ["sputum", "TEST", 19, 25], ["adenovirus", "PROBLEM", 40, 50], ["PPA", "TEST", 107, 110], ["adenovirus", "PROBLEM", 115, 125]]], ["For BAL specimens, the lowest observed PPA was 85.7% for coronavirus.", [["BAL specimens", "ANATOMY", 4, 17], ["coronavirus", "DISEASE", 57, 68], ["PPA", "CHEMICAL", 39, 42], ["BAL specimens", "CANCER", 4, 17], ["coronavirus", "ORGANISM", 57, 68], ["BAL specimens", "TEST", 4, 17], ["PPA", "TEST", 39, 42], ["coronavirus", "PROBLEM", 57, 68]]], ["Atypical bacterial detections were rare overall, with the most frequent coming from Mycoplasma pneumoniae, which demonstrated PPA and NPA of 87.5% to 100%.", [["Mycoplasma pneumoniae", "DISEASE", 84, 105], ["PPA", "CHEMICAL", 126, 129], ["Mycoplasma pneumoniae", "ORGANISM", 84, 105], ["Mycoplasma pneumoniae", "SPECIES", 84, 105], ["Mycoplasma pneumoniae", "SPECIES", 84, 105], ["Atypical bacterial detections", "PROBLEM", 0, 29], ["Mycoplasma pneumoniae", "PROBLEM", 84, 105], ["PPA", "TEST", 126, 129], ["NPA", "TEST", 134, 137], ["bacterial detections", "OBSERVATION", 9, 29], ["Mycoplasma pneumoniae", "OBSERVATION", 84, 105], ["PPA", "OBSERVATION_MODIFIER", 126, 129]]], ["Discordant results were attributed in most cases to low levels of analyte, i.e., at or near the LoD; investigation with independent molecular assays found evidence of analyte presence in the majority of false-positive and nearly all false-negative specimens (Table 10).DISCUSSIONLower respiratory tract infections can be caused by a wide range of pathogens.", [["specimens", "ANATOMY", 248, 257], ["respiratory tract", "ANATOMY", 285, 302], ["respiratory tract infections", "DISEASE", 285, 313], ["independent molecular assays", "TEST", 120, 148], ["analyte presence", "PROBLEM", 167, 183], ["DISCUSSIONLower respiratory tract infections", "PROBLEM", 269, 313], ["pathogens", "PROBLEM", 347, 356], ["respiratory tract", "ANATOMY", 285, 302], ["infections", "OBSERVATION", 303, 313], ["wide", "OBSERVATION_MODIFIER", 333, 337], ["pathogens", "OBSERVATION", 347, 356]]], ["Commonly, multiple diagnostic tests, including culture, molecular detection, and antigen detection, may be ordered to aid in the diagnosis of these infections.", [["infections", "DISEASE", 148, 158], ["multiple diagnostic tests", "TEST", 10, 35], ["culture", "TEST", 47, 54], ["molecular detection", "TEST", 56, 75], ["antigen detection", "TEST", 81, 98], ["these infections", "PROBLEM", 142, 158], ["infections", "OBSERVATION", 148, 158]]], ["While awaiting the results of diagnostic testing, many patients are placed on broad-spectrum antibiotic therapy.", [["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["diagnostic testing", "TEST", 30, 48], ["broad-spectrum antibiotic therapy", "TREATMENT", 78, 111], ["antibiotic therapy", "OBSERVATION", 93, 111]]], ["In the absence of a clear diagnosis, antibiotic de-escalation may be delayed or rarely initiated.", [["antibiotic de-escalation", "TREATMENT", 37, 61]]], ["Furthermore, it is estimated that 30% of cases of community-acquired pneumonia (CAP) have no identified etiological cause (15).", [["pneumonia", "DISEASE", 69, 78], ["CAP", "DISEASE", 80, 83], ["community-acquired pneumonia", "PROBLEM", 50, 78], ["pneumonia", "OBSERVATION", 69, 78], ["no identified", "UNCERTAINTY", 90, 103]]], ["Due to the insensitivity of culture, the Infectious Disease Society of America (IDSA) does not recommend culture of lower respiratory tract specimens for ambulatory patients with CAP, owing to the low yield of culture and resulting minimal impact on patient care (16).", [["lower respiratory tract specimens", "ANATOMY", 116, 149], ["Infectious Disease", "DISEASE", 41, 59], ["CAP", "DISEASE", 179, 182], ["patients", "ORGANISM", 165, 173], ["patient", "ORGANISM", 250, 257], ["patients", "SPECIES", 165, 173], ["patient", "SPECIES", 250, 257], ["culture", "TEST", 28, 35], ["culture", "TEST", 105, 112], ["lower respiratory tract specimens", "PROBLEM", 116, 149], ["CAP", "TREATMENT", 179, 182], ["culture", "TEST", 210, 217], ["Infectious", "OBSERVATION_MODIFIER", 41, 51], ["respiratory tract", "ANATOMY", 122, 139]]], ["Culture remains the recommendation for patients with severe CAP and for hospitalized patients with pneumonia.", [["CAP", "DISEASE", 60, 63], ["pneumonia", "DISEASE", 99, 108], ["patients", "ORGANISM", 39, 47], ["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 39, 47], ["patients", "SPECIES", 85, 93], ["Culture", "TEST", 0, 7], ["severe CAP", "PROBLEM", 53, 63], ["pneumonia", "PROBLEM", 99, 108], ["pneumonia", "OBSERVATION", 99, 108]]], ["Molecular methods for a variety of infectious processes have shown a clear increase in sensitivity and rapid turnaround times (17\u201319).DISCUSSIONThis evaluation of the PN panel demonstrates the performance of this multiplex IVD test in selected analytical validation studies and a large prospective set of residual samples collected from a geographically and demographically diverse patient population.", [["samples", "ANATOMY", 314, 321], ["samples", "CANCER", 314, 321], ["patient", "ORGANISM", 382, 389], ["patient", "SPECIES", 382, 389], ["infectious processes", "PROBLEM", 35, 55], ["the PN panel", "TEST", 163, 175], ["this multiplex IVD test", "TEST", 208, 231], ["selected analytical validation studies", "TEST", 235, 273], ["a large prospective set of residual samples", "PROBLEM", 278, 321], ["infectious", "OBSERVATION", 35, 45], ["clear", "OBSERVATION_MODIFIER", 69, 74], ["increase", "OBSERVATION_MODIFIER", 75, 83], ["large", "OBSERVATION_MODIFIER", 280, 285], ["diverse", "OBSERVATION_MODIFIER", 374, 381]]], ["With the exception of a few targets that were not circulating in the population during the study period (e.g., MERS-CoV, Chlamydia pneumoniae, and some AMR genes), considerable numbers of most analytes were detected in both specimen types, allowing the determination of sensitivity/PPA and specificity/NPA.", [["specimen", "ANATOMY", 224, 232], ["Chlamydia pneumoniae", "DISEASE", 121, 141], ["MERS-CoV", "ORGANISM", 111, 119], ["Chlamydia pneumoniae", "ORGANISM", 121, 141], ["Chlamydia pneumoniae", "SPECIES", 121, 141], ["MERS-CoV", "SPECIES", 111, 119], ["Chlamydia pneumoniae", "SPECIES", 121, 141], ["the study", "TEST", 87, 96], ["MERS", "PROBLEM", 111, 115], ["CoV", "PROBLEM", 116, 119], ["Chlamydia pneumoniae", "PROBLEM", 121, 141], ["some AMR genes", "PROBLEM", 147, 161], ["most analytes", "PROBLEM", 188, 201], ["sensitivity", "TEST", 270, 281], ["PPA", "PROBLEM", 282, 285], ["NPA", "TEST", 302, 305], ["few", "OBSERVATION_MODIFIER", 24, 27], ["targets", "OBSERVATION", 28, 35], ["Chlamydia pneumoniae", "OBSERVATION", 121, 141]]], ["The panel detects 15 routinely encountered Gram-positive and Gram-negative pathogens.", [["Gram-", "GENE_OR_GENE_PRODUCT", 43, 48], ["Gram", "GENE_OR_GENE_PRODUCT", 61, 65], ["The panel", "TEST", 0, 9], ["Gram", "TEST", 61, 65], ["negative pathogens", "OBSERVATION", 66, 84]]], ["The sensitivity of this assay was >95% for 10 of these analytes in both BAL and sputum specimens.", [["BAL", "ANATOMY", 72, 75], ["sputum specimens", "ANATOMY", 80, 96], ["BAL", "CELL", 72, 75], ["this assay", "TEST", 19, 29], ["these analytes", "TEST", 49, 63], ["both BAL", "TEST", 67, 75], ["sputum specimens", "TEST", 80, 96]]], ["Sensitivities for the other five organisms ranged from 75% to 91.7%.", [["Sensitivities", "TEST", 0, 13], ["the other five organisms", "TEST", 18, 42]]], ["Specificity for all targets in both specimen types was >91%.DISCUSSIONThe most challenging observation from these data is the discrepancy between the PN panel and culture for the detection and quantification of bacterial analytes.", [["specimen", "ANATOMY", 36, 44], ["Specificity", "TEST", 0, 11], ["these data", "TEST", 108, 118], ["the PN panel", "TEST", 146, 158], ["culture", "TEST", 163, 170], ["the detection", "TEST", 175, 188], ["bacterial analytes", "PROBLEM", 211, 229], ["most challenging", "OBSERVATION_MODIFIER", 74, 90], ["bacterial analytes", "OBSERVATION", 211, 229]]], ["As shown in Table 6, the PN panel demonstrated a lower specificity for bacterial analytes that were commonly detected (S. aureus and P. aeruginosa) than qRefCx.", [["S. aureus", "ORGANISM", 119, 128], ["P. aeruginosa", "ORGANISM", 133, 146], ["S. aureus", "SPECIES", 119, 128], ["P. aeruginosa", "SPECIES", 133, 146], ["S. aureus", "SPECIES", 119, 128], ["P. aeruginosa", "SPECIES", 133, 146], ["the PN panel", "TEST", 21, 33], ["bacterial analytes", "PROBLEM", 71, 89], ["S. aureus", "PROBLEM", 119, 128], ["P. aeruginosa", "PROBLEM", 133, 146]]], ["This finding correlates with those for other diagnostic assays that have been developed for the detection of lower respiratory tract pathogens (20), highlighting the increased sensitivity of molecular methods compared to culture for common pathogens.", [["lower respiratory tract", "ANATOMY", 109, 132], ["respiratory tract pathogens", "DISEASE", 115, 142], ["lower", "ORGANISM", 109, 114], ["respiratory tract", "ORGANISM_SUBDIVISION", 115, 132], ["other diagnostic assays", "TEST", 39, 62], ["lower respiratory tract pathogens", "PROBLEM", 109, 142], ["the increased sensitivity of molecular methods", "PROBLEM", 162, 208], ["culture", "TEST", 221, 228], ["common pathogens", "PROBLEM", 233, 249], ["lower", "ANATOMY_MODIFIER", 109, 114], ["respiratory tract", "ANATOMY", 115, 132], ["increased", "OBSERVATION_MODIFIER", 166, 175]]], ["This is attributed to multiple factors.", [["multiple factors", "PROBLEM", 22, 38], ["attributed to", "UNCERTAINTY", 8, 21], ["multiple", "OBSERVATION_MODIFIER", 22, 30], ["factors", "OBSERVATION", 31, 38]]], ["While culture remains the gold standard in the diagnosis of bacterial respiratory tract infections, it may be difficult to accurately recover all pathogens in clinical samples, as the organisms are in a complex matrix.", [["respiratory tract", "ANATOMY", 70, 87], ["samples", "ANATOMY", 168, 175], ["respiratory tract infections", "DISEASE", 70, 98], ["tract", "ORGANISM_SUBDIVISION", 82, 87], ["samples", "CANCER", 168, 175], ["matrix", "CELLULAR_COMPONENT", 211, 217], ["culture", "TEST", 6, 13], ["bacterial respiratory tract infections", "PROBLEM", 60, 98], ["clinical samples", "TEST", 159, 175], ["bacterial", "OBSERVATION_MODIFIER", 60, 69], ["respiratory tract infections", "OBSERVATION", 70, 98]]], ["In addition, culture results would be more affected by host immune response and prior antibiotic usage.", [["culture", "TEST", 13, 20], ["prior antibiotic usage", "TREATMENT", 80, 102]]], ["Culture is also subject to the criteria of each laboratory and to interpretation by the technologists examining those cultures.", [["Culture", "TEST", 0, 7], ["those cultures", "TEST", 112, 126]]], ["The panel is more robust against variability than could be attributed to the sample matrix, different techniques among laboratories, and recovery of more fastidious organisms.", [["sample matrix", "ANATOMY", 77, 90], ["The panel", "TEST", 0, 9], ["the sample matrix", "PROBLEM", 73, 90], ["more fastidious organisms", "PROBLEM", 149, 174], ["more robust", "OBSERVATION_MODIFIER", 13, 24]]], ["A potential drawback of molecular methods is the detection of nonviable organisms, but that may aid in the de-escalation of antibiotics in the absence of organism detection by culture in patients with prior antibiotic exposure.DISCUSSIONThe PN panel was shown to reliably detect and quantify bacterial genomes (Table 1) and was also shown to be able to detect the relative abundance of each target in contrived polymicrobial specimens (Table 2).", [["specimens", "ANATOMY", 425, 434], ["polymicrobial", "DISEASE", 411, 424], ["patients", "ORGANISM", 187, 195], ["bacterial genomes", "DNA", 292, 309], ["patients", "SPECIES", 187, 195], ["nonviable organisms", "PROBLEM", 62, 81], ["antibiotics", "TREATMENT", 124, 135], ["organism detection", "TEST", 154, 172], ["culture", "TEST", 176, 183], ["prior antibiotic exposure", "TREATMENT", 201, 226], ["PN panel", "TEST", 241, 249], ["bacterial genomes", "PROBLEM", 292, 309]]], ["Further work is needed to determine if detection of organisms at low abundances in the PN panel that are not identified in culture is significant for patient outcomes.", [["patient", "ORGANISM", 150, 157], ["patient", "SPECIES", 150, 157], ["organisms at low abundances", "PROBLEM", 52, 79], ["the PN panel", "TEST", 83, 95], ["culture", "TEST", 123, 130]]], ["Preliminary work done concurrently during this trial demonstrated the potential use of this panel as a diagnostic tool (12).DISCUSSIONA challenge of interpretation of respiratory cultures or results from molecular diagnostics like the PN panel is determining if the organisms detected are clinically significant.", [["respiratory cultures", "ANATOMY", 167, 187], ["this panel", "TEST", 87, 97], ["respiratory cultures", "TEST", 167, 187], ["molecular diagnostics", "TEST", 204, 225], ["the PN panel", "TEST", 231, 243], ["the organisms", "PROBLEM", 262, 275]]], ["Many clinically significant organisms may be normal flora of the oropharyngeal tract, particularly when they are present in a lower abundance.", [["oropharyngeal tract", "ANATOMY", 65, 84], ["oropharyngeal tract", "ORGANISM_SUBDIVISION", 65, 84], ["Many clinically significant organisms", "PROBLEM", 0, 37], ["the oropharyngeal tract", "PROBLEM", 61, 84], ["significant", "OBSERVATION_MODIFIER", 16, 27], ["organisms", "OBSERVATION", 28, 37], ["may be", "UNCERTAINTY", 38, 44], ["normal", "OBSERVATION", 45, 51], ["flora", "OBSERVATION_MODIFIER", 52, 57], ["oropharyngeal tract", "ANATOMY", 65, 84]]], ["In the culture of lower respiratory tract specimens, it is important to report significant amounts of pathogens from sputum (often defined as presence of the organism in the second or third quadrant) or \u2265104 CFU in BAL specimens.", [["lower respiratory tract specimens", "ANATOMY", 18, 51], ["sputum", "ANATOMY", 117, 123], ["BAL specimens", "ANATOMY", 215, 228], ["sputum", "ORGANISM_SUBSTANCE", 117, 123], ["BAL specimens", "CANCER", 215, 228], ["the culture", "TEST", 3, 14], ["lower respiratory tract specimens", "PROBLEM", 18, 51], ["pathogens from sputum", "PROBLEM", 102, 123], ["the organism", "PROBLEM", 154, 166], ["BAL specimens", "TEST", 215, 228], ["lower", "ANATOMY_MODIFIER", 18, 23], ["respiratory tract", "ANATOMY", 24, 41]]], ["Previous studies have shown that quantitative PCR can be a means to differentiate commensalism from pathogenicity by looking at the nucleic acid burden (21).", [["commensalism", "DISEASE", 82, 94], ["nucleic acid", "CHEMICAL", 132, 144], ["Previous studies", "TEST", 0, 16], ["quantitative PCR", "TEST", 33, 49], ["pathogenicity", "PROBLEM", 100, 113], ["the nucleic acid burden", "TEST", 128, 151]]], ["To promote adherence to current IDSA recommendations, the PN panel reports only organisms that are detected at >103.5 copies/ml.", [["the PN panel", "TEST", 54, 66], ["organisms", "PROBLEM", 80, 89]]], ["It then places the positive results into semiquantitative bins of 104, 105, 106, and \u2265107.", [["semiquantitative bins", "TEST", 41, 62]]], ["In culture, it may be difficult to find significant organisms present in lower, but still clinically relevant, amounts in the presence of large numbers of other pathogenic or commensal organisms.", [["culture", "TEST", 3, 10], ["significant organisms", "PROBLEM", 40, 61], ["other pathogenic or commensal organisms", "PROBLEM", 155, 194], ["significant", "OBSERVATION_MODIFIER", 40, 51], ["organisms", "OBSERVATION", 52, 61], ["lower", "ANATOMY_MODIFIER", 73, 78], ["large", "OBSERVATION_MODIFIER", 138, 143], ["numbers", "OBSERVATION_MODIFIER", 144, 151], ["commensal organisms", "OBSERVATION", 175, 194]]], ["The PN panel demonstrated that detection of organisms near the limit of detection was not influenced by the presence of a high burden of other organisms (Table 2).DISCUSSIONThe data collected in this prospective study demonstrate that the PN panel is sensitive for the detection of bacterial analytes, as only a limited number of false negatives were observed when the PN panel was compared to qRefCx or SOC (Table 6).", [["The PN panel", "TEST", 0, 12], ["organisms", "PROBLEM", 44, 53], ["a high burden of other organisms", "PROBLEM", 120, 152], ["The data", "TEST", 173, 181], ["this prospective study", "TEST", 195, 217], ["the PN panel", "TEST", 235, 247], ["bacterial analytes", "PROBLEM", 282, 300], ["false negatives", "PROBLEM", 330, 345], ["the PN panel", "TEST", 365, 377], ["bacterial analytes", "OBSERVATION", 282, 300], ["false negatives", "OBSERVATION", 330, 345]]], ["This indicates that the panel cutoff of 103.5 genomes/ml is appropriate.", [["the panel cutoff", "TEST", 20, 36]]], ["The false negatives were attributed to organisms present in numbers below the lowest PN panel bin due to misidentifications at the central reference lab.DISCUSSIONThe PN panel is additionally able to provide preliminary indication of potential antimicrobial susceptibility data for some commonly encountered pathogens via detection of selected AMR genes.", [["AMR genes", "DNA", 344, 353], ["The false negatives", "TEST", 0, 19], ["organisms", "PROBLEM", 39, 48], ["misidentifications", "PROBLEM", 105, 123], ["PN panel", "TEST", 167, 175], ["potential antimicrobial susceptibility data", "PROBLEM", 234, 277], ["selected AMR genes", "PROBLEM", 335, 353], ["false negatives", "OBSERVATION", 4, 19]]], ["Detection of mecA/mecC in conjunction with MREJ was shown to have high PPA and NPA with an independent molecular method, ranging from 87.5% to 95.9%.", [["PPA", "CHEMICAL", 71, 74], ["NPA", "CHEMICAL", 79, 82], ["mecA", "GENE_OR_GENE_PRODUCT", 13, 17], ["mecC", "GENE_OR_GENE_PRODUCT", 18, 22], ["mecA", "DNA", 13, 17], ["mecC", "DNA", 18, 22], ["MREJ", "DNA", 43, 47], ["mecA/mecC", "TREATMENT", 13, 22], ["high PPA", "PROBLEM", 66, 74], ["NPA", "TEST", 79, 82]]], ["The panel is also able to detect CTX-M-type extended-spectrum beta-lactamases (ESBLs).", [["CTX", "CHEMICAL", 33, 36], ["extended-spectrum beta-lactamases", "GENE_OR_GENE_PRODUCT", 44, 77], ["ESBLs", "GENE_OR_GENE_PRODUCT", 79, 84], ["ESBLs", "PROTEIN", 79, 84], ["The panel", "TEST", 0, 9], ["CTX", "TEST", 33, 36], ["ESBLs", "TEST", 79, 84]]], ["Since the emergence of CTX-M-type ESBLs in the 1990s, these enzymes have become the most prevalent type of ESBL in a variety of settings throughout the world (22\u201324).", [["CTX", "CHEMICAL", 23, 26], ["CTX", "TEST", 23, 26], ["type ESBLs", "TEST", 29, 39], ["these enzymes", "TEST", 54, 67], ["ESBL", "PROBLEM", 107, 111], ["most prevalent", "OBSERVATION_MODIFIER", 84, 98], ["ESBL", "OBSERVATION", 107, 111]]], ["CTX-M-type ESBLs are most prominent in E. coli and Klebsiella spp.; E. coli strains carrying CTX-M are prominent causes of community-onset urinary tract and bloodstream infections.", [["urinary tract", "ANATOMY", 139, 152], ["bloodstream", "ANATOMY", 157, 168], ["CTX", "CHEMICAL", 0, 3], ["CTX", "CHEMICAL", 93, 96], ["urinary tract and bloodstream infections", "DISEASE", 139, 179], ["CTX-M-type ESBLs", "GENE_OR_GENE_PRODUCT", 0, 16], ["E. coli", "ORGANISM", 39, 46], ["Klebsiella spp.", "ORGANISM", 51, 66], ["E. coli", "ORGANISM", 68, 75], ["strains", "ORGANISM", 76, 83], ["CTX-M", "GENE_OR_GENE_PRODUCT", 93, 98], ["urinary tract", "ORGANISM_SUBDIVISION", 139, 152], ["E. coli", "SPECIES", 39, 46], ["Klebsiella spp.", "SPECIES", 51, 66], ["E. coli", "SPECIES", 68, 75], ["E. coli", "SPECIES", 39, 46], ["Klebsiella spp.", "SPECIES", 51, 66], ["E. coli", "SPECIES", 68, 75], ["CTX", "TEST", 0, 3], ["M-type ESBLs", "PROBLEM", 4, 16], ["E. coli", "PROBLEM", 39, 46], ["Klebsiella spp.", "PROBLEM", 51, 66], ["E. coli strains carrying CTX", "PROBLEM", 68, 96], ["community-onset urinary tract", "PROBLEM", 123, 152], ["bloodstream infections", "PROBLEM", 157, 179], ["most prominent", "OBSERVATION_MODIFIER", 21, 35], ["E. coli", "OBSERVATION", 39, 46], ["Klebsiella spp.", "OBSERVATION", 51, 66], ["coli strains", "OBSERVATION", 71, 83], ["prominent", "OBSERVATION_MODIFIER", 103, 112], ["community", "OBSERVATION_MODIFIER", 123, 132], ["urinary tract", "ANATOMY", 139, 152], ["bloodstream infections", "OBSERVATION", 157, 179]]], ["CTX-M results are reported when any member of the family Enterobacteriaceae, Acinetobacter spp., or P. aeruginosa is detected, as these organisms have all been reported to potentially harbor ESBLs.DISCUSSIONThe PN panel may provide actionable information on antimicrobial susceptibility for some key organisms.", [["CTX", "CHEMICAL", 0, 3], ["Acinetobacter spp.", "DISEASE", 77, 95], ["P. aeruginosa", "DISEASE", 100, 113], ["Acinetobacter spp.", "ORGANISM", 77, 95], ["P. aeruginosa", "ORGANISM", 100, 113], ["ESBLs", "GENE_OR_GENE_PRODUCT", 191, 196], ["ESBLs", "PROTEIN", 191, 196], ["Acinetobacter spp.", "SPECIES", 77, 95], ["P. aeruginosa", "SPECIES", 100, 113], ["Acinetobacter spp.", "SPECIES", 77, 95], ["P. aeruginosa", "SPECIES", 100, 113], ["CTX", "TEST", 0, 3], ["Enterobacteriaceae", "PROBLEM", 57, 75], ["Acinetobacter spp.", "PROBLEM", 77, 95], ["P. aeruginosa", "PROBLEM", 100, 113], ["harbor ESBLs", "PROBLEM", 184, 196], ["PN panel", "TEST", 211, 219], ["antimicrobial susceptibility", "TEST", 258, 286], ["some key organisms", "PROBLEM", 291, 309]]], ["However, appropriate antimicrobial therapy for many targets, particularly in areas where resistance is common, may require follow-up culture and susceptibility testing.", [["appropriate antimicrobial therapy", "TREATMENT", 9, 42], ["follow-up culture", "TEST", 123, 140], ["susceptibility testing", "TEST", 145, 167]]], ["This is especially true for organisms with mutation-based resistance, such as S. pneumoniae and P. aeruginosa.", [["S. pneumoniae", "ORGANISM", 78, 91], ["P. aeruginosa", "ORGANISM", 96, 109], ["S. pneumoniae", "SPECIES", 78, 91], ["P. aeruginosa", "SPECIES", 96, 109], ["S. pneumoniae", "SPECIES", 78, 91], ["P. aeruginosa", "SPECIES", 96, 109], ["organisms", "PROBLEM", 28, 37], ["mutation-based resistance", "PROBLEM", 43, 68], ["S. pneumoniae", "PROBLEM", 78, 91], ["P. aeruginosa", "PROBLEM", 96, 109], ["pneumoniae", "OBSERVATION", 81, 91]]], ["Implementation of these panels for routine clinical testing still requires additional culture or appropriate follow-up by the performing laboratories to ensure thorough evaluation of AST phenotypes.DISCUSSIONRoutine detection of viral analytes and atypical bacteria in upper respiratory tract specimens has been demonstrated on previous BioFire respiratory panels.", [["upper respiratory tract specimens", "ANATOMY", 269, 302], ["AST", "GENE_OR_GENE_PRODUCT", 183, 186], ["upper respiratory tract specimens", "CANCER", 269, 302], ["these panels", "TEST", 18, 30], ["routine clinical testing", "TEST", 35, 59], ["additional culture", "TEST", 75, 93], ["thorough evaluation", "TEST", 160, 179], ["AST", "TEST", 183, 186], ["viral analytes", "PROBLEM", 229, 243], ["atypical bacteria in upper respiratory tract specimens", "PROBLEM", 248, 302], ["previous BioFire respiratory panels", "TEST", 328, 363], ["atypical", "OBSERVATION_MODIFIER", 248, 256], ["bacteria", "OBSERVATION", 257, 265], ["upper", "ANATOMY_MODIFIER", 269, 274], ["respiratory tract", "ANATOMY", 275, 292]]], ["This panel demonstrates performance attributes similar to those of the existing panels (25, 26).", [["This panel", "TEST", 0, 10], ["the existing panels", "TEST", 67, 86]]], ["A notable difference with this panel is the combined identification of viral subtypes that are reported distinctly in other molecular diagnostic tests (e.g., \u201ccoronavirus\u201d as a whole, rather than specific identification of HKU1, OC43, etc., or \u201cinfluenza A virus\u201d with no additional subtype information).", [["coronavirus", "ORGANISM", 159, 170], ["HKU1", "GENE_OR_GENE_PRODUCT", 223, 227], ["OC43", "GENE_OR_GENE_PRODUCT", 229, 233], ["influenza A virus", "ORGANISM", 245, 262], ["this panel", "TEST", 26, 36], ["viral subtypes", "PROBLEM", 71, 85], ["HKU1", "PROBLEM", 223, 227], ["OC43", "PROBLEM", 229, 233], ["influenza", "PROBLEM", 245, 254], ["notable", "OBSERVATION_MODIFIER", 2, 9], ["difference", "OBSERVATION", 10, 20], ["viral subtypes", "OBSERVATION", 71, 85]]], ["While some of these data may be useful for epidemiological purposes, they should not influence treatment and patient care.", [["patient", "ORGANISM", 109, 116], ["patient", "SPECIES", 109, 116], ["epidemiological purposes", "TEST", 43, 67], ["treatment", "TREATMENT", 95, 104]]], ["The PN panel should have similar if not expanded clinical utility in these populations, facilitating faster access to appropriate treatment and improved clinical outcomes (27, 28).", [["The PN panel", "TEST", 0, 12], ["appropriate treatment", "TREATMENT", 118, 139]]], ["The panel also exceeds the utility of previous respiratory panels with the inclusion of Legionella pneumophila and the ability to detect a variety of serogroups (11).", [["Legionella pneumophila", "ORGANISM", 88, 110], ["Legionella pneumophila", "SPECIES", 88, 110], ["Legionella pneumophila", "SPECIES", 88, 110], ["The panel", "TEST", 0, 9], ["previous respiratory panels", "TEST", 38, 65], ["Legionella pneumophila", "PROBLEM", 88, 110], ["Legionella pneumophila", "OBSERVATION", 88, 110]]], ["The PN panel provides a method with improved sensitivity for the diagnosis of Legionnaires\u2019 disease, which is estimated to account for 2% to 6% of CAP.", [["Legionnaires\u2019 disease", "DISEASE", 78, 99], ["CAP", "DISEASE", 147, 150], ["The PN panel", "TEST", 0, 12], ["Legionnaires\u2019 disease", "PROBLEM", 78, 99], ["CAP", "PROBLEM", 147, 150], ["Legionnaires", "OBSERVATION", 78, 90]]], ["The current standard is a urine antigen test, which has a sensitivity of only 80% and is limited to detection of serogroup 1, while studies have shown that the use of PCR has improved sensitivity over the current gold standard (29).DISCUSSIONThe results for MERS-CoV are masked in the PN panel product that is FDA cleared and available in the United States.", [["urine", "ANATOMY", 26, 31], ["urine", "ORGANISM_SUBSTANCE", 26, 31], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 258, 266], ["serogroup 1", "SPECIES", 113, 124], ["MERS-CoV", "SPECIES", 258, 266], ["a urine antigen test", "TEST", 24, 44], ["serogroup", "PROBLEM", 113, 122], ["PCR", "TEST", 167, 170]]], ["This analyte is reported in the BioFire PNplus panel, which is sold outside the United States and has also been cleared by the FDA with a modified intended use to specifically aid in the differential diagnosis of MERS-CoV infections only in cases meeting MERS-CoV clinical and/or epidemiological criteria.DISCUSSIONThe PN panel is intended for the use of both sputum and BAL fluid.", [["sputum", "ANATOMY", 360, 366], ["BAL fluid", "ANATOMY", 371, 380], ["MERS-CoV infections", "DISEASE", 213, 232], ["MERS-CoV", "ORGANISM", 213, 221], ["sputum", "ORGANISM_SUBSTANCE", 360, 366], ["BAL fluid", "ORGANISM_SUBSTANCE", 371, 380], ["MERS-CoV", "SPECIES", 213, 221], ["MERS", "PROBLEM", 213, 217], ["CoV infections", "PROBLEM", 218, 232], ["PN panel", "TEST", 319, 327], ["both sputum and BAL fluid", "TEST", 355, 380], ["BAL", "ANATOMY", 371, 374], ["fluid", "OBSERVATION", 375, 380]]], ["Concurrent bacterial cultures have shown high rates of correlation between sputum and BAL specimens (30).", [["sputum", "ANATOMY", 75, 81], ["BAL specimens", "ANATOMY", 86, 99], ["sputum", "ORGANISM_SUBSTANCE", 75, 81], ["BAL specimens", "CANCER", 86, 99], ["Concurrent bacterial cultures", "TEST", 0, 29], ["sputum", "TEST", 75, 81], ["BAL specimens", "TEST", 86, 99]]], ["While viral detection is traditionally done with nasopharyngeal samples, studies comparing use of nasopharyngeal swabs and BAL specimens using the BioFire FilmArray Respiratory (RP) panel (an off-label use of the product) have displayed high levels of correlation, with BAL specimens generally having a higher diagnostic yield (31, 32).DISCUSSIONA weakness of this study was that a majority of the specimens enrolled were from hospitalized patients, but this likely reflects the severity of illness in this population and adherence to guidelines suggesting that diagnostic testing is not warranted in ambulatory patients.", [["nasopharyngeal samples", "ANATOMY", 49, 71], ["nasopharyngeal swabs", "ANATOMY", 98, 118], ["BAL specimens", "ANATOMY", 123, 136], ["BAL specimens", "ANATOMY", 270, 283], ["specimens", "ANATOMY", 398, 407], ["illness", "DISEASE", 491, 498], ["nasopharyngeal samples", "CANCER", 49, 71], ["nasopharyngeal swabs", "ORGANISM_SUBSTANCE", 98, 118], ["BAL specimens", "CANCER", 123, 136], ["specimens", "CANCER", 398, 407], ["patients", "ORGANISM", 440, 448], ["patients", "ORGANISM", 612, 620], ["patients", "SPECIES", 440, 448], ["patients", "SPECIES", 612, 620], ["viral detection", "TEST", 6, 21], ["nasopharyngeal samples", "TEST", 49, 71], ["nasopharyngeal swabs", "TEST", 98, 118], ["BAL specimens", "TEST", 123, 136], ["the BioFire FilmArray Respiratory (RP) panel", "TEST", 143, 187], ["BAL specimens", "TEST", 270, 283], ["weakness", "PROBLEM", 348, 356], ["this study", "TEST", 360, 370], ["illness", "PROBLEM", 491, 498], ["diagnostic testing", "TEST", 562, 580]]], ["The data from this study indicate that specimens collected from hospitalized patients and those in outpatient settings had similar incidences of most analytes.DISCUSSIONThe use of a panel that provides sensitive and specific detection of respiratory tract pathogens has been shown to improve patient outcomes and is a recommended tool for antimicrobial stewardship initiatives (33\u201335).", [["specimens", "ANATOMY", 39, 48], ["respiratory tract", "ANATOMY", 238, 255], ["respiratory tract pathogens", "DISEASE", 238, 265], ["patients", "ORGANISM", 77, 85], ["tract", "ORGANISM_SUBDIVISION", 250, 255], ["patient", "ORGANISM", 292, 299], ["patients", "SPECIES", 77, 85], ["patient", "SPECIES", 292, 299], ["this study", "TEST", 14, 24], ["specimens", "TEST", 39, 48], ["most analytes", "PROBLEM", 145, 158], ["a panel", "TEST", 180, 187], ["respiratory tract pathogens", "PROBLEM", 238, 265], ["antimicrobial stewardship initiatives", "TREATMENT", 339, 376], ["respiratory tract", "ANATOMY", 238, 255]]], ["The PN panel expands on these existing technologies to provide an easy-to-use, rapid sample-to-answer platform that can detect viral entities and atypical bacteria known to cause pneumonia, in addition to providing a semiquantitative result for 15 commonly encountered bacterial analytes.", [["pneumonia", "DISEASE", 179, 188], ["The PN panel", "TEST", 0, 12], ["rapid sample", "TEST", 79, 91], ["viral entities", "PROBLEM", 127, 141], ["atypical bacteria", "PROBLEM", 146, 163], ["pneumonia", "PROBLEM", 179, 188], ["bacterial analytes", "PROBLEM", 269, 287], ["pneumonia", "OBSERVATION", 179, 188]]], ["An earlier study using an RUO version of the PN panel on BAL from patients suspected of having ventilator-associated pneumonia concluded that the panel would provide data that could guide appropriate management in this patient population (36).DISCUSSIONThe occurrence and impact of viral and bacterial coinfections in pneumonia are not well characterized, but recent studies have shown that coinfection is not unusual in community-acquired pneumonia in adults and was responsible for higher morbidity and mortality (37).", [["BAL", "ANATOMY", 57, 60], ["pneumonia", "DISEASE", 117, 126], ["viral and bacterial coinfections", "DISEASE", 282, 314], ["pneumonia", "DISEASE", 318, 327], ["coinfection", "DISEASE", 391, 402], ["pneumonia", "DISEASE", 440, 449], ["patients", "ORGANISM", 66, 74], ["patient", "ORGANISM", 219, 226], ["patients", "SPECIES", 66, 74], ["patient", "SPECIES", 219, 226], ["An earlier study", "TEST", 0, 16], ["the PN panel", "TEST", 41, 53], ["BAL", "TEST", 57, 60], ["ventilator-associated pneumonia", "PROBLEM", 95, 126], ["the panel", "TEST", 142, 151], ["viral and bacterial coinfections", "PROBLEM", 282, 314], ["pneumonia", "PROBLEM", 318, 327], ["recent studies", "TEST", 360, 374], ["coinfection", "PROBLEM", 391, 402], ["acquired pneumonia", "PROBLEM", 431, 449], ["higher morbidity", "PROBLEM", 484, 500], ["pneumonia", "OBSERVATION", 117, 126], ["viral", "OBSERVATION_MODIFIER", 282, 287], ["bacterial", "OBSERVATION_MODIFIER", 292, 301], ["coinfections", "OBSERVATION", 302, 314], ["pneumonia", "OBSERVATION", 318, 327], ["well characterized", "OBSERVATION_MODIFIER", 336, 354], ["coinfection", "OBSERVATION", 391, 402], ["pneumonia", "OBSERVATION", 440, 449]]], ["Therefore, it is anticipated that the PN panel could significantly affect the management of patients with coinfections.DISCUSSIONCurrent algorithms for the diagnosis of pneumonia can include multiple methods; molecular methods are most common for viral agents and many atypical bacteria, and culture remains the gold standard for the diagnosis of bacterial pneumonia.", [["coinfections", "DISEASE", 106, 118], ["pneumonia", "DISEASE", 169, 178], ["pneumonia", "DISEASE", 357, 366], ["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100], ["the PN panel", "TEST", 34, 46], ["coinfections", "PROBLEM", 106, 118], ["pneumonia", "PROBLEM", 169, 178], ["multiple methods", "PROBLEM", 191, 207], ["molecular methods", "TREATMENT", 209, 226], ["viral agents", "TREATMENT", 247, 259], ["many atypical bacteria", "PROBLEM", 264, 286], ["culture", "TEST", 292, 299], ["bacterial pneumonia", "PROBLEM", 347, 366], ["coinfections", "OBSERVATION", 106, 118], ["pneumonia", "OBSERVATION", 169, 178], ["atypical", "OBSERVATION_MODIFIER", 269, 277], ["bacteria", "OBSERVATION", 278, 286], ["bacterial", "OBSERVATION_MODIFIER", 347, 356], ["pneumonia", "OBSERVATION", 357, 366]]], ["Culture suffers from lower sensitivity than molecular methods, in addition to variable methods of interpretation and reporting among and within an institution.", [["Culture", "TEST", 0, 7], ["molecular methods", "TEST", 44, 61], ["lower sensitivity", "OBSERVATION_MODIFIER", 21, 38]]], ["Culture can also take an average of 48 to 72 h for actionable results to become available.", [["Culture", "TEST", 0, 7]]], ["Implementation of the PN panel will require consideration of appropriate test utilization in individual patient populations, but it has the potential to be a powerful decision-making tool for patient management.", [["patient", "ORGANISM", 104, 111], ["patient", "ORGANISM", 192, 199], ["patient", "SPECIES", 104, 111], ["patient", "SPECIES", 192, 199], ["the PN panel", "TEST", 18, 30], ["appropriate test utilization", "TREATMENT", 61, 89], ["patient management", "TREATMENT", 192, 210]]], ["This panel could be utilized for rapid de-escalation or initiation of antibiotics and promoting improved patient care outcomes.", [["patient", "ORGANISM", 105, 112], ["patient", "SPECIES", 105, 112], ["This panel", "TEST", 0, 10], ["rapid de-escalation", "TREATMENT", 33, 52], ["antibiotics", "TREATMENT", 70, 81]]], ["Further studies are needed to evaluate the clinical impact of this panel and the significance of molecular detection in the absence of culture confirmation.", [["Further studies", "TEST", 0, 15], ["this panel", "TEST", 62, 72], ["molecular detection", "TEST", 97, 116], ["culture confirmation", "TEST", 135, 155]]], ["Some of the data from this trial have been examined to determine the potential impact on patient care (12).", [["patient", "ORGANISM", 89, 96], ["patient", "SPECIES", 89, 96]]]], "17a3e104f7cc221071733d71ed24c4f491ceea19": [["IntroductionCoronavirus disease 2019 (COVID- 19) is an acute respiratory infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 1-3 .IntroductionBecause it is highly contagious, people are generally susceptible, and it is mainly transmitted via respiratory droplets, COVID-19 is spreading all over the world.", [["respiratory droplets", "ANATOMY", 280, 300], ["IntroductionCoronavirus disease", "DISEASE", 0, 31], ["COVID- 19", "CHEMICAL", 38, 47], ["respiratory infectious disease", "DISEASE", 61, 91], ["acute respiratory syndrome coronavirus", "DISEASE", 109, 147], ["COVID-19", "CHEMICAL", 302, 310], ["people", "ORGANISM", 213, 219], ["people", "SPECIES", 213, 219], ["IntroductionCoronavirus disease 2019 (COVID- 19", "SPECIES", 0, 47], ["severe acute respiratory syndrome coronavirus", "SPECIES", 102, 147], ["SARS-CoV", "SPECIES", 151, 159], ["IntroductionCoronavirus disease", "PROBLEM", 0, 31], ["COVID", "TEST", 38, 43], ["an acute respiratory infectious disease", "PROBLEM", 52, 91], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 102, 147], ["SARS", "TEST", 151, 155], ["CoV", "TEST", 156, 159], ["COVID", "TEST", 302, 307], ["acute", "OBSERVATION_MODIFIER", 55, 60], ["respiratory", "ANATOMY", 61, 72], ["infectious", "OBSERVATION", 73, 83], ["severe", "OBSERVATION_MODIFIER", 102, 108], ["acute", "OBSERVATION_MODIFIER", 109, 114], ["respiratory syndrome", "OBSERVATION", 115, 135], ["highly", "OBSERVATION_MODIFIER", 194, 200], ["contagious", "OBSERVATION", 201, 211], ["respiratory droplets", "OBSERVATION", 280, 300], ["spreading", "OBSERVATION_MODIFIER", 314, 323]]], ["It has been reported in more than 200 countries, and the number of deaths worldwide is also increasing.", [["deaths", "DISEASE", 67, 73], ["increasing", "OBSERVATION_MODIFIER", 92, 102]]], ["SARS-CoV-2 infection mainly affects the respiratory tract, and the main clinical manifestations are fever, dry cough, rhinorrhea and fatigue.", [["respiratory tract", "ANATOMY", 40, 57], ["SARS-CoV-2 infection", "DISEASE", 0, 20], ["fever", "DISEASE", 100, 105], ["dry cough", "DISEASE", 107, 116], ["rhinorrhea", "DISEASE", 118, 128], ["fatigue", "DISEASE", 133, 140], ["SARS-CoV-2", "ORGANISM", 0, 10], ["respiratory tract", "ORGANISM_SUBDIVISION", 40, 57], ["SARS-CoV-2", "SPECIES", 0, 10], ["SARS", "PROBLEM", 0, 4], ["CoV-2 infection", "PROBLEM", 5, 20], ["the respiratory tract", "PROBLEM", 36, 57], ["fever", "PROBLEM", 100, 105], ["dry cough", "PROBLEM", 107, 116], ["rhinorrhea", "PROBLEM", 118, 128], ["fatigue", "PROBLEM", 133, 140], ["CoV", "OBSERVATION_MODIFIER", 5, 8], ["infection", "OBSERVATION", 11, 20], ["respiratory tract", "ANATOMY", 40, 57], ["main", "OBSERVATION_MODIFIER", 67, 71], ["rhinorrhea", "OBSERVATION", 118, 128], ["fatigue", "OBSERVATION", 133, 140]]], ["Many cases of COVID-19 are acute and resolve quickly, but the disease can also be fatal, with a mortality rate of approximately 3% 4 .", [["COVID", "TEST", 14, 19], ["the disease", "PROBLEM", 58, 69], ["a mortality rate", "TEST", 94, 110], ["acute", "OBSERVATION_MODIFIER", 27, 32], ["disease", "OBSERVATION", 62, 69]]], ["The fatality rate of critically ill patients admitted to the intensive care unit (ICU) is relatively high, the results from a study of 52 critically ill patients with COVID-19 who were admitted to the intensive care unit (ICU) of Wuhan Jin Yin-tan hospital (Wuhan, China) between late December, 2019, and Jan 26, 2020 showed that 32 (61.5%) patients had died within 28 days, and the median duration from ICU admission to death was 7 (IQR 3-11) days in the non-survivors 5 .", [["critically ill", "DISEASE", 21, 35], ["critically ill", "DISEASE", 138, 152], ["death", "DISEASE", 421, 426], ["patients", "ORGANISM", 36, 44], ["patients", "ORGANISM", 153, 161], ["patients", "ORGANISM", 341, 349], ["patients", "SPECIES", 36, 44], ["patients", "SPECIES", 153, 161], ["patients", "SPECIES", 341, 349], ["a study", "TEST", 124, 131]]], ["Many clinical studies have also suggested that patients with COVID-19 have multiple organ damage, including the circulatory system, urinary system, nervous system, and digestive system, among others.", [["organ", "ANATOMY", 84, 89], ["circulatory system", "ANATOMY", 112, 130], ["urinary system", "ANATOMY", 132, 146], ["nervous system", "ANATOMY", 148, 162], ["digestive system", "ANATOMY", 168, 184], ["organ damage", "DISEASE", 84, 96], ["patients", "ORGANISM", 47, 55], ["organ", "ORGAN", 84, 89], ["circulatory system", "ANATOMICAL_SYSTEM", 112, 130], ["urinary system", "MULTI-TISSUE_STRUCTURE", 132, 146], ["nervous system", "ANATOMICAL_SYSTEM", 148, 162], ["digestive", "ORGAN", 168, 177], ["system", "ANATOMICAL_SYSTEM", 178, 184], ["patients", "SPECIES", 47, 55], ["Many clinical studies", "TEST", 0, 21], ["COVID", "TEST", 61, 66], ["multiple organ damage", "PROBLEM", 75, 96], ["organ", "ANATOMY", 84, 89], ["damage", "OBSERVATION", 90, 96], ["circulatory system", "ANATOMY", 112, 130], ["urinary system", "ANATOMY", 132, 146], ["nervous system", "ANATOMY", 148, 162], ["digestive system", "ANATOMY", 168, 184]]], ["The presence and number of these complications are high-risk factors that aggravate a patient's condition and correlate with a poor prognosis.Clinical features of COVID-19 with liver injuryThe whole genome sequencing results showed that SARS-CoV-2 shares 82% genome sequence similarity to SARS-CoV, and 50% genome sequence homology to Middle East respiratory syndrome coronavirus (MERS-CoV) 22 SARS-CoV, Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and SARS-CoV-2 are all coronaviruses and known to cause severe respiratory symptoms 11 .", [["liver", "ANATOMY", 177, 182], ["respiratory", "ANATOMY", 523, 534], ["liver injury", "DISEASE", 177, 189], ["SARS", "DISEASE", 289, 293], ["Middle East respiratory syndrome coronavirus", "DISEASE", 335, 379], ["Middle East Respiratory Syndrome Coronavirus", "DISEASE", 404, 448], ["respiratory symptoms", "DISEASE", 523, 543], ["patient", "ORGANISM", 86, 93], ["liver", "ORGAN", 177, 182], ["SARS-CoV-2", "ORGANISM", 237, 247], ["SARS-CoV", "ORGANISM", 289, 297], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 335, 379], ["MERS-CoV", "ORGANISM", 381, 389], ["SARS-CoV", "ORGANISM", 394, 402], ["Middle East Respiratory Syndrome Coronavirus", "ORGANISM", 404, 448], ["MERS-CoV", "ORGANISM", 450, 458], ["SARS-CoV-2", "ORGANISM", 464, 474], ["coronaviruses", "ORGANISM", 483, 496], ["SARS-CoV-2", "DNA", 237, 247], ["patient", "SPECIES", 86, 93], ["SARS-CoV-2", "SPECIES", 464, 474], ["SARS-CoV", "SPECIES", 237, 245], ["SARS-CoV", "SPECIES", 289, 297], ["Middle East respiratory syndrome coronavirus", "SPECIES", 335, 379], ["MERS-CoV", "SPECIES", 381, 389], ["SARS-CoV", "SPECIES", 394, 402], ["Middle East Respiratory Syndrome Coronavirus (MERS-CoV", "SPECIES", 404, 458], ["SARS-CoV-2", "SPECIES", 464, 474], ["these complications", "PROBLEM", 27, 46], ["a patient's condition", "PROBLEM", 84, 105], ["COVID", "TEST", 163, 168], ["liver injury", "PROBLEM", 177, 189], ["The whole genome sequencing", "TEST", 189, 216], ["SARS", "TEST", 237, 241], ["CoV", "TEST", 242, 245], ["SARS", "TEST", 289, 293], ["CoV", "TEST", 294, 297], ["genome sequence homology", "TEST", 307, 331], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 335, 379], ["SARS", "PROBLEM", 394, 398], ["CoV", "PROBLEM", 399, 402], ["Middle East Respiratory Syndrome", "PROBLEM", 404, 436], ["Coronavirus", "PROBLEM", 437, 448], ["SARS", "PROBLEM", 464, 468], ["all coronaviruses", "PROBLEM", 479, 496], ["severe respiratory symptoms", "PROBLEM", 516, 543], ["number", "OBSERVATION_MODIFIER", 17, 23], ["complications", "OBSERVATION", 33, 46], ["liver", "ANATOMY", 177, 182], ["injury", "OBSERVATION", 183, 189], ["Middle", "ANATOMY_MODIFIER", 335, 341], ["respiratory syndrome", "OBSERVATION", 347, 367], ["Middle", "ANATOMY_MODIFIER", 404, 410], ["Respiratory Syndrome", "OBSERVATION", 416, 436]]], ["As many as 60% of patients infected with SARS-CoV have liver damage 23 , and some patients infected with MERS-CoV also have liver damage 24 19 .Clinical features of COVID-19 with liver injuryThe above indicate that the incidence of liver injury in severe or critically ill cases is significantly higher than that in mild cases of COVID-19, and the probability of patients with liver function impairment requiring ICU treatment is increased.", [["liver", "ANATOMY", 55, 60], ["liver", "ANATOMY", 124, 129], ["liver", "ANATOMY", 179, 184], ["liver", "ANATOMY", 232, 237], ["liver", "ANATOMY", 377, 382], ["SARS", "DISEASE", 41, 45], ["liver damage", "DISEASE", 55, 67], ["liver damage", "DISEASE", 124, 136], ["liver injury", "DISEASE", 179, 191], ["liver injury", "DISEASE", 232, 244], ["critically ill", "DISEASE", 258, 272], ["liver function impairment", "DISEASE", 377, 402], ["patients", "ORGANISM", 18, 26], ["SARS-CoV", "ORGANISM", 41, 49], ["liver", "ORGAN", 55, 60], ["patients", "ORGANISM", 82, 90], ["MERS-CoV", "ORGANISM", 105, 113], ["liver", "ORGAN", 124, 129], ["liver", "ORGAN", 179, 184], ["liver", "ORGAN", 232, 237], ["patients", "ORGANISM", 363, 371], ["liver", "ORGAN", 377, 382], ["patients", "SPECIES", 18, 26], ["patients", "SPECIES", 82, 90], ["patients", "SPECIES", 363, 371], ["SARS-CoV", "SPECIES", 41, 49], ["MERS-CoV", "SPECIES", 105, 113], ["SARS", "PROBLEM", 41, 45], ["liver damage", "PROBLEM", 55, 67], ["liver damage", "PROBLEM", 124, 136], ["COVID", "TEST", 165, 170], ["liver injury", "PROBLEM", 179, 191], ["liver injury", "PROBLEM", 232, 244], ["critically ill cases", "PROBLEM", 258, 278], ["COVID", "TEST", 330, 335], ["liver function impairment", "PROBLEM", 377, 402], ["ICU treatment", "TREATMENT", 413, 426], ["infected", "OBSERVATION", 27, 35], ["liver", "ANATOMY", 55, 60], ["infected", "OBSERVATION", 91, 99], ["liver", "ANATOMY", 124, 129], ["liver", "ANATOMY", 179, 184], ["injury", "OBSERVATION", 185, 191], ["liver", "ANATOMY", 232, 237], ["injury", "OBSERVATION", 238, 244], ["severe", "OBSERVATION_MODIFIER", 248, 254], ["significantly", "OBSERVATION_MODIFIER", 282, 295], ["higher", "OBSERVATION_MODIFIER", 296, 302], ["mild", "OBSERVATION_MODIFIER", 316, 320], ["liver", "ANATOMY", 377, 382], ["increased", "OBSERVATION_MODIFIER", 430, 439]]], ["Another single-center study of 138 patients with COVID-19 showed that the levels of ALT and AST in patients who required ICU treatment were significantly higher than those in patients who did not require ICU treatment 10 .", [["patients", "ORGANISM", 35, 43], ["ALT", "GENE_OR_GENE_PRODUCT", 84, 87], ["AST", "SIMPLE_CHEMICAL", 92, 95], ["patients", "ORGANISM", 99, 107], ["patients", "ORGANISM", 175, 183], ["ALT", "PROTEIN", 84, 87], ["AST", "PROTEIN", 92, 95], ["patients", "SPECIES", 35, 43], ["patients", "SPECIES", 99, 107], ["patients", "SPECIES", 175, 183], ["center study", "TEST", 15, 27], ["COVID", "TEST", 49, 54], ["the levels", "TEST", 70, 80], ["ALT", "TEST", 84, 87], ["AST", "TEST", 92, 95], ["ICU treatment", "TREATMENT", 121, 134], ["ICU treatment", "TREATMENT", 204, 217], ["ALT", "ANATOMY", 84, 87]]], ["Moreover, in a large cohort of 1099 patients from 552 hospitals in 31 provinces or provincial municipalities, the total incidence of elevated total bilirubin was approximately 10%, of which the incidence in severe and nonsevere patients was approximately 13.3% and 9.9%, respectively; the incidence of increased total bilirubin in patients who needed to be moved to the ICU, needed mechanical ventilation, or died was higher than in other patients (20.8% vs 9.8%) 5 .", [["bilirubin", "CHEMICAL", 148, 157], ["bilirubin", "CHEMICAL", 318, 327], ["bilirubin", "CHEMICAL", 148, 157], ["bilirubin", "CHEMICAL", 318, 327], ["patients", "ORGANISM", 36, 44], ["bilirubin", "GENE_OR_GENE_PRODUCT", 148, 157], ["patients", "ORGANISM", 228, 236], ["bilirubin", "GENE_OR_GENE_PRODUCT", 318, 327], ["patients", "ORGANISM", 331, 339], ["patients", "ORGANISM", 439, 447], ["patients", "SPECIES", 36, 44], ["patients", "SPECIES", 228, 236], ["patients", "SPECIES", 331, 339], ["patients", "SPECIES", 439, 447], ["elevated total bilirubin", "PROBLEM", 133, 157], ["increased total bilirubin", "PROBLEM", 302, 327], ["mechanical ventilation", "TREATMENT", 382, 404], ["large", "OBSERVATION_MODIFIER", 15, 20], ["elevated", "OBSERVATION_MODIFIER", 133, 141], ["severe", "OBSERVATION_MODIFIER", 207, 213], ["nonsevere", "OBSERVATION_MODIFIER", 218, 227], ["increased", "OBSERVATION_MODIFIER", 302, 311], ["total bilirubin", "OBSERVATION", 312, 327]]], ["The above studies suggest that liver biochemical indicators may be used as predictors of severity and prognosis of COVID-19 patients.", [["liver", "ANATOMY", 31, 36], ["liver", "ORGAN", 31, 36], ["patients", "ORGANISM", 124, 132], ["patients", "SPECIES", 124, 132], ["The above studies", "TEST", 0, 17], ["COVID", "TEST", 115, 120], ["liver", "ANATOMY", 31, 36]]], ["Thus, clinicians should pay more attention to changes in liver biochemical indicators and also identify patients with liver damage in a timely manner.Direct damageThe results from biopsies in a death COVID-19 patient showed moderate microvascular steatosis and mild portal and lobular activity in liver tissue 25 .", [["liver", "ANATOMY", 57, 62], ["liver", "ANATOMY", 118, 123], ["biopsies", "ANATOMY", 180, 188], ["microvascular", "ANATOMY", 233, 246], ["portal", "ANATOMY", 266, 272], ["lobular", "ANATOMY", 277, 284], ["liver tissue", "ANATOMY", 297, 309], ["liver damage", "DISEASE", 118, 130], ["death", "DISEASE", 194, 199], ["steatosis", "DISEASE", 247, 256], ["liver", "ORGAN", 57, 62], ["patients", "ORGANISM", 104, 112], ["liver", "ORGAN", 118, 123], ["biopsies", "CANCER", 180, 188], ["patient", "ORGANISM", 209, 216], ["microvascular", "TISSUE", 233, 246], ["portal", "MULTI-TISSUE_STRUCTURE", 266, 272], ["lobular", "CANCER", 277, 284], ["liver tissue", "TISSUE", 297, 309], ["patients", "SPECIES", 104, 112], ["patient", "SPECIES", 209, 216], ["liver biochemical indicators", "TEST", 57, 85], ["liver damage", "PROBLEM", 118, 130], ["Direct damage", "PROBLEM", 150, 163], ["biopsies", "TEST", 180, 188], ["a death COVID", "TEST", 192, 205], ["moderate microvascular steatosis", "PROBLEM", 224, 256], ["mild portal and lobular activity in liver tissue", "PROBLEM", 261, 309], ["liver", "ANATOMY", 57, 62], ["liver", "ANATOMY", 118, 123], ["damage", "OBSERVATION", 124, 130], ["damage", "OBSERVATION", 157, 163], ["moderate", "OBSERVATION_MODIFIER", 224, 232], ["microvascular", "ANATOMY", 233, 246], ["steatosis", "OBSERVATION", 247, 256], ["mild", "OBSERVATION_MODIFIER", 261, 265], ["portal", "ANATOMY", 266, 272], ["lobular activity", "OBSERVATION", 277, 293], ["liver", "ANATOMY", 297, 302]]], ["In another four autopsy in a death COVID-19 patient showed mild zone 3 sinusoidal dilatation, patchy hepatic necrosis, mild increase in sinusoidal lymphocytes are the main pathologic changes of liver in case 3 and case 4, and RT-PCR showed direct evidence of the SARS-CoV-2 RNA sequence in the liver tissues in case 1 26 .Direct damageThrough learning of Tian et al report 26 , Li et al observed foci of hepatic necrosis in adjacent to terminal hepatic veins and peri-portal area, and found no significant surrounding inflammatory cellular infiltration, which consistent with the pattern of acute liver injury 27 .", [["sinusoidal", "ANATOMY", 71, 81], ["hepatic", "ANATOMY", 101, 108], ["sinusoidal lymphocytes", "ANATOMY", 136, 158], ["liver", "ANATOMY", 194, 199], ["liver tissues", "ANATOMY", 294, 307], ["foci", "ANATOMY", 396, 400], ["hepatic", "ANATOMY", 404, 411], ["hepatic veins", "ANATOMY", 445, 458], ["peri-portal area", "ANATOMY", 463, 479], ["cellular", "ANATOMY", 531, 539], ["liver", "ANATOMY", 597, 602], ["death", "DISEASE", 29, 34], ["hepatic necrosis", "DISEASE", 101, 117], ["hepatic necrosis", "DISEASE", 404, 420], ["acute liver injury", "DISEASE", 591, 609], ["patient", "ORGANISM", 44, 51], ["hepatic", "ORGAN", 101, 108], ["sinusoidal lymphocytes", "CELL", 136, 158], ["liver", "ORGAN", 194, 199], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 263, 273], ["liver tissues", "TISSUE", 294, 307], ["hepatic", "PATHOLOGICAL_FORMATION", 404, 411], ["hepatic veins", "MULTI-TISSUE_STRUCTURE", 445, 458], ["peri-portal area", "TISSUE", 463, 479], ["cellular", "CELL", 531, 539], ["liver", "ORGAN", 597, 602], ["sinusoidal lymphocytes", "CELL_TYPE", 136, 158], ["SARS-CoV-2 RNA sequence", "DNA", 263, 286], ["patient", "SPECIES", 44, 51], ["a death COVID", "TEST", 27, 40], ["mild zone 3 sinusoidal dilatation", "PROBLEM", 59, 92], ["patchy hepatic necrosis", "PROBLEM", 94, 117], ["mild increase in sinusoidal lymphocytes", "PROBLEM", 119, 158], ["RT-PCR", "TEST", 226, 232], ["the SARS", "TEST", 259, 267], ["CoV", "TEST", 268, 271], ["RNA sequence", "TEST", 274, 286], ["Direct damage", "PROBLEM", 322, 335], ["hepatic necrosis", "PROBLEM", 404, 420], ["significant surrounding inflammatory cellular infiltration", "PROBLEM", 494, 552], ["acute liver injury", "PROBLEM", 591, 609], ["mild", "OBSERVATION_MODIFIER", 59, 63], ["zone", "OBSERVATION_MODIFIER", 64, 68], ["sinusoidal dilatation", "OBSERVATION", 71, 92], ["patchy", "OBSERVATION_MODIFIER", 94, 100], ["hepatic", "ANATOMY", 101, 108], ["necrosis", "OBSERVATION", 109, 117], ["mild", "OBSERVATION_MODIFIER", 119, 123], ["increase", "OBSERVATION_MODIFIER", 124, 132], ["sinusoidal lymphocytes", "OBSERVATION", 136, 158], ["main", "OBSERVATION_MODIFIER", 167, 171], ["pathologic", "OBSERVATION", 172, 182], ["liver", "ANATOMY", 194, 199], ["SARS", "OBSERVATION", 263, 267], ["liver tissues", "ANATOMY", 294, 307], ["damage", "OBSERVATION", 329, 335], ["foci", "OBSERVATION", 396, 400], ["hepatic", "ANATOMY", 404, 411], ["necrosis", "OBSERVATION", 412, 420], ["terminal", "ANATOMY_MODIFIER", 436, 444], ["hepatic veins", "ANATOMY", 445, 458], ["peri-portal area", "ANATOMY", 463, 479], ["no", "UNCERTAINTY", 491, 493], ["significant", "OBSERVATION_MODIFIER", 494, 505], ["surrounding", "OBSERVATION_MODIFIER", 506, 517], ["inflammatory", "OBSERVATION_MODIFIER", 518, 530], ["cellular infiltration", "OBSERVATION", 531, 552], ["consistent with", "UNCERTAINTY", 560, 575], ["acute", "OBSERVATION_MODIFIER", 591, 596], ["liver", "ANATOMY", 597, 602], ["injury", "OBSERVATION", 603, 609]]], ["The above studies may indicate that hepatic injuries may be related to direct viral attack.", [["hepatic", "ANATOMY", 36, 43], ["hepatic injuries", "DISEASE", 36, 52], ["hepatic", "ORGAN", 36, 43], ["The above studies", "TEST", 0, 17], ["hepatic injuries", "PROBLEM", 36, 52], ["direct viral attack", "PROBLEM", 71, 90], ["hepatic", "ANATOMY", 36, 43], ["injuries", "OBSERVATION", 44, 52], ["may be related to", "UNCERTAINTY", 53, 70], ["viral attack", "OBSERVATION", 78, 90]]], ["It has been confirmed that SARS-CoV-2 enters host cells through binding of its S protein to angiotensin-converting enzyme 2 (ACE2) on the surface of the host cell.", [["cells", "ANATOMY", 50, 55], ["surface", "ANATOMY", 138, 145], ["cell", "ANATOMY", 158, 162], ["angiotensin", "CHEMICAL", 92, 103], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 27, 37], ["host cells", "CELL", 45, 55], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 92, 123], ["ACE2", "GENE_OR_GENE_PRODUCT", 125, 129], ["surface", "CELLULAR_COMPONENT", 138, 145], ["host cell", "CELL", 153, 162], ["host cells", "CELL_TYPE", 45, 55], ["S protein", "PROTEIN", 79, 88], ["angiotensin-converting enzyme 2", "PROTEIN", 92, 123], ["ACE2", "PROTEIN", 125, 129], ["host cell", "CELL_TYPE", 153, 162], ["SARS", "TEST", 27, 31], ["CoV", "TEST", 32, 35], ["angiotensin", "TEST", 92, 103], ["enzyme", "TEST", 115, 121], ["SARS", "OBSERVATION", 27, 31], ["host cell", "OBSERVATION", 153, 162]]], ["ACE2 is the most important cell receptor that mediates the entry of SARS-CoV-2 into target cells [28] [29] .", [["cell", "ANATOMY", 27, 31], ["cells", "ANATOMY", 91, 96], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["cell", "CELL", 27, 31], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 68, 78], ["cells", "CELL", 91, 96], ["ACE2", "PROTEIN", 0, 4], ["target cells", "CELL_TYPE", 84, 96], ["ACE2", "TREATMENT", 0, 4], ["SARS", "TEST", 68, 72], ["CoV", "TEST", 73, 76]]], ["However, based on single-cell sequencing and animal model analysis of liver tissue, ChaiX's team found that the expression level of ACE2 in liver tissue was only approximately 0.31% and that specific expression of ACE2 in bile duct epithelial cells was 20 This article is protected by copyright.", [["liver tissue", "ANATOMY", 70, 82], ["liver tissue", "ANATOMY", 140, 152], ["bile duct epithelial cells", "ANATOMY", 222, 248], ["liver tissue", "TISSUE", 70, 82], ["ACE2", "GENE_OR_GENE_PRODUCT", 132, 136], ["liver tissue", "TISSUE", 140, 152], ["ACE2", "GENE_OR_GENE_PRODUCT", 214, 218], ["bile duct epithelial cells", "CELL", 222, 248], ["ACE2", "PROTEIN", 132, 136], ["ACE2", "PROTEIN", 214, 218], ["bile duct epithelial cells", "CELL_TYPE", 222, 248], ["single-cell sequencing", "TEST", 18, 40], ["animal model analysis", "TEST", 45, 66], ["ACE2 in liver tissue", "TEST", 132, 152], ["ACE2 in bile duct epithelial cells", "TEST", 214, 248], ["liver", "ANATOMY", 70, 75], ["liver tissue", "ANATOMY", 140, 152], ["bile duct", "ANATOMY", 222, 231], ["epithelial cells", "OBSERVATION", 232, 248]]], ["All rights reserved.Accepted Articletimes higher than that in hepatocyte 30 .", [["hepatocyte", "ANATOMY", 62, 72], ["hepatocyte 30", "CELL", 62, 75], ["higher", "OBSERVATION_MODIFIER", 42, 48], ["hepatocyte", "ANATOMY", 62, 72]]], ["Considering limited number of autopsy cases in patients with COVID-19 studied and the relatively low expression of ACE2 in liver, liver damage directly caused by SARS-CoV-2 infection of hepatocytes deserves further investigation.", [["liver", "ANATOMY", 123, 128], ["liver", "ANATOMY", 130, 135], ["hepatocytes", "ANATOMY", 186, 197], ["liver damage", "DISEASE", 130, 142], ["SARS", "DISEASE", 162, 166], ["infection", "DISEASE", 173, 182], ["COVID-19", "CHEMICAL", 61, 69], ["patients", "ORGANISM", 47, 55], ["ACE2", "GENE_OR_GENE_PRODUCT", 115, 119], ["liver", "ORGAN", 123, 128], ["liver", "ORGAN", 130, 135], ["SARS-CoV-2", "ORGANISM", 162, 172], ["hepatocytes", "CELL", 186, 197], ["ACE2", "PROTEIN", 115, 119], ["hepatocytes", "CELL_TYPE", 186, 197], ["patients", "SPECIES", 47, 55], ["SARS-CoV", "SPECIES", 162, 170], ["COVID", "TEST", 61, 66], ["ACE2 in liver", "PROBLEM", 115, 128], ["liver damage", "PROBLEM", 130, 142], ["SARS", "PROBLEM", 162, 166], ["CoV-2 infection of hepatocytes", "PROBLEM", 167, 197], ["further investigation", "TEST", 207, 228], ["liver", "ANATOMY", 123, 128], ["liver", "ANATOMY", 130, 135], ["damage", "OBSERVATION", 136, 142], ["SARS", "OBSERVATION", 162, 166], ["infection", "OBSERVATION", 173, 182], ["hepatocytes", "ANATOMY", 186, 197]]], ["Moreover, biomarkers for cholangiocyte injury, such as gamma-glutamyl transferase (GGT) and alkaline phosphatase (ALP) have also been seen in some patients 31 , and consistent with injury to biliary epithelial cells, and about 10% of COVID-19 patients have elevated total bilirubin level.These might suggest that SARS-CoV-2 might directly bind to cholangiocytes expressing ACE2 result in cholangiocyte injury.Accepted ArticleHuang C 18 and colleagues found that liver injury in COVID-19 patients differed from that in SARS patients.", [["cholangiocyte", "ANATOMY", 25, 38], ["biliary epithelial cells", "ANATOMY", 191, 215], ["cholangiocytes", "ANATOMY", 347, 361], ["cholangiocyte", "ANATOMY", 388, 401], ["liver", "ANATOMY", 462, 467], ["cholangiocyte injury", "DISEASE", 25, 45], ["bilirubin", "CHEMICAL", 272, 281], ["liver injury", "DISEASE", 462, 474], ["SARS", "DISEASE", 518, 522], ["gamma-glutamyl", "CHEMICAL", 55, 69], ["bilirubin", "CHEMICAL", 272, 281], ["gamma-glutamyl transferase", "GENE_OR_GENE_PRODUCT", 55, 81], ["GGT", "GENE_OR_GENE_PRODUCT", 83, 86], ["alkaline phosphatase", "GENE_OR_GENE_PRODUCT", 92, 112], ["ALP", "GENE_OR_GENE_PRODUCT", 114, 117], ["patients", "ORGANISM", 147, 155], ["biliary epithelial cells", "CELL", 191, 215], ["patients", "ORGANISM", 243, 251], ["bilirubin", "GENE_OR_GENE_PRODUCT", 272, 281], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 313, 323], ["cholangiocytes", "CELL", 347, 361], ["ACE2", "GENE_OR_GENE_PRODUCT", 373, 377], ["cholangiocyte", "CANCER", 388, 401], ["liver", "ORGAN", 462, 467], ["patients", "ORGANISM", 487, 495], ["patients", "ORGANISM", 523, 531], ["gamma-glutamyl transferase", "PROTEIN", 55, 81], ["GGT", "PROTEIN", 83, 86], ["alkaline phosphatase", "PROTEIN", 92, 112], ["ALP", "PROTEIN", 114, 117], ["biliary epithelial cells", "CELL_TYPE", 191, 215], ["ACE2", "PROTEIN", 373, 377], ["patients", "SPECIES", 147, 155], ["patients", "SPECIES", 243, 251], ["patients", "SPECIES", 487, 495], ["patients", "SPECIES", 523, 531], ["SARS-CoV", "SPECIES", 313, 321], ["biomarkers", "TEST", 10, 20], ["cholangiocyte injury", "PROBLEM", 25, 45], ["gamma-glutamyl transferase", "TEST", 55, 81], ["GGT", "TEST", 83, 86], ["alkaline phosphatase (ALP", "TEST", 92, 117], ["injury to biliary epithelial cells", "PROBLEM", 181, 215], ["COVID", "TEST", 234, 239], ["elevated total bilirubin level", "PROBLEM", 257, 287], ["SARS", "PROBLEM", 313, 317], ["cholangiocyte injury", "PROBLEM", 388, 408], ["liver injury", "PROBLEM", 462, 474], ["COVID", "TEST", 478, 483], ["cholangiocyte", "ANATOMY", 25, 38], ["consistent with", "UNCERTAINTY", 165, 180], ["injury", "OBSERVATION", 181, 187], ["biliary epithelial", "ANATOMY", 191, 209], ["elevated", "OBSERVATION_MODIFIER", 257, 265], ["total bilirubin", "OBSERVATION", 266, 281], ["SARS", "OBSERVATION", 313, 317], ["cholangiocyte", "ANATOMY", 388, 401], ["injury", "OBSERVATION", 402, 408], ["liver", "ANATOMY", 462, 467], ["injury", "OBSERVATION", 468, 474]]], ["Liver injury as the first manifestation in COVID-19 patients was very rare, with most being secondary liver injury.", [["Liver", "ANATOMY", 0, 5], ["liver", "ANATOMY", 102, 107], ["Liver injury", "DISEASE", 0, 12], ["liver injury", "DISEASE", 102, 114], ["Liver", "ORGAN", 0, 5], ["patients", "ORGANISM", 52, 60], ["liver", "ORGAN", 102, 107], ["patients", "SPECIES", 52, 60], ["Liver injury", "PROBLEM", 0, 12], ["COVID", "TEST", 43, 48], ["secondary liver injury", "PROBLEM", 92, 114], ["injury", "OBSERVATION", 6, 12], ["liver", "ANATOMY", 102, 107], ["injury", "OBSERVATION", 108, 114]]], ["It was speculated that in addition to the virus itself causing liver injury, immune injury, systemic inflammatory response syndrome (SIRS), cytokine storms, ischemia and hypoxia reperfusion injury, and drug-induced injury may be the main mechanisms that cause secondary liver injury in patients with COVID-19 [11] [12] 14, 27 .Antibody-dependent enhancement (ADE)In addition to receptor-mediated viral infection, antibody-dependent enhancement of infection (ADE) may occur in patients with SARS 32 .", [["liver", "ANATOMY", 63, 68], ["liver", "ANATOMY", 270, 275], ["liver injury", "DISEASE", 63, 75], ["immune injury", "DISEASE", 77, 90], ["systemic inflammatory response syndrome", "DISEASE", 92, 131], ["SIRS", "DISEASE", 133, 137], ["ischemia", "DISEASE", 157, 165], ["hypoxia", "DISEASE", 170, 177], ["drug-induced injury", "DISEASE", 202, 221], ["liver injury", "DISEASE", 270, 282], ["viral infection", "DISEASE", 396, 411], ["infection", "DISEASE", 447, 456], ["ADE", "DISEASE", 458, 461], ["SARS", "DISEASE", 490, 494], ["COVID-19", "CHEMICAL", 300, 308], ["liver", "ORGAN", 63, 68], ["liver", "ORGAN", 270, 275], ["patients", "ORGANISM", 286, 294], ["patients", "ORGANISM", 476, 484], ["cytokine", "PROTEIN", 140, 148], ["patients", "SPECIES", 286, 294], ["patients", "SPECIES", 476, 484], ["the virus", "PROBLEM", 38, 47], ["liver injury", "PROBLEM", 63, 75], ["immune injury", "PROBLEM", 77, 90], ["systemic inflammatory response syndrome", "PROBLEM", 92, 131], ["SIRS", "PROBLEM", 133, 137], ["cytokine storms", "PROBLEM", 140, 155], ["ischemia", "PROBLEM", 157, 165], ["hypoxia reperfusion injury", "PROBLEM", 170, 196], ["drug-induced injury", "PROBLEM", 202, 221], ["secondary liver injury", "PROBLEM", 260, 282], ["COVID", "TEST", 300, 305], ["Antibody", "TEST", 327, 335], ["dependent enhancement", "PROBLEM", 336, 357], ["receptor-mediated viral infection", "PROBLEM", 378, 411], ["antibody", "TEST", 413, 421], ["dependent enhancement of infection", "PROBLEM", 422, 456], ["SARS", "PROBLEM", 490, 494], ["virus", "OBSERVATION", 42, 47], ["liver", "ANATOMY", 63, 68], ["injury", "OBSERVATION", 69, 75], ["systemic", "OBSERVATION_MODIFIER", 92, 100], ["inflammatory response syndrome", "OBSERVATION", 101, 131], ["ischemia", "OBSERVATION", 157, 165], ["hypoxia", "OBSERVATION_MODIFIER", 170, 177], ["reperfusion injury", "OBSERVATION", 178, 196], ["liver", "ANATOMY", 270, 275], ["injury", "OBSERVATION", 276, 282], ["dependent enhancement", "OBSERVATION_MODIFIER", 336, 357], ["viral", "OBSERVATION_MODIFIER", 396, 401], ["infection", "OBSERVATION", 402, 411], ["dependent", "OBSERVATION_MODIFIER", 422, 431], ["enhancement", "OBSERVATION_MODIFIER", 432, 443], ["infection", "OBSERVATION", 447, 456]]], ["ADE refers to the interaction of a virus-specific antibody with Fc receptor (FcR) and/or complement receptor (CR) to enhance the ability of the virus to enter granulocytes, monocytes, and macrophages.", [["granulocytes", "ANATOMY", 159, 171], ["monocytes", "ANATOMY", 173, 182], ["macrophages", "ANATOMY", 188, 199], ["ADE", "DISEASE", 0, 3], ["Fc receptor", "GENE_OR_GENE_PRODUCT", 64, 75], ["FcR", "GENE_OR_GENE_PRODUCT", 77, 80], ["complement receptor", "GENE_OR_GENE_PRODUCT", 89, 108], ["CR", "GENE_OR_GENE_PRODUCT", 110, 112], ["granulocytes", "CELL", 159, 171], ["monocytes", "CELL", 173, 182], ["macrophages", "CELL", 188, 199], ["virus-specific antibody", "PROTEIN", 35, 58], ["Fc receptor", "PROTEIN", 64, 75], ["FcR", "PROTEIN", 77, 80], ["complement receptor", "PROTEIN", 89, 108], ["CR", "PROTEIN", 110, 112], ["granulocytes", "CELL_TYPE", 159, 171], ["monocytes", "CELL_TYPE", 173, 182], ["macrophages", "CELL_TYPE", 188, 199], ["a virus", "TEST", 33, 40], ["specific antibody", "TEST", 41, 58], ["complement receptor (CR", "TEST", 89, 112], ["the virus", "PROBLEM", 140, 149], ["granulocytes", "TEST", 159, 171], ["monocytes", "TEST", 173, 182], ["macrophages", "ANATOMY", 188, 199]]], ["The virus constantly replicates in the above cells, resulting in increased virus production and aggravating infection.Antibody-dependent enhancement (ADE)Previous studies have reported that antibodies against the SARS-CoV spike protein trigger ADE, causing SARS-CoV to enter immune cells that do not express ACE2 and immune damage 33 .", [["cells", "ANATOMY", 45, 50], ["immune cells", "ANATOMY", 275, 287], ["infection", "DISEASE", 108, 117], ["cells", "CELL", 45, 50], ["SARS-CoV", "ORGANISM", 213, 221], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 257, 265], ["immune cells", "CELL", 275, 287], ["ACE2", "GENE_OR_GENE_PRODUCT", 308, 312], ["antibodies", "PROTEIN", 190, 200], ["SARS-CoV spike protein", "PROTEIN", 213, 235], ["immune cells", "CELL_TYPE", 275, 287], ["ACE2", "PROTEIN", 308, 312], ["SARS-CoV", "SPECIES", 213, 221], ["SARS-CoV", "SPECIES", 257, 265], ["The virus", "PROBLEM", 0, 9], ["increased virus production", "PROBLEM", 65, 91], ["aggravating infection", "PROBLEM", 96, 117], ["Antibody", "TEST", 118, 126], ["dependent enhancement", "PROBLEM", 127, 148], ["Previous studies", "TEST", 154, 170], ["antibodies", "TEST", 190, 200], ["the SARS", "PROBLEM", 209, 217], ["CoV spike protein trigger ADE", "PROBLEM", 218, 247], ["SARS", "PROBLEM", 257, 261], ["CoV", "PROBLEM", 262, 265], ["immune cells", "PROBLEM", 275, 287], ["ACE2", "TEST", 308, 312], ["immune damage", "PROBLEM", 317, 330], ["virus", "OBSERVATION", 4, 9], ["above cells", "OBSERVATION", 39, 50], ["increased", "OBSERVATION_MODIFIER", 65, 74], ["virus production", "OBSERVATION", 75, 91], ["aggravating", "OBSERVATION_MODIFIER", 96, 107], ["infection", "OBSERVATION", 108, 117], ["dependent enhancement", "OBSERVATION_MODIFIER", 127, 148]]], ["The liver contains a large number of cells related to the immune response.", [["liver", "ANATOMY", 4, 9], ["cells", "ANATOMY", 37, 42], ["liver", "ORGAN", 4, 9], ["cells", "CELL", 37, 42], ["a large number of cells", "PROBLEM", 19, 42], ["liver", "ANATOMY", 4, 9], ["large", "OBSERVATION_MODIFIER", 21, 26], ["number of cells", "OBSERVATION", 27, 42], ["immune response", "OBSERVATION", 58, 73]]], ["Whether ADE can also mediate SARS-CoV-2 to This article is protected by copyright.", [["ADE", "DISEASE", 8, 11]]], ["All rights reserved.Accepted Articleinfect immune cells by a non-ACE2-dependent pathway and participate in liver injury caused by SARS-CoV-2 is a concern.Accepted ArticleSystemic Inflammatory Response Syndrome (SIRS) and Cytokine Storms(Accepted Articleas the liver, myocardium and kidney.", [["Articleinfect immune cells", "ANATOMY", 29, 55], ["liver", "ANATOMY", 107, 112], ["liver", "ANATOMY", 260, 265], ["myocardium", "ANATOMY", 267, 277], ["kidney", "ANATOMY", 282, 288], ["liver injury", "DISEASE", 107, 119], ["SARS", "DISEASE", 130, 134], ["SIRS", "DISEASE", 211, 215], ["Articleinfect immune cells", "CELL", 29, 55], ["non-ACE2", "GENE_OR_GENE_PRODUCT", 61, 69], ["liver", "ORGAN", 107, 112], ["SARS-CoV-2", "ORGANISM", 130, 140], ["liver", "ORGAN", 260, 265], ["myocardium", "MULTI-TISSUE_STRUCTURE", 267, 277], ["kidney", "ORGAN", 282, 288], ["Articleinfect immune cells", "CELL_LINE", 29, 55], ["non-ACE2", "PROTEIN", 61, 69], ["Cytokine", "PROTEIN", 221, 229], ["SARS-CoV", "SPECIES", 130, 138], ["Articleinfect immune cells", "TREATMENT", 29, 55], ["a non-ACE2-dependent pathway", "TREATMENT", 59, 87], ["liver injury", "PROBLEM", 107, 119], ["SARS", "PROBLEM", 130, 134], ["ArticleSystemic Inflammatory Response Syndrome", "PROBLEM", 163, 209], ["SIRS", "PROBLEM", 211, 215], ["Cytokine Storms", "PROBLEM", 221, 236], ["immune cells", "OBSERVATION", 43, 55], ["liver", "ANATOMY", 107, 112], ["injury", "OBSERVATION", 113, 119], ["Inflammatory Response Syndrome", "OBSERVATION", 179, 209], ["Cytokine Storms", "OBSERVATION", 221, 236], ["liver", "ANATOMY", 260, 265], ["myocardium", "ANATOMY", 267, 277], ["kidney", "ANATOMY", 282, 288]]], ["These results suggest that the SIRS and cytokine storms caused by SARS-CoV-2 infection may be one of the important mechanisms of liver injury.Ischemia and hypoxia reperfusion injuryPatients with COVID-19 have varying degrees of hypoxemia, with more than 40% requiring oxygen therapy 5 Drug hepatotoxicity( Figure 2) In China, the incidence of drug-induced liver injury is second only to viral hepatitis and fatty liver disease (including alcoholic and non-alcoholic).", [["liver", "ANATOMY", 129, 134], ["liver", "ANATOMY", 356, 361], ["fatty liver", "ANATOMY", 407, 418], ["SIRS", "DISEASE", 31, 35], ["SARS", "DISEASE", 66, 70], ["infection", "DISEASE", 77, 86], ["liver injury", "DISEASE", 129, 141], ["Ischemia", "DISEASE", 142, 150], ["hypoxia", "DISEASE", 155, 162], ["hypoxemia", "DISEASE", 228, 237], ["oxygen", "CHEMICAL", 268, 274], ["hepatotoxicity", "DISEASE", 290, 304], ["liver injury", "DISEASE", 356, 368], ["viral hepatitis", "DISEASE", 387, 402], ["fatty liver disease", "DISEASE", 407, 426], ["alcoholic and non-alcoholic)", "DISEASE", 438, 466], ["COVID-19", "CHEMICAL", 195, 203], ["oxygen", "CHEMICAL", 268, 274], ["SARS-CoV-2", "ORGANISM", 66, 76], ["liver", "ORGAN", 129, 134], ["oxygen", "SIMPLE_CHEMICAL", 268, 274], ["liver", "ORGAN", 356, 361], ["liver", "ORGAN", 413, 418], ["cytokine", "PROTEIN", 40, 48], ["SARS-CoV", "SPECIES", 66, 74], ["the SIRS", "PROBLEM", 27, 35], ["cytokine storms", "PROBLEM", 40, 55], ["SARS", "PROBLEM", 66, 70], ["CoV-2 infection", "PROBLEM", 71, 86], ["liver injury", "PROBLEM", 129, 141], ["Ischemia", "PROBLEM", 142, 150], ["hypoxia reperfusion injuryPatients", "PROBLEM", 155, 189], ["COVID", "TEST", 195, 200], ["hypoxemia", "PROBLEM", 228, 237], ["oxygen therapy", "TREATMENT", 268, 282], ["Drug hepatotoxicity", "PROBLEM", 285, 304], ["drug-induced liver injury", "PROBLEM", 343, 368], ["viral hepatitis", "PROBLEM", 387, 402], ["fatty liver disease", "PROBLEM", 407, 426], ["infection", "OBSERVATION", 77, 86], ["liver", "ANATOMY", 129, 134], ["injury", "OBSERVATION", 135, 141], ["hypoxia reperfusion", "OBSERVATION", 155, 174], ["hypoxemia", "OBSERVATION", 228, 237], ["liver", "ANATOMY", 356, 361], ["injury", "OBSERVATION", 362, 368], ["viral", "OBSERVATION_MODIFIER", 387, 392], ["hepatitis", "OBSERVATION", 393, 402], ["fatty", "OBSERVATION", 407, 412], ["liver", "ANATOMY", 413, 418]]], ["Drugs commonly causing liver injury include traditional Chinese patent medicines containing components of saikosaponins [38] [39] , antitumor drugs, antituberculosis drugs, antimalarial drugs and antibiotics [40] [41] .", [["liver", "ANATOMY", 23, 28], ["antitumor", "ANATOMY", 132, 141], ["liver injury", "DISEASE", 23, 35], ["saikosaponins [38] [39]", "CHEMICAL", 106, 129], ["saikosaponins", "CHEMICAL", 106, 119], ["liver", "ORGAN", 23, 28], ["saikosaponins [38] [39]", "SIMPLE_CHEMICAL", 106, 129], ["antitumor", "CANCER", 132, 141], ["antituberculosis drugs", "SIMPLE_CHEMICAL", 149, 171], ["Drugs", "TREATMENT", 0, 5], ["liver injury", "PROBLEM", 23, 35], ["traditional Chinese patent medicines", "TREATMENT", 44, 80], ["saikosaponins", "TREATMENT", 106, 119], ["antitumor drugs", "TREATMENT", 132, 147], ["antituberculosis drugs", "TREATMENT", 149, 171], ["antimalarial drugs", "TREATMENT", 173, 191], ["antibiotics", "TREATMENT", 196, 207], ["liver", "ANATOMY", 23, 28], ["injury", "OBSERVATION", 29, 35]]], ["Most patients with COVID-19 have fever, and many of them use antipyretic and analgesic drugs, which contain This article is protected by copyright.", [["fever", "DISEASE", 33, 38], ["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["COVID", "TEST", 19, 24], ["fever", "PROBLEM", 33, 38], ["antipyretic", "TREATMENT", 61, 72], ["analgesic drugs", "TREATMENT", 77, 92]]], ["All rights reserved.Accepted Articleacetaminophen and are known to cause liver damage, overdose of these drugs can cause liver damage.", [["liver", "ANATOMY", 73, 78], ["liver", "ANATOMY", 121, 126], ["Articleacetaminophen", "CHEMICAL", 29, 49], ["liver damage", "DISEASE", 73, 85], ["overdose", "DISEASE", 87, 95], ["liver damage", "DISEASE", 121, 133], ["Articleacetaminophen", "CHEMICAL", 29, 49], ["Articleacetaminophen", "SIMPLE_CHEMICAL", 29, 49], ["liver", "ORGAN", 73, 78], ["liver", "ORGAN", 121, 126], ["Articleacetaminophen", "TREATMENT", 29, 49], ["liver damage", "PROBLEM", 73, 85], ["these drugs", "TREATMENT", 99, 110], ["liver damage", "PROBLEM", 121, 133], ["liver", "ANATOMY", 73, 78], ["damage", "OBSERVATION", 79, 85], ["liver", "ANATOMY", 121, 126], ["damage", "OBSERVATION", 127, 133]]], ["Currently, there is no clearly effective antiviral drug, and many patients in the outbreak were given lopinavir, abidor, ritonavir and other antiviral drugs.", [["lopinavir, abidor, ritonavir", "CHEMICAL", 102, 130], ["lopinavir", "CHEMICAL", 102, 111], ["abidor", "CHEMICAL", 113, 119], ["ritonavir", "CHEMICAL", 121, 130], ["patients", "ORGANISM", 66, 74], ["lopinavir", "SIMPLE_CHEMICAL", 102, 111], ["abidor", "SIMPLE_CHEMICAL", 113, 119], ["ritonavir", "SIMPLE_CHEMICAL", 121, 130], ["patients", "SPECIES", 66, 74], ["lopinavir", "TREATMENT", 102, 111], ["abidor", "TREATMENT", 113, 119], ["ritonavir", "TREATMENT", 121, 130], ["other antiviral drugs", "TREATMENT", 135, 156], ["no clearly", "UNCERTAINTY", 20, 30], ["effective", "OBSERVATION_MODIFIER", 31, 40], ["antiviral drug", "OBSERVATION", 41, 55]]], ["The latest study published in JCI 42 reported that CYP3A4 plays an important role in ritonavir's mediating of hepatotoxicity, and the CYP3A metabolic pathways can produce electrophilic content, oxygen free radical, etc, they can be covalent binding with macromolecular substances within the liver cells, cause system membrane lipid peroxidation, destruction of membrane integrity and membrane Ca 2 + -ATPase, disrupt cell internal and external Ca 2 + homeostasis, influence function of critical organelles such as mitochondria, endoplasmic reticulum, and eventually lead to liver cell damage and even death.Accepted ArticleMoreover, the combination of overdose of lopinavir and ritonavir can activate the endoplasmic reticulum stress pathway in the liver, inhibit the proliferation of hepatocytes, induce apoptosis of hepatocytes through the caspase cascade system, induce inflammatory reactions and accelerate liver injury by aggravating oxidative stress [43] [44] .", [["liver cells", "ANATOMY", 291, 302], ["membrane", "ANATOMY", 317, 325], ["membrane", "ANATOMY", 361, 369], ["membrane", "ANATOMY", 384, 392], ["cell", "ANATOMY", 417, 421], ["organelles", "ANATOMY", 495, 505], ["mitochondria", "ANATOMY", 514, 526], ["endoplasmic reticulum", "ANATOMY", 528, 549], ["liver cell", "ANATOMY", 574, 584], ["endoplasmic reticulum", "ANATOMY", 705, 726], ["liver", "ANATOMY", 749, 754], ["hepatocytes", "ANATOMY", 785, 796], ["hepatocytes", "ANATOMY", 818, 829], ["liver", "ANATOMY", 911, 916], ["ritonavir", "CHEMICAL", 85, 94], ["hepatotoxicity", "DISEASE", 110, 124], ["oxygen", "CHEMICAL", 194, 200], ["Ca", "CHEMICAL", 393, 395], ["Ca", "CHEMICAL", 444, 446], ["liver cell damage", "DISEASE", 574, 591], ["death", "DISEASE", 601, 606], ["overdose", "DISEASE", 652, 660], ["lopinavir", "CHEMICAL", 664, 673], ["ritonavir", "CHEMICAL", 678, 687], ["liver injury", "DISEASE", 911, 923], ["ritonavir", "CHEMICAL", 85, 94], ["oxygen", "CHEMICAL", 194, 200], ["Ca 2 +", "CHEMICAL", 393, 399], ["Ca 2 +", "CHEMICAL", 444, 450], ["lopinavir", "CHEMICAL", 664, 673], ["ritonavir", "CHEMICAL", 678, 687], ["CYP3A4", "GENE_OR_GENE_PRODUCT", 51, 57], ["ritonavir", "SIMPLE_CHEMICAL", 85, 94], ["CYP3A", "GENE_OR_GENE_PRODUCT", 134, 139], ["oxygen", "SIMPLE_CHEMICAL", 194, 200], ["free radical", "SIMPLE_CHEMICAL", 201, 213], ["liver cells", "CELL", 291, 302], ["membrane", "CELLULAR_COMPONENT", 361, 369], ["membrane", "CELLULAR_COMPONENT", 384, 392], ["Ca 2 + -ATPase", "GENE_OR_GENE_PRODUCT", 393, 407], ["cell", "CELL", 417, 421], ["Ca 2 +", "SIMPLE_CHEMICAL", 444, 450], ["organelles", "CELLULAR_COMPONENT", 495, 505], ["mitochondria", "CELLULAR_COMPONENT", 514, 526], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 528, 549], ["liver cell", "CELL", 574, 584], ["lopinavir", "SIMPLE_CHEMICAL", 664, 673], ["ritonavir", "SIMPLE_CHEMICAL", 678, 687], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 705, 726], ["liver", "ORGAN", 749, 754], ["hepatocytes", "CELL", 785, 796], ["hepatocytes", "CELL", 818, 829], ["caspase", "GENE_OR_GENE_PRODUCT", 842, 849], ["liver", "ORGAN", 911, 916], ["CYP3A4", "PROTEIN", 51, 57], ["CYP3A", "PROTEIN", 134, 139], ["liver cells", "CELL_TYPE", 291, 302], ["membrane Ca 2 + -ATPase", "PROTEIN", 384, 407], ["hepatocytes", "CELL_TYPE", 785, 796], ["hepatocytes", "CELL_TYPE", 818, 829], ["The latest study", "TEST", 0, 16], ["ritonavir", "TREATMENT", 85, 94], ["hepatotoxicity", "PROBLEM", 110, 124], ["electrophilic content", "PROBLEM", 171, 192], ["oxygen free radical", "TREATMENT", 194, 213], ["system membrane lipid peroxidation", "PROBLEM", 310, 344], ["destruction of membrane integrity", "PROBLEM", 346, 379], ["membrane Ca", "TEST", 384, 395], ["ATPase", "PROBLEM", 401, 407], ["critical organelles", "PROBLEM", 486, 505], ["endoplasmic reticulum", "PROBLEM", 528, 549], ["liver cell damage", "PROBLEM", 574, 591], ["death", "PROBLEM", 601, 606], ["lopinavir", "TREATMENT", 664, 673], ["ritonavir", "TREATMENT", 678, 687], ["the endoplasmic reticulum stress pathway in the liver", "PROBLEM", 701, 754], ["the proliferation of hepatocytes", "PROBLEM", 764, 796], ["apoptosis of hepatocytes", "PROBLEM", 805, 829], ["the caspase cascade system", "TREATMENT", 838, 864], ["inflammatory reactions", "PROBLEM", 873, 895], ["accelerate liver injury", "PROBLEM", 900, 923], ["aggravating oxidative stress", "PROBLEM", 927, 955], ["hepatotoxicity", "OBSERVATION", 110, 124], ["electrophilic content", "OBSERVATION", 171, 192], ["liver", "ANATOMY", 291, 296], ["lipid peroxidation", "OBSERVATION", 326, 344], ["membrane integrity", "OBSERVATION", 361, 379], ["cell", "OBSERVATION_MODIFIER", 417, 421], ["internal", "OBSERVATION_MODIFIER", 422, 430], ["external Ca", "ANATOMY", 435, 446], ["endoplasmic reticulum", "OBSERVATION", 528, 549], ["liver", "ANATOMY", 574, 579], ["cell damage", "OBSERVATION", 580, 591], ["liver", "ANATOMY", 749, 754], ["proliferation", "OBSERVATION", 768, 781], ["hepatocytes", "ANATOMY", 785, 796], ["inflammatory", "OBSERVATION_MODIFIER", 873, 885], ["liver", "ANATOMY", 911, 916]]], ["Some scholars believe that HIV protease inhibitors can effectively suppress SARS-CoV-2 replication, nevertheless, Shen's team confirmed that the risk of liver damage was increased in patients taking both hormones and HIV protease inhibitors 45 .", [["liver", "ANATOMY", 153, 158], ["SARS", "DISEASE", 76, 80], ["liver damage", "DISEASE", 153, 165], ["HIV", "ORGANISM", 27, 30], ["CoV-2", "ORGANISM", 81, 86], ["liver", "ORGAN", 153, 158], ["patients", "ORGANISM", 183, 191], ["patients", "SPECIES", 183, 191], ["HIV", "SPECIES", 27, 30], ["HIV", "SPECIES", 217, 220], ["HIV protease inhibitors", "TREATMENT", 27, 50], ["SARS", "PROBLEM", 76, 80], ["liver damage", "PROBLEM", 153, 165], ["both hormones", "TREATMENT", 199, 212], ["HIV protease inhibitors", "TREATMENT", 217, 240], ["liver", "ANATOMY", 153, 158], ["damage", "OBSERVATION", 159, 165], ["increased", "OBSERVATION_MODIFIER", 170, 179]]], ["The incidence of liver injury caused by different drugs is varies, but the incidence increases with the increase in drug types.", [["liver", "ANATOMY", 17, 22], ["liver injury", "DISEASE", 17, 29], ["liver", "ORGAN", 17, 22], ["liver injury", "PROBLEM", 17, 29], ["the increase in drug types", "PROBLEM", 100, 126], ["liver", "ANATOMY", 17, 22], ["injury", "OBSERVATION", 23, 29], ["different", "OBSERVATION_MODIFIER", 40, 49], ["drugs", "OBSERVATION", 50, 55], ["increase", "OBSERVATION_MODIFIER", 104, 112], ["drug types", "OBSERVATION", 116, 126]]], ["The diagnosis of drug-induced liver injury requires the combination of medical history and relevant tests to exclude other liver diseases and assess the association between liver injury and suspected drugs by causality.Recurrence or aggravation of existing liver diseaseChronic liver disease is a major disease burden globally.", [["liver", "ANATOMY", 30, 35], ["liver", "ANATOMY", 123, 128], ["liver", "ANATOMY", 173, 178], ["liver", "ANATOMY", 257, 262], ["liver", "ANATOMY", 278, 283], ["liver injury", "DISEASE", 30, 42], ["liver diseases", "DISEASE", 123, 137], ["liver injury", "DISEASE", 173, 185], ["liver disease", "DISEASE", 257, 270], ["Chronic liver disease", "DISEASE", 270, 291], ["liver", "ORGAN", 30, 35], ["liver", "ORGAN", 123, 128], ["liver", "ORGAN", 173, 178], ["liver", "ORGAN", 257, 262], ["liver", "ORGAN", 278, 283], ["drug-induced liver injury", "PROBLEM", 17, 42], ["relevant tests", "TEST", 91, 105], ["other liver diseases", "PROBLEM", 117, 137], ["liver injury", "PROBLEM", 173, 185], ["Recurrence", "PROBLEM", 219, 229], ["aggravation", "PROBLEM", 233, 244], ["existing liver disease", "PROBLEM", 248, 270], ["Chronic liver disease", "PROBLEM", 270, 291], ["a major disease burden globally", "PROBLEM", 295, 326], ["liver", "ANATOMY", 30, 35], ["injury", "OBSERVATION", 36, 42], ["liver", "ANATOMY", 123, 128], ["diseases", "OBSERVATION", 129, 137], ["liver", "ANATOMY", 173, 178], ["injury", "OBSERVATION", 179, 185], ["liver", "ANATOMY", 257, 262], ["disease", "OBSERVATION", 263, 270], ["liver", "ANATOMY", 278, 283], ["disease", "OBSERVATION", 284, 291], ["major", "OBSERVATION_MODIFIER", 297, 302], ["disease", "OBSERVATION", 303, 310]]], ["Liver diseases, including chronic viral hepatitis, alcohol-related liver disease, non-alcoholic fatty liver disease, and autoimmune hepatitis, affect approximately 300 million people in China.", [["Liver", "ANATOMY", 0, 5], ["liver", "ANATOMY", 67, 72], ["non-alcoholic fatty liver", "ANATOMY", 82, 107], ["Liver diseases", "DISEASE", 0, 14], ["chronic viral hepatitis", "DISEASE", 26, 49], ["alcohol", "CHEMICAL", 51, 58], ["liver disease", "DISEASE", 67, 80], ["non-alcoholic fatty liver disease", "DISEASE", 82, 115], ["autoimmune hepatitis", "DISEASE", 121, 141], ["alcohol", "CHEMICAL", 51, 58], ["Liver", "ORGAN", 0, 5], ["liver", "ORGAN", 67, 72], ["liver", "ORGAN", 102, 107], ["people", "ORGANISM", 176, 182], ["people", "SPECIES", 176, 182], ["Liver diseases", "PROBLEM", 0, 14], ["chronic viral hepatitis", "PROBLEM", 26, 49], ["liver disease", "PROBLEM", 67, 80], ["non-alcoholic fatty liver disease", "PROBLEM", 82, 115], ["autoimmune hepatitis", "PROBLEM", 121, 141], ["diseases", "OBSERVATION", 6, 14], ["chronic", "OBSERVATION_MODIFIER", 26, 33], ["viral", "OBSERVATION_MODIFIER", 34, 39], ["hepatitis", "OBSERVATION", 40, 49], ["liver", "ANATOMY", 67, 72], ["disease", "OBSERVATION", 73, 80], ["non-alcoholic", "OBSERVATION_MODIFIER", 82, 95], ["fatty liver disease", "OBSERVATION", 96, 115], ["autoimmune hepatitis", "OBSERVATION", 121, 141]]], ["A retrospective analysis of 333 COVID-19 inpatients 19 showed that 12 Accepted Article had a history of hepatitis B and that 2 had a history of hepatitis C. In another study of baseline liver biochemical parameters in 324 cases in the Shanghai area, the HBsAg-positivity rate in COVID-19 patients reached 6.5% 46Prevention and treatmentFor COVID-19 patients with mild liver biochemical abnormalities, the primary disease should be treated actively when antiviral and supportive treatments are given to inhibit viral replication, reduce inflammation and improve immunity, and preventive application of liver-protecting and enzyme-lowering drugs is not recommended.", [["liver", "ANATOMY", 186, 191], ["liver", "ANATOMY", 368, 373], ["liver", "ANATOMY", 601, 606], ["hepatitis B", "DISEASE", 104, 115], ["hepatitis C.", "DISEASE", 144, 156], ["HBsAg", "CHEMICAL", 254, 259], ["liver biochemical abnormalities", "DISEASE", 368, 399], ["primary disease", "DISEASE", 405, 420], ["inflammation", "DISEASE", 536, 548], ["liver", "ORGAN", 186, 191], ["HBsAg", "GENE_OR_GENE_PRODUCT", 254, 259], ["patients", "ORGANISM", 288, 296], ["patients", "ORGANISM", 349, 357], ["liver", "ORGAN", 368, 373], ["liver", "ORGAN", 601, 606], ["HBsAg", "PROTEIN", 254, 259], ["patients", "SPECIES", 288, 296], ["patients", "SPECIES", 349, 357], ["hepatitis B", "SPECIES", 104, 115], ["A retrospective analysis", "TEST", 0, 24], ["COVID", "TEST", 32, 37], ["hepatitis B", "PROBLEM", 104, 115], ["hepatitis C.", "PROBLEM", 144, 156], ["the HBsAg", "TEST", 250, 259], ["positivity rate", "TEST", 260, 275], ["COVID", "TEST", 279, 284], ["treatment", "TREATMENT", 327, 336], ["COVID", "TEST", 340, 345], ["mild liver biochemical abnormalities", "PROBLEM", 363, 399], ["the primary disease", "PROBLEM", 401, 420], ["antiviral", "TREATMENT", 453, 462], ["supportive treatments", "TREATMENT", 467, 488], ["viral replication", "TREATMENT", 510, 527], ["inflammation", "PROBLEM", 536, 548], ["enzyme-lowering drugs", "TREATMENT", 622, 643], ["hepatitis", "OBSERVATION", 104, 113], ["hepatitis", "OBSERVATION", 144, 153], ["liver", "ANATOMY", 186, 191], ["mild", "OBSERVATION_MODIFIER", 363, 367], ["liver", "ANATOMY", 368, 373], ["biochemical abnormalities", "OBSERVATION", 374, 399], ["liver", "ANATOMY", 601, 606]]], ["With acute liver injury, clinicians should analyze and judge the causes of liver injury and take appropriate measures, while closely monitoring ALT, AST, total bilirubin, direct bilirubin, albumin, and PTA (INR).Prevention and treatmentThe occurrence of acute liver failure should also be identified, and liver-protecting and enzyme-lowering drugs, for which the composition and mechanism of action are relatively clear, should be chosen.", [["liver", "ANATOMY", 11, 16], ["liver", "ANATOMY", 75, 80], ["liver", "ANATOMY", 260, 265], ["liver", "ANATOMY", 305, 310], ["acute liver injury", "DISEASE", 5, 23], ["liver injury", "DISEASE", 75, 87], ["bilirubin", "CHEMICAL", 160, 169], ["bilirubin", "CHEMICAL", 178, 187], ["acute liver failure", "DISEASE", 254, 273], ["bilirubin", "CHEMICAL", 160, 169], ["bilirubin", "CHEMICAL", 178, 187], ["liver", "ORGAN", 11, 16], ["liver", "ORGAN", 75, 80], ["ALT", "SIMPLE_CHEMICAL", 144, 147], ["AST", "SIMPLE_CHEMICAL", 149, 152], ["bilirubin", "SIMPLE_CHEMICAL", 160, 169], ["bilirubin", "SIMPLE_CHEMICAL", 178, 187], ["albumin", "GENE_OR_GENE_PRODUCT", 189, 196], ["PTA", "SIMPLE_CHEMICAL", 202, 205], ["liver", "ORGAN", 260, 265], ["liver", "ORGAN", 305, 310], ["ALT", "PROTEIN", 144, 147], ["AST", "PROTEIN", 149, 152], ["albumin", "PROTEIN", 189, 196], ["PTA", "PROTEIN", 202, 205], ["INR", "PROTEIN", 207, 210], ["acute liver injury", "PROBLEM", 5, 23], ["liver injury", "PROBLEM", 75, 87], ["ALT", "TEST", 144, 147], ["AST", "TEST", 149, 152], ["total bilirubin", "TEST", 154, 169], ["direct bilirubin", "TEST", 171, 187], ["albumin", "TEST", 189, 196], ["PTA", "TEST", 202, 205], ["INR", "TEST", 207, 210], ["treatment", "TREATMENT", 227, 236], ["acute liver failure", "PROBLEM", 254, 273], ["enzyme-lowering drugs", "TREATMENT", 326, 347], ["acute", "OBSERVATION_MODIFIER", 5, 10], ["liver", "ANATOMY", 11, 16], ["injury", "OBSERVATION", 17, 23], ["liver", "ANATOMY", 75, 80], ["injury", "OBSERVATION", 81, 87], ["acute", "OBSERVATION_MODIFIER", 254, 259], ["liver", "ANATOMY", 260, 265], ["failure", "OBSERVATION", 266, 273], ["liver", "ANATOMY", 305, 310]]], ["Nonetheless, too many drug types should not be administered (generally no more than 2), and the dosage should not be too large.", [["large", "OBSERVATION", 121, 126]]], ["For patients with severe and critical COVID-19 disease with liver injury, which should be considered to be caused by cytokine storms and microcirculation ischemia and hypoxia, respiratory and circulatory support should be strengthened.Prevention and treatmentIf necessary, extracorporeal membrane oxygenation should be performed to improve the blood oxygen saturation of patients.", [["liver", "ANATOMY", 60, 65], ["respiratory", "ANATOMY", 176, 187], ["extracorporeal membrane", "ANATOMY", 273, 296], ["blood", "ANATOMY", 344, 349], ["liver injury", "DISEASE", 60, 72], ["ischemia", "DISEASE", 154, 162], ["hypoxia", "DISEASE", 167, 174], ["oxygen", "CHEMICAL", 350, 356], ["oxygen", "CHEMICAL", 350, 356], ["patients", "ORGANISM", 4, 12], ["liver", "ORGAN", 60, 65], ["extracorporeal membrane", "MULTI-TISSUE_STRUCTURE", 273, 296], ["blood", "ORGANISM_SUBSTANCE", 344, 349], ["oxygen", "SIMPLE_CHEMICAL", 350, 356], ["patients", "ORGANISM", 371, 379], ["cytokine", "PROTEIN", 117, 125], ["patients", "SPECIES", 4, 12], ["patients", "SPECIES", 371, 379], ["severe and critical COVID-19 disease", "PROBLEM", 18, 54], ["liver injury", "PROBLEM", 60, 72], ["cytokine storms", "PROBLEM", 117, 132], ["microcirculation ischemia", "PROBLEM", 137, 162], ["hypoxia", "PROBLEM", 167, 174], ["respiratory and circulatory support", "TREATMENT", 176, 211], ["treatment", "TREATMENT", 250, 259], ["extracorporeal membrane oxygenation", "TREATMENT", 273, 308], ["the blood oxygen saturation", "TEST", 340, 367], ["severe", "OBSERVATION_MODIFIER", 18, 24], ["19 disease", "OBSERVATION", 44, 54], ["liver", "ANATOMY", 60, 65], ["injury", "OBSERVATION", 66, 72], ["cytokine storms", "OBSERVATION", 117, 132], ["hypoxia", "OBSERVATION", 167, 174], ["circulatory support", "OBSERVATION", 192, 211]]], ["Patients with acute liver failure should be given intensive monitoring and symptomatic and supportive treatment, and hypoproteinemia should be corrected.", [["liver", "ANATOMY", 20, 25], ["acute liver failure", "DISEASE", 14, 33], ["hypoproteinemia", "DISEASE", 117, 132], ["Patients", "ORGANISM", 0, 8], ["liver", "ORGAN", 20, 25], ["Patients", "SPECIES", 0, 8], ["acute liver failure", "PROBLEM", 14, 33], ["intensive monitoring", "TEST", 50, 70], ["supportive treatment", "TREATMENT", 91, 111], ["hypoproteinemia", "PROBLEM", 117, 132], ["acute", "OBSERVATION_MODIFIER", 14, 19], ["liver", "ANATOMY", 20, 25], ["failure", "OBSERVATION", 26, 33], ["hypoproteinemia", "OBSERVATION", 117, 132]]], ["In cases of liver injury caused by drugs, in addition to conventional anti-inflammatory liver protection treatment, stopping or reducing the amount of the suspected drugs should be considered, and the degree of liver damage should be assessed, followed by adjustment of the treatment plan.", [["liver", "ANATOMY", 12, 17], ["liver", "ANATOMY", 88, 93], ["liver", "ANATOMY", 211, 216], ["liver injury", "DISEASE", 12, 24], ["liver damage", "DISEASE", 211, 223], ["liver", "ORGAN", 12, 17], ["liver", "ORGAN", 88, 93], ["liver", "ORGAN", 211, 216], ["liver injury", "PROBLEM", 12, 24], ["drugs", "TREATMENT", 35, 40], ["conventional anti-inflammatory liver protection treatment", "TREATMENT", 57, 114], ["the suspected drugs", "TREATMENT", 151, 170], ["liver damage", "PROBLEM", 211, 223], ["the treatment plan", "TREATMENT", 270, 288], ["liver", "ANATOMY", 12, 17], ["injury", "OBSERVATION", 18, 24], ["anti-inflammatory", "OBSERVATION_MODIFIER", 70, 87], ["liver", "ANATOMY", 88, 93], ["liver", "ANATOMY", 211, 216], ["damage", "OBSERVATION", 217, 223]]], ["Anti-HBV or Anti-HCV treatment should not be discontinued, but large doses of hormones should not be used simultaneously.", [["Anti-HBV", "CHEMICAL", 0, 8], ["Anti-HBV", "SPECIES", 0, 8], ["Anti-HBV", "TREATMENT", 0, 8], ["Anti-HCV treatment", "TREATMENT", 12, 30], ["large doses of hormones", "TREATMENT", 63, 86], ["Anti-HCV", "OBSERVATION", 12, 20]]], ["Overall, the prevention and treatment experience of liver injury in SARS patients can provide some reference for COVID-19 patients with liver injury.", [["liver", "ANATOMY", 52, 57], ["liver", "ANATOMY", 136, 141], ["liver injury", "DISEASE", 52, 64], ["SARS", "DISEASE", 68, 72], ["liver injury", "DISEASE", 136, 148], ["liver", "ORGAN", 52, 57], ["patients", "ORGANISM", 73, 81], ["patients", "ORGANISM", 122, 130], ["liver", "ORGAN", 136, 141], ["patients", "SPECIES", 73, 81], ["patients", "SPECIES", 122, 130], ["liver injury", "PROBLEM", 52, 64], ["COVID", "TEST", 113, 118], ["liver injury", "PROBLEM", 136, 148], ["liver", "ANATOMY", 52, 57], ["injury", "OBSERVATION", 58, 64], ["liver", "ANATOMY", 136, 141], ["injury", "OBSERVATION", 142, 148]]], ["For example, active prevention and control of the inflammatory response in the early stage of the disease is not only conducive to reducing the nonspecific inflammation of the liver This article is protected by copyright.", [["liver", "ANATOMY", 176, 181], ["inflammation", "DISEASE", 156, 168], ["liver", "ORGAN", 176, 181], ["active prevention", "TREATMENT", 13, 30], ["the inflammatory response", "PROBLEM", 46, 71], ["the disease", "PROBLEM", 94, 105], ["the nonspecific inflammation of the liver", "PROBLEM", 140, 181], ["active", "OBSERVATION_MODIFIER", 13, 19], ["inflammatory", "OBSERVATION_MODIFIER", 50, 62], ["early stage", "OBSERVATION_MODIFIER", 79, 90], ["disease", "OBSERVATION", 98, 105], ["nonspecific", "OBSERVATION_MODIFIER", 144, 155], ["inflammation", "OBSERVATION", 156, 168], ["liver", "ANATOMY", 176, 181]]], ["All rights reserved.Accepted Articlebut also to preventing the occurrence of systemic inflammatory response syndrome to reduce the probability of mild disease developing into severe or critical disease.ConclusionsCOVID-19 combined with liver injury is very common, and the incidence of liver injury in patients with severe or critical COVID-19 disease is higher than that in patients with mild disease.", [["liver", "ANATOMY", 236, 241], ["liver", "ANATOMY", 286, 291], ["systemic inflammatory response syndrome", "DISEASE", 77, 116], ["liver injury", "DISEASE", 236, 248], ["liver injury", "DISEASE", 286, 298], ["liver", "ORGAN", 236, 241], ["liver", "ORGAN", 286, 291], ["patients", "ORGANISM", 302, 310], ["patients", "ORGANISM", 375, 383], ["patients", "SPECIES", 302, 310], ["patients", "SPECIES", 375, 383], ["systemic inflammatory response syndrome", "PROBLEM", 77, 116], ["mild disease", "PROBLEM", 146, 158], ["critical disease", "PROBLEM", 185, 201], ["ConclusionsCOVID", "TEST", 202, 218], ["liver injury", "PROBLEM", 236, 248], ["liver injury", "PROBLEM", 286, 298], ["severe or critical COVID-19 disease", "PROBLEM", 316, 351], ["mild disease", "PROBLEM", 389, 401], ["systemic", "OBSERVATION_MODIFIER", 77, 85], ["inflammatory response syndrome", "OBSERVATION", 86, 116], ["mild", "OBSERVATION_MODIFIER", 146, 150], ["disease", "OBSERVATION", 151, 158], ["severe", "OBSERVATION_MODIFIER", 175, 181], ["critical", "OBSERVATION_MODIFIER", 185, 193], ["disease", "OBSERVATION", 194, 201], ["liver", "ANATOMY", 236, 241], ["injury", "OBSERVATION", 242, 248], ["liver", "ANATOMY", 286, 291], ["injury", "OBSERVATION", 292, 298], ["severe", "OBSERVATION_MODIFIER", 316, 322], ["19 disease", "OBSERVATION", 341, 351], ["higher", "OBSERVATION_MODIFIER", 355, 361], ["mild", "OBSERVATION_MODIFIER", 389, 393], ["disease", "OBSERVATION", 394, 401]]], ["Liver injury in patients with COVID-19 may be caused by a variety of mechanisms, such as direct virus infection, immune injury, drug-induced liver injury, systemic inflammatory response, ischemia and hypoxia, and recurrence or exacerbation of the underlying liver disease, among others.ConclusionsSince the liver is an important processing organ of the body, impaired liver function seriously affects the body's anabolism and prognosis of the disease.", [["Liver", "ANATOMY", 0, 5], ["liver", "ANATOMY", 141, 146], ["liver", "ANATOMY", 258, 263], ["liver", "ANATOMY", 307, 312], ["organ", "ANATOMY", 340, 345], ["body", "ANATOMY", 353, 357], ["liver", "ANATOMY", 368, 373], ["body", "ANATOMY", 405, 409], ["Liver injury", "DISEASE", 0, 12], ["COVID-19", "CHEMICAL", 30, 38], ["infection", "DISEASE", 102, 111], ["immune injury", "DISEASE", 113, 126], ["liver injury", "DISEASE", 141, 153], ["ischemia", "DISEASE", 187, 195], ["hypoxia", "DISEASE", 200, 207], ["liver disease", "DISEASE", 258, 271], ["impaired liver function", "DISEASE", 359, 382], ["COVID-19", "CHEMICAL", 30, 38], ["Liver", "ORGAN", 0, 5], ["patients", "ORGANISM", 16, 24], ["liver", "ORGAN", 141, 146], ["liver", "ORGAN", 258, 263], ["liver", "ORGAN", 307, 312], ["organ", "ORGAN", 340, 345], ["body", "ORGANISM_SUBDIVISION", 353, 357], ["liver", "ORGAN", 368, 373], ["body", "ORGANISM_SUBDIVISION", 405, 409], ["patients", "SPECIES", 16, 24], ["Liver injury", "PROBLEM", 0, 12], ["COVID", "TEST", 30, 35], ["direct virus infection", "PROBLEM", 89, 111], ["immune injury", "PROBLEM", 113, 126], ["drug-induced liver injury", "PROBLEM", 128, 153], ["systemic inflammatory response", "PROBLEM", 155, 185], ["ischemia", "PROBLEM", 187, 195], ["hypoxia", "PROBLEM", 200, 207], ["recurrence", "PROBLEM", 213, 223], ["exacerbation", "PROBLEM", 227, 239], ["the underlying liver disease", "PROBLEM", 243, 271], ["the disease", "PROBLEM", 439, 450], ["injury", "OBSERVATION", 6, 12], ["liver", "ANATOMY", 141, 146], ["injury", "OBSERVATION", 147, 153], ["systemic", "OBSERVATION_MODIFIER", 155, 163], ["inflammatory", "OBSERVATION_MODIFIER", 164, 176], ["ischemia", "OBSERVATION", 187, 195], ["hypoxia", "OBSERVATION", 200, 207], ["exacerbation", "OBSERVATION_MODIFIER", 227, 239], ["liver", "ANATOMY", 258, 263], ["disease", "OBSERVATION", 264, 271], ["liver", "ANATOMY", 307, 312], ["important", "OBSERVATION", 319, 328], ["body", "ANATOMY_MODIFIER", 353, 357], ["impaired", "OBSERVATION", 359, 367], ["liver", "ANATOMY", 368, 373], ["disease", "OBSERVATION", 443, 450]]], ["Therefore, clinicians should pay more attention to the occurrence of liver damage in the diagnosis and treatment of COVID-19 and analyze comprehensively the pathogenesis of liver injury in COVD-19 patients to develop a reasonable individualized treatment strategy.", [["liver", "ANATOMY", 69, 74], ["liver", "ANATOMY", 173, 178], ["liver damage", "DISEASE", 69, 81], ["liver injury", "DISEASE", 173, 185], ["COVID-19", "CHEMICAL", 116, 124], ["liver", "ORGAN", 69, 74], ["COVID-19", "CELL", 116, 124], ["liver", "ORGAN", 173, 178], ["patients", "ORGANISM", 197, 205], ["patients", "SPECIES", 197, 205], ["liver damage", "PROBLEM", 69, 81], ["COVID", "TEST", 116, 121], ["liver injury", "PROBLEM", 173, 185], ["a reasonable individualized treatment strategy", "TREATMENT", 217, 263], ["liver", "ANATOMY", 69, 74], ["damage", "OBSERVATION", 75, 81], ["liver", "ANATOMY", 173, 178], ["injury", "OBSERVATION", 179, 185]]]], "PMC3130781": [["IntroductionCeacam1 is a member of a large family of carcinoembryonic antigen proteins [2].", [["IntroductionCeacam1", "GENE_OR_GENE_PRODUCT", 0, 19], ["carcinoembryonic antigen", "GENE_OR_GENE_PRODUCT", 53, 77], ["IntroductionCeacam1", "PROTEIN", 0, 19], ["carcinoembryonic antigen proteins", "PROTEIN", 53, 86], ["carcinoembryonic antigen proteins", "TREATMENT", 53, 86]]], ["It is primarily a type I transmembrane protein with multiple splice variants [9], though soluble forms also exist.", [["type I transmembrane protein", "PROTEIN", 18, 46], ["a type I transmembrane protein", "PROBLEM", 16, 46], ["multiple splice variants", "PROBLEM", 52, 76], ["splice variants", "OBSERVATION", 61, 76]]], ["Ceacam1 is widely expressed on a variety of tissues including endothelium [10], epithelium [11], hematopoietic cells [12] and both hematologic and solid tumors, and interacts in a homophilic and heterophilic fashion with physiological and pathogen-associated ligands, including carcinoembryonic antigen and the Neisseria spp. proteins [13].IntroductionSome Ceacam1 isoforms contain intracellular ITIM motifs, and activation of Ceacam1 results in the recruitment of the SHP-1 and SHP-2 phosphatases [8], [14], which dephosphorylate substrates across a range of signaling pathways.", [["tissues", "ANATOMY", 44, 51], ["endothelium", "ANATOMY", 62, 73], ["epithelium", "ANATOMY", 80, 90], ["hematopoietic cells", "ANATOMY", 97, 116], ["hematologic", "ANATOMY", 131, 142], ["solid tumors", "ANATOMY", 147, 159], ["intracellular", "ANATOMY", 382, 395], ["Ceacam1", "CHEMICAL", 0, 7], ["hematologic and solid tumors", "DISEASE", 131, 159], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 0, 7], ["tissues", "TISSUE", 44, 51], ["endothelium", "TISSUE", 62, 73], ["epithelium", "TISSUE", 80, 90], ["hematopoietic cells", "CELL", 97, 116], ["hematologic", "CANCER", 131, 142], ["solid tumors", "CANCER", 147, 159], ["carcinoembryonic antigen", "GENE_OR_GENE_PRODUCT", 278, 302], ["Neisseria spp", "ORGANISM", 311, 324], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 357, 364], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 382, 395], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 427, 434], ["SHP-1", "GENE_OR_GENE_PRODUCT", 469, 474], ["SHP-2", "GENE_OR_GENE_PRODUCT", 479, 484], ["[14]", "SIMPLE_CHEMICAL", 503, 507], ["Ceacam1", "PROTEIN", 0, 7], ["hematopoietic cells", "CELL_TYPE", 97, 116], ["carcinoembryonic antigen", "PROTEIN", 278, 302], ["Ceacam1 isoforms", "PROTEIN", 357, 373], ["intracellular ITIM motifs", "PROTEIN", 382, 407], ["Ceacam1", "PROTEIN", 427, 434], ["SHP-1 and SHP-2 phosphatases", "PROTEIN", 469, 497], ["Ceacam1", "TREATMENT", 0, 7], ["hematopoietic cells", "TEST", 97, 116], ["both hematologic and solid tumors", "PROBLEM", 126, 159], ["physiological and pathogen-associated ligands", "PROBLEM", 221, 266], ["carcinoembryonic antigen", "TEST", 278, 302], ["the Neisseria spp", "PROBLEM", 307, 324], ["proteins", "TEST", 326, 334], ["IntroductionSome Ceacam1 isoforms", "TREATMENT", 340, 373], ["intracellular ITIM motifs", "TREATMENT", 382, 407], ["Ceacam1 results", "TEST", 427, 442], ["the SHP", "TEST", 465, 472], ["SHP", "TEST", 479, 482], ["dephosphorylate substrates", "TREATMENT", 515, 541], ["hematopoietic cells", "OBSERVATION", 97, 116], ["hematologic", "ANATOMY", 131, 142], ["solid", "OBSERVATION_MODIFIER", 147, 152], ["tumors", "OBSERVATION", 153, 159], ["Neisseria spp", "OBSERVATION", 311, 324], ["intracellular ITIM", "OBSERVATION", 382, 400]]], ["Ceacam1 thus inhibits T cell receptor (TCR) signaling and suppresses multiple aspects of T cell function.", [["T cell", "ANATOMY", 22, 28], ["T cell", "ANATOMY", 89, 95], ["Ceacam1", "CHEMICAL", 0, 7], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 0, 7], ["T cell receptor", "GENE_OR_GENE_PRODUCT", 22, 37], ["TCR", "GENE_OR_GENE_PRODUCT", 39, 42], ["T cell", "CELL", 89, 95], ["Ceacam1", "PROTEIN", 0, 7], ["T cell receptor", "PROTEIN", 22, 37], ["TCR", "PROTEIN", 39, 42], ["Ceacam1", "TREATMENT", 0, 7], ["T cell receptor", "TREATMENT", 22, 37], ["cell function", "OBSERVATION", 91, 104]]], ["Ceacam1 agonists attenuate cytokine secretion, T cell polarization and cytolytic function.", [["T cell", "ANATOMY", 47, 53], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 0, 7], ["T cell", "CELL", 47, 53], ["cytokine", "PROTEIN", 27, 35], ["Ceacam1 agonists", "TREATMENT", 0, 16], ["cytokine secretion", "PROBLEM", 27, 45], ["T cell polarization", "TEST", 47, 66], ["cytolytic function", "TEST", 71, 89], ["cytolytic function", "OBSERVATION", 71, 89]]], ["In vivo, ligation of Ceacam1 with soluble ligands or over-expression of ITIM-containing Ceacam1 isoforms on T cells attenuates experimental colitis [7], [8].", [["T cells", "ANATOMY", 108, 115], ["colitis", "DISEASE", 140, 147], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 21, 28], ["ITIM", "GENE_OR_GENE_PRODUCT", 72, 76], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 88, 95], ["T cells", "CELL", 108, 115], ["Ceacam1", "PROTEIN", 21, 28], ["ITIM", "PROTEIN", 72, 76], ["Ceacam1 isoforms", "PROTEIN", 88, 104], ["T cells", "CELL_TYPE", 108, 115], ["ligation", "TREATMENT", 9, 17], ["Ceacam1 with soluble ligands", "TREATMENT", 21, 49], ["ITIM", "PROBLEM", 72, 76], ["Ceacam1 isoforms", "PROBLEM", 88, 104], ["experimental colitis", "PROBLEM", 127, 147], ["colitis", "OBSERVATION", 140, 147]]], ["Additionally, Ceacam1 is also expressed on intestinal T cells in patients with Celiac disease [15] and ulcerative colitis [16], and may represent an attempt by the immune system to negatively regulate these inflammatory processes.IntroductionIn addition to immune regulation, Ceacam1 exerts a wide variety of other biological functions.", [["intestinal T cells", "ANATOMY", 43, 61], ["Celiac disease", "DISEASE", 79, 93], ["ulcerative colitis", "DISEASE", 103, 121], ["Ceacam1", "CHEMICAL", 276, 283], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 14, 21], ["intestinal T cells", "CELL", 43, 61], ["patients", "ORGANISM", 65, 73], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 276, 283], ["Ceacam1", "PROTEIN", 14, 21], ["intestinal T cells", "CELL_TYPE", 43, 61], ["Ceacam1", "PROTEIN", 276, 283], ["patients", "SPECIES", 65, 73], ["intestinal T cells", "TREATMENT", 43, 61], ["Celiac disease", "PROBLEM", 79, 93], ["ulcerative colitis", "PROBLEM", 103, 121], ["these inflammatory processes", "PROBLEM", 201, 229], ["IntroductionIn", "TREATMENT", 230, 244], ["immune regulation", "TREATMENT", 257, 274], ["Ceacam1", "TREATMENT", 276, 283], ["Ceacam1", "OBSERVATION", 14, 21], ["intestinal", "ANATOMY", 43, 53], ["Celiac", "ANATOMY", 79, 85], ["ulcerative", "OBSERVATION_MODIFIER", 103, 113], ["colitis", "OBSERVATION", 114, 121], ["may represent", "UNCERTAINTY", 132, 145], ["inflammatory", "OBSERVATION", 207, 219]]], ["It is a cell-cell adhesion molecule [17], [18], and a receptor for a variety of commensal and pathogenic microbes in mouse and man [17], [19], [20], [21].", [["cell", "ANATOMY", 8, 12], ["cell", "ANATOMY", 13, 17], ["cell-cell adhesion molecule [17]", "GENE_OR_GENE_PRODUCT", 8, 40], ["[18]", "SIMPLE_CHEMICAL", 42, 46], ["mouse", "ORGANISM", 117, 122], ["[19]", "SIMPLE_CHEMICAL", 137, 141], ["[20]", "SIMPLE_CHEMICAL", 143, 147], ["[21]", "SIMPLE_CHEMICAL", 149, 153], ["cell-cell adhesion molecule", "PROTEIN", 8, 35], ["mouse", "SPECIES", 117, 122], ["man", "SPECIES", 127, 130], ["mouse", "SPECIES", 117, 122], ["a cell-cell adhesion molecule", "TREATMENT", 6, 35]]], ["Ceacam1 also regulates angiogenesis [6], energy homeostasis [22], and tumor biology [23], [24], [25].", [["tumor", "ANATOMY", 70, 75], ["Ceacam1", "CHEMICAL", 0, 7], ["tumor", "DISEASE", 70, 75], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 0, 7], ["tumor", "CANCER", 70, 75], ["[24]", "SIMPLE_CHEMICAL", 90, 94], ["Ceacam1", "PROTEIN", 0, 7]]], ["Ceacam1 regulates the tumorigenesis of colon cancers, and is a prognostic factor in lung adenocarcinoma.", [["colon cancers", "ANATOMY", 39, 52], ["lung adenocarcinoma", "ANATOMY", 84, 103], ["Ceacam1", "CHEMICAL", 0, 7], ["colon cancers", "DISEASE", 39, 52], ["lung adenocarcinoma", "DISEASE", 84, 103], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 0, 7], ["colon cancers", "CANCER", 39, 52], ["lung adenocarcinoma", "CANCER", 84, 103], ["Ceacam1", "PROTEIN", 0, 7], ["Ceacam1", "TREATMENT", 0, 7], ["colon cancers", "PROBLEM", 39, 52], ["a prognostic factor", "PROBLEM", 61, 80], ["lung adenocarcinoma", "PROBLEM", 84, 103], ["colon", "ANATOMY", 39, 44], ["cancers", "OBSERVATION", 45, 52], ["lung", "ANATOMY", 84, 88], ["adenocarcinoma", "OBSERVATION", 89, 103]]], ["Tumor expression of Ceacam1 may regulate tumor angiogenesis and invasion, and the expression of both Ceacam1 and CEA by tumors may inhibit the functions of tumor infiltrating lymphocytes.IntroductionAllo-BMT is an established therapy with curative intent for a variety of hematologic malignancies and non-malignant conditions [26].", [["Tumor", "ANATOMY", 0, 5], ["tumor", "ANATOMY", 41, 46], ["tumors", "ANATOMY", 120, 126], ["tumor infiltrating lymphocytes", "ANATOMY", 156, 186], ["hematologic malignancies", "ANATOMY", 272, 296], ["tumor", "DISEASE", 41, 46], ["tumors", "DISEASE", 120, 126], ["tumor", "DISEASE", 156, 161], ["malignancies", "DISEASE", 284, 296], ["Tumor", "CANCER", 0, 5], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 20, 27], ["tumor", "CANCER", 41, 46], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 101, 108], ["CEA", "GENE_OR_GENE_PRODUCT", 113, 116], ["tumors", "CANCER", 120, 126], ["tumor infiltrating lymphocytes", "CELL", 156, 186], ["hematologic malignancies", "CANCER", 272, 296], ["Ceacam1", "PROTEIN", 20, 27], ["Ceacam1", "PROTEIN", 101, 108], ["CEA", "PROTEIN", 113, 116], ["tumor infiltrating lymphocytes", "CELL_TYPE", 156, 186], ["Tumor expression of Ceacam1", "PROBLEM", 0, 27], ["tumor angiogenesis", "PROBLEM", 41, 59], ["invasion", "PROBLEM", 64, 72], ["both Ceacam1 and CEA", "PROBLEM", 96, 116], ["tumors", "PROBLEM", 120, 126], ["tumor infiltrating lymphocytes", "PROBLEM", 156, 186], ["an established therapy", "TREATMENT", 211, 233], ["curative intent", "TREATMENT", 239, 254], ["hematologic malignancies", "PROBLEM", 272, 296], ["non-malignant conditions", "PROBLEM", 301, 325], ["Ceacam1", "OBSERVATION", 20, 27], ["tumor", "OBSERVATION", 41, 46], ["invasion", "OBSERVATION_MODIFIER", 64, 72], ["both", "OBSERVATION_MODIFIER", 96, 100], ["Ceacam1", "OBSERVATION", 101, 108], ["CEA", "ANATOMY", 113, 116], ["tumors", "OBSERVATION", 120, 126], ["tumor", "OBSERVATION_MODIFIER", 156, 161], ["infiltrating lymphocytes", "OBSERVATION", 162, 186]]], ["Alloreactive T cells of donor origin play a criticial role in both GVHD, a major complication of allo-BMT, and graft-versus-tumor activity, a major contributor to the efficacy of allo-BMT as a cancer therapy.IntroductionDonor-recipient antigenic disparity, donor T cells, and tissue injury resulting in inflammation due to the conditioning regimen all contribute to GVHD, which primarily affects intestines, liver, skin and thymus [27].IntroductionCeacam1 is expressed both on leukocytes (especially T cells), as well as on epithelial and endothelial cells, which are prominent components of the parenchyma of the above-mentioned GVHD target organs.", [["T cells", "ANATOMY", 13, 20], ["graft", "ANATOMY", 111, 116], ["tumor", "ANATOMY", 124, 129], ["cancer", "ANATOMY", 193, 199], ["donor T cells", "ANATOMY", 257, 270], ["tissue", "ANATOMY", 276, 282], ["intestines", "ANATOMY", 396, 406], ["liver", "ANATOMY", 408, 413], ["skin", "ANATOMY", 415, 419], ["thymus", "ANATOMY", 424, 430], ["leukocytes", "ANATOMY", 477, 487], ["T cells", "ANATOMY", 500, 507], ["epithelial", "ANATOMY", 524, 534], ["endothelial cells", "ANATOMY", 539, 556], ["parenchyma", "ANATOMY", 596, 606], ["organs", "ANATOMY", 642, 648], ["GVHD", "DISEASE", 67, 71], ["tumor", "DISEASE", 124, 129], ["cancer", "DISEASE", 193, 199], ["tissue injury", "DISEASE", 276, 289], ["inflammation", "DISEASE", 303, 315], ["GVHD", "DISEASE", 366, 370], ["GVHD", "DISEASE", 630, 634], ["T cells", "CELL", 13, 20], ["graft", "TISSUE", 111, 116], ["-versus-tumor", "CANCER", 116, 129], ["allo-BMT", "SIMPLE_CHEMICAL", 179, 187], ["cancer", "CANCER", 193, 199], ["donor T cells", "CELL", 257, 270], ["tissue", "TISSUE", 276, 282], ["intestines", "ORGAN", 396, 406], ["liver", "ORGAN", 408, 413], ["skin", "ORGAN", 415, 419], ["thymus", "ORGAN", 424, 430], ["IntroductionCeacam1", "GENE_OR_GENE_PRODUCT", 436, 455], ["leukocytes", "CELL", 477, 487], ["T cells", "CELL", 500, 507], ["epithelial", "CELL", 524, 534], ["endothelial cells", "CELL", 539, 556], ["parenchyma", "TISSUE", 596, 606], ["organs", "ORGAN", 642, 648], ["Alloreactive T cells", "CELL_TYPE", 0, 20], ["donor T cells", "CELL_TYPE", 257, 270], ["IntroductionCeacam1", "PROTEIN", 436, 455], ["leukocytes", "CELL_TYPE", 477, 487], ["T cells", "CELL_TYPE", 500, 507], ["epithelial and endothelial cells", "CELL_TYPE", 524, 556], ["Alloreactive T cells", "TREATMENT", 0, 20], ["allo-BMT", "TREATMENT", 97, 105], ["graft", "TREATMENT", 111, 116], ["tumor activity", "PROBLEM", 124, 138], ["allo-BMT", "TREATMENT", 179, 187], ["a cancer therapy", "TREATMENT", 191, 207], ["IntroductionDonor", "TREATMENT", 208, 225], ["recipient antigenic disparity", "PROBLEM", 226, 255], ["donor T cells", "PROBLEM", 257, 270], ["tissue injury", "PROBLEM", 276, 289], ["inflammation", "PROBLEM", 303, 315], ["the conditioning regimen", "TREATMENT", 323, 347], ["GVHD", "PROBLEM", 366, 370], ["leukocytes", "TEST", 477, 487], ["epithelial and endothelial cells", "PROBLEM", 524, 556], ["GVHD", "OBSERVATION", 67, 71], ["graft", "OBSERVATION", 111, 116], ["tumor", "OBSERVATION", 124, 129], ["cancer", "OBSERVATION", 193, 199], ["tissue", "ANATOMY", 276, 282], ["injury", "OBSERVATION", 283, 289], ["inflammation", "OBSERVATION", 303, 315], ["GVHD", "OBSERVATION", 366, 370], ["intestines", "ANATOMY", 396, 406], ["liver", "ANATOMY", 408, 413], ["skin", "ANATOMY", 415, 419], ["thymus", "ANATOMY", 424, 430], ["leukocytes", "ANATOMY", 477, 487], ["epithelial", "ANATOMY_MODIFIER", 524, 534], ["endothelial cells", "OBSERVATION", 539, 556], ["prominent", "OBSERVATION_MODIFIER", 568, 577], ["components", "OBSERVATION_MODIFIER", 578, 588], ["parenchyma", "ANATOMY_MODIFIER", 596, 606], ["GVHD", "OBSERVATION", 630, 634]]], ["In addition, Ceacam1 is upregulated on many tumors.", [["tumors", "ANATOMY", 44, 50], ["tumors", "DISEASE", 44, 50], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 13, 20], ["tumors", "CANCER", 44, 50], ["Ceacam1", "PROTEIN", 13, 20], ["many tumors", "PROBLEM", 39, 50], ["Ceacam1", "OBSERVATION", 13, 20], ["many", "OBSERVATION_MODIFIER", 39, 43], ["tumors", "OBSERVATION", 44, 50]]], ["In this report, we assess the impact of Ceacam1 on alloreactive T cells in the donor allograft, as well as the effects of Ceacam1 deficiency on recipients of allo-BMT with respect to GVHD and GVT activity.Ceacam1 on donor T cells and recipient tissues can regulate GVHD mortality ::: ResultsWe assessed Ceacam1 regulation of GHVD on donor T cells or recipients in two well-described major histocompatibility complex (MHC) class I/II-disparate models C57BL/6 (B6, H-2b)\u2192BALB/c (H-2d) and BALB/c\u2192B10.BR (H-2k).", [["alloreactive T cells", "ANATOMY", 51, 71], ["allograft", "ANATOMY", 85, 94], ["T cells", "ANATOMY", 222, 229], ["tissues", "ANATOMY", 244, 251], ["T cells", "ANATOMY", 339, 346], ["Ceacam1", "CHEMICAL", 40, 47], ["Ceacam1", "CHEMICAL", 122, 129], ["GVHD", "DISEASE", 183, 187], ["Ceacam1", "CHEMICAL", 205, 212], ["GVHD", "DISEASE", 265, 269], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 40, 47], ["alloreactive T cells", "CELL", 51, 71], ["allograft", "ORGAN", 85, 94], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 122, 129], ["recipients", "ORGANISM", 144, 154], ["GVT", "CANCER", 192, 195], ["Ceacam1", "SIMPLE_CHEMICAL", 205, 212], ["donor T cells", "CELL", 216, 229], ["recipient tissues", "TISSUE", 234, 251], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 303, 310], ["GHVD", "GENE_OR_GENE_PRODUCT", 325, 329], ["donor T cells", "CELL", 333, 346], ["recipients", "ORGANISM", 350, 360], ["C57BL/6", "ORGANISM", 450, 457], ["B6, H-2b", "ORGANISM", 459, 467], ["H-2k", "GENE_OR_GENE_PRODUCT", 502, 506], ["Ceacam1", "PROTEIN", 40, 47], ["alloreactive T cells", "CELL_TYPE", 51, 71], ["Ceacam1", "PROTEIN", 122, 129], ["Ceacam1", "PROTEIN", 205, 212], ["donor T cells", "CELL_TYPE", 216, 229], ["Ceacam1", "PROTEIN", 303, 310], ["GHVD", "PROTEIN", 325, 329], ["donor T cells", "CELL_TYPE", 333, 346], ["major histocompatibility complex", "PROTEIN", 383, 415], ["MHC", "PROTEIN", 417, 420], ["BALB/c\u2192B10", "CELL_LINE", 487, 497], ["H-2k", "PROTEIN", 502, 506], ["Ceacam1", "PROBLEM", 40, 47], ["alloreactive T cells", "TREATMENT", 51, 71], ["the donor allograft", "TREATMENT", 75, 94], ["Ceacam1 deficiency", "PROBLEM", 122, 140], ["allo-BMT", "TREATMENT", 158, 166], ["GVHD", "PROBLEM", 183, 187], ["GVT activity", "PROBLEM", 192, 204], ["Ceacam1 on donor T cells", "TREATMENT", 205, 229], ["GHVD", "PROBLEM", 325, 329], ["donor T cells", "TREATMENT", 333, 346], ["B6", "TEST", 459, 461], ["BALB", "TEST", 469, 473], ["BALB/c\u2192B10", "TREATMENT", 487, 497], ["Ceacam1", "OBSERVATION", 40, 47], ["alloreactive T cells", "OBSERVATION", 51, 71], ["donor allograft", "OBSERVATION", 79, 94], ["Ceacam1 deficiency", "OBSERVATION", 122, 140], ["GVHD", "OBSERVATION", 183, 187], ["GVT activity", "OBSERVATION", 192, 204], ["GVHD", "OBSERVATION", 265, 269]]], ["We used Ceacam1\u2212/\u2212 B6 mice [28], Ceacam1-transgenic (Tg) B6 mice (described in Figure S1), and Ceacam1\u2212/\u2212 BALB/c mice [28] as the source of donor T cells or recipients.", [["T cells", "ANATOMY", 146, 153], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 33, 40], ["-transgenic (Tg) B6 mice", "ORGANISM", 40, 64], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 95, 102], ["donor T cells", "CELL", 140, 153], ["recipients", "ORGANISM", 157, 167], ["Ceacam1", "PROTEIN", 33, 40], ["Ceacam1", "PROTEIN", 95, 102], ["donor T cells", "CELL_TYPE", 140, 153], ["mice", "SPECIES", 22, 26], ["mice", "SPECIES", 60, 64], ["mice", "SPECIES", 113, 117], ["mice", "SPECIES", 60, 64], ["mice", "SPECIES", 113, 117], ["Ceacam1\u2212/\u2212 B6 mice", "TREATMENT", 8, 26], ["Ceacam1-transgenic (Tg) B6 mice", "TREATMENT", 33, 64], ["Ceacam1", "TREATMENT", 95, 102], ["donor T cells", "TREATMENT", 140, 153]]], ["In all experiments, recipients received split-dose lethal irradiation (BALB/c: 8.5 Gy, B10.BR: 11 Gy) and a graft of 5\u00d7106 allogeneic T cell depleted bone marrow (TCD-BM) of wildtype (WT) origin, with or without splenic T cells.Ceacam1 on donor T cells and recipient tissues can regulate GVHD mortality ::: ResultsWe first transplanted irradiated BALB/c mice with B6 TCD-BM with WT or Ceacam1\u2212/\u2212 T cells, and observed that recipients of Ceacam1\u2212/\u2212 T cells had significantly increased mortality compared to recipients of WT T cells (Figure 1A, left).", [["graft", "ANATOMY", 108, 113], ["T cell", "ANATOMY", 134, 140], ["bone marrow", "ANATOMY", 150, 161], ["TCD-BM", "ANATOMY", 163, 169], ["splenic T cells", "ANATOMY", 212, 227], ["T cells", "ANATOMY", 245, 252], ["tissues", "ANATOMY", 267, 274], ["B6 TCD-BM", "ANATOMY", 364, 373], ["Ceacam1\u2212/\u2212 T cells", "ANATOMY", 385, 403], ["Ceacam1\u2212/\u2212 T cells", "ANATOMY", 437, 455], ["T cells", "ANATOMY", 523, 530], ["Ceacam1", "CHEMICAL", 228, 235], ["GVHD", "DISEASE", 288, 292], ["recipients", "ORGANISM", 20, 30], ["graft", "TISSUE", 108, 113], ["T cell", "CELL", 134, 140], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 150, 161], ["TCD-BM", "CELL", 163, 169], ["splenic T cells", "CELL", 212, 227], ["Ceacam1", "SIMPLE_CHEMICAL", 228, 235], ["donor T cells", "CELL", 239, 252], ["recipient tissues", "TISSUE", 257, 274], ["BALB/c mice", "ORGANISM", 347, 358], ["B6 TCD-BM", "CELL", 364, 373], ["Ceacam1\u2212/\u2212 T cells", "CELL", 385, 403], ["recipients", "ORGANISM", 423, 433], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 437, 444], ["WT T cells", "CELL", 520, 530], ["splenic T cells", "CELL_TYPE", 212, 227], ["Ceacam1", "PROTEIN", 228, 235], ["donor T cells", "CELL_TYPE", 239, 252], ["Ceacam1\u2212/\u2212 T cells", "CELL_LINE", 385, 403], ["Ceacam1\u2212/\u2212 T cells", "CELL_LINE", 437, 455], ["WT T cells", "CELL_TYPE", 520, 530], ["mice", "SPECIES", 354, 358], ["mice", "SPECIES", 354, 358], ["split-dose lethal irradiation", "TREATMENT", 40, 69], ["a graft of 5\u00d7106 allogeneic T cell depleted bone marrow", "TREATMENT", 106, 161], ["wildtype (WT) origin", "PROBLEM", 174, 194], ["splenic T cells", "PROBLEM", 212, 227], ["Ceacam1 on donor T cells", "TREATMENT", 228, 252], ["B6 TCD", "TEST", 364, 370], ["WT", "TEST", 379, 381], ["Ceacam1\u2212/\u2212 T cells", "TREATMENT", 385, 403], ["Ceacam1", "TEST", 437, 444], ["T cells", "PROBLEM", 448, 455], ["significantly increased mortality", "PROBLEM", 460, 493], ["WT T cells", "PROBLEM", 520, 530], ["graft", "OBSERVATION", 108, 113], ["allogeneic T cell depleted bone marrow", "OBSERVATION", 123, 161], ["without", "UNCERTAINTY", 204, 211], ["splenic", "ANATOMY", 212, 219], ["T cells", "OBSERVATION", 220, 227], ["GVHD", "OBSERVATION", 288, 292], ["BM", "ANATOMY", 371, 373], ["left", "ANATOMY_MODIFIER", 543, 547]]], ["We confirmed this in a second MHC-disparate allo-BMT model, BALB/c\u2192B10.BR (Figure 1A, right).Ceacam1 on donor T cells and recipient tissues can regulate GVHD mortality ::: ResultsWe next asked whether T cells overexpressing Ceacam1 would cause less disease, and transplanted BALB/c recipients with 0.5\u00d7106 or 1\u00d7106 donor WT or Ceacam 1-Tg T cells.", [["T cells", "ANATOMY", 110, 117], ["tissues", "ANATOMY", 132, 139], ["T cells", "ANATOMY", 201, 208], ["Ceacam 1-Tg T cells", "ANATOMY", 327, 346], ["Ceacam1", "CHEMICAL", 93, 100], ["GVHD", "DISEASE", 153, 157], ["Ceacam1", "CHEMICAL", 224, 231], ["BALB/c\u2192B10", "ORGANISM", 60, 70], ["Ceacam1", "SIMPLE_CHEMICAL", 93, 100], ["donor T cells", "CELL", 104, 117], ["recipient tissues", "TISSUE", 122, 139], ["T cells", "CELL", 201, 208], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 224, 231], ["BALB/c recipients", "ORGANISM", 275, 292], ["Ceacam 1", "GENE_OR_GENE_PRODUCT", 327, 335], ["MHC", "PROTEIN", 30, 33], ["BALB/c\u2192B10", "CELL_LINE", 60, 70], ["BR", "PROTEIN", 71, 73], ["Ceacam1", "PROTEIN", 93, 100], ["donor T cells", "CELL_TYPE", 104, 117], ["T cells", "CELL_TYPE", 201, 208], ["Ceacam1", "PROTEIN", 224, 231], ["Ceacam 1-Tg T cells", "CELL_LINE", 327, 346], ["disparate allo-BMT model", "TREATMENT", 34, 58], ["BALB/c\u2192B10", "TREATMENT", 60, 70], ["Ceacam1 on donor T cells", "TREATMENT", 93, 117], ["less disease", "PROBLEM", 244, 256], ["transplanted BALB/c recipients", "TREATMENT", 262, 292], ["donor WT", "TEST", 315, 323], ["Ceacam", "TEST", 327, 333], ["right", "ANATOMY_MODIFIER", 86, 91], ["GVHD", "OBSERVATION", 153, 157]]], ["At both doses, recipients of Ceacam1-Tg T cells showed attenuated mortality (Figure 1B).Ceacam1 on donor T cells and recipient tissues can regulate GVHD mortality ::: ResultsFinally, we assessed the role of Ceacam1 on tissues of allo-BMT recipients, and transferred TCD-BM+T cells into WT vs. Ceacam1\u2212/\u2212 BALB/c recipients.", [["Ceacam1-Tg T cells", "ANATOMY", 29, 47], ["T cells", "ANATOMY", 105, 112], ["tissues", "ANATOMY", 127, 134], ["tissues", "ANATOMY", 218, 225], ["TCD-BM+T cells", "ANATOMY", 266, 280], ["Ceacam1", "CHEMICAL", 88, 95], ["GVHD", "DISEASE", 148, 152], ["recipients", "ORGANISM", 15, 25], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 29, 36], ["Ceacam1", "SIMPLE_CHEMICAL", 88, 95], ["donor T cells", "CELL", 99, 112], ["recipient tissues", "TISSUE", 117, 134], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 207, 214], ["tissues", "TISSUE", 218, 225], ["allo-BMT recipients", "CELL", 229, 248], ["TCD-BM+T cells", "CELL", 266, 280], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 293, 300], ["Ceacam1-Tg T cells", "CELL_LINE", 29, 47], ["Ceacam1", "PROTEIN", 88, 95], ["donor T cells", "CELL_TYPE", 99, 112], ["Ceacam1", "PROTEIN", 207, 214], ["TCD-BM+T cells", "CELL_TYPE", 266, 280], ["Ceacam1", "PROTEIN", 293, 300], ["Ceacam1", "TEST", 29, 36], ["attenuated mortality", "PROBLEM", 55, 75], ["Ceacam1 on donor T cells", "TREATMENT", 88, 112], ["allo-BMT recipients", "TREATMENT", 229, 248], ["Ceacam1", "TREATMENT", 293, 300], ["BALB/c recipients", "TREATMENT", 304, 321], ["GVHD", "OBSERVATION", 148, 152], ["BM", "ANATOMY", 270, 272]]], ["This revealed that Ceacam1\u2212/\u2212 recipients had increased early (but not overall) mortality, with nearly 50% of mice succumbing within the first week (Figure 1C).Ceacam1 is an important regulator of GVHD target organ damage ::: ResultsWe next asked whether Ceacam1 regulated GVHD target organ damage, and again assessed effects of Ceacam1 deficiency or overexpression on donor T cells, and Ceacam1\u2212/\u2212 allo-BMT recipients.Ceacam1 is an important regulator of GVHD target organ damage ::: ResultsWe observed that recipients of Ceacam1\u2212/\u2212 T cells had more severe large intestinal GVHD (Figure 2A).", [["organ", "ANATOMY", 208, 213], ["organ", "ANATOMY", 284, 289], ["donor T cells", "ANATOMY", 368, 381], ["organ", "ANATOMY", 467, 472], ["Ceacam1\u2212/\u2212 T cells", "ANATOMY", 522, 540], ["intestinal", "ANATOMY", 563, 573], ["GVHD", "DISEASE", 196, 200], ["organ damage", "DISEASE", 208, 220], ["GVHD", "DISEASE", 272, 276], ["organ damage", "DISEASE", 284, 296], ["Ceacam1", "CHEMICAL", 328, 335], ["GVHD", "DISEASE", 455, 459], ["organ damage", "DISEASE", 467, 479], ["GVHD", "DISEASE", 574, 578], ["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 19, 27], ["mice", "ORGANISM", 109, 113], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 159, 166], ["organ", "ORGAN", 208, 213], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 254, 261], ["organ", "ORGAN", 284, 289], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 328, 335], ["donor T cells", "CELL", 368, 381], ["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 387, 395], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 418, 425], ["organ", "ORGAN", 467, 472], ["recipients", "ORGANISM", 508, 518], ["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 522, 530], ["intestinal", "ORGAN", 563, 573], ["Ceacam1", "PROTEIN", 159, 166], ["Ceacam1", "PROTEIN", 254, 261], ["Ceacam1", "PROTEIN", 328, 335], ["donor T cells", "CELL_TYPE", 368, 381], ["Ceacam1", "PROTEIN", 418, 425], ["Ceacam1\u2212/\u2212 T cells", "CELL_LINE", 522, 540], ["mice", "SPECIES", 109, 113], ["mice", "SPECIES", 109, 113], ["Ceacam1\u2212/\u2212 recipients", "TREATMENT", 19, 40], ["Ceacam1", "TREATMENT", 159, 166], ["Ceacam1 regulated GVHD target organ damage", "PROBLEM", 254, 296], ["Ceacam1 deficiency", "PROBLEM", 328, 346], ["donor T cells", "TREATMENT", 368, 381], ["Ceacam1\u2212", "TREATMENT", 387, 395], ["allo-BMT recipients", "TREATMENT", 398, 417], ["Ceacam1", "TREATMENT", 418, 425], ["Ceacam1\u2212", "TEST", 522, 530], ["T cells", "PROBLEM", 533, 540], ["severe large intestinal GVHD", "PROBLEM", 550, 578], ["increased", "OBSERVATION_MODIFIER", 45, 54], ["Ceacam1 deficiency", "OBSERVATION", 328, 346], ["severe", "OBSERVATION_MODIFIER", 550, 556], ["large", "OBSERVATION_MODIFIER", 557, 562], ["intestinal", "ANATOMY", 563, 573], ["GVHD", "OBSERVATION", 574, 578]]], ["Surprisingly however, these mice exhibited less thymic GVHD, as determined by thymic cellularity and numbers of CD4+CD8+ double-positive (DP) thymocytes (Figure 2).", [["thymic", "ANATOMY", 48, 54], ["thymic", "ANATOMY", 78, 84], ["CD4+CD8+ double-positive (DP) thymocytes", "ANATOMY", 112, 152], ["GVHD", "DISEASE", 55, 59], ["mice", "ORGANISM", 28, 32], ["thymic GVHD", "CANCER", 48, 59], ["CD4", "GENE_OR_GENE_PRODUCT", 112, 115], ["CD8", "GENE_OR_GENE_PRODUCT", 116, 119], ["CD4", "PROTEIN", 112, 115], ["CD8", "PROTEIN", 116, 119], ["double-positive (DP) thymocytes", "CELL_TYPE", 121, 152], ["mice", "SPECIES", 28, 32], ["mice", "SPECIES", 28, 32], ["less thymic GVHD", "PROBLEM", 43, 59], ["thymic cellularity", "TEST", 78, 96], ["CD4", "TEST", 112, 115], ["CD8", "TEST", 116, 119], ["less", "OBSERVATION_MODIFIER", 43, 47], ["thymic GVHD", "OBSERVATION", 48, 59], ["thymic", "ANATOMY", 78, 84], ["cellularity", "OBSERVATION", 85, 96], ["thymocytes", "ANATOMY", 142, 152]]], ["Thymic cellularity from age/sex-matched non-transplanted animals are shown in Figure S2.", [["Thymic", "ANATOMY", 0, 6], ["Thymic cellularity", "CANCER", 0, 18], ["Thymic cellularity", "PROBLEM", 0, 18], ["cellularity", "OBSERVATION", 7, 18], ["Figure S2", "OBSERVATION", 78, 87]]], ["We also observed a modest trend towards less skin GVHD in recipients of Ceacam1\u2212/\u2212 T cells (Figure 2C), suggesting that Ceacam1\u2212/\u2212 T cells caused preferential damage to the (large) intestines.Ceacam1 is an important regulator of GVHD target organ damage ::: ResultsIn experiments comparing recipients of WT and Ceacam1-Tg T cells on day 21 post-transplant, we found that recipients of Ceacam1-Tg T cells demonstrated significantly less GVHD of the liver, intestines, and thymus compared to recipients of WT T cells, but similar skin GVHD (Figures 2D\u2013F).", [["skin", "ANATOMY", 45, 49], ["Ceacam1\u2212/\u2212 T cells", "ANATOMY", 72, 90], ["Ceacam1\u2212/\u2212 T cells", "ANATOMY", 120, 138], ["intestines", "ANATOMY", 181, 191], ["organ", "ANATOMY", 241, 246], ["Ceacam1-Tg T cells", "ANATOMY", 311, 329], ["Ceacam1-Tg T cells", "ANATOMY", 385, 403], ["liver", "ANATOMY", 448, 453], ["intestines", "ANATOMY", 455, 465], ["thymus", "ANATOMY", 471, 477], ["WT T cells", "ANATOMY", 504, 514], ["skin", "ANATOMY", 528, 532], ["GVHD", "DISEASE", 50, 54], ["GVHD", "DISEASE", 229, 233], ["organ damage", "DISEASE", 241, 253], ["GVHD", "DISEASE", 436, 440], ["GVHD", "DISEASE", 533, 537], ["skin", "ORGAN", 45, 49], ["recipients", "ORGANISM", 58, 68], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 72, 79], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 120, 127], ["intestines", "ORGAN", 181, 191], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 192, 199], ["organ", "ORGAN", 241, 246], ["recipients", "ORGANISM", 290, 300], ["Ceacam1-Tg T cells", "CELL", 311, 329], ["recipients", "ORGANISM", 371, 381], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 385, 392], ["liver", "ORGAN", 448, 453], ["intestines", "ORGAN", 455, 465], ["thymus", "ORGAN", 471, 477], ["recipients", "ORGANISM", 490, 500], ["WT T cells", "CELL", 504, 514], ["skin", "ORGAN", 528, 532], ["Ceacam1\u2212/\u2212 T cells", "CELL_LINE", 72, 90], ["Ceacam1\u2212/\u2212 T cells", "CELL_TYPE", 120, 138], ["Ceacam1", "PROTEIN", 192, 199], ["Ceacam1-Tg T cells", "CELL_LINE", 311, 329], ["Ceacam1-Tg T cells", "CELL_LINE", 385, 403], ["WT T cells", "CELL_TYPE", 504, 514], ["a modest trend", "PROBLEM", 17, 31], ["less skin GVHD", "PROBLEM", 40, 54], ["Ceacam1", "TEST", 72, 79], ["T cells", "PROBLEM", 83, 90], ["Ceacam1", "TEST", 120, 127], ["T cells", "PROBLEM", 131, 138], ["preferential damage to the (large) intestines", "PROBLEM", 146, 191], ["Ceacam1", "TREATMENT", 192, 199], ["WT", "TEST", 304, 306], ["Ceacam1", "TEST", 311, 318], ["transplant", "TREATMENT", 345, 355], ["Ceacam1", "TEST", 385, 392], ["Tg T cells", "TEST", 393, 403], ["significantly less GVHD of the liver", "PROBLEM", 417, 453], ["thymus", "PROBLEM", 471, 477], ["WT T cells", "PROBLEM", 504, 514], ["similar skin GVHD", "PROBLEM", 520, 537], ["modest", "OBSERVATION_MODIFIER", 19, 25], ["skin", "ANATOMY", 45, 49], ["GVHD", "OBSERVATION", 50, 54], ["preferential damage", "OBSERVATION", 146, 165], ["intestines", "ANATOMY", 181, 191], ["significantly", "OBSERVATION_MODIFIER", 417, 430], ["less", "OBSERVATION_MODIFIER", 431, 435], ["GVHD", "OBSERVATION", 436, 440], ["liver", "ANATOMY", 448, 453], ["intestines", "ANATOMY", 455, 465], ["thymus", "ANATOMY", 471, 477], ["skin", "ANATOMY", 528, 532], ["GVHD", "OBSERVATION", 533, 537]]], ["This appears to suggest that Ceacam1-Tg T cells caused less GVHD overall, with relatively little organ specificity.Ceacam1 is an important regulator of GVHD target organ damage ::: ResultsFinally, we assessed Ceacam1\u2212/\u2212 allo-BMT recipients on day 14 post-transplant.", [["Ceacam1-Tg T cells", "ANATOMY", 29, 47], ["organ", "ANATOMY", 97, 102], ["organ", "ANATOMY", 164, 169], ["GVHD", "DISEASE", 60, 64], ["GVHD", "DISEASE", 152, 156], ["organ damage", "DISEASE", 164, 176], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 29, 36], ["organ", "ORGAN", 97, 102], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 115, 122], ["organ", "ORGAN", 164, 169], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 209, 216], ["Ceacam1", "PROTEIN", 29, 36], ["Tg T cells", "CELL_TYPE", 37, 47], ["Ceacam1", "PROTEIN", 115, 122], ["Ceacam1", "PROTEIN", 209, 216], ["Ceacam1", "TEST", 29, 36], ["less GVHD", "PROBLEM", 55, 64], ["Ceacam1", "TREATMENT", 115, 122], ["Ceacam1", "TEST", 209, 216], ["allo-BMT recipients", "TREATMENT", 220, 239], ["transplant", "TREATMENT", 255, 265], ["appears to suggest", "UNCERTAINTY", 5, 23], ["Ceacam1", "OBSERVATION", 29, 36], ["less", "OBSERVATION_MODIFIER", 55, 59], ["GVHD", "OBSERVATION", 60, 64], ["transplant", "OBSERVATION", 255, 265]]], ["In correspondence with increased early GVHD mortality, Ceacam1\u2212/\u2212 allo-BMT recipients showed increased large bowel damage and thymic GVHD (Figure 2G\u2013H).Ceacam1 regulates donor T cell numbers in lymphoid tissues and target organs during GVHD ::: ResultsWe next assessed the numbers of donor CD4 and CD8 effector T cells after transfer of Ceacam1\u2212/\u2212 or Ceacam1-Tg T cell-containing allografts, or in Ceacam1\u2212/\u2212 allo-BMT recipients.Ceacam1 regulates donor T cell numbers in lymphoid tissues and target organs during GVHD ::: ResultsComparing recipients of WT T cells with those receiving Ceacam1\u2212/\u2212 T cells, we observed increased numbers of Ceacam1\u2212/\u2212 donor alloactivated effector T cells in the spleen, MLN, and IEL of allo-BMT recipients (Figure 3A), which was associated with a concomitant decrease in the number of Ceacam1\u2212/\u2212 alloactivated CD4 and CD8 T cells in the PLN and liver.Ceacam1 regulates donor T cell numbers in lymphoid tissues and target organs during GVHD ::: ResultsWhen we analyzed organs of recipients of allografts containing WT vs. Ceacam1-Tg T cells, we noted decreased numbers of donor effector T cells in the MLN, PLN, and liver (Figure 3B).", [["bowel", "ANATOMY", 109, 114], ["thymic", "ANATOMY", 126, 132], ["T cell", "ANATOMY", 176, 182], ["lymphoid tissues", "ANATOMY", 194, 210], ["organs", "ANATOMY", 222, 228], ["CD4", "ANATOMY", 290, 293], ["CD8 effector T cells", "ANATOMY", 298, 318], ["Ceacam1-Tg T cell", "ANATOMY", 351, 368], ["allografts", "ANATOMY", 380, 390], ["T cell", "ANATOMY", 453, 459], ["lymphoid tissues", "ANATOMY", 471, 487], ["organs", "ANATOMY", 499, 505], ["WT T cells", "ANATOMY", 553, 563], ["Ceacam1\u2212/\u2212 T cells", "ANATOMY", 585, 603], ["effector T cells", "ANATOMY", 669, 685], ["spleen", "ANATOMY", 693, 699], ["MLN", "ANATOMY", 701, 704], ["IEL", "ANATOMY", 710, 713], ["CD4", "ANATOMY", 841, 844], ["CD8 T cells", "ANATOMY", 849, 860], ["PLN", "ANATOMY", 868, 871], ["liver", "ANATOMY", 876, 881], ["T cell", "ANATOMY", 906, 912], ["lymphoid tissues", "ANATOMY", 924, 940], ["organs", "ANATOMY", 952, 958], ["organs", "ANATOMY", 999, 1005], ["allografts", "ANATOMY", 1023, 1033], ["Ceacam1-Tg T cells", "ANATOMY", 1052, 1070], ["effector T cells", "ANATOMY", 1108, 1124], ["MLN", "ANATOMY", 1132, 1135], ["PLN", "ANATOMY", 1137, 1140], ["liver", "ANATOMY", 1146, 1151], ["GVHD", "DISEASE", 39, 43], ["bowel damage", "DISEASE", 109, 121], ["GVHD", "DISEASE", 133, 137], ["GVHD", "DISEASE", 236, 240], ["GVHD", "DISEASE", 513, 517], ["GVHD", "DISEASE", 966, 970], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 55, 62], ["bowel", "ORGAN", 109, 114], ["thymic", "ORGAN", 126, 132], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 152, 159], ["donor T cell", "CELL", 170, 182], ["lymphoid tissues", "TISSUE", 194, 210], ["organs", "ORGAN", 222, 228], ["CD4", "GENE_OR_GENE_PRODUCT", 290, 293], ["CD8", "GENE_OR_GENE_PRODUCT", 298, 301], ["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 337, 345], ["\u2212", "GENE_OR_GENE_PRODUCT", 346, 347], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 351, 358], ["allografts", "TISSUE", 380, 390], ["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 398, 406], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 429, 436], ["donor T cell", "CELL", 447, 459], ["lymphoid tissues", "TISSUE", 471, 487], ["organs", "ORGAN", 499, 505], ["recipients", "ORGANISM", 539, 549], ["WT T cells", "CELL", 553, 563], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 585, 592], ["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 638, 646], ["T cells", "CELL", 678, 685], ["spleen", "ORGAN", 693, 699], ["MLN", "CELL", 701, 704], ["IEL", "CELL", 710, 713], ["allo-BMT recipients", "CELL", 717, 736], ["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 816, 824], ["CD4", "GENE_OR_GENE_PRODUCT", 841, 844], ["CD8 T", "GENE_OR_GENE_PRODUCT", 849, 854], ["PLN", "MULTI-TISSUE_STRUCTURE", 868, 871], ["liver", "ORGAN", 876, 881], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 882, 889], ["donor T cell", "CELL", 900, 912], ["lymphoid tissues", "TISSUE", 924, 940], ["organs", "ORGAN", 952, 958], ["organs", "ORGAN", 999, 1005], ["recipients", "ORGANISM", 1009, 1019], ["allografts", "TISSUE", 1023, 1033], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 1052, 1059], ["effector T cells", "CELL", 1108, 1124], ["MLN", "MULTI-TISSUE_STRUCTURE", 1132, 1135], ["PLN", "MULTI-TISSUE_STRUCTURE", 1137, 1140], ["liver", "ORGAN", 1146, 1151], ["Ceacam1", "PROTEIN", 55, 62], ["Ceacam1", "PROTEIN", 152, 159], ["donor CD4 and CD8 effector T cells", "CELL_TYPE", 284, 318], ["Ceacam1\u2212", "PROTEIN", 337, 345], ["Ceacam1", "PROTEIN", 351, 358], ["Ceacam1", "PROTEIN", 429, 436], ["WT T cells", "CELL_TYPE", 553, 563], ["Ceacam1\u2212/\u2212 T cells", "CELL_LINE", 585, 603], ["Ceacam1\u2212/\u2212 donor alloactivated effector T cells", "CELL_TYPE", 638, 685], ["MLN", "CELL_TYPE", 701, 704], ["IEL", "CELL_TYPE", 710, 713], ["Ceacam1\u2212/\u2212 alloactivated CD4 and CD8 T cells", "CELL_TYPE", 816, 860], ["PLN", "CELL_TYPE", 868, 871], ["Ceacam1", "PROTEIN", 882, 889], ["Ceacam1-Tg T cells", "CELL_LINE", 1052, 1070], ["donor effector T cells", "CELL_TYPE", 1102, 1124], ["MLN", "CELL_TYPE", 1132, 1135], ["PLN", "CELL_TYPE", 1137, 1140], ["increased early GVHD mortality", "PROBLEM", 23, 53], ["Ceacam1", "TREATMENT", 55, 62], ["allo-BMT recipients", "TREATMENT", 66, 85], ["increased large bowel damage", "PROBLEM", 93, 121], ["thymic GVHD", "PROBLEM", 126, 137], ["Ceacam1 regulates", "TREATMENT", 152, 169], ["donor T cell numbers", "TEST", 170, 190], ["donor CD4", "TEST", 284, 293], ["Ceacam1\u2212", "TEST", 337, 345], ["Ceacam1", "TEST", 351, 358], ["Tg T cell", "TREATMENT", 359, 368], ["allografts", "TREATMENT", 380, 390], ["allo-BMT recipients", "TREATMENT", 409, 428], ["Ceacam1 regulates", "TREATMENT", 429, 446], ["donor T cell numbers", "TEST", 447, 467], ["WT T cells", "PROBLEM", 553, 563], ["Ceacam1", "TEST", 585, 592], ["T cells", "PROBLEM", 596, 603], ["Ceacam1\u2212", "TEST", 638, 646], ["allo-BMT recipients", "TREATMENT", 717, 736], ["a concomitant decrease", "PROBLEM", 776, 798], ["Ceacam1\u2212", "TEST", 816, 824], ["Ceacam1 regulates", "TREATMENT", 882, 899], ["donor T cell numbers", "TEST", 900, 920], ["recipients of allografts", "TREATMENT", 1009, 1033], ["Ceacam1", "TEST", 1052, 1059], ["donor effector T cells", "PROBLEM", 1102, 1124], ["PLN", "TEST", 1137, 1140], ["increased", "OBSERVATION_MODIFIER", 23, 32], ["early", "OBSERVATION_MODIFIER", 33, 38], ["GVHD", "OBSERVATION", 39, 43], ["increased", "OBSERVATION_MODIFIER", 93, 102], ["large", "OBSERVATION_MODIFIER", 103, 108], ["bowel", "ANATOMY", 109, 114], ["damage", "OBSERVATION", 115, 121], ["thymic GVHD", "OBSERVATION", 126, 137], ["donor T cell numbers", "OBSERVATION", 170, 190], ["lymphoid tissues", "OBSERVATION", 194, 210], ["GVHD", "OBSERVATION", 236, 240], ["donor CD4", "OBSERVATION", 284, 293], ["donor T cell numbers", "OBSERVATION", 447, 467], ["lymphoid tissues", "OBSERVATION", 471, 487], ["GVHD", "OBSERVATION", 513, 517], ["increased", "OBSERVATION_MODIFIER", 617, 626], ["spleen", "ANATOMY", 693, 699], ["MLN", "ANATOMY", 701, 704], ["concomitant", "OBSERVATION_MODIFIER", 778, 789], ["decrease", "OBSERVATION_MODIFIER", 790, 798], ["PLN", "ANATOMY", 868, 871], ["liver", "ANATOMY", 876, 881], ["donor T cell numbers", "OBSERVATION", 900, 920], ["lymphoid tissues", "OBSERVATION", 924, 940], ["GVHD", "OBSERVATION", 966, 970], ["allografts", "OBSERVATION", 1023, 1033], ["decreased", "OBSERVATION_MODIFIER", 1081, 1090], ["donor effector T cells", "OBSERVATION", 1102, 1124], ["MLN", "ANATOMY", 1132, 1135], ["PLN", "ANATOMY", 1137, 1140], ["liver", "ANATOMY", 1146, 1151]]], ["Via histopathological analysis, we also observed decreased numbers of total lymphocytic infiltrates into the liver, small and large bowels by histopathology (Figure 3B), as well as decreased neutrophilic infiltrates in these organs (data not shown).", [["lymphocytic infiltrates", "ANATOMY", 76, 99], ["liver", "ANATOMY", 109, 114], ["bowels", "ANATOMY", 132, 138], ["neutrophilic infiltrates", "ANATOMY", 191, 215], ["organs", "ANATOMY", 225, 231], ["lymphocytic infiltrates", "TISSUE", 76, 99], ["liver", "ORGAN", 109, 114], ["bowels", "ORGAN", 132, 138], ["neutrophilic infiltrates", "PATHOLOGICAL_FORMATION", 191, 215], ["organs", "ORGAN", 225, 231], ["histopathological analysis", "TEST", 4, 30], ["total lymphocytic infiltrates into the liver", "PROBLEM", 70, 114], ["small and large bowels", "PROBLEM", 116, 138], ["decreased neutrophilic infiltrates in these organs", "PROBLEM", 181, 231], ["decreased", "OBSERVATION_MODIFIER", 49, 58], ["numbers", "OBSERVATION_MODIFIER", 59, 66], ["total", "OBSERVATION_MODIFIER", 70, 75], ["lymphocytic infiltrates", "OBSERVATION", 76, 99], ["liver", "ANATOMY", 109, 114], ["small", "OBSERVATION_MODIFIER", 116, 121], ["large", "ANATOMY_MODIFIER", 126, 131], ["bowels", "ANATOMY", 132, 138], ["decreased", "OBSERVATION_MODIFIER", 181, 190], ["neutrophilic", "OBSERVATION_MODIFIER", 191, 203], ["infiltrates", "OBSERVATION", 204, 215], ["organs", "ANATOMY", 225, 231]]], ["Finally, we assessed infiltrating T cells in WT and Ceacam1\u2212/\u2212 allo-BMT recipients, and observed increased numbers of donor alloactivated effector T cells in the MLN and IEL of Ceacam1\u2212/\u2212 allo-BMT recipients, but decreased numbers of these cells in the PLN and liver (Figure 3C).Ceacam1 regulates the sensitivity of the small intestine to radiation injury ::: ResultsThe accelerated early mortality of Ceacam1\u2212/\u2212 allo-BMT recipients, together with increased accumulation of donor T cells in GI tract and mesenteric lymph nodes, but decreased numbers peripheral lymph nodes (Figure 3C), led us to ask whether Ceacam1 had differential effects in regulating GVHD target organ damage for various target organs and tissues.", [["infiltrating T cells", "ANATOMY", 21, 41], ["effector T cells", "ANATOMY", 138, 154], ["MLN", "ANATOMY", 162, 165], ["IEL", "ANATOMY", 170, 173], ["cells", "ANATOMY", 240, 245], ["PLN", "ANATOMY", 253, 256], ["liver", "ANATOMY", 261, 266], ["small intestine", "ANATOMY", 320, 335], ["donor T cells", "ANATOMY", 474, 487], ["GI tract", "ANATOMY", 491, 499], ["mesenteric lymph nodes", "ANATOMY", 504, 526], ["peripheral lymph nodes", "ANATOMY", 550, 572], ["organ", "ANATOMY", 667, 672], ["organs", "ANATOMY", 699, 705], ["tissues", "ANATOMY", 710, 717], ["Ceacam1", "CHEMICAL", 279, 286], ["Ceacam1", "CHEMICAL", 608, 615], ["GVHD", "DISEASE", 655, 659], ["organ damage", "DISEASE", 667, 679], ["infiltrating T cells", "CELL", 21, 41], ["WT", "CELL", 45, 47], ["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 52, 60], ["effector T cells", "CELL", 138, 154], ["MLN", "CELL", 162, 165], ["IEL", "CELL", 170, 173], ["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 177, 185], ["cells", "CELL", 240, 245], ["PLN", "MULTI-TISSUE_STRUCTURE", 253, 256], ["liver", "ORGAN", 261, 266], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 279, 286], ["small intestine", "ORGAN", 320, 335], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 402, 409], ["T cells", "CELL", 480, 487], ["GI tract", "MULTI-TISSUE_STRUCTURE", 491, 499], ["mesenteric lymph nodes", "MULTI-TISSUE_STRUCTURE", 504, 526], ["peripheral lymph nodes", "MULTI-TISSUE_STRUCTURE", 550, 572], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 608, 615], ["organ", "ORGAN", 667, 672], ["organs", "ORGAN", 699, 705], ["tissues", "TISSUE", 710, 717], ["infiltrating T cells", "CELL_TYPE", 21, 41], ["donor alloactivated effector T cells", "CELL_TYPE", 118, 154], ["MLN", "CELL_TYPE", 162, 165], ["IEL", "CELL_TYPE", 170, 173], ["PLN", "CELL_TYPE", 253, 256], ["Ceacam1", "PROTEIN", 279, 286], ["donor T cells", "CELL_TYPE", 474, 487], ["Ceacam1", "PROTEIN", 608, 615], ["infiltrating T cells", "PROBLEM", 21, 41], ["WT", "TEST", 45, 47], ["Ceacam1\u2212", "TEST", 52, 60], ["allo-BMT recipients", "TREATMENT", 63, 82], ["Ceacam1\u2212", "TREATMENT", 177, 185], ["allo-BMT recipients", "TREATMENT", 188, 207], ["Ceacam1 regulates", "TREATMENT", 279, 296], ["the small intestine to radiation injury", "PROBLEM", 316, 355], ["Ceacam1", "TEST", 402, 409], ["allo-BMT recipients", "TREATMENT", 413, 432], ["increased accumulation of donor T cells in GI tract", "PROBLEM", 448, 499], ["mesenteric lymph nodes", "PROBLEM", 504, 526], ["decreased numbers peripheral lymph nodes", "PROBLEM", 532, 572], ["GVHD target organ damage", "PROBLEM", 655, 679], ["various target organs and tissues", "PROBLEM", 684, 717], ["increased", "OBSERVATION_MODIFIER", 97, 106], ["MLN", "ANATOMY", 162, 165], ["PLN", "ANATOMY", 253, 256], ["liver", "ANATOMY", 261, 266], ["small", "OBSERVATION_MODIFIER", 320, 325], ["intestine", "ANATOMY", 326, 335], ["radiation injury", "OBSERVATION", 339, 355], ["early", "OBSERVATION_MODIFIER", 383, 388], ["mortality", "OBSERVATION_MODIFIER", 389, 398], ["increased", "OBSERVATION_MODIFIER", 448, 457], ["accumulation", "OBSERVATION_MODIFIER", 458, 470], ["donor T cells", "OBSERVATION", 474, 487], ["GI tract", "ANATOMY", 491, 499], ["mesenteric", "ANATOMY", 504, 514], ["lymph nodes", "OBSERVATION", 515, 526], ["decreased", "OBSERVATION_MODIFIER", 532, 541], ["numbers", "OBSERVATION_MODIFIER", 542, 549], ["peripheral", "OBSERVATION_MODIFIER", 550, 560], ["lymph nodes", "OBSERVATION", 561, 572], ["GVHD", "OBSERVATION", 655, 659], ["tissues", "ANATOMY", 710, 717]]], ["In the context of Ceacam1\u2212/\u2212 recipients, we therefore tested the radiation sensitivity of Ceacam1\u2212/\u2212 mice used as hosts, by irradiating WT and Ceacam1\u2212/\u2212 BALB/c mice and assessing survival.", [["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 18, 26], ["Ceacam1\u2212/\u2212 mice", "ORGANISM", 90, 105], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 143, 150], ["Ceacam1\u2212", "PROTEIN", 90, 98], ["Ceacam1", "PROTEIN", 143, 150], ["mice", "SPECIES", 101, 105], ["mice", "SPECIES", 161, 165], ["mice", "SPECIES", 101, 105], ["mice", "SPECIES", 161, 165], ["Ceacam1\u2212/\u2212 recipients", "TREATMENT", 18, 39], ["the radiation sensitivity", "TEST", 61, 86], ["Ceacam1\u2212/\u2212 mice", "TREATMENT", 90, 105]]], ["Ceacam1\u2212/\u2212 animals showed increased kinetics of mortality, and in some cases, overall mortality after radiation injury (Figure 4A).", [["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 0, 8], ["Ceacam1\u2212", "TREATMENT", 0, 8], ["increased kinetics of mortality", "PROBLEM", 26, 57], ["radiation injury", "PROBLEM", 102, 118], ["increased", "OBSERVATION_MODIFIER", 26, 35], ["kinetics", "OBSERVATION_MODIFIER", 36, 44]]], ["We then enumerated regenerating and surviving crypts in the small intestine (terminal ileum) at 84 hours after irradiation to assess intestinal radiation damage, and observed that Ceacam1\u2212/\u2212 mice had fewer regenerating and surviving crypts as compared with WT counterparts (Figure 4B and D), indicating greater damage to the small intestine across a wide range of radiation doses.", [["crypts", "ANATOMY", 46, 52], ["small intestine", "ANATOMY", 60, 75], ["ileum", "ANATOMY", 86, 91], ["intestinal", "ANATOMY", 133, 143], ["crypts", "ANATOMY", 233, 239], ["small intestine", "ANATOMY", 325, 340], ["crypts", "MULTI-TISSUE_STRUCTURE", 46, 52], ["small intestine", "ORGAN", 60, 75], ["terminal ileum", "MULTI-TISSUE_STRUCTURE", 77, 91], ["intestinal", "ORGAN", 133, 143], ["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 180, 188], ["crypts", "MULTI-TISSUE_STRUCTURE", 233, 239], ["intestine", "ORGAN", 331, 340], ["Ceacam1\u2212", "PROTEIN", 180, 188], ["mice", "SPECIES", 191, 195], ["mice", "SPECIES", 191, 195], ["surviving crypts in the small intestine", "PROBLEM", 36, 75], ["irradiation", "TREATMENT", 111, 122], ["intestinal radiation damage", "PROBLEM", 133, 160], ["greater damage to the small intestine", "PROBLEM", 303, 340], ["radiation doses", "TREATMENT", 364, 379], ["surviving crypts", "OBSERVATION", 36, 52], ["small intestine", "ANATOMY", 60, 75], ["terminal", "ANATOMY_MODIFIER", 77, 85], ["ileum", "ANATOMY", 86, 91], ["intestinal", "ANATOMY", 133, 143], ["radiation damage", "OBSERVATION", 144, 160], ["greater", "OBSERVATION_MODIFIER", 303, 310], ["damage", "OBSERVATION", 311, 317], ["small intestine", "ANATOMY", 325, 340], ["wide", "OBSERVATION_MODIFIER", 350, 354]]], ["It is thus quite likely that our radiation-containing conditioning regimen for transplant recipients also contributes in part to their survival kinetics, selective GVHD target organ damage (Figure 2G\u2013H), and the selective accumulation of donor T cells in lymphoid tissues and target organs (Figure 3C) in these recipients.Donor Ceacam1\u2212/\u2212 CD8 T cells express higher levels of integrin \u03b14\u03b27 post-transplant ::: ResultsNext, we studied a variety of possible mechanisms by which Ceacam1 may regulate donor T cell function.", [["organ", "ANATOMY", 176, 181], ["donor T cells", "ANATOMY", 238, 251], ["lymphoid tissues", "ANATOMY", 255, 271], ["organs", "ANATOMY", 283, 289], ["Ceacam1\u2212/\u2212 CD8 T cells", "ANATOMY", 328, 350], ["T cell", "ANATOMY", 503, 509], ["GVHD", "DISEASE", 164, 168], ["organ damage", "DISEASE", 176, 188], ["Ceacam1", "CHEMICAL", 476, 483], ["recipients", "ORGANISM", 90, 100], ["organ", "ORGAN", 176, 181], ["T cells", "CELL", 244, 251], ["lymphoid tissues", "TISSUE", 255, 271], ["organs", "ORGAN", 283, 289], ["recipients", "ORGANISM", 311, 321], ["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 328, 336], ["integrin \u03b14\u03b27", "GENE_OR_GENE_PRODUCT", 376, 389], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 476, 483], ["donor T cell", "CELL", 497, 509], ["donor T cells", "CELL_TYPE", 238, 251], ["Donor Ceacam1\u2212/\u2212 CD8 T cells", "CELL_LINE", 322, 350], ["integrin", "PROTEIN", 376, 384], ["\u03b27", "PROTEIN", 387, 389], ["Ceacam1", "PROTEIN", 476, 483], ["our radiation-containing conditioning regimen", "TREATMENT", 29, 74], ["transplant recipients", "TREATMENT", 79, 100], ["their survival kinetics", "PROBLEM", 129, 152], ["selective GVHD target organ damage", "PROBLEM", 154, 188], ["donor T cells in lymphoid tissues", "PROBLEM", 238, 271], ["Donor Ceacam1\u2212", "TREATMENT", 322, 336], ["CD8 T cells", "TREATMENT", 339, 350], ["thus quite likely", "UNCERTAINTY", 6, 23], ["selective", "OBSERVATION_MODIFIER", 212, 221], ["accumulation", "OBSERVATION_MODIFIER", 222, 234], ["donor T cells", "OBSERVATION", 238, 251], ["lymphoid tissues", "OBSERVATION", 255, 271]]], ["We analyzed donor WT and Ceacam1\u2212/\u2212 alloactivated splenic T cells on day 14 after allo-BMT for trafficking molecules, and found that Ceacam1\u2212/\u2212 CD8+ CD44+CD62L\u2212 effector T cells expressed higher levels of integrin \u03b27 subunit and the gut homing integrin \u03b14\u03b27 (Figure 5A), which is important for intestinal GVHD [31], [32], [33].", [["splenic T cells", "ANATOMY", 50, 65], ["Ceacam1\u2212/\u2212 CD8+ CD44+CD62L\u2212 effector T cells", "ANATOMY", 133, 177], ["gut", "ANATOMY", 233, 236], ["intestinal", "ANATOMY", 294, 304], ["GVHD", "DISEASE", 305, 309], ["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 25, 33], ["splenic T cells", "CELL", 50, 65], ["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 133, 141], ["CD8", "GENE_OR_GENE_PRODUCT", 144, 147], ["CD44", "GENE_OR_GENE_PRODUCT", 149, 153], ["CD62L", "GENE_OR_GENE_PRODUCT", 154, 159], ["integrin \u03b27", "GENE_OR_GENE_PRODUCT", 205, 216], ["integrin \u03b14\u03b27", "GENE_OR_GENE_PRODUCT", 244, 257], ["Figure 5A", "GENE_OR_GENE_PRODUCT", 259, 268], ["intestinal", "ORGAN", 294, 304], ["Ceacam1\u2212/\u2212 alloactivated splenic T cells", "CELL_LINE", 25, 65], ["Ceacam1\u2212", "PROTEIN", 133, 141], ["CD8", "PROTEIN", 144, 147], ["CD44", "PROTEIN", 149, 153], ["CD62L", "PROTEIN", 154, 159], ["effector T cells", "CELL_TYPE", 161, 177], ["integrin \u03b27 subunit", "PROTEIN", 205, 224], ["gut homing integrin \u03b14\u03b27", "PROTEIN", 233, 257], ["Figure 5A", "PROTEIN", 259, 268], ["donor WT", "TEST", 12, 20], ["Ceacam1\u2212/\u2212 alloactivated splenic T cells", "TREATMENT", 25, 65], ["allo-BMT", "TREATMENT", 82, 90], ["trafficking molecules", "PROBLEM", 95, 116], ["Ceacam1\u2212", "TEST", 133, 141], ["CD8", "TEST", 144, 147], ["CD44", "TEST", 149, 153], ["CD62L", "TEST", 154, 159], ["effector T cells", "PROBLEM", 161, 177], ["integrin \u03b2", "TREATMENT", 205, 215], ["intestinal GVHD", "PROBLEM", 294, 309], ["splenic", "ANATOMY", 50, 57], ["gut", "ANATOMY", 233, 236], ["intestinal", "ANATOMY", 294, 304], ["GVHD", "OBSERVATION", 305, 309]]], ["However, WT vs. Ceacam1\u2212/\u2212 CD4 effector T cells had similar integrin \u03b27 subunit expression, yet also accumulated in greater numbers in the gut (Figure 3A), suggesting that regulation of target organ damage by Ceacam1 is very likely to involve multiple additional mechanisms beyond trafficking molecule expression.", [["Ceacam1\u2212/\u2212 CD4 effector T cells", "ANATOMY", 16, 47], ["gut", "ANATOMY", 139, 142], ["organ", "ANATOMY", 193, 198], ["organ damage", "DISEASE", 193, 205], ["Ceacam1", "CHEMICAL", 209, 216], ["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 16, 24], ["integrin \u03b27", "GENE_OR_GENE_PRODUCT", 60, 71], ["gut", "ORGANISM_SUBDIVISION", 139, 142], ["organ", "ORGAN", 193, 198], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 209, 216], ["Ceacam1\u2212/\u2212 CD4 effector T cells", "CELL_LINE", 16, 47], ["integrin", "PROTEIN", 60, 68], ["\u03b27 subunit", "PROTEIN", 69, 79], ["Ceacam1", "PROTEIN", 209, 216], ["Ceacam1\u2212", "TREATMENT", 16, 24], ["CD4 effector T cells", "TREATMENT", 27, 47], ["target organ damage", "PROBLEM", 186, 205], ["greater", "OBSERVATION_MODIFIER", 116, 123], ["numbers", "OBSERVATION_MODIFIER", 124, 131], ["gut", "ANATOMY", 139, 142], ["trafficking molecule expression", "OBSERVATION", 281, 312]]], ["Additionally, levels of the \u03b1E subunit, which forms integrin \u03b1E\u03b27, were similar, as were levels of CCR9, CD31, PSGL1, CCR7, CXCR3, and LFA1 (data not shown).Donor Ceacam1\u2212/\u2212 CD8 T cells express higher levels of integrin \u03b14\u03b27 post-transplant ::: ResultsWhen we assessed the expression of trafficking molecules in recipients of WT vs. Ceacam1-Tg T cell allografts, we found no significant differences in levels of \u03b27 subunit, integrin \u03b14\u03b27 (Figure 5B), or any other molecules.", [["Ceacam1\u2212/\u2212 CD8 T cells", "ANATOMY", 163, 185], ["Ceacam1-Tg T cell allografts", "ANATOMY", 333, 361], ["\u03b1E", "GENE_OR_GENE_PRODUCT", 28, 30], ["integrin \u03b1E\u03b27", "GENE_OR_GENE_PRODUCT", 52, 65], ["CCR9", "GENE_OR_GENE_PRODUCT", 99, 103], ["CD31", "GENE_OR_GENE_PRODUCT", 105, 109], ["PSGL1", "GENE_OR_GENE_PRODUCT", 111, 116], ["CCR7", "GENE_OR_GENE_PRODUCT", 118, 122], ["CXCR3", "GENE_OR_GENE_PRODUCT", 124, 129], ["LFA1", "GENE_OR_GENE_PRODUCT", 135, 139], ["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 163, 171], ["integrin \u03b14\u03b27", "GENE_OR_GENE_PRODUCT", 211, 224], ["recipients", "ORGANISM", 312, 322], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 333, 340], ["\u03b27 subunit", "GENE_OR_GENE_PRODUCT", 412, 422], ["integrin \u03b14\u03b27", "GENE_OR_GENE_PRODUCT", 424, 437], ["Figure 5B", "GENE_OR_GENE_PRODUCT", 439, 448], ["\u03b1E subunit", "PROTEIN", 28, 38], ["integrin \u03b1E\u03b27", "PROTEIN", 52, 65], ["CCR9", "PROTEIN", 99, 103], ["CD31", "PROTEIN", 105, 109], ["PSGL1", "PROTEIN", 111, 116], ["CCR7", "PROTEIN", 118, 122], ["CXCR3", "PROTEIN", 124, 129], ["LFA1", "PROTEIN", 135, 139], ["Donor Ceacam1\u2212/\u2212 CD8 T cells", "CELL_LINE", 157, 185], ["integrin", "PROTEIN", 211, 219], ["\u03b27", "PROTEIN", 222, 224], ["trafficking molecules", "PROTEIN", 287, 308], ["Ceacam1", "PROTEIN", 333, 340], ["\u03b27 subunit", "PROTEIN", 412, 422], ["integrin \u03b14\u03b27", "PROTEIN", 424, 437], ["Figure 5B", "PROTEIN", 439, 448], ["the \u03b1E subunit", "TEST", 24, 38], ["integrin \u03b1E\u03b2", "TEST", 52, 64], ["CCR9", "TEST", 99, 103], ["CD31", "TEST", 105, 109], ["PSGL1", "TEST", 111, 116], ["CCR7", "TEST", 118, 122], ["CXCR3", "TEST", 124, 129], ["LFA1", "TEST", 135, 139], ["Donor Ceacam1\u2212", "TREATMENT", 157, 171], ["CD8 T cells", "TREATMENT", 174, 185], ["Ceacam1", "TEST", 333, 340], ["Tg T cell allografts", "TREATMENT", 341, 361], ["significant differences in levels", "PROBLEM", 375, 408], ["integrin", "TEST", 424, 432], ["any other molecules", "PROBLEM", 454, 473], ["CCR9", "ANATOMY", 99, 103], ["CCR7", "ANATOMY", 118, 122], ["cell allografts", "OBSERVATION", 346, 361], ["no", "UNCERTAINTY", 372, 374], ["significant", "OBSERVATION_MODIFIER", 375, 386]]], ["This is consistent with the systemic reduction in GVHD in recipients of Ceacam1-Tg T cells.", [["Ceacam1-Tg T cells", "ANATOMY", 72, 90], ["GVHD", "DISEASE", 50, 54], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 72, 79], ["Ceacam1-Tg T cells", "CELL_LINE", 72, 90], ["the systemic reduction", "PROBLEM", 24, 46], ["GVHD", "PROBLEM", 50, 54], ["Ceacam1", "TEST", 72, 79], ["consistent with", "UNCERTAINTY", 8, 23], ["systemic", "OBSERVATION_MODIFIER", 28, 36], ["reduction", "OBSERVATION_MODIFIER", 37, 46], ["GVHD", "OBSERVATION", 50, 54]]], ["Finally, we assessed trafficking molecules in irradiated WT vs. Ceacam1\u2212/\u2212 recipients of identical donor allografts, and observed again that donor CD8, but not CD4 splenic T cells in Ceacam1\u2212/\u2212 recipients had a trend towards increased expression of the \u03b27 subunit, although this was not directly reflected in increased expression of integrin \u03b14\u03b27.", [["allografts", "ANATOMY", 105, 115], ["CD4 splenic T cells", "ANATOMY", 160, 179], ["allografts", "TISSUE", 105, 115], ["CD8", "GENE_OR_GENE_PRODUCT", 147, 150], ["CD4", "GENE_OR_GENE_PRODUCT", 160, 163], ["\u03b27", "GENE_OR_GENE_PRODUCT", 253, 255], ["integrin \u03b14\u03b27", "GENE_OR_GENE_PRODUCT", 333, 346], ["trafficking molecules", "PROTEIN", 21, 42], ["donor CD8", "CELL_TYPE", 141, 150], ["CD4 splenic T cells", "CELL_TYPE", 160, 179], ["\u03b27 subunit", "PROTEIN", 253, 263], ["integrin \u03b14\u03b27", "PROTEIN", 333, 346], ["Ceacam1\u2212", "TREATMENT", 64, 72], ["identical donor allografts", "TREATMENT", 89, 115], ["donor CD8", "TEST", 141, 150], ["donor allografts", "OBSERVATION", 99, 115], ["splenic", "ANATOMY", 164, 171]]], ["Taken together, these observations suggest that regulation of trafficking molecule expression by Ceacam1 is only one component of how it regulates GVHD target organ damage.Ceacam1 is expressed on T cells during alloactivation ::: ResultsCeacam1 can be found on activated T cells [7], [8], [29] and, we thus performed a kinetic analysis of Ceacam1 expression on T cells during alloactivation.", [["organ", "ANATOMY", 159, 164], ["T cells", "ANATOMY", 196, 203], ["T cells", "ANATOMY", 271, 278], ["T cells", "ANATOMY", 361, 368], ["GVHD", "DISEASE", 147, 151], ["organ damage", "DISEASE", 159, 171], ["ResultsCeacam1", "CHEMICAL", 230, 244], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 97, 104], ["organ", "ORGAN", 159, 164], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 172, 179], ["T cells", "CELL", 196, 203], ["ResultsCeacam1", "GENE_OR_GENE_PRODUCT", 230, 244], ["T cells", "CELL", 271, 278], ["[8]", "SIMPLE_CHEMICAL", 284, 287], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 339, 346], ["T cells", "CELL", 361, 368], ["Ceacam1", "PROTEIN", 97, 104], ["Ceacam1", "PROTEIN", 172, 179], ["T cells", "CELL_TYPE", 196, 203], ["ResultsCeacam1", "PROTEIN", 230, 244], ["activated T cells", "CELL_TYPE", 261, 278], ["Ceacam1", "PROTEIN", 339, 346], ["T cells", "CELL_TYPE", 361, 368], ["trafficking molecule expression", "TREATMENT", 62, 93], ["GVHD target organ damage", "PROBLEM", 147, 171], ["activated T cells", "TEST", 261, 278], ["a kinetic analysis", "TEST", 317, 335], ["Ceacam1 expression", "PROBLEM", 339, 357], ["alloactivation", "TREATMENT", 376, 390]]], ["We adoptively transferred CFSE-labeled B6 T cells into irradiated BALB/c recipients, and observed transient expression only on day 2 after alloactivation (Figure 6and data not shown).", [["B6 T cells", "ANATOMY", 39, 49], ["CFSE", "CHEMICAL", 26, 30], ["CFSE", "CHEMICAL", 26, 30], ["CFSE", "SIMPLE_CHEMICAL", 26, 30], ["B6 T cells", "CELL", 39, 49], ["BALB/c recipients", "ORGANISM", 66, 83], ["CFSE-labeled B6 T cells", "CELL_LINE", 26, 49], ["irradiated BALB/c recipients", "TREATMENT", 55, 83]]], ["Furthermore, only CFSElo alloactivated T cells, which have divided \u22654 times in 48 hours, expressed low but consistently detectable levels of Ceacam1 (Figure 6A).", [["CFSElo alloactivated T cells", "ANATOMY", 18, 46], ["T cells", "CELL", 39, 46], ["Ceacam1 (Figure 6A", "GENE_OR_GENE_PRODUCT", 141, 159], ["CFSElo alloactivated T cells", "CELL_LINE", 18, 46], ["Ceacam1", "PROTEIN", 141, 148]]], ["These kinetics are consistent with a role for Ceacam1 in regulating early events in T cell alloactivation.Ceacam1 regulates the alloactivation and proliferation of T cells ::: ResultsBecause the expression of Ceacam1 on alloreactive T cells after adoptive transfer occurred in vivo with similar kinetics as T cell alloactivation [30], we asked whether Ceacam1 on either donor alloreactive T cells or radio-resistant cells in allo-BMT recipients could regulate this process.", [["T cell", "ANATOMY", 84, 90], ["T cells", "ANATOMY", 164, 171], ["alloreactive T cells", "ANATOMY", 220, 240], ["T cell", "ANATOMY", 307, 313], ["alloreactive T cells", "ANATOMY", 376, 396], ["cells", "ANATOMY", 416, 421], ["Ceacam1", "CHEMICAL", 46, 53], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 46, 53], ["T cell", "CELL", 84, 90], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 106, 113], ["T cells", "CELL", 164, 171], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 209, 216], ["alloreactive T cells", "CELL", 220, 240], ["T cell", "CELL", 307, 313], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 352, 359], ["alloreactive T cells", "CELL", 376, 396], ["radio-resistant cells", "CELL", 400, 421], ["allo-BMT", "CELL", 425, 433], ["recipients", "ORGANISM", 434, 444], ["Ceacam1", "PROTEIN", 46, 53], ["Ceacam1", "PROTEIN", 106, 113], ["T cells", "CELL_TYPE", 164, 171], ["Ceacam1", "PROTEIN", 209, 216], ["alloreactive T cells", "CELL_TYPE", 220, 240], ["Ceacam1", "PROTEIN", 352, 359], ["donor alloreactive T cells", "CELL_TYPE", 370, 396], ["radio-resistant cells", "CELL_LINE", 400, 421], ["Ceacam1", "TREATMENT", 46, 53], ["T cell alloactivation", "TREATMENT", 84, 105], ["Ceacam1 regulates", "TREATMENT", 106, 123], ["Ceacam1 on alloreactive T cells", "TREATMENT", 209, 240], ["adoptive transfer", "TREATMENT", 247, 264], ["T cell alloactivation", "TREATMENT", 307, 328], ["Ceacam1", "TREATMENT", 352, 359], ["donor alloreactive T cells", "TREATMENT", 370, 396], ["radio-resistant cells", "TREATMENT", 400, 421], ["allo-BMT recipients", "TREATMENT", 425, 444], ["consistent with", "UNCERTAINTY", 19, 34], ["cell alloactivation", "OBSERVATION", 86, 105]]], ["We transferred CFSE-labeled purified B6 WT or Ceacam1\u2212/\u2212 splenic T cells into irradiated BALB/c recipients and analyzed donor T cells in spleens on day 3.Ceacam1 regulates the alloactivation and proliferation of T cells ::: ResultsWe observed that relative to isotype control staining, an increased percentage of alloactivated CFSElo CD4 Ceacam1\u2212/\u2212 T cells were positive for the alloactivation marker CD25, and that a greater percentage of these cells downregulated CD62L than WT T cells (Figure 6B\u2013C), suggesting that more of them became activated.", [["Ceacam1\u2212/\u2212 splenic T cells", "ANATOMY", 46, 72], ["T cells", "ANATOMY", 126, 133], ["spleens", "ANATOMY", 137, 144], ["T cells", "ANATOMY", 212, 219], ["CFSElo CD4 Ceacam1\u2212/\u2212 T cells", "ANATOMY", 327, 356], ["cells", "ANATOMY", 446, 451], ["WT T cells", "ANATOMY", 477, 487], ["CFSE", "CHEMICAL", 15, 19], ["CFSE", "CHEMICAL", 15, 19], ["CFSE", "SIMPLE_CHEMICAL", 15, 19], ["B6 WT", "ORGANISM", 37, 42], ["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 46, 54], ["splenic T cells", "CELL", 57, 72], ["BALB/c recipients", "ORGANISM", 89, 106], ["donor T cells", "CELL", 120, 133], ["spleens", "ORGAN", 137, 144], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 154, 161], ["T cells", "CELL", 212, 219], ["CD4", "GENE_OR_GENE_PRODUCT", 334, 337], ["CD25", "GENE_OR_GENE_PRODUCT", 401, 405], ["cells", "CELL", 446, 451], ["CD62L", "GENE_OR_GENE_PRODUCT", 466, 471], ["WT T cells", "CELL", 477, 487], ["Figure 6B\u2013C", "CELL", 489, 500], ["CFSE-labeled purified B6 WT", "CELL_LINE", 15, 42], ["Ceacam1\u2212/\u2212 splenic T cells", "CELL_LINE", 46, 72], ["donor T cells", "CELL_TYPE", 120, 133], ["Ceacam1", "PROTEIN", 154, 161], ["T cells", "CELL_TYPE", 212, 219], ["alloactivated CFSElo CD4 Ceacam1\u2212/\u2212 T cells", "CELL_LINE", 313, 356], ["alloactivation marker CD25", "PROTEIN", 379, 405], ["CD62L", "PROTEIN", 466, 471], ["WT T cells", "CELL_TYPE", 477, 487], ["WT", "TEST", 40, 42], ["Ceacam1\u2212", "TEST", 46, 54], ["splenic T cells", "TREATMENT", 57, 72], ["irradiated BALB/c recipients", "TREATMENT", 78, 106], ["donor T cells", "TREATMENT", 120, 133], ["Ceacam1 regulates", "TREATMENT", 154, 171], ["isotype control staining", "PROBLEM", 260, 284], ["alloactivated CFSElo CD4 Ceacam1\u2212", "TEST", 313, 346], ["T cells", "PROBLEM", 349, 356], ["the alloactivation marker CD25", "TEST", 375, 405], ["Figure 6B\u2013C", "TEST", 489, 500], ["splenic", "ANATOMY", 57, 64], ["spleens", "ANATOMY", 137, 144], ["increased", "OBSERVATION_MODIFIER", 289, 298]]], ["Additionally, an increased percentage of donor Ceacam1\u2212/\u2212 CD4 T cells had divided to a CFSElo alloactivated state (Figure 6D), suggesting enhanced proliferation in the absence of Ceacam1.Ceacam1 regulates the alloactivation and proliferation of T cells ::: ResultsWe repeated these experiments with alloreactive Ceacam1-Tg T cells and as expected, observed a decrease in numbers of CFSElo T cells as assessed by CFSE dilution (Figure 6E).", [["Ceacam1\u2212/\u2212 CD4 T cells", "ANATOMY", 47, 69], ["T cells", "ANATOMY", 245, 252], ["Ceacam1-Tg T cells", "ANATOMY", 312, 330], ["CFSElo T cells", "ANATOMY", 382, 396], ["CFSE", "CHEMICAL", 412, 416], ["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 47, 55], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 179, 186], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 187, 194], ["T cells", "CELL", 245, 252], ["Ceacam1-Tg T cells", "CELL", 312, 330], ["CFSElo T cells", "CELL", 382, 396], ["CFSE", "SIMPLE_CHEMICAL", 412, 416], ["donor Ceacam1\u2212/\u2212 CD4 T cells", "CELL_TYPE", 41, 69], ["Ceacam1", "PROTEIN", 179, 186], ["Ceacam1", "PROTEIN", 187, 194], ["T cells", "CELL_TYPE", 245, 252], ["alloreactive Ceacam1-Tg T cells", "CELL_LINE", 299, 330], ["CFSElo T cells", "CELL_TYPE", 382, 396], ["donor Ceacam1\u2212", "TEST", 41, 55], ["CD4 T cells", "PROBLEM", 58, 69], ["enhanced proliferation", "PROBLEM", 138, 160], ["Ceacam1 regulates", "TREATMENT", 187, 204], ["these experiments", "TEST", 276, 293], ["alloreactive Ceacam1", "TEST", 299, 319], ["a decrease in numbers of CFSElo T cells", "PROBLEM", 357, 396], ["increased", "OBSERVATION_MODIFIER", 17, 26], ["percentage", "OBSERVATION_MODIFIER", 27, 37], ["donor Ceacam1\u2212", "OBSERVATION", 41, 55], ["suggesting", "UNCERTAINTY", 127, 137], ["enhanced", "OBSERVATION_MODIFIER", 138, 146], ["proliferation", "OBSERVATION", 147, 160], ["decrease", "OBSERVATION_MODIFIER", 359, 367]]], ["This is consistent with an inhibitory role for Ceacam1 in the proliferation of alloreactive T cells.", [["alloreactive T cells", "ANATOMY", 79, 99], ["Ceacam1", "CHEMICAL", 47, 54], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 47, 54], ["alloreactive T cells", "CELL", 79, 99], ["Ceacam1", "PROTEIN", 47, 54], ["alloreactive T cells", "CELL_TYPE", 79, 99], ["Ceacam1", "PROBLEM", 47, 54], ["alloreactive T cells", "PROBLEM", 79, 99], ["consistent with", "UNCERTAINTY", 8, 23], ["Ceacam1", "OBSERVATION", 47, 54], ["proliferation", "OBSERVATION_MODIFIER", 62, 75], ["alloreactive T cells", "OBSERVATION", 79, 99]]], ["However, we did not observe significant differences in alloactivation between Ceacam1-Tg vs. WT donor T cells (data not shown).Ceacam1 regulates the alloactivation and proliferation of T cells ::: ResultsLastly, we assessed the role of Ceacam1 expression on radio-resistant cells in allo-BMT recipients for donor T cell alloactivation.", [["donor T cells", "ANATOMY", 96, 109], ["T cells", "ANATOMY", 185, 192], ["cells", "ANATOMY", 274, 279], ["T cell", "ANATOMY", 313, 319], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 78, 85], ["WT donor T cells", "CELL", 93, 109], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 127, 134], ["T cells", "CELL", 185, 192], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 236, 243], ["cells", "CELL", 274, 279], ["allo-BMT recipients", "CELL", 283, 302], ["donor T cell", "CELL", 307, 319], ["Ceacam1", "PROTEIN", 78, 85], ["WT donor T cells", "CELL_TYPE", 93, 109], ["Ceacam1", "PROTEIN", 127, 134], ["T cells", "CELL_TYPE", 185, 192], ["Ceacam1", "PROTEIN", 236, 243], ["radio-resistant cells", "CELL_LINE", 258, 279], ["Ceacam1", "TEST", 78, 85], ["Ceacam1 regulates", "TREATMENT", 127, 144], ["Ceacam1 expression", "PROBLEM", 236, 254], ["radio-resistant cells", "TREATMENT", 258, 279], ["allo-BMT recipients", "TREATMENT", 283, 302], ["donor T cell alloactivation", "TREATMENT", 307, 334], ["cell alloactivation", "OBSERVATION", 315, 334]]], ["We transferred CFSE-labeled B6 T cells into irradiated WT vs. Ceacam1\u2212/\u2212 BALB/c mice, and analyzed donor T cells in spleens on day 3.", [["B6 T cells", "ANATOMY", 28, 38], ["T cells", "ANATOMY", 105, 112], ["spleens", "ANATOMY", 116, 123], ["CFSE", "CHEMICAL", 15, 19], ["CFSE", "CHEMICAL", 15, 19], ["CFSE", "SIMPLE_CHEMICAL", 15, 19], ["B6 T cells", "CELL", 28, 38], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 62, 69], ["T cells", "CELL", 105, 112], ["spleens", "ORGAN", 116, 123], ["CFSE-labeled B6 T cells", "CELL_LINE", 15, 38], ["Ceacam1", "PROTEIN", 62, 69], ["donor T cells", "CELL_TYPE", 99, 112], ["mice", "SPECIES", 80, 84], ["mice", "SPECIES", 80, 84], ["Ceacam1", "TREATMENT", 62, 69], ["BALB/c mice", "TREATMENT", 73, 84], ["donor T cells", "TREATMENT", 99, 112], ["spleens", "ANATOMY", 116, 123]]], ["Here, we did not observe differences in proliferation (data not shown), but donor CD4 T cells in Ceacam1\u2212/\u2212 allogeneic recipients did exhibit an increase in alloactivation as measured by CD25 (Figure 6F).Ceacam1 does not significantly influence T cell polarization, cytolysis or dendritic cell function in GVHD ::: ResultsWe measured serum cytokines in recipients of WT, Ceacam1-Tg and Ceacam1\u2212/\u2212 T cells on days 7 and 14 post-transplant, and observed that levels of IFN\u03b3, TNF, IL-2, IL-4, IL-6, IL-10, and IL-12p70 were similar (data not shown).", [["CD4 T cells", "ANATOMY", 82, 93], ["T cell", "ANATOMY", 245, 251], ["dendritic cell", "ANATOMY", 279, 293], ["serum", "ANATOMY", 334, 339], ["Ceacam1\u2212/\u2212 T cells", "ANATOMY", 386, 404], ["Ceacam1", "CHEMICAL", 204, 211], ["GVHD", "DISEASE", 306, 310], ["Ceacam1", "CHEMICAL", 204, 211], ["CD4", "GENE_OR_GENE_PRODUCT", 82, 85], ["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 97, 105], ["CD25", "GENE_OR_GENE_PRODUCT", 187, 191], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 204, 211], ["T cell", "CELL", 245, 251], ["dendritic cell", "CELL", 279, 293], ["serum", "ORGANISM_SUBSTANCE", 334, 339], ["recipients", "ORGANISM", 353, 363], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 371, 378], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 386, 393], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 467, 471], ["TNF", "GENE_OR_GENE_PRODUCT", 473, 476], ["IL-2", "GENE_OR_GENE_PRODUCT", 478, 482], ["IL-4", "GENE_OR_GENE_PRODUCT", 484, 488], ["IL-6", "GENE_OR_GENE_PRODUCT", 490, 494], ["IL-10", "GENE_OR_GENE_PRODUCT", 496, 501], ["IL-12p70", "GENE_OR_GENE_PRODUCT", 507, 515], ["CD4 T cells", "CELL_TYPE", 82, 93], ["CD25", "PROTEIN", 187, 191], ["Ceacam1", "PROTEIN", 204, 211], ["serum cytokines", "PROTEIN", 334, 349], ["Ceacam1-Tg and Ceacam1\u2212/\u2212 T cells", "CELL_LINE", 371, 404], ["IFN\u03b3", "PROTEIN", 467, 471], ["TNF", "PROTEIN", 473, 476], ["IL", "PROTEIN", 507, 509], ["donor CD4 T cells", "TEST", 76, 93], ["Ceacam1\u2212", "TEST", 97, 105], ["allogeneic recipients", "TREATMENT", 108, 129], ["an increase in alloactivation", "PROBLEM", 142, 171], ["cytolysis", "PROBLEM", 266, 275], ["dendritic cell function", "PROBLEM", 279, 302], ["serum cytokines", "TEST", 334, 349], ["WT", "TEST", 367, 369], ["Ceacam1", "TEST", 371, 378], ["Tg", "TEST", 379, 381], ["Ceacam1", "TEST", 386, 393], ["IFN\u03b3", "TEST", 467, 471], ["TNF", "TEST", 473, 476], ["IL", "TEST", 478, 480], ["IL", "TEST", 484, 486], ["IL", "TEST", 490, 492], ["IL", "TEST", 496, 498], ["IL", "TEST", 507, 509], ["increase", "OBSERVATION_MODIFIER", 145, 153], ["cell polarization", "OBSERVATION", 247, 264], ["dendritic cell", "OBSERVATION", 279, 293]]], ["Percentages of FoxP3+ donor regulatory T cells and expression of T-bet were also similar between recipients of WT, Ceacam1-Tg and Ceacam1\u2212/\u2212 T cells (data not shown andTable 1), and stimulation of splenocytes harvested on day 14 after BMT post-transplant from these three groups revealed essentially no IL-17+ donor T cells (not shown), and similar percentages of donor IFN\u03b3+ T cells (data not shown andTable 1).Ceacam1 does not significantly influence T cell polarization, cytolysis or dendritic cell function in GVHD ::: ResultsAs Ceacam1 can regulate the cytolytic responses of lymphocytes [34], [35], [36], [37], [38], we assessed the cytolytic function of WT vs. Ceacam1\u2212/\u2212 alloactivated CD8 T cells from the spleens of allo-BMT recipients on day 14.", [["FoxP3+ donor regulatory T cells", "ANATOMY", 15, 46], ["Ceacam1\u2212/\u2212 T cells", "ANATOMY", 130, 148], ["splenocytes", "ANATOMY", 197, 208], ["IL-17+ donor T cells", "ANATOMY", 303, 323], ["T cells", "ANATOMY", 376, 383], ["T cell", "ANATOMY", 453, 459], ["dendritic cell", "ANATOMY", 487, 501], ["lymphocytes", "ANATOMY", 581, 592], ["CD8 T cells", "ANATOMY", 693, 704], ["spleens", "ANATOMY", 714, 721], ["Ceacam1", "CHEMICAL", 412, 419], ["GVHD", "DISEASE", 514, 518], ["Ceacam1", "CHEMICAL", 412, 419], ["FoxP3", "GENE_OR_GENE_PRODUCT", 15, 20], ["T-bet", "GENE_OR_GENE_PRODUCT", 65, 70], ["recipients", "ORGANISM", 97, 107], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 115, 122], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 130, 137], ["splenocytes", "CELL", 197, 208], ["IL-17", "GENE_OR_GENE_PRODUCT", 303, 308], ["T cells", "CELL", 316, 323], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 370, 374], ["T cells", "CELL", 376, 383], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 412, 419], ["T cell", "CELL", 453, 459], ["dendritic cell", "CELL", 487, 501], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 533, 540], ["lymphocytes", "CELL", 581, 592], ["[35]", "SIMPLE_CHEMICAL", 599, 603], ["[37]", "SIMPLE_CHEMICAL", 611, 615], ["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 668, 676], ["CD8", "GENE_OR_GENE_PRODUCT", 693, 696], ["spleens", "ORGAN", 714, 721], ["allo-BMT recipients", "CELL", 725, 744], ["FoxP3", "PROTEIN", 15, 20], ["donor regulatory T cells", "CELL_TYPE", 22, 46], ["T-bet", "PROTEIN", 65, 70], ["Ceacam1", "PROTEIN", 115, 122], ["Ceacam1\u2212/\u2212 T cells", "CELL_LINE", 130, 148], ["splenocytes", "CELL_TYPE", 197, 208], ["IL-17", "PROTEIN", 303, 308], ["donor T cells", "CELL_TYPE", 310, 323], ["IFN\u03b3", "PROTEIN", 370, 374], ["T cells", "CELL_TYPE", 376, 383], ["Ceacam1", "PROTEIN", 412, 419], ["Ceacam1", "PROTEIN", 533, 540], ["lymphocytes", "CELL_TYPE", 581, 592], ["Ceacam1\u2212/\u2212 alloactivated CD8 T cells", "CELL_LINE", 668, 704], ["Percentages", "TEST", 0, 11], ["FoxP3", "TEST", 15, 20], ["donor regulatory T cells", "PROBLEM", 22, 46], ["T-bet", "TEST", 65, 70], ["WT", "TEST", 111, 113], ["Ceacam1", "TEST", 115, 122], ["Ceacam1", "TEST", 130, 137], ["BMT post-transplant", "TREATMENT", 235, 254], ["IL", "TEST", 303, 305], ["donor T cells", "PROBLEM", 310, 323], ["Ceacam1", "TEST", 412, 419], ["cytolysis", "PROBLEM", 474, 483], ["dendritic cell function", "PROBLEM", 487, 510], ["GVHD", "PROBLEM", 514, 518], ["the cytolytic responses", "TEST", 554, 577], ["lymphocytes", "TEST", 581, 592], ["Ceacam1\u2212", "TREATMENT", 668, 676], ["\u2212 alloactivated CD8 T cells", "TREATMENT", 677, 704], ["allo-BMT recipients", "TREATMENT", 725, 744], ["FoxP3", "OBSERVATION", 15, 20], ["splenocytes", "ANATOMY", 197, 208], ["no", "UNCERTAINTY", 300, 302], ["cell polarization", "OBSERVATION", 455, 472], ["dendritic cell", "OBSERVATION", 487, 501], ["spleens", "ANATOMY", 714, 721]]], ["Ceacam1\u2212/\u2212 CD8 T cells and WT CD8 T cells demonstrated similar cytolysis against 51Cr-radiolabeled allogeneic A20 B cell lymphoma cells and EL4 controls (Table 1).", [["Ceacam1\u2212/\u2212 CD8 T cells", "ANATOMY", 0, 22], ["WT CD8 T cells", "ANATOMY", 27, 41], ["A20 B cell lymphoma cells", "ANATOMY", 110, 135], ["EL4", "ANATOMY", 140, 143], ["51Cr", "CHEMICAL", 81, 85], ["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 0, 8], ["51Cr", "SIMPLE_CHEMICAL", 81, 85], ["A20 B cell lymphoma cells", "CELL", 110, 135], ["EL4 controls", "CELL", 140, 152], ["Ceacam1\u2212/\u2212 CD8 T cells", "CELL_LINE", 0, 22], ["WT CD8 T cells", "CELL_TYPE", 27, 41], ["51Cr-radiolabeled allogeneic A20 B cell lymphoma cells", "CELL_LINE", 81, 135], ["EL4 controls", "CELL_LINE", 140, 152], ["Ceacam1\u2212", "TEST", 0, 8], ["WT CD8 T cells", "TEST", 27, 41], ["similar cytolysis", "PROBLEM", 55, 72], ["51Cr", "TEST", 81, 85], ["radiolabeled allogeneic A20 B cell lymphoma cells", "TREATMENT", 86, 135], ["EL4 controls", "TEST", 140, 152], ["allogeneic A20 B cell lymphoma cells", "OBSERVATION", 99, 135]]], ["Lastly, we found no differences in DC numbers, activation state (CD80, CD86, MHC class II) from the infusion of Ceacam1\u2212/\u2212 or Ceacam1-Tg T cells (Table 1), or in Ceacam1\u2212/\u2212 allo-BMT recipients.Ceacam1\u2212/\u2212 donor T cells have enhanced graft-versus-tumor activity towards A20 lymphoma but not renal cell carcinom ::: ResultsFinally, we assessed the GVT activity of Ceacam1\u2212/\u2212 donor alloreactive T cells against A20 lymphoma and RENCA renal cell carcinoma.", [["DC", "ANATOMY", 35, 37], ["Ceacam1\u2212/\u2212", "ANATOMY", 112, 122], ["Ceacam1-Tg T cells", "ANATOMY", 126, 144], ["Ceacam1\u2212/\u2212 donor T cells", "ANATOMY", 193, 217], ["graft", "ANATOMY", 232, 237], ["tumor", "ANATOMY", 245, 250], ["A20 lymphoma", "ANATOMY", 268, 280], ["renal cell carcinom", "ANATOMY", 289, 308], ["Ceacam1\u2212/\u2212 donor alloreactive T cells", "ANATOMY", 361, 398], ["A20 lymphoma", "ANATOMY", 407, 419], ["RENCA renal cell carcinoma", "ANATOMY", 424, 450], ["tumor", "DISEASE", 245, 250], ["lymphoma", "DISEASE", 272, 280], ["lymphoma", "DISEASE", 411, 419], ["renal cell carcinoma", "DISEASE", 430, 450], ["CD80", "GENE_OR_GENE_PRODUCT", 65, 69], ["CD86", "GENE_OR_GENE_PRODUCT", 71, 75], ["MHC class II", "GENE_OR_GENE_PRODUCT", 77, 89], ["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 112, 120], ["\u2212", "GENE_OR_GENE_PRODUCT", 121, 122], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 126, 133], ["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 162, 170], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 193, 200], ["graft-versus-tumor", "CANCER", 232, 250], ["A20 lymphoma", "CANCER", 268, 280], ["renal cell carcinom", "CELL", 289, 308], ["GVT", "CANCER", 345, 348], ["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 361, 369], ["T cells", "CELL", 391, 398], ["A20 lymphoma", "CANCER", 407, 419], ["RENCA renal cell carcinoma", "CANCER", 424, 450], ["DC", "CELL_TYPE", 35, 37], ["CD80", "PROTEIN", 65, 69], ["CD86", "PROTEIN", 71, 75], ["MHC class II", "PROTEIN", 77, 89], ["Ceacam1\u2212", "PROTEIN", 112, 120], ["Ceacam1", "PROTEIN", 126, 133], ["Tg T cells", "CELL_TYPE", 134, 144], ["Ceacam1\u2212/\u2212 donor T cells", "CELL_LINE", 193, 217], ["Ceacam1\u2212/\u2212 donor alloreactive T cells", "CELL_LINE", 361, 398], ["CD80", "TEST", 65, 69], ["Ceacam1\u2212", "TREATMENT", 112, 120], ["Ceacam1", "TREATMENT", 126, 133], ["allo-BMT recipients", "TREATMENT", 173, 192], ["Ceacam1\u2212", "TREATMENT", 193, 201], ["donor T cells", "TREATMENT", 204, 217], ["enhanced graft", "TREATMENT", 223, 237], ["tumor activity", "PROBLEM", 245, 259], ["A20 lymphoma", "PROBLEM", 268, 280], ["Ceacam1\u2212", "TEST", 361, 369], ["\u2212 donor alloreactive T cells", "TREATMENT", 370, 398], ["A20 lymphoma", "PROBLEM", 407, 419], ["RENCA renal cell carcinoma", "PROBLEM", 424, 450], ["no", "UNCERTAINTY", 17, 19], ["graft", "OBSERVATION", 232, 237], ["tumor", "OBSERVATION", 245, 250], ["A20 lymphoma", "OBSERVATION", 268, 280], ["renal", "ANATOMY", 289, 294], ["cell carcinom", "OBSERVATION", 295, 308], ["A20 lymphoma", "OBSERVATION", 407, 419], ["renal", "ANATOMY", 430, 435], ["cell carcinoma", "OBSERVATION", 436, 450]]], ["Recipients of Ceacam1\u2212/\u2212 donor T cells had improved survival in the A20 lymphoma model (Figure 7A), but both T cell replete groups showed comparable survival in the RENCA solid tumor model (Figure 7B).", [["Ceacam1\u2212/\u2212 donor T cells", "ANATOMY", 14, 38], ["A20 lymphoma", "ANATOMY", 68, 80], ["T cell", "ANATOMY", 109, 115], ["RENCA solid tumor", "ANATOMY", 165, 182], ["lymphoma", "DISEASE", 72, 80], ["tumor", "DISEASE", 177, 182], ["Recipients", "ORGANISM", 0, 10], ["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 14, 22], ["T cells", "CELL", 31, 38], ["A20 lymphoma", "CANCER", 68, 80], ["T cell", "CELL", 109, 115], ["RENCA solid tumor", "CANCER", 165, 182], ["Ceacam1\u2212/\u2212 donor T cells", "CELL_LINE", 14, 38], ["Ceacam1\u2212/\u2212 donor T cells", "TREATMENT", 14, 38], ["both T cell replete groups", "TEST", 104, 130], ["A20 lymphoma", "OBSERVATION", 68, 80], ["RENCA", "ANATOMY", 165, 170], ["solid tumor", "OBSERVATION", 171, 182]]], ["When we analyzed these two tumor lines for Ceacam1 expression, we noted that all A20 lymphoma cells uniformly expressed high levels, while only a subset of RENCA cells expressed some Ceacam1 (Figure 7C).DiscussionIn this report, we show that Ceacam1, which is found on both donor alloreactive T cells as well as non-hematopoietic tissues such as gastrointestinal and hepatic epithelium, can regulate both donor T cell function and the sensitivity of allo-BMT recipients to radiation-containing preparative regimens.", [["tumor lines", "ANATOMY", 27, 38], ["A20 lymphoma cells", "ANATOMY", 81, 99], ["RENCA cells", "ANATOMY", 156, 167], ["alloreactive T cells", "ANATOMY", 280, 300], ["non-hematopoietic tissues", "ANATOMY", 312, 337], ["gastrointestinal", "ANATOMY", 346, 362], ["hepatic epithelium", "ANATOMY", 367, 385], ["T cell", "ANATOMY", 411, 417], ["tumor", "DISEASE", 27, 32], ["lymphoma", "DISEASE", 85, 93], ["tumor lines", "CELL", 27, 38], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 43, 50], ["A20 lymphoma cells", "CELL", 81, 99], ["RENCA cells", "CELL", 156, 167], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 183, 190], ["Figure 7C", "GENE_OR_GENE_PRODUCT", 192, 201], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 242, 249], ["alloreactive T cells", "CELL", 280, 300], ["non-hematopoietic tissues", "TISSUE", 312, 337], ["gastrointestinal", "ORGAN", 346, 362], ["hepatic epithelium", "TISSUE", 367, 385], ["T cell", "CELL", 411, 417], ["tumor lines", "CELL_LINE", 27, 38], ["Ceacam1", "PROTEIN", 43, 50], ["A20 lymphoma cells", "CELL_LINE", 81, 99], ["RENCA cells", "CELL_LINE", 156, 167], ["Ceacam1", "PROTEIN", 183, 190], ["Ceacam1", "PROTEIN", 242, 249], ["donor alloreactive T cells", "CELL_TYPE", 274, 300], ["Ceacam1 expression", "PROBLEM", 43, 61], ["all A20 lymphoma cells", "PROBLEM", 77, 99], ["RENCA cells", "PROBLEM", 156, 167], ["Ceacam1", "PROBLEM", 242, 249], ["donor alloreactive T cells", "TREATMENT", 274, 300], ["non-hematopoietic tissues", "PROBLEM", 312, 337], ["gastrointestinal and hepatic epithelium", "PROBLEM", 346, 385], ["allo-BMT recipients", "TREATMENT", 450, 469], ["radiation", "TREATMENT", 473, 482], ["preparative regimens", "TREATMENT", 494, 514], ["tumor lines", "OBSERVATION", 27, 38], ["A20 lymphoma cells", "OBSERVATION", 81, 99], ["high", "OBSERVATION_MODIFIER", 120, 124], ["levels", "OBSERVATION_MODIFIER", 125, 131], ["Ceacam1", "OBSERVATION_MODIFIER", 183, 190], ["Ceacam1", "OBSERVATION", 242, 249], ["alloreactive T cells", "OBSERVATION", 280, 300], ["non-hematopoietic tissues", "OBSERVATION", 312, 337], ["gastrointestinal", "ANATOMY", 346, 362], ["hepatic", "ANATOMY", 367, 374], ["epithelium", "ANATOMY_MODIFIER", 375, 385]]], ["In addition, Ceacam1 on donor T cells and tumors may modulate GVT activity.", [["donor T cells", "ANATOMY", 24, 37], ["tumors", "ANATOMY", 42, 48], ["GVT", "ANATOMY", 62, 65], ["tumors", "DISEASE", 42, 48], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 13, 20], ["donor T cells", "CELL", 24, 37], ["tumors", "CANCER", 42, 48], ["GVT", "GENE_OR_GENE_PRODUCT", 62, 65], ["Ceacam1", "PROTEIN", 13, 20], ["donor T cells", "CELL_TYPE", 24, 37], ["Ceacam1 on donor T cells", "TREATMENT", 13, 37], ["tumors", "PROBLEM", 42, 48], ["Ceacam1", "OBSERVATION", 13, 20], ["GVT activity", "OBSERVATION", 62, 74]]], ["Ceacam1 on both the donor allograft and recipient tissues thus appears to represent an important regulator of GVHD and GVT morbidity and mortality via both T cell dependent and independent mechanisms, suggesting that therapeutic approaches which modulate Ceacam1 may need to assess and balance GVHD vs. GVT.DiscussionCeacam1 on T cells has previously been shown to restrain CD4 T cell polarization, cytokine secretion and cytotoxicity.", [["donor allograft", "ANATOMY", 20, 35], ["tissues", "ANATOMY", 50, 57], ["T cell", "ANATOMY", 156, 162], ["T cells", "ANATOMY", 328, 335], ["CD4 T cell", "ANATOMY", 374, 384], ["Ceacam1", "CHEMICAL", 0, 7], ["GVHD", "DISEASE", 110, 114], ["GVT", "DISEASE", 119, 122], ["GVHD", "DISEASE", 294, 298], ["GVT", "DISEASE", 303, 306], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 0, 7], ["allograft", "TISSUE", 26, 35], ["recipient tissues", "TISSUE", 40, 57], ["GVT", "CANCER", 119, 122], ["T cell", "CELL", 156, 162], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 255, 262], ["DiscussionCeacam1", "SIMPLE_CHEMICAL", 307, 324], ["T cells", "CELL", 328, 335], ["CD4 T cell", "CELL", 374, 384], ["Ceacam1", "PROTEIN", 0, 7], ["Ceacam1", "PROTEIN", 255, 262], ["DiscussionCeacam1", "PROTEIN", 307, 324], ["T cells", "CELL_TYPE", 328, 335], ["CD4", "PROTEIN", 374, 377], ["cytokine", "PROTEIN", 399, 407], ["Ceacam1", "PROBLEM", 0, 7], ["the donor allograft", "TREATMENT", 16, 35], ["GVHD", "PROBLEM", 110, 114], ["GVT morbidity", "PROBLEM", 119, 132], ["GVHD", "PROBLEM", 294, 298], ["GVT", "PROBLEM", 303, 306], ["cytokine secretion", "PROBLEM", 399, 417], ["cytotoxicity", "PROBLEM", 422, 434], ["donor allograft", "OBSERVATION", 20, 35], ["appears to represent", "UNCERTAINTY", 63, 83], ["GVHD", "OBSERVATION", 110, 114], ["cell dependent", "OBSERVATION_MODIFIER", 158, 172]]], ["In our GVHD model systems however, we found similar T cell polarization and cytokine secretion when we analyzed donor alloreactive T cells ex vivo (Table 1).", [["T cell", "ANATOMY", 52, 58], ["alloreactive T cells", "ANATOMY", 118, 138], ["GVHD", "DISEASE", 7, 11], ["T cell", "CELL", 52, 58], ["alloreactive T cells", "CELL", 118, 138], ["cytokine", "PROTEIN", 76, 84], ["donor alloreactive T cells", "CELL_TYPE", 112, 138], ["similar T cell polarization", "PROBLEM", 44, 71], ["cytokine secretion", "PROBLEM", 76, 94], ["donor alloreactive T cells", "TREATMENT", 112, 138], ["GVHD", "OBSERVATION", 7, 11], ["cell polarization", "OBSERVATION", 54, 71]]], ["We ascribe this to the strongly proinflammatory cytokine milieu found in recipients following myeloablative radiation treatment, as well as the ubiquitous presence of alloantigen, which together promote strong Th1 differentiation regardless of Ceacam1 expression.", [["alloantigen", "GENE_OR_GENE_PRODUCT", 167, 178], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 244, 251], ["proinflammatory cytokine", "PROTEIN", 32, 56], ["alloantigen", "PROTEIN", 167, 178], ["Ceacam1", "PROTEIN", 244, 251], ["myeloablative radiation treatment", "TREATMENT", 94, 127], ["Ceacam1 expression", "OBSERVATION", 244, 262]]], ["However, in our model systems Ceacam1 regulated T cell activation, and numbers of donor alloactivated T cells in both lymphoid tissues and GVHD target tissues, in patterns that generally correlated with levels target organ damage (Figures 2", [["T cell", "ANATOMY", 48, 54], ["alloactivated T cells", "ANATOMY", 88, 109], ["lymphoid tissues", "ANATOMY", 118, 134], ["GVHD target tissues", "ANATOMY", 139, 158], ["organ", "ANATOMY", 217, 222], ["GVHD", "DISEASE", 139, 143], ["organ damage", "DISEASE", 217, 229], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 30, 37], ["T cell", "CELL", 48, 54], ["T cells", "CELL", 102, 109], ["lymphoid tissues", "TISSUE", 118, 134], ["GVHD target tissues", "TISSUE", 139, 158], ["organ", "ORGAN", 217, 222], ["Ceacam1", "PROTEIN", 30, 37], ["donor alloactivated T cells", "CELL_TYPE", 82, 109], ["donor alloactivated T cells", "TREATMENT", 82, 109], ["GVHD target tissues", "PROBLEM", 139, 158], ["levels target organ damage", "PROBLEM", 203, 229], ["cell activation", "OBSERVATION", 50, 65], ["both", "ANATOMY_MODIFIER", 113, 117], ["lymphoid tissues", "ANATOMY", 118, 134], ["GVHD", "OBSERVATION", 139, 143]]]], "PMC7358764": [["RISK FACTORS AND RISK BEHAVIORS ::: INTRODUCTIONCVRFs, including obesity, dyslipidemia, hypertension, and at-risk behaviors including eating habits, physical inactivity, screen time, and smoking and electronic cigarette use are common in youth (Table 1).4 Autopsy studies have demonstrated that the presence and intensity of such CVRFs is associated with atherosclerotic development and burden in childhood and young adulthood.2,5 Moreover, modifiable CVRFs such as obesity, dyslipidemia, and hypertension track from childhood to adulthood; for example, an overweight teen has a 75% likelihood of becoming an obese adult.6 Thus, the timely management of CVRFs in youth has the potential to reduce or delay atherosclerotic cardiovascular disease in adulthood, particularly for youth with conditions predisposing them to increased CV risk.3 Prospectively evaluating the impact of CVRF management in youth on the occurrence of manifest atherosclerotic cardiovascular disease in adulthood in a randomized controlled manner would be logistically very difficult and likely unethical given the weight of evidence to date.", [["atherosclerotic", "ANATOMY", 355, 370], ["cardiovascular", "ANATOMY", 722, 736], ["cardiovascular", "ANATOMY", 949, 963], ["obesity", "DISEASE", 65, 72], ["dyslipidemia", "DISEASE", 74, 86], ["hypertension", "DISEASE", 88, 100], ["physical inactivity", "DISEASE", 149, 168], ["smoking", "CHEMICAL", 187, 194], ["CVRFs", "DISEASE", 330, 335], ["atherosclerotic", "DISEASE", 355, 370], ["obesity", "DISEASE", 466, 473], ["dyslipidemia", "DISEASE", 475, 487], ["hypertension", "DISEASE", 493, 505], ["CVRFs", "DISEASE", 654, 659], ["atherosclerotic cardiovascular disease", "DISEASE", 706, 744], ["atherosclerotic cardiovascular disease", "DISEASE", 933, 971], ["CVRFs", "MULTI-TISSUE_STRUCTURE", 452, 457], ["cardiovascular", "ANATOMICAL_SYSTEM", 722, 736], ["cardiovascular", "ANATOMICAL_SYSTEM", 949, 963], ["obesity", "PROBLEM", 65, 72], ["dyslipidemia", "PROBLEM", 74, 86], ["hypertension", "PROBLEM", 88, 100], ["Autopsy studies", "TEST", 256, 271], ["such CVRFs", "PROBLEM", 325, 335], ["atherosclerotic development", "PROBLEM", 355, 382], ["modifiable CVRFs", "PROBLEM", 441, 457], ["obesity", "PROBLEM", 466, 473], ["dyslipidemia", "PROBLEM", 475, 487], ["hypertension track", "PROBLEM", 493, 511], ["an obese adult", "PROBLEM", 606, 620], ["CVRFs", "TREATMENT", 654, 659], ["delay atherosclerotic cardiovascular disease", "PROBLEM", 700, 744], ["increased CV risk", "PROBLEM", 819, 836], ["CVRF management", "TREATMENT", 878, 893], ["manifest atherosclerotic cardiovascular disease", "PROBLEM", 924, 971], ["obesity", "OBSERVATION", 65, 72], ["dyslipidemia", "OBSERVATION", 74, 86], ["hypertension", "OBSERVATION", 88, 100], ["associated with", "UNCERTAINTY", 339, 354], ["atherosclerotic", "OBSERVATION_MODIFIER", 355, 370], ["burden", "OBSERVATION_MODIFIER", 387, 393], ["obesity", "OBSERVATION", 466, 473], ["dyslipidemia", "OBSERVATION", 475, 487], ["hypertension", "OBSERVATION", 493, 505], ["obese", "OBSERVATION", 609, 614], ["atherosclerotic", "OBSERVATION_MODIFIER", 706, 721], ["cardiovascular disease", "OBSERVATION", 722, 744], ["increased", "OBSERVATION_MODIFIER", 819, 828], ["CV risk", "OBSERVATION", 829, 836], ["atherosclerotic", "OBSERVATION_MODIFIER", 933, 948], ["cardiovascular disease", "OBSERVATION", 949, 971]]], ["On this basis, the United States Preventive Services Task Force (USPSTF) has indicated that insufficient evidence exists to recommend in favor of or against screening of lipid disorders and blood pressure in youth.7,8 Despite this, as outlined below, indirect evidence suggests that the early and effective management of CVRFs can result in improvements in manifest cardiovascular disease in adulthood and non-invasive measures of atherosclerotic burden and vascular dysfunction in youth.", [["blood", "ANATOMY", 190, 195], ["cardiovascular", "ANATOMY", 366, 380], ["atherosclerotic", "ANATOMY", 431, 446], ["vascular", "ANATOMY", 458, 466], ["lipid disorders", "DISEASE", 170, 185], ["CVRFs", "DISEASE", 321, 326], ["cardiovascular disease", "DISEASE", 366, 388], ["atherosclerotic", "DISEASE", 431, 446], ["vascular dysfunction", "DISEASE", 458, 478], ["lipid", "SIMPLE_CHEMICAL", 170, 175], ["blood", "ORGANISM_SUBSTANCE", 190, 195], ["CVRFs", "SIMPLE_CHEMICAL", 321, 326], ["cardiovascular", "ANATOMICAL_SYSTEM", 366, 380], ["atherosclerotic", "IMMATERIAL_ANATOMICAL_ENTITY", 431, 446], ["vascular", "MULTI-TISSUE_STRUCTURE", 458, 466], ["lipid disorders", "PROBLEM", 170, 185], ["blood pressure", "TEST", 190, 204], ["CVRFs", "TREATMENT", 321, 326], ["manifest cardiovascular disease in adulthood", "PROBLEM", 357, 401], ["atherosclerotic burden", "PROBLEM", 431, 453], ["vascular dysfunction in youth", "PROBLEM", 458, 487], ["cardiovascular disease", "OBSERVATION", 366, 388], ["atherosclerotic", "OBSERVATION_MODIFIER", 431, 446], ["burden", "OBSERVATION", 447, 453], ["vascular", "ANATOMY", 458, 466], ["dysfunction", "OBSERVATION", 467, 478]]], ["For example, early statin initiation in youth with FH has recently been shown to result in significant reductions in cardiovascular disease in adulthood, compared with their FH-affected parents, who had not started statin therapy until adulthood.9", [["cardiovascular", "ANATOMY", 117, 131], ["statin", "CHEMICAL", 19, 25], ["FH", "DISEASE", 51, 53], ["cardiovascular disease", "DISEASE", 117, 139], ["statin", "CHEMICAL", 215, 221], ["statin", "CHEMICAL", 19, 25], ["statin", "CHEMICAL", 215, 221], ["cardiovascular", "ANATOMICAL_SYSTEM", 117, 131], ["early statin", "TREATMENT", 13, 25], ["cardiovascular disease", "PROBLEM", 117, 139], ["statin therapy", "TREATMENT", 215, 229], ["early", "OBSERVATION_MODIFIER", 13, 18], ["statin", "OBSERVATION", 19, 25], ["significant", "OBSERVATION_MODIFIER", 91, 102], ["reductions", "OBSERVATION_MODIFIER", 103, 113], ["cardiovascular disease", "OBSERVATION", 117, 139]]]]}